BEFORE THE

INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: SACRAMENTO CONVENTION CENTER

3RD FLOOR

SACRAMENTO, CALIFORNIA

DATE: MARCH 12, 2009

9 A.M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 82459

INDEX

ITEM DESCRIPTION NO.

PAGE

CALL TO ORDER

003

ROLL CALL

006

APPROVAL OF MINUTES FROM AUGUST 12-13, SEPTEMBER 25TH AND DECEMBER 9-10, 2008 MEETINGS AND JANUARY 29TH-30TH, 2009 I COC MEETINGS.

ADOPTION OF REGULATION 100502, DEFINITION OF "CALIFORNIA SUPPLIER."

INITIATION OF THE OAL PROCESS TO AMEND CIRM MEDICAL AND ETHICAL STANDARDS REGULATIONS REGARDING OVERSIGHT AND CONSENT REQUIREMENTS FOR USE OF BLASTOCYSTS AND SOMATIC CELLS.

ADOPTION OF REGULATION 100081, "EXEMPTION" PETITION FOR HESC LINE.

CHAIRMAN'S REPORT

PRESIDENT'S REPORT

AUDITED FINANCIAL STATEMENTS 07-08 AUDITORS REPORT TO MANAGEMENT 07-08

UPDATE ON PRIVATE BOND PLACEMENT PROGRAM.

CLOSED SESSION (NOT REPORTED)

PUBLIC REPORT OF ANY ACTION TAKEN

ACTION ITEMS

CONSIDERATION OF AMENDMENTS TO ICOC BYLAWS AND INTERNAL GOVERNANCE POLICY REGARDING VICE-CHAIR(S).

CONSIDERATION OF AMENDMENT TO LOWER CIRM SALARY RANGE FOR VICE-CHAIR.

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

CONSIDERATION OF ELECTION OF VICE-CHAIR(S). CONSIDERATION OF STAFF RECOMMENDATIONS ON RESEARCH FUNDING PRIORITIES. CONSIDERATION OF FUNDING FOR APPROVED BRIDGES TO STEM CELL RESEARCH GRANT APPLICATIONS. CONSIDERATION OF FUNDING FOR APPROVED TRAINING PROGRAM II GRANT APPLICATIONS. CONSIDERATION OF AMENDMENT TO CIRM TRAVEL POLICY WITH REGARD TO MEAL REIMBURSEMENT CONSIDERATION OF NEW SCIENTIFIC MEMBERS FOR GRANTS WORKING GROUP. CONSIDERATION OF AMENDMENT TO CONTRACT WITH REMCHO, JOHANSEN AND PURCELL. 4

1	CACDAMENTO CALLEODNIA, THIRDDAY MADCH 12, 2000
1	SACRAMENTO, CALIFORNIA; THURSDAY, MARCH 12, 2009
2	9 A.M.
3	
4	CHAIRMAN KLEIN: WHAT I'D LIKE TO DO HERE
5	IS CALL THE MEETING TO ORDER, ASK MELISSA KING TO
6	LEAD US IN THE PLEDGE OF ALLEGIANCE FOLLOWED BY THE
7	ROLL CALL, AND WE WILL PROCEED.
8	(THE PLEDGE OF ALLEGIANCE.)
9	MS. KING: RICARDO AZZIZ.
10	DR. AZZI Z: PRESENT.
11	MS. KING: ROBERT PRICE FOR ROBERT
12	BI RGENEAU.
13	DR. PRICE: PRESENT.
14	MS. KING: FLOYD BLOOM. GORDON GILL FOR
15	DAVID BRENNER.
16	DR. GILL: PRESENT.
17	MS. KING: JACOB LEVIN FOR SUSAN BRYANT.
18	DR. LEVIN: HERE.
19	MS. KING: MARSHA CHANDLER. MARCY FEIT.
20	MS. FEIT: HERE.
21	MS. KING: MICHAEL FRIEDMAN. LEEZA
22	GI BBONS.
23	MS. GIBBONS: HERE.
24	MS. KING: MICHAEL GOLDBERG.
25	MR. GOLDBERG: HERE.
	5

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

	DARRISTERS REPORTING SERVICE
1	MS. KING: SAM HAWGOOD.
2	DR. HAWGOOD: HERE.
3	MS. KING: BOB KLEIN.
4	CHAIRMAN KLEIN: HERE.
5	MS. KING: SHERRY LANSING. GERALD LEVEY.
6	TED LOVE.
7	DR. LOVE: HERE.
8	MS. KING: ED PENHOET. PHIL PIZZO.
9	CLAIRE POMEROY.
10	DR. POMEROY: HERE.
11	MS. KING: FRANCISCO PRIETO.
12	DR. PRI ETO: HERE.
13	MS. KING: CARMEN PULIAFITO.
14	DR. PULI AFI TO: HERE.
15	MS. KING: ROBERT QUINT.
16	DR. QUINT: HERE.
17	MS. KING: JOHN REED. DUANE ROTH.
18	MR. ROTH: HERE.
19	MS. KING: JOAN SAMUELSON. DAVID
20	SERRANO-SEWELL.
21	MR. SERRANO-SEWALL: HERE.
22	MS. KING: JEFF SHEEHY.
23	MR. SHEEHY: HERE.
24	MS. KING: JON SHESTACK. AND OSWALD
25	STEWARD.
	4
	6

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	CHAIRMAN KLEIN: THANK YOU VERY MUCH,
2	MELISSA. WHILE WE WAIT FOR ONE ADDITIONAL PERSON TO
3	JOIN BY PHONE OR TO ARRIVE TO COMPLEMENT THE MEMBERS
4	THAT ARE HERE IN PERSON, I'D LIKE TO BEGIN WITH THE
5	CHAIRMAN'S REPORT, AND WE WILL COME BACK TO THE
6	CONSENT ITEMS.
7	THIS IS OBVIOUSLY A WEEK FOR CELEBRATION.
8	THE PRESIDENT WAS SPECTACULAR IN THE WHITE HOUSE. I
9	WAS FORTUNATE ENOUGH TO BE INVITED TO THAT CEREMONY.
10	THE PRESIDENT, I CAN TELL YOU, WAS NOT ONLY
11	COMMITTING HIMSELF, BUT DOING SO ENTHUSIASTICALLY TO
12	MAKE CERTAIN THAT EMBRYONIC STEM CELL RESEARCH AND
13	MORE BROADLY SCIENCE COULD MOVE FORWARD BASED ON
14	SCIENTIFIC FINDINGS RATHER THAN IDEOLOGY. IT WAS
15	CLEAR THAT HE WAS ENERGIZED BY HIS POSITION, THAT HE
16	WAS PROUD OF CHAMPIONING SCIENCE, THAT HE SAW
17	TREMENDOUS VALUE IN MAKING CERTAIN THAT EMBRYONIC
18	STEM CELL RESEARCH WAS PART OF THE SPECTRUM OF
19	SCIENTIFIC INQUIRY THAT COULD BE CONDUCTED ALONG
20	WITH ADULT STEM CELL RESEARCH, CORD BLOOD STEM CELL
21	RESEARCH, AMNIOTIC CELLS.
22	HE WANTS TO MAKE CERTAIN THAT THERE'S A
23	CLEAR MESSAGE FOR THIS COUNTRY AND FOR THE WORLD
24	WHERE SCIENCE IN THIS COUNTRY WILL ADVANCE BASED
25	UPON THE BEST INFORMATION THAT WE CAN DERIVE IN
	7

1	PURSUIT OF THE NATURE OF THE UNIVERSE AND THE NATURE
2	OF THE HUMAN BODY AND THE FUTURE OF THERAPIES.
3	WE HAD A NUMBER OF INDIVIDUALS FROM
4	CALIFORNIA THAT WERE THERE. NOBEL PRIZE WINNER
5	MICHAEL BISHOP WAS THERE. HAROLD VARMUS, WHO
6	FORMERLY WAS AT UC SAN FRANCISCO, AND IS ONE OF THE
7	CO-ADVISERS FOR THE PRESIDENT, WAS PRESENT. IRV
8	WEISSMAN FROM STANFORD WAS PRESENT. THERE WAS A
9	GREAT GROUP OF DELEGATES FROM AROUND THE COUNTRY.
10	BASICALLY IT WAS A GROUP OF ABOUT 150 INDIVIDUALS,
11	INCLUDING A GOOD 15 MEMBERS, SENIOR MEMBERS, OF
12	CONGRESS.
13	NANCY PELOSI, REPRESENTING THE COUNTRY AND
14	COMING FROM SAN FRANCISCO, WAS IN THE FRONT ROW, AS
15	ONE MIGHT EXPECT. NEXT TO HER WAS ORIN HATCH. AND
16	THEY HAD, I THINK, A VERY GOOD CELEBRATION OF THE
17	FACT THAT THIS WAS AN ISSUE THEY COULD AGREE ON. A
18	PRO-LIFE REPUBLICAN WHO BELIEVES THIS IS A PRO-LIFE
19	POLICY, AND A CHOICE DEMOCRATIC LEADER WHO BELIEVES
20	THIS IS A GREAT SCIENTIFIC ISSUE, SCIENTIFIC
21	FREEDOM, AND A COMMITMENT TO PURSUING THERAPIES FOR
22	PATIENTS. COMING FROM TWO DIFFERENT PERSPECTIVES,
23	IT WAS TREMENDOUS TO SEE THEIR MUTUAL ENTHUSIASM FOR
24	THIS COMMITMENT TO EMBRYONIC STEM CELL RESEARCH AND
25	SCIENTIFIC FREEDOM.
	_

1	I'M GOING TO ADDRESS THE UPDATE ON THE
2	BOND PROGRAM AS ITEM 10, SO I'M GOING TO KEEP THIS
3	ITEM RELATIVELY SHORT AND MOVE TO THE PRESIDENT'S
4	REPORT.
5	MR. SERRANO-SEWELL: ALONG THOSE LINES OF
6	BEING IN WASHINGTON, D.C., SPEAKING WITH BOARD AND
7	LEGISLATIVE LEADERS, I THOUGHT IT WAS GREAT, BUT WE
8	HAVE PHOTOGRAPHIC EVIDENCE THAT YOU WERE IN
9	WASHINGTON I WANTED TO SHARE WITH EVERYONE IF WE
10	CAN. MAYBE LATER.
11	CHAIRMAN KLEIN: WE HAVE MAYBE THEY
12	COULD FOLLOW THE PRESIDENT'S REPORT WITH THIS. IT
13	WILL BE A SURPRISE TO ME TOO.
14	DR. TROUNSON: WHILE WE'RE WAITING FOR
15	THINGS TO APPEAR, MAYBE I COULD ASK DON GIBBONS FROM
16	WHEREVER HE'S SITTING JUST TO REPORT ON AMENDMENTS
17	TO THE CURRICULUM, THE HIGH SCHOOL CURRICULUM, WHILE
18	WE'RE WAITING FOR MY POWERPOINT TO COME UP, IF
19	THAT'S OKAY.
20	MR. GIBBONS: SO OVER THE PAST FEW WEEKS,
21	I'VE BEEN WORKING WITH SENATOR PRO TEM STEINBERG'S
22	OFFICE AND SENATOR ROMERO'S OFFICE ON A PROJECT TO
23	SEE IF WE CAN'T GET SOME STEM CELL SCIENCE
24	INTEGRATED INTO THE SCHOOL SYSTEM. IT TURNED OUT WE
25	HAD A VERY TINY WINDOW OF OPPORTUNITY. THE
	Q

1	CURRICULUM COMMISSION LOOKS AT THE HIGH SCHOOL K
2	THROUGH 12 CURRICULUM KIND OF LIKE PAINTING THE
3	GOLDEN GATE BRIDGE. THEY START ON ONE END, WORK
4	THROUGH IT, AND THEY START OVER AGAIN, SO THEY GET
5	NEW HISTORY, HUMANITIES, SCIENCE. SO THE SCIENCE
6	PIECE, THE FRAMEWORK WAS VOTED ON YESTERDAY.
7	SO IF WE DIDN'T GET STEM CELLS INTO IT
8	YESTERDAY, WE'D HAVE TO WAIT ANOTHER SIX YEARS. SO
9	SENATOR ROMERO DID SOME PREWORK, I DID SOME PREWORK,
10	WE BOTH TESTIFIED, AND THEY AMENDED THE FRAMEWORK
11	THEY'RE READY TO PASS TO INCLUDE STEM CELLS IN THE
12	CURRICULUM GOING FORWARD.
13	AND I'LL BE BRINGING A REPORT BACK TO YOU
14	NEXT WEEK ON WHAT THAT COULD MEAN FOR CIRM AND HOW
15	WE WOULD BE INVOLVED.
16	CHAIRMAN KLEIN: AND LEGISLATIVE
17	INITIATIVES BY SENATOR ROMERO WILL COME TO THE
18	LEGISLATIVE COMMITTEE SO THAT WE CAN LOOK AT THOSE
19	OPTIONS. WE ALSO HAD THE BENEFIT OF HAVING
20	ASSEMBLYMAN TOM TORLICKSON HERE YESTERDAY AT THE
21	RECEPTION WHO INDICATED ENTHUSIASM AS A FOLLOW-ON TO
22	HIS DISCUSSIONS OF THE LAST YEAR WITH THIS AGENCY
23	ABOUT SEEING WHAT WE COULD DO IN ENERGIZING HIGH
24	SCHOOL STUDENTS THROUGHOUT THE STATE TO GO INTO
25	SCIENCE, PARTICULARLY BIOMEDICAL SCIENCE. SO HE'S

1	GOT SOME VERY INTERESTING PROPOSALS AS WELL, WHICH
2	WE'LL BRING FORWARD AT THAT TIME.
3	DR. POMEROY: I JUST WANTED TO
4	CONGRATULATE DON AND THE TEAM BECAUSE, AS WE ALL
5	REMEMBER, ONE OF THE GOALS THAT WE IDENTIFIED WAS
6	GETTING MORE PUBLIC UNDERSTANDING OF STEM CELL
7	RESEARCH, AND THAT REQUIRES A BASIC SCIENCE
8	UNDERSTANDING AND THINGS LIKE PUTTING THIS INTO THE
9	CURRICULUM. SO THIS IS ACTUALLY DIRECTLY RESPONSIVE
10	TO ONE OF THE PRIORITIES THAT WE'VE TALKED ABOUT,
11	AND I HOPE THAT WE WILL CONTINUE TO HEAR MORE ABOUT
12	IT BECAUSE IT IS ESSENTIAL TO OUR MISSION.
13	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
14	DR. TROUNSON: THANK YOU, CHAIR. AND I
15	THINK DON HAS ACTUALLY DONE A TREMENDOUS JOB ON THE
16	EDUCATION PROGRAM. WE INTEND TO DO MORE IN THAT
17	AREA. I THINK THE MORE WE HAVE OUR COMMUNITY IN
18	SUPPORT THE BETTER, AS CLAIRE SAID.
19	ALSO, JUST IF YOU HAVE HAD A CHANCE TO
20	LOOK AT THE ANNUAL REPORT, WHICH DON WAS RESPONSIBLE
21	FOR, IT'S A FABULOUS DOCUMENT, EASY TO READ,
22	SOMETHING THAT YOU DON'T MIND HAVING AROUND. IT
23	LOOKS REALLY PRETTY, AND THERE'S LOTS OF GOOD
24	INFORMATION IN THERE. SO THANK YOU TO DON AND THANK
25	YOU TO ALL THE STAFF WHO HELPED PUT THAT TOGETHER.

1	CHAIRMAN KLEIN: AND, DR. TROUNSON, I
2	BELIEVE DON ASSIGNED AMY ADAMS THE LEAD ON THAT.
3	WE'VE HAD NUMEROUS CONVERSATIONS WITH AMY. SHE
4	WORKED LATE AT NIGHT, EARLY IN THE MORNING. IT'S A
5	REAL COMMITMENT. SHE'S NOT HERE TODAY FOR US TO
6	GIVE HER A HAND OF APPLAUSE. BUT WHEN YOU DO SEE
7	HER, PLEASE THANK HER FOR HER COMMITTED WORK, REALLY
8	SERIOUSLY COMMITTED WORK UNDER DON'S LEADERSHIP.
9	DR. TROUNSON: THANK YOU. SO, AS USUAL,
10	BEGIN WITH SOME STUDIES WHICH I FEEL I SHOULD DRAW
11	TO YOUR ATTENTION. AND THE FIRST ONE IS A STUDY
12	REPORTED IN <i>NATURE</i> BY THE GROUP FROM GENENTECH UNDER
13	MARC TISSIER-LAVIGNE'S DIRECTION AND ALSO COLLEAGUES
14	AT THE SALK INSTITUTE. THIS IS ON ALZHEIMER'S
15	DISEASE. AND THE QUOTE FROM ED PENHOET IS IT WAS
16	THE BEST PAPER HE EVER READ. SO I ACTUALLY THINK I
17	AGREE WITH HIM. IT'S CERTAINLY ONE OF THE BEST
18	PAPERS THAT I'VE EVER READ. SO IF YOU HAVE AN
19	INTEREST IN THIS AREA, YOU SHOULD FOLLOW THIS STORY
20	ALONG.
21	ALZHEIMER'S DISEASE IS REALLY
22	CHARACTERIZED BY ABUNDANT BETA AMYLOID PRECURSOR
23	PROTEIN, THE THING THEY CALL APP, WHICH RESULTS IN
24	TANGLES AND AGGREGATES, PROTEIN AGGREGATES, IN THE
25	BRAIN. AND SO APP, THIS PROTEIN, AND THE DEATH

	2121111212222 1121 01111 (0 0211 1 0 0
1	RECEPTOR, IT'S A DREADFUL NAME, BUT IT IS A DEATH
2	RECEPTOR 6, THEY ACTIVATE CASPASES. CASPASES ARE
3	RESPONSIBLE FOR CELL DEATH. IF YOU GET ACTIVATION
4	OF CASPASE 6 IN PARTICULAR, YOU WILL GET PAIRING OF
5	THE NEURONS, THE PRONGS, IF YOU LIKE, ON THE NEURONS
6	AND THE AXONS. AND YOU WILL GET DEATH OF PRIMARY
7	NERVES IN THE BRAIN.
8	AND IT'S NORMALLY REQUIRED, THE DEATH
9	RECEPTOR, FOR NORMAL FUNCTION AND PARTICULARLY FOR
10	WHAT THEY CALL AXONAL PRUNING IN DEVELOPMENT, SO
11	IT'S AN IMPORTANT GENE IN DEVELOPMENT. BUT IF IT
12	GOES WRONG, IT'S A REALLY, REALLY DANGEROUS THING TO
13	HAVE ABOUT.
14	SO WHAT THEY'VE DONE IS SHOW THAT THE
15	DEATH RECEPTOR IS ACTIVATED LOCALLY AFTER TROPHIC
16	DEPRIVATION. THAT MEANS THAT THERE'S A LACK OF
17	GROWTH TROPHICS IN THE BRAIN, AND PARTICULARLY
18	BRAIN-DERIVED NEUROTROPHIN, AND THAT TRIGGERS
19	SHEDDING OF A FRAGMENT OFF OF THE APP. SO A SMALL
20	FRAGMENT COMES OFF THAT PROTEIN THAT'S THERE IN
21	ABUNDANCE AND THROUGH CLEAVAGE OF AN AMINO ACID
22	FRAGMENT, AND THAT'S THE THING THAT BINDS TO THE
23	DEATH RECEPTOR AND TRIGGERS THE CASPASE 6 AND THE
24	AXONAL DEGENERATION AND, HENCE, ALZHEIMER'S DISEASE.
25	THIS IS A VERY IMPORTANT OBSERVATION OF

1	BASIC SCIENCE FROM THAT REALLY TERRIFIC GROUP AT
2	GENENTECH AND AT THE SALK.
3	I WANT TO DRAW YOU WHY HAS IT GOT MUCH
4	TO DO WITH STEM CELLS? WELL, THE TROPHIC FACTOR
5	DEPRIVATION REALLY IS THE LACK, AS I SAID, OF BDNF,
6	THIS BRAIN-DERIVED NEUROTROPHIC FACTOR. IF YOU CAN
7	REMEMBER THE TALK THAT WAS GIVEN TO US BY FRANK
8	LAFERLA FROM IRVINE, HE SHOWED THAT EMBRYONIC STEM
9	CELL-DERIVED CELLS, WHEN THEY'RE TRANSPLANTED INTO
10	THE BRAIN, REVERSE THE BEHAVIORAL CHARACTERISTICS,
11	THE DEFICITS IN ALZHEIMER'S DISEASE, BUT DIDN'T
12	CHANGE THE TANGLES OR AGGREGATES, AND THEN HE WENT
13	TO SHOW THAT, IN FACT, HE'D GET PRETTY MUCH THE SAME
14	RESPONSE FROM THE BDNF, INJECTION OF THE BDNF INTO
15	THE VENTRICLES OF AN ANIMAL WITH ALZHEIMER'S
16	DI SEASE.
17	SO NOW I'M CONNECTING THESE TWO THINGS
18	TOGETHER FOR YOU. SO THE STEM CELL RESEARCH ON ONE
19	HAND THAT WE'VE BEEN SUPPORTING AND THIS BEAUTIFUL
20	WORK FROM TESSIER-LEVIGNE, I THINK, IS REALLY GOING
21	TO BE A LANDMARK IN THIS DISEASE. SO EITHER THROUGH
22	GROWTH FACTOR TREATMENT OR MAYBE CELL THERAPIES, I
23	THINK WE MIGHT EXPECT SOME INCREASED INTEREST, VERY
24	MUCH INCREASED INTEREST FOR CLINICAL TRIAL WORK IN
25	THIS AREA.
	1.4

1	AND I KNOW MEMBERS OF THE BOARD AND THE
2	PUBLIC ARE ALWAYS INTERESTED IN ALZHEIMER'S DISEASE,
3	DREADFUL DISEASE. ANYTHING OF THIS SUBSTANCE, I
4	THINK, I SHOULD DRAW TO YOUR ATTENTION. BUT IN
5	PARTICULAR, HOW IT CONNECTS WITH WHAT WE'RE DOING
6	AND WHAT WE'RE SUPPORTING. NEXT SLIDE.
7	SO I'VE JUST GIVEN YOU A CARTOON IN THERE.
8	YOU'VE GOT THE APP, THE BIG MOLECULE, OFF IT COMES
9	THAT SMALL BLUE MOLECULE, AND UNDER THIS GROWTH
10	FACTOR DEPRIVATION, IT BINDS TO THE DEATH RECEPTOR
11	6, ACTIVATES THE CASPASE 6S, WHICH THEN GO IN AND
12	START DESTROYING PARTICULARLY THE AXONS AND
13	DENDRITES AND NEURONS LEADING TO ALZHEIMER'S
14	DISEASE. WITH APOLOGIES TO SOME BEAUTIFUL SCIENCE,
15	I THREW THAT IN JUST TO HELP. SORRY, TED. YES.
16	DR. LOVE: WEREN'T THEIR CLINICAL TRIALS
17	INJECTING BDNF INTO THE BRAIN?
18	CHAIRMAN KLEIN: IF YOU COULD, TED, DR.
19	LOVE, SPEAK INTO THE MICROPHONE, IT WILL HELP THE
20	TRANSCRI PTI ON.
21	DR. LOVE: I JUST WANTED, ALAN, DID THE
22	PAPER TALK ABOUT THE CLINICAL TRIALS THAT USED BDNF?
23	DR. TROUNSON: NO, THEY DIDN'T. THEY
24	DIDN'T CONNECT THE TWO, SO I'M CONNECTING IT FOR
25	YOU. THEY DIDN'T CONNECT IT, BUT IT JUST SEEMS SO
	15

1	OBVIOUS THE CONNECTION WITH BDNF FROM THE LAFERLA
2	STUDY.
3	DR. PENHOET: LAFERLA'S WORK HAS NOT BEEN
4	PUBLI SHED YET.
5	DR. TROUNSON: THERE'S ED, IS IT? THANK
6	YOU, ED. I THINK THAT'S CORRECT, BUT IT WAS GIVEN
7	HERE AS FRANK SPOKE TO US AS A GROUP HERE.
8	DID I QUOTE YOU CORRECTLY, ED?
9	DR. PENHOET: YES.
10	DR. TROUNSON: SO ANOTHER STUDY WHICH I
11	THINK IS REALLY IMPORTANT IS A PAPER, AGAIN,
12	PUBLISHED IN MARCH IN <i>NATURE</i> ON WHAT THEY CALL
13	PIGGYBAC TRANSPOSITION OR TRANSPOSON, WHICH IS
14	CALLED PIGGYBAC. THESE MOLECULES REALLY ENTER THE
15	GENOME VERY READILY. THEY ENTER AND THEY EXIT
16	REALLY READILY. AND SO WHAT THEY'VE DONE HERE IS IN
17	THE IPS AREA IS TO USE PIGGYBAC TRANSPOSON OR
18	TRANSPOSITION TO TAKE IN THOSE TRANSCRIPTION FACTORS
19	THAT ACTUALLY REPROGRAM AN ADULT SKIN CELL TO AN
20	EMBRYONIC STEM CELL-LIKE CELL. SO THEY CAN ACTUALLY
21	DO THAT WITH THIS TRANSPOSITION. THEY TAKE IT IN.
22	WHAT'S INTERESTING IN THIS PAPER IS THAT
23	THEY'VE GOT IT UNDER AN INDUCIBLE SYSTEM. SO IF YOU
24	ADD DOXYCYCLINE, IT TURNS ON THE GENE. SO NOW
25	YOU'VE GOT BEAUTIFUL REGULATING AND TURN ON THE GENE

1	FOR AS LONG AS YOU LIKE AND THEN TURN IT OFF. BUT
2	MORE IMPORTANTLY, I THINK, OR JUST AS IMPORTANTLY,
3	YOU ARE GOING TO EXCISE THE WHOLE THING. SO BECAUSE
4	IT'S A TRANSPOSON, IT'S EASILY EXCISED. YOU CAN
5	TAKE IT OUT. SO AFTER YOU'VE TURNED THE CELLS INTO
6	EMBRYONIC STEM CELL-LIKE PLURIPOTENTIAL CELLS, YOU
7	CAN GET RID OF THE VIRAL ELEMENTS IN THE EXOGENOUS
8	GENES. THIS IS WHAT WE'VE BEEN LOOKING FOR, SOME
9	WAY IN WHICH TO REMOVE THOSE ELEMENTS BECAUSE
10	CLEARLY NO REGULATORY BODY OR NONE THAT I KNOW OF
11	WOULD BE HAPPY ABOUT THOSE ELEMENTS IN CLINICAL
12	WORK.
13	SO THIS IS VERY IMPORTANT TECHNOLOGY.
14	WHETHER IT'S THE ONE THAT WILL BE EVENTUALLY USED IN
15	THIS WAY, I DON'T KNOW. BUT IT'S VERY CLEVER
16	MOLECULAR SCIENCE, AND I THINK IT'S BEEN NOTED
17	AMONGST SCIENTISTS AS A VERY IMPORTANT STUDY. SO I
18	THOUGHT YOU SHOULD BE AWARE OF IT.
19	IT'S ALSO A GROUP IN GERMANY HANS SCHOLAR,
20	WHO HANS WOULD LOVE TO WORK ON HUMAN EMBRYONIC STEM
21	CELLS, BUT HASN'T EVER BEEN ALLOWED, BUT HE DOES
22	BEAUTIFUL WORK ON THE MOUSE. HE'S ONE OF THE
23	WORLD'S BEST SCIENTISTS. AND HE'S JUST DEMONSTRATED
24	THAT YOU CAN USE YOU ONLY NEED ONE TRANSCRIPTION
25	FACTOR, OCT-4, TO PUT INTO NEURAL STEM CELLS TO TURN

1	THEM INTO IPS CELLS. I THINK THAT'S EXTREMELY
2	INTERESTING BECAUSE IT SETS NEURAL STEM CELLS APART
3	FROM MOST OTHER CELL TYPES. AND I THINK IT'S A VERY
4	NICE PIECE OF WORK PUBLISHED IN THE JOURNAL CELL.
5	THERE'S ALSO NOT A SAD STORY, ONE WHICH IS
6	NOT A GOOD STORY THAT WAS PUBLISHED IN THE JOURNAL
7	PLOS, AND IT IS A REPORT OF TUMORS AFTER FETAL
8	NEURAL TRANSPORTS. THIS WORK WAS DONE IN RUSSIA.
9	THIS CLINICAL WORK DONE IN RUSSIA. YOU WILL
10	RECOGNIZE THAT RUSSIA IS ONE OF THOSE PLACES WHICH
11	IS NOT WELL REGULATED FOR MEDICAL RESEARCH. IN
12	FACT, IT'S NOT REGULATED MUCH AT ALL.
13	AND THERE ARE A LOT OF PATIENTS WHO TRAVEL
14	TO RUSSIA AND OTHER PLACES FOR MEDICAL TOURISM, AND
15	I CAN COMPLETELY UNDERSTAND WHAT DRIVES PARENTS TO
16	DO THAT, BUT IT'S USUALLY NOT A GOOD THING TO DO
17	BECAUSE, AS IN THIS CASE, WE'RE NOT REALLY SURE WHAT
18	SORT OF CELLS OR WHAT THE PREPARATION OF THE CELLS
19	WERE, BUT THEY WERE NEURAL STEM CELLS THAT WERE
20	GIVEN TO THIS YOUNG BOY WITH ATAXIA, SERIOUS ATAXIA
21	GENETIC DISEASE. AND THE OUTCOME WAS TUMORS, AND
22	TUMORS FROM AT LEAST TWO OF THE DONOR CELL TYPES, SO
23	THERE WAS AT LEAST TWO DONORS INVOLVED, TWO FETAL
24	NEURON DONORS, AND THE OUTCOME IS VERY DISAPPOINTING
25	BECAUSE TUMORS, IN AN ATTEMPT TO CORRECT THIS

1	DISEASE, TUMORS IN BOTH THE SPINAL COLUMN AND THE
2	BRAIN. AND THOSE TUMORS ARE DONOR RELATED.
3	NOW, WE'VE NEVER SEEN THIS, AND I DON'T
4	RECALL SEEING ANY OF THIS HAPPENING WHEN FETAL BRAIN
5	CELLS WERE INJECTED IN A RAFT OF OTHER STUDIES
6	BEFOREHAND, NOR OF THE KIND OF STUDIES THAT ARE
7	BEING DONE FOR BATTEN'S DISEASE. SO I THINK THIS IS
8	A CONCERN. IT TELLS THAT THERE ARE RISKS OUT THERE.
9	THE RISKS ARE NOT KNOWING EXACTLY WHAT ARE BEING
10	USED, BUT ALSO THEY MAY HAVE BEEN NEURAL STEM CELLS,
11	AND WE MAY HAVE SEEN SOMETHING THAT WE SHOULD BE
12	CONCERNED ABOUT.
13	I BRING THAT TO YOUR ATTENTION BECAUSE I
14	THINK IT'S A SERIOUS ISSUE. IT'S ONE WHICH IS
15	APPARENTLY ADDITIONAL EXAMPLES HAVE HAPPENED FROM
16	CANADA WHERE YOUNG PEOPLE HAVE GONE TO TREATMENT IN
17	RUSSIA AS WELL. NOW, I DON'T KNOW IF THIS IS
18	BECAUSE THERE'S A LOT MORE TREATMENT BEING DONE IN
19	RUSSIA OR WHETHER THE PROCESS OR THE PROCEDURES ARE
20	NOT APPROPRIATE. BUT THE RISKS IN THESE AREAS ARE
21	SUBSTANTIAL, AND WE NEED TO BE CAREFUL. AND VERY
22	IMPORTANTLY WE NEED TO UNDERSTAND WHAT'S HAPPENING
23	WHEN WE DO GIVE PATIENTS THESE CELLS.
24	SO I THINK IT'S NOT A GOOD STORY. THE
25	CHILD IS OKAY, BECAUSE THEY'RE SOLID TUMORS, AND
	10

1	THEY'VE LEFT THEM IN PLACE AT THIS STAGE OR TAKEN
2	SAMPLES OF SOME OF THEM, BUT IT'S JUST NOT A GOOD
3	OUTCOME.
4	I ALSO HAD THE CHANCE OF VISITING THE
5	GROUP AT SCRIPPS AT NOVARTIS RESEARCH INSTITUTE AS
6	WELL. I HAVE TO REPORT TO YOU THAT IT'S AN
7	ASTONISHING PLACE. SOMETIME YOU OUGHT TO GO THERE,
8	AND I PICKED UP ONE OF THEIR PAPERS. THEY'VE GOT A
9	LARGE RAFT OF PAPERS. WHAT THIS GROUP IS DOING IS
10	TAKING ALL OF THE ASSAYS THAT HAVE BEEN DEVELOPED BY
11	STEM CELL RESEARCH TEAMS AROUND THE COUNTRY,
12	PARTICULARLY IN CALIFORNIA, AND THEY'RE USING THESE
13	ASSAYS TO SCREEN SMALL MOLECULAR LIBRARIES. THESE
14	ARE THE LIBRARIES WHICH ARE REALLY KEY TO
15	IDENTIFYING NEW CANDIDATE DRUGS.
16	AND THEY'VE FOUND A RAFT OF THESE THINGS,
17	AND I POINT TO YOU THIS PAPER BECAUSE IT'S GOING TO
18	BE ONE OF MANY. SO THIS IS WORK THAT'S BEING DONE
19	BY PETE SCHULTZ AND HIS COLLEAGUES IS ASTONISHING.
20	THERE'S GOING TO BE A LOT OF NEW CANDIDATE DRUGS
21	APPEAR FOR EXPANSION OF STEM CELL TYPES FOR DRIVING
22	CELLS INTO DIFFERENTIATION PROGRAMS, IN THIS CASE
23	TOWARDS THE BETA CELL EXPANSION, BUT THEY'VE GOT
24	WORK ON HEMATOPOETIC STEM CELLS AND THEN CARDIAC
25	DIFFERENTIATION OF CARDIAC CELLS FROM HUMAN
	20

1	EMBRYONIC STEM CELLS.
2	THERE'S GOING TO BE A RAFT OF REALLY
3	IMPORTANT WORK FLOW FROM THERE. HERE IS ANOTHER
4	LINK, IF YOU LIKE, BETWEEN THE WORK THAT WE'VE BEEN
5	SUPPORTING AND SOME FANTASTIC WORK THAT'S COMING OUT
6	OF THAT PARTICULAR GROUP. AND I THINK YOU NEED TO
7	RECOGNIZE IT BECAUSE IT WILL PROBABLY BE THE FRONT
8	END, I THINK, OF SOME OF THE CLINICAL TRIAL WORK
9	THAT WILL COME THROUGH THESE SMALL MOLECULE
10	CANDIDATES. VERY, VERY IMPRESSIVE.
11	SO WHAT HAVE WE BEEN DOING ESSENTIALLY IN
12	STIMULATING THE RESEARCH IN CALIFORNIA? I GOT THE
13	STAFF TO TAKE A LOOK AT THE NUMBER OF PUBLICATIONS
14	AND PROPORTION OF PUBLICATION BY YEAR, AND YOU CAN
15	SEE HERE ON THE X AXIS, THE LOWER AXIS IS YEAR, ON
16	THE Y AXIS THE NUMBER OF PUBLICATIONS. YOU CAN SEE
17	THAT THE NUMBER OF PUBLICATIONS IN STEM CELLS AND IN
18	HUMAN EMBRYONIC STEM CELLS IS RISING IN CALIFORNIA.
19	AND WE'D EXPECT THAT TO CONTINUE TO STRONGLY RISE.
20	THIS IS IN RESPONSE TO CIRM AND THE FUNDING OF THESE
21	REALLY TOP-LINE SCIENTISTS HERE IN CALIFORNIA.
22	IF YOU LOOK AT AS A PERCENTAGE OF U.S.
23	PUBLICATIONS, AGAIN, YOU CAN SEE CALIFORNIA REALLY
24	TAKING OFF IN THE HUMAN EMBRYONIC STEM CELL AREA.
25	AND THAT'S OBVIOUSLY THE STIMULUS THAT CAME FROM THE

1	EARLY SEED GRANTING, BUT ALSO THE STEM CELL
2	PROPORTION OF PUBLICATIONS RISING. AND IN THE NEXT
3	ONE, THIS IS THE PERCENTAGE OF TOTAL PUBMED
4	PUBLICATIONS. THAT'S THE WHOLE WORLD. AND YOU CAN,
5	AGAIN, SEE HOW CALIFORNIA IS RISING IN BOTH STEM
6	CELLS AND HUMAN EMBRYONIC STEM CELLS BECAUSE THESE
7	ARE THE PAPERS WHICH WERE IDENTIFIED WITH STEM CELLS
8	OR HUMAN EMBRYONIC STEM CELLS IN THE TITLE.
9	WE ARE STIMULATING VERY STRONGLY
10	PUBLICATIONS AND PARTICULARLY PUBLICATIONS IN THE
11	TOP-LINE JOURNALS. AND SO I THINK IT IS A MESSAGE
12	OF PRODUCTIVITY THAT'S COMING VERY STRONGLY AS A
13	RESULT OF THE STIMULUS OF OUR RESEARCH TEAMS.
14	THE NEW PERSONNEL AT THE INSTITUTE, KELLY
15	SHEPARD IS A SCIENCE OFFICER. SHE COMES FROM
16	PARALLEL SYNTHESIS TECHNOLOGIES. AND REBECCA
17	JORGENSON IS A NEW SCIENCE OFFICER WHO'S COME FROM
18	THE NIH, BOTH EXTREMELY WELCOME TO HAVE ON BOARD.
19	MY PRIORITIES, BRIEFLY, REVISION OF THE
20	STRATEGIC PLAN. WE'VE HAD MEETINGS WITH INDUSTRY,
21	AND YESTERDAY WE COMPLETED THE MEETINGS IN THE
22	PUBLIC. THANKS TO JEFF AND TO MICHAEL FOR HELPING
23	CHAIR THOSE PUBLIC SESSIONS. THEY WERE TERRIFIC.
24	AND TO ED FOR CHAIRING THE INDUSTRY SESSIONS, GREAT.
25	IT WAS VERY USEFUL AND VERY INTERESTING TO HAVE THE

2	WE'VE HAD A LOT OF CAPABILITY MEETINGS
_	
3	WITH BOTH COMMERCIAL GROUPS AND INSTITUTIONS. WE'VE
4	BEEN PLANNING AHEAD FOR THE FINANCIAL AND STRATEGIC
5	ADJUSTMENTS FOR OUR ACTIVITIES.
6	WE'VE BEEN FOCUSING ON AUTISM
7	OPPORTUNITIES FOR CIRM. I'LL GET MARIE TO BRIEFLY
8	DISCUSS THAT IN A MOMENT. AND WE'VE BEEN EXAMINING
9	OPPORTUNITIES IN THE SMALL MOLECULAR DISCOVERIES
10	THAT I'VE JUST TOLD YOU ABOUT. ALSO DEVELOPING
11	NETWORKS IN U.S. SCIENCE AND INDUSTRY. WE THINK
12	THAT THESE NETWORKS ARE EXTREMELY IMPORTANT, SO ARE
13	NETWORKING WITH FDA, NIH, BUT MANY DIFFERENT
14	ORGANIZATIONS IS INCREASING. AND I THINK WE SEE
15	PARTNERSHIPS AS BEING VERY IMPORTANT FOR US, NOT
16	ONLY AROUND THE WORLD, BUT ALSO THROUGHOUT THE U.S.
17	GRANT REVIEWS COMPLETED, THE EARLY
18	TRANSLATIONAL RESEARCH WAS COMPLETED AT THE GRANTS
19	WORKING GROUP IN FEBRUARY. IT WILL COME IN APRIL TO
20	THE ICOC FOR CONSIDERATION AND APPROVAL, IF
21	APPROPRI ATE.
22	UPCOMING RFA'S IS A BASIC RESEARCH
23	INITIATIVE. AGAIN, THE RFA IS RELEASED. WE'RE AT
24	THE MOMENT LOOKING AT THE PRELIMINARY ALLOCATION TO
25	OUTCOME. I THINK THERE WERE ABOUT 135 APPLICATIONS
	23
112 113 114 115 116 117 118 119 220 221 222 223	THAT THESE NETWORKS ARE EXTREMELY IMPORTANT, SO ARE NETWORKING WITH FDA, NIH, BUT MANY DIFFERENT ORGANIZATIONS IS INCREASING. AND I THINK WE SEE PARTNERSHIPS AS BEING VERY IMPORTANT FOR US, NOT ONLY AROUND THE WORLD, BUT ALSO THROUGHOUT THE U.S. GRANT REVIEWS COMPLETED, THE EARLY TRANSLATIONAL RESEARCH WAS COMPLETED AT THE GRANTS WORKING GROUP IN FEBRUARY. IT WILL COME IN APRIL TO THE ICOC FOR CONSIDERATION AND APPROVAL, IF APPROPRIATE. UPCOMING RFA'S IS A BASIC RESEARCH INITIATIVE. AGAIN, THE RFA IS RELEASED. WE'RE AT THE MOMENT LOOKING AT THE PRELIMINARY ALLOCATION TO OUTCOME. I THINK THERE WERE ABOUT 135 APPLICATIONS

1	RECEIVED FOR THIS INITIATIVE. WE'RE EXPECTING THE
2	GRANTS WORKING GROUP REVIEW IN JUNE, AND IT WILL
3	COME TO THE ICOC IN AUGUST.
4	THE DISEASE TEAM RESEARCH AWARDS, WHICH
5	EVERYBODY IS TALKING ABOUT THROUGHOUT CALIFORNIA,
6	INDEED THE WORLD, THAT'S BEEN RELEASED IN FEBRUARY.
7	THE PREAPPLICATIONS ARE TO BE WITH US IN MARCH, THIS
8	MONTH, SO THEY'RE ABOUT TO ARRIVE. THE GRANTS
9	WORKING GROUP REVIEW WILL BE IN SEPTEMBER AND ICOC
10	APPROVAL IN THE FALL.
11	SO LOT OF WORK COMING UP FOR ALL OF US,
12	BUT IT'S GOING TO BE REALLY, REALLY INTERESTING WHEN
13	WE GET TO THE DISEASE TEAMS.
14	I WANT TO TALK TO YOU ABOUT THE BUDGET
15	ALLOCATION AND EXPENDITURE REPORT. WE DO THIS
16	MONTHLY, IF I CAN HAVE THE NEXT SLIDE. THIS IS OUR
17	INTERNAL REPORT. WE GIVE IT TO YOU MONTHLY.
18	MARGARET UNFORTUNATELY IS ILL, SO I'M GIVING IT TO
19	YOU HERE. I THINK WE'RE WELL BELOW BUDGET RIGHT
20	ACROSS THE BOARD. I THINK THAT'S WHAT YOU EXPECT US
21	TO BE IN THIS CURRENT ENVIRONMENT.
22	SO AS A PERCENTAGE OF BUDGET ALLOCATED,
23	THE FAR COLUMN SHOWS WHAT THE ALLOCATION IS TO THE
24	END OF JANUARY. SO WE'RE WELL AND A TRULY BELOW 50
25	PERCENT, SO WE WOULD BE WELL AND TRULY UNDER BUDGET.

1	THERE ARE MORE EXPENDITURES IN THE SECOND
2	HALF OF THE YEAR, BUT I REPORT TO YOU THAT WE'RE
3	SAILING VERY EVENLY. AND THANKS TO MICHAEL GOLDBERG
4	FOR KEEPING AN EYE ON THESE MATTERS FOR US AS WELL.
5	AN AUDIT REPORT THAT'S GOING TO COME THIS
6	MORNING, IF THE AUDITORS ARE HERE. CHAIR, DO YOU
7	WANT A BRIEF AT THIS POINT?
8	CHAIRMAN KLEIN: YES, IF YOU COULD PLEASE
9	PROCEED. I BELIEVE AUDITORS ARE PRESENT.
10	DR. TROUNSON: ARE THEY HERE? THE BOARD
11	MEMBERS HAVE THE AUDITOR'S REPORT.
12	MS. WALKER-DAVY: GOOD MORNING. MY NAME
13	IS SHELLY WALKER-DAVY. I'M AN AUDIT MANAGER AT
14	MACIAS, GINI & O'CONNELL, AND I'M THE AUDITOR IN
15	CHARGE OF THE CIRM FINANCIAL AUDIT.
16	I ASSUME YOU EACH HAVE THE TWO PRODUCTS
17	THAT WE PROVIDE AS A RESULT OF OUR AUDIT. BEFORE I
18	BEGIN, I'D LIKE THANK YOU FOR HAVING US SERVE AS
19	YOUR AUDITORS THIS YEAR AND I GUESS A NEW CONTRACT.
20	AND I'D LIKE TO THANK THE STAFF AT CIRM FOR THE
21	COURTESLES THEY EXTENDED TO OUR STAFF DURING THE
22	FIELD WORK. IT WAS VERY HELPFUL.
23	I'M GOING TO START WITH THE REPORT TO THE
24	BOARD. IT'S THE SMALLER OF THE TWO REPORTS. I'M
25	GOING TO BRIEFLY GO OVER BOTH OF THESE; AND IF YOU
	25

1	HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM.
2	THE REPORT TO THE BOARD DEFINES OUR
3	RESPONSIBILITIES. AND OUR RESPONSIBILITY AS
4	AUDITORS IS TO GATHER ENOUGH EVIDENCE TO EXPRESS AN
5	OPINION ON THE FINANCIAL STATEMENTS PREPARED BY
6	MANAGEMENT THAT ARE FREE FROM MATERIAL MISSTATEMENT
7	AND THEY'RE FAIRLY PRESENTED. IN OUR PLANNING OF
8	OUR AUDIT, WE CONSIDER CIRM'S INTERNAL CONTROLS OR
9	FINANCIAL REPORTING AS A BASIS OF OUR AUDIT
10	PROCEDURES, BUT NOT FOR THE PURPOSE OF EXPRESSING AN
11	OPINION ON THOSE INTERNAL CONTROLS.
12	ON PAGE 1 THERE IS A DEFINITION OF THREE
13	TYPES OF DEFICIENCIES THAT WE CONSIDERED DURING OUR
14	AUDIT. THE FIRST IS THE CONTROLLED EFFICIENCY WHICH
15	IS MOST LENIENT OF THE THREE. IT MEANS THAT DURING
16	THE COURSE OF NORMAL BUSINESS PROCEDURES, MANAGEMENT
17	DID NOT DETECT OR PREVENT ANY KIND OF MISSTATEMENT
18	RELATED TO THE FINANCIAL STATEMENTS. THE SECOND
19	WOULD BE THE SIGNIFICANT DEFICIENCY. THAT MEANS AS
20	A COMBINATION OF CONTROLLED DEFICIENCIES THAT MIGHT
21	AFFECT THE ENTITY'S ABILITY TO AUTHORIZE, RECORD, OR
22	PROCESS FINANCIAL REPORTING ESTIMATES. AND THERE'S
23	A LIKELIHOOD THAT THERE BE A MISSTATEMENT IN THE
24	FINANCIAL STATEMENTS AS A RESULT. THE THIRD WOULD
25	BE A MATERIAL WEAKNESS, WHICH IS A SIGNIFICANT

1	DEFICIENCY OR COMBINATION OF SIGNIFICANT
2	DEFICIENCIES THAT RESULT IN A REMOTE MORE THAN
3	REMOTE LIKELIHOOD THERE WOULD BE A MISSTATEMENT IN
4	THE FINANCIAL STATEMENTS AND WOULD NOT BE PREVENTED
5	OR DETECTED BY ANY OF THE CONTROLS THAT THE ENTITY
6	MAY HAVE.
7	WE'RE PROUD TO SAY THAT WE DID NOT
8	IDENTIFY ANY SUCH DEFICIENCIES DURING THE COURSE OF
9	OUR AUDIT.
10	I'M GOING TO MOVE ON TO SOME OF THE
11	REQUIRED COMMUNICATIONS THAT WE DO AS PART OF THIS
12	REPORT. I'M GOING TO MOVE TO PAGE 3. MANAGEMENT IS
13	RESPONSIBLE FOR SELECTING THE ACCOUNTING POLICIES
14	USED BY CIRM. DURING THE COURSE OF THE AUDIT, WE
15	NOTED NO TRANSACTIONS ENTERED IN BY CIRM DURING THE
16	YEAR THAT LACKED GUIDANCE OR CONSENSUS. WE DID NOT
17	HAVE ANY DIFFICULTIES IN DEALING WITH MANAGEMENT.
18	(INTERRUPTION IN PROCEEDINGS.)
19	CHAIRMAN KLEIN: IF WE COULD GET ONE OF
20	MEMBERS THAT'S ON THE PHONE TO MUTE THEIR PHONE IF
21	THEY'RE GOING TO BE AWAY FROM THEIR PHONE FOR A
22	MOMENT. WE'RE GETTING FEEDBACK OF SIGNIFICANCE.
23	THANK YOU.
24	MS. WALKER-DAVY: WE DID NOT ENCOUNTER ANY
25	SIGNIFICANT DEALING DIFFICULTIES IN OUR DEALINGS

1	WITH MANAGEMENT DURING THE COURSE OF OUR AUDIT. WE
2	ALSO DEFINE AND EXPLAIN ANY CORRECTED OR UNCORRECTED
3	MISSTATEMENTS. OUR PROFESSIONAL STANDARDS REQUIRE
4	THAT WE ACCUMULATE ALL KNOWN AND LIKELY
5	MISSTATEMENTS IDENTIFIED DURING THE AUDIT, AND THOSE
6	ARE EITHER TRIVIAL OR COMMUNICATED TO THE
7	APPROPRIATE LEVEL OF MANAGEMENT. MANAGEMENT HAS
8	CORRECTED ALL SUCH MISSTATEMENTS. IN ADDITION, NONE
9	OF THE MISSTATEMENTS THAT WERE DETECTED AS A RESULT
10	OF OUR AUDIT PROCEDURES AND CORRECTED BY MANAGEMENT
11	WERE MATERIAL EITHER INDIVIDUALLY OR IN AGGREGATE TO
12	THE FINANCIAL STATEMENTS TAKEN AS A WHOLE.
13	WE DID NOT EXPERIENCE ANY DISAGREEMENTS
14	WITH MANAGEMENT DURING THE AUDIT. AND IN SOME CASES
15	MANAGEMENT MAY DECIDE TO CONSULT ACCOUNTANTS DURING
16	THE AUDIT ON ACCOUNTING MATTERS SIMILAR TO OPINION
17	SHOPPING IN CERTAIN CIRCUMSTANCES. DURING OUR AUDIT
18	AND TO OUR KNOWLEDGE, NO SUCH CONSULTATIONS
19	OCCURRED.
20	AND FINALLY, GENERALLY WE WOULD DISCUSS
21	ANY MATTERS THAT CAME UP, ANY RECOMMENDATIONS
22	PERHAPS, ANY BEST PRACTICES DURING THE COURSE OF OUR
23	AUDIT. THAT WOULD BE IN THIS LAST SECTION. AND
24	WE'RE PLEASED TO SAY WE DID NOT HAVE ANY
25	RECOMMENDATIONS OR AUDIT FINDINGS AS A RESULT OF OUR

1	AUDI T.
2	SO I'M GOING TO GO OVER TO THE FINANCIAL
3	STATEMENT. I KNOW YOU WENT OVER THE BUDGET AND
4	WHATNOT, SO JUST GENERALLY SPEAKING, THE SIGNIFICANT
5	CHANGES FROM THE PRIOR YEAR TO THIS YEAR WOULD BE,
6	OF COURSE, THE BOND REVENUE RECEIVED, THE \$250
7	MILLION. AND, OF COURSE, REPAYMENT OF THE BONDS AND
8	THE BOND ANTICIPATION NOTES FROM THE PRIOR YEAR WERE
9	REPAID DURING THE YEAR. THAT WAS ONE OF THE LARGEST
10	OUTFLOWS. ALSO, YOUR RESEARCH GRANTS OF 261 MILLION
11	AND THE INCREASE IN STATE OPERATIONS AS CIRM SORT OF
12	BEGINS TO GROW AND EXPAND. AND THEN THE LARGEST
13	REVENUE ALSO INCLUDES INTEREST INCOME OF ABOUT \$10
14	MI LLI ON.
15	SO THOSE ARE THE INFLOWS AND THE OUTFLOWS.
16	DOES ANYBODY HAVE ANY OTHER QUESTIONS? ALL RIGHT.
17	THANK YOU VERY MUCH.
18	CHAIRMAN KLEIN: THANK YOU. WE REALLY
19	APPRECIATE YOUR STAFF'S HELP. AND MY UNDERSTANDING
20	IS THAT FOR NEXT YEAR, DR. ROBSON, WE HAVE A
21	SCHEDULE SET UP SO THAT OUR GOAL IS FOR THESE AUDITS
22	TO BE MOVED ON A PACE THAT WILL ALLOW US TO HAVE AN
23	OVERSIGHT COMMITTEE MEETING IN NOVEMBER OR DECEMBER.
24	IS THAT A CORRECT STATEMENT?
25	DR. ROBSON: THAT'S RIGHT.

	CHALDMAN WITH AND MY DELLEF LC THAT
1	CHAIRMAN KLEIN: AND MY BELIEF IS THAT
2	IT'S ALREADY BEEN BOOKED WITH THE AUDITORS TO
3	ACHI EVE THAT SCHEDULE.
4	DR. ROBSON: I THINK SO. MARGARET
5	FERGUSON HAS BEEN SCHEDULING THAT, BUT I THINK SHE
6	HAS, YES.
7	CHAIRMAN KLEIN: AND ADDITIONALLY, THERE'S
8	A CRITICAL PATH SUBSCHEDULE TO DEAL WITH THE
9	CONTROLLER'S REVIEW. SO I THINK WE HAVE SOME FAIRLY
10	ADVANCED PLANNING IN PLACE THAT'S VERY HELPFUL.
11	THANK YOU VERY MUCH.
12	DR. TROUNSON: THANK YOU.
13	DR. LOVE: WHAT ARE OUR AUDITING FEES?
14	DR. TROUNSON: WHAT ARE THE AUDIT FEES? I
15	DON'T KNOW THAT OFFHAND.
16	CHAIRMAN KLEIN: OUR AUDITOR IS IN THE
17	BACK THERE. COULD YOU TELL US THE DOLLAR AMOUNT OF
18	THE AUDITING FEES?
19	DR. TROUNSON: AUDIT FEES.
20	MS. WALKER-DAVY: I'M SORRY. I WAS ALMOST
21	OUT THE DOOR. IT SEEMS TO ME THEY'RE ABOUT 55,000,
22	I THINK. THEY HAVE A SMALL INCREMENT EVERY YEAR.
23	DR. LOVE: FOR THAT LEVEL OF FEES, MY
24	SUSPICION IS THAT THE LEVEL OF AUDITING THAT'S GOING
25	ON IS CONSIDERABLY LOWER THAN A PUBLIC COMPANY
	30

1	MEETING 404.
2	MS. WALKER-DAVY: ACTUALLY WE DO CONSIDER
3	A LOT OF THE INTERNAL CONTROLS AND USE SIMILAR
4	PROGRAMS TO DOCUMENT INTERNAL CONTROLS BECAUSE WE
5	HAVE NEW STANDARDS THAT REQUIRE WE DO THAT. SO IN
6	TERMS OF DOCUMENTING, 404 REFERS TO THE
7	SARBANES-OXLEY IN PARAGRAPH 404, AND SPECIFICALLY
8	FRAUD AND INTERNAL CONTROL DOCUMENTATION. SO WE
9	DEAL WITH THAT BECAUSE WE HAVE STANDARDS THAT
10	REQUIRE IT, SO THAT IS MOST OF IT.
11	WHEN YOU REFER TO A LARGE COMPANY, YOU'RE
12	PROBABLY REFERRING TO AN ORGANIZATION THAT HAS
13	SEVERAL THOUSANDS OF TRANSACTIONS EVERY MONTH. AND
14	THIS ORGANIZATION JUST ISN'T AS BIG AS THAT. SO THE
15	TIME NECESSARY TO GATHER THE EVIDENCE IS LESS
16	BECAUSE THERE'S NOT AS MANY TRANSACTIONS. BUT IN
17	TERMS OF DOCUMENTING, WHAT IS REQUIRED FOR OUR
18	STANDARDS, IT SHOULD BE THE SAME AS ANY OTHER
19	CORPORATION OR ORGANIZATION.
20	DR. LOVE: THANK YOU.
21	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
22	DR. TROUNSON: SO IN ADDITION, THE BOARD
23	ASKED US ON THE LAST OCCASION TO GIVE YOU SOME
24	INFORMATION ON TRAVEL. AND THAT'S IN YOUR
25	DOCUMENTS. SO PLEASE, THOSE THAT ARE INTERESTED IN

1	THAT ITEM, YOU WILL FIND THAT IN THE DOCUMENT.
2	BINDER TAB 9, MELISSA TELLS ME.
3	SO IF I COULD NOW HAND OVER TO DR. CSETE.
4	DR. CSETE: MR. CHAIRMAN AND MEMBERS OF
5	THE BOARD AND MEMBERS OF THE PUBLIC, WE'RE HAPPY TO
6	ANNOUNCE THAT WE'RE WELL INTO OUR PLANNING OF AN
7	AUTISM WORKSHOP FOR MAY 28TH AND 29TH. AS YOU KNOW,
8	WE HAVE BEEN ORGANIZING WORKSHOPS DURING THE LAST
9	YEAR TO BRING IN EXPERTS FROM A VARIETY OF FIELDS TO
10	GIVE US ADVICE ABOUT WHERE THE FIELD IS,
11	STATE-OF-THE-ART, AND ADVISE US ON A RESEARCH
12	AGENDA.
13	WE'RE NOT HAVING THIS AUTISM WORKSHOP
14	BECAUSE WE'RE ADVOCATING STEM CELL THERAPIES FOR
15	AUTISM. RATHER, LOOKING AHEAD AND BRINGING EXPERTS
16	IN STEM CELL BIOLOGY TOGETHER WITH EXPERTS IN
17	VARIOUS ASPECTS OF THESE BEHAVIORAL DISORDERS.
18	I'VE HAD CONSIDERABLE HELP IN ORGANIZING
19	FROM ASHA NIGH, AND ED PENHOET HAS AGREED TO BE A
20	MODERATOR FOR THIS INTERESTING WORKSHOP. AND WE'VE
21	ALSO GOTTEN INPUT FROM JON SHESTACK.
22	SO WE WILL HAVE TWO DAYS OF WORK. THE
23	FIRST DAY WILL BE INTERACTIVE PANELS, AND WE'RE
24	GOING TO DIVIDE THIS UP, FIRST AN UPDATE ON THE
25	PATHOPHYSIOLOGY AND CLINICAL SPECTRUM OF THESE
	32

1	DISORDERS. THE SECOND PANEL WILL BRING TOGETHER
2	EXPERTS ON DIVERSE ANIMAL MODELS. IT'S REALLY
3	INTERESTING THAT VERY DIFFERENT GENETIC DEFECTS HAVE
4	CONVERGED TO A SIMILAR BEHAVIORAL PHENOTYPE. AND
5	HAVING THESE COMPARED SIDE BY SIDE, I THINK, WILL
6	GIVE US SOME INSIGHTS.
7	AND THEN, OF COURSE, THERE'S DISEASE IN A
8	DISH PANEL IN WHICH WE WILL GET UPDATED ON THE IPS
9	CELLS THAT HAVE BEEN ISOLATED FROM PATIENTS WITH
10	AUTISM AND THE KINDS OF END POINTS OF ANALYSIS THAT
11	MAY BE IMPORTANT FOR HIGH THROUGHPUT DEVELOPMENT OF
12	NEW DRUG THERAPIES.
13	WE'RE ALSO BRINGING TOGETHER EXPERTS IN
14	IMPLANTATION OF STEM CELLS INTO THE BRAIN AS AN
15	INFORMATION SESSION FOR THE REST OF THE SCIENTISTS
16	AT THE WORKSHOP.
17	ON DAY TWO, ANALOGOUS TO THE NATIONAL
18	ACADEMY-TYPE MEETINGS, WE WILL BREAK OUR EXPERTS UP
19	INTO MULTIDISCIPLINARY GROUPS AND HAVE CLINICIANS
20	AMONG THEM TO COME BACK TO US WITH THEIR OPTIMAL
21	OPINIONS ABOUT WHAT A RESEARCH AGENDA SHOULD BE
22	INDEPENDENT OF CIRM. AND THEN WE CAN USE THAT
23	INFORMATION TO LOOK AND SEE WHERE CIRM COULD
24	POSSIBLY BE CONTRIBUTING TO A CHANGE IN THE
25	THERAPIES AVAILABLE TO PATIENTS WITH AUTISM AND

1	RELATED DI SORDERS.
2	CHAIRMAN KLEIN: THANK YOU VERY MUCH, DR.
3	CSETE.
4	MR. ROTH: WHERE IS THAT MEETING?
5	DR. TROUNSON: THE MEETING WILL BE IN SAN
6	FRANCISCO ON MAY 28TH, 29TH.
7	MR. ROTH: JUST A REQUEST THAT WE
8	CONSIDER I KNOW THE IMMUNOLOGY WORKSHOP WAS IN
9	SAN FRANCISCO AND NOW THIS ONE IS IN SAN FRANCISCO.
10	SO BEING MINDFUL OF TRYING TO MOVE SOME OF THESE
11	AROUND THE STATE.
12	DR. TROUNSON: THANK YOU, DUANE.
13	CHAIRMAN KLEIN: I THINK THIS IS VERY
14	I MPORTANT.
15	MR. SHESTACK: I JUST WANTED TO SAY THIS
16	SOUNDS QUITE EXCELLENT. THE ONE THING I TALKED TO
17	DR. CSETE ABOUT BEFORE WAS I UNDERSTAND YOU WANT TO
18	KEEP THESE MEETINGS SMALL, AND THE FOCUS IS REALLY
19	ON EDUCATING CIRM STAFF SO THAT THEY CAN PUT OUT
20	BETTER POTENTIAL RFA'S IN THE FAR FUTURE FOR AUTISM.
21	BUT IF WE COULD ALSO GET REPRESENTATION FROM SOME OF
22	THE MAJOR SOME OF THE YOUNGER OR NEWER POST DOCS
23	AT SOME OF THE MAJOR STEM CELL LABS IN THE STATE,
24	EVEN IN THE GALLERY OF A MEETING LIKE THIS, IT WOULD
25	ACTUALLY RESULT IN AUTISM-RELATED PROPOSALS MUCH

1	EARLI ER.
2	FOR INSTANCE, WE'VE HAD NONE SO FAR IN THE
3	HISTORY OF CIRM, WHICH IS FINE BECAUSE THE
4	OPPORTUNITY WASN'T THERE. BUT THE OPPORTUNITY IS
5	THERE NOW, AND ANYTHING WE COULD DO TO JUMP START
6	THAT AND TO ALLOW PEOPLE TO COMPETE WOULD BE MUCH
7	DESI RED.
8	CHAIRMAN KLEIN: I THINK THAT'S AN
9	EXCELLENT SUGGESTION. MAYBE, DR. CSETE, YOU COULD
10	REPORT BACK TO US THE NEXT BOARD MEETING ABOUT YOUR
11	EVALUATION OF THAT, BUT ALSO LIKE TO COUPLE THAT
12	WITH DUANE ROTH'S COMMENT IN THAT IN TERMS OF OUR
13	OBJECTIVES HERE, WE WANT TO MAKE CERTAIN THAT WE ARE
14	GEOGRAPHICALLY WITHIN THE STATE PROVIDING ACCESS FOR
15	SCIENTISTS, CLINICIANS, AND LEADERS WITHIN EACH
16	REGION TO ACCESS THESE WORKSHOPS.
17	SO HAVING THEM IN SAN DIEGO, HAVING THEM
18	IN L.A., AS WELL AS SAN FRANCISCO IS VERY VALUABLE.
19	THAT DOES REQUIRE ADDITIONAL TRAVEL, BUT WE THINK
20	THE TRAVEL REALLY IS AN INVESTMENT IN DRIVING
21	SCIENCE FORWARD, WHICH IS OUR MISSION AND THERAPIES
22	FORWARD. SO WE NEED TO UNDERSTAND THAT AS MOVING
23	SIGNIFICANT NUMBERS OF STAFF TO LOCATIONS, OTHER
24	LOCATIONS IN THE STATE, WILL MEAN AUGMENTATIONS IN
25	THE TRAVEL, BUT IT IS PART OF OUR ESSENTIAL FUNCTION

1	TO MAKE SURE THAT WE'RE SERVING THE ENTIRE STATE AND
2	PROMOTING KNOWLEDGE AND DRIVING NEW INTEREST IN NEW
3	THERAPIES AND NEW DISEASE AREAS, LIKE AUTISM, AREAS
4	OF OPPORTUNITY THROUGHOUT THE STATE.
5	IN CONNECTION WITH THE COMMENT THAT WAS
6	JUST MADE IF, IN FACT, SOME TRAVEL STIPENDS HAVE TO
7	BE MADE FOR YOUNG INVESTIGATORS WHO MAY HAVE
8	POTENTIAL INTEREST IN AN AREA, I THINK THAT'S
9	SOMETHING THE STAFF SHOULD CONSIDER.
10	DR. TROUNSON: JUST ON THAT, CHAIR, RIGHT.
11	THIS IS AN INVITATION, SO WE'RE INVITING SPECIFIC
12	PEOPLE. WE WANT TO KEEP IT AT A RELATIVELY SMALL
13	MANAGEABLE SIZE SO THAT WE CAN GET REALLY TARGETED
14	INPUTS. SO, OF COURSE
15	MR. SHESTACK: DR. TROUNSON, I KNOW THAT'S
16	TRUE, BUT THE AUTISM COMMUNITY HAS SPENT A LOT OF
17	TIME SITTING AROUND A TABLE TALKING TO ITSELF. AND
18	IF THERE IS POTENTIAL FOR IT TO FOR PEOPLE FROM
19	NEW LABS TO BE EXPOSED TO IT, IT WOULD BE GREAT TO
20	DO IT SOONER RATHER THAN LATER. THAT'S ALL.
21	CHAIRMAN KLEIN: I THINK JON'S COMMENT,
22	DR. TROUNSON, WAS IF SOME OF THESE YOUNGER
23	INVESTIGATORS COULD EVEN BE OBSERVERS IN THE GALLERY
24	WERE HIS WORDS.
25	MR. SHESTACK: THEY DON'T NEED TO
	36

1	PARTICIPATE. PEOPLE TRULY NEED TO KNOW THAT THIS IS
2	POTENTIALLY A SUBJECT OF REAL INTEREST. AND THE
3	ONLY WAY THEY KNOW IT IS IF THEY ACTUALLY SEE IT AND
4	THEN TAKE IT BACK TO THEIR INSTITUTIONS. THIS WAS
5	EXACTLY THE PROCESS WE HAD TO DO WHEN WE STARTED
6	ONLY 12 AUTISM RESEARCHERS, AND NOW WE HAVE SEVERAL
7	HUNDRED. IT WAS A TEDIOUS, PAINSTAKING, FILLING UP
8	THE BACK ROWS OF MEETINGS SO THERE WAS A POTENTIAL
9	FUNDI NG.
10	CHAIRMAN KLEIN: OKAY. DR. TROUNSON,
11	WOULD YOU LIKE TO MAKE ANOTHER COMMENT, OR DR.
12	PULIAFITO WOULD LIKE TO MAKE A COMMENT.
13	DR. PULIAFITO: I HAVE A QUESTION, WHICH
14	IS I THINK IT'S VERY IMPORTANT
15	(INTERRUPTION IN PROCEEDINGS.)
16	CHAIRMAN KLEIN: IF ONLINE MEMBERS COULD
17	MAKE SURE, IF THEY'RE GOING TO LEAVE THE LINE FOR
18	ANY REASON, WE ENJOY THE MUSIC, BUT IT'S IMPORTANT
19	TO PUT YOUR PHONE ON MUTE AND MAKE SURE, IF THERE'S
20	AN AUTOMATIC MUSIC WHEN YOU ARE ON HOLD, NOT TO PUT
21	US ON HOLD. THANK YOU.
22	DR. PULIAFITO: I WITHDRAW MY COMMENT.
23	DR. TROUNSON: THERE'S NO WORK THAT I'VE
24	SEEN PUBLISHED. IT IS OF INTEREST THAT ONE OF OUR
25	GRANTEES HAS TOLD ME THAT HE HAS IDENTIFIED A
	27

1	MOLECULAR PATHWAY WHICH APPEARS TO CREATE
2	AUTISTIC-TYPE BEHAVIOR IN AN ANIMAL MODEL. AND THAT
3	WAS THE VERY FIRST TIME. SO WE'RE EXPECTING TO SEE
4	SOMETHING, AGAIN, SURPRISINGLY FLOW OUT OF THE WORK
5	THAT WE'RE DOING MORE BROADLY. AND WE'VE INVITED
6	THAT PERSON TO COME ALONG AS WELL AS THE PEOPLE WHO
7	REPRESENTED THE PEOPLE WHO ARE DOING THE HIGH
8	THROUGHPUT SCREENING. SO WE ARE BROADLY TRYING TO
9	GATHER A TARGETED WAY TO SEE IF THERE'S SOMETHING
10	THAT WE CAN SPECIFICALLY DO IN THIS STEM CELL AREA
11	FOR THIS DREADFUL CONDITION OR THIS PARTICULAR
12	PROBLEM A LOT OF PEOPLE KNOW ABOUT, OF COURSE.
13	CHAIRMAN KLEIN: DR. POMEROY.
14	DR. POMEROY: ALAN, YOU MENTIONED THAT YOU
15	HAD INCLUDED THE TRAVEL INFORMATION IN HERE. AND I
16	DO HAVE A QUESTION ABOUT THE INTERNATIONAL SOCIETY
17	OF STEM CELL RESEARCH. IT SAYS IN HERE THAT SEVERAL
	OF STEM CELL RESEARCH. IT SAYS IN HERE THAT SEVERAL OF THE CIRM STAFF MEMBERS SERVE ON THE BOARD OF
18	
18 19	OF THE CIRM STAFF MEMBERS SERVE ON THE BOARD OF
18 19 20	OF THE CIRM STAFF MEMBERS SERVE ON THE BOARD OF ISSCR. SO HOW DO YOU I'M JUST READING FROM THE
18 19 20 21	OF THE CIRM STAFF MEMBERS SERVE ON THE BOARD OF ISSCR. SO HOW DO YOU I'M JUST READING FROM THE MATERIALS YOU GAVE US. SO HOW DO YOU ENSURE THAT
18 19 20 21 22	OF THE CIRM STAFF MEMBERS SERVE ON THE BOARD OF ISSCR. SO HOW DO YOU I'M JUST READING FROM THE MATERIALS YOU GAVE US. SO HOW DO YOU ENSURE THAT THERE'S NO CONFLICT WHEN WE AWARD \$100,000 TO THAT
18 19 20 21 22 23	OF THE CIRM STAFF MEMBERS SERVE ON THE BOARD OF ISSCR. SO HOW DO YOU I'M JUST READING FROM THE MATERIALS YOU GAVE US. SO HOW DO YOU ENSURE THAT THERE'S NO CONFLICT WHEN WE AWARD \$100,000 TO THAT ORGANIZATION WHEN WE HAVE STAFF MEMBERS SERVING ON
17 18 19 20 21 22 23 24	OF THE CIRM STAFF MEMBERS SERVE ON THE BOARD OF ISSCR. SO HOW DO YOU I'M JUST READING FROM THE MATERIALS YOU GAVE US. SO HOW DO YOU ENSURE THAT THERE'S NO CONFLICT WHEN WE AWARD \$100,000 TO THAT ORGANIZATION WHEN WE HAVE STAFF MEMBERS SERVING ON THE BOARD?

1	NO I EXIT COMPLETELY FROM THIS AREA.
2	CHAIRMAN KLEIN: DR. TROUNSON IS RECUSED
3	FROM THOSE DISCUSSIONS.
4	DR. POMEROY: SO THIS STATEMENT THAT THERE
5	ARE MAYBE I MISREAD IT.
6	DR. ROBSON: THERE'S SEVERAL MEMBERS WHO
7	SERVE ON SUBCOMMITTEES WITH THE ISSCR, BUT THERE'S,
8	AS FAR AS I KNOW, ONLY ONE BOARD MEMBER. SORRY OF
9	THAT WAS MISWRITTEN.
10	DR. POMEROY: THANK YOU.
11	CHAIRMAN KLEIN: YES. DR. TROUNSON.
12	DR. PENHOET: BOB, REPEAT YOUR COMMENT
13	ABOUT THE MUSIC ON THE PHONE BECAUSE WHOEVER HAD IT
14	ON PROBABLY WASN'T LISTENING WHILE YOU WERE MAKING
15	THAT COMMENT.
16	CHAIRMAN KLEIN: THANK YOU, DR. PENHOET.
17	SO WHOMEVER HAD THE MUSIC, REMEMBER, IF YOU PUT US
18	ON HOLD, YOUR MUSIC WILL PROBABLY COME ON
19	AUTOMATICALLY. SO PLEASE CONSTRAIN YOURSELF FROM
20	PUTTING US ON HOLD. BUT THANK YOU VERY MUCH, DR.
21	PENHOET.
22	DR. TROUNSON: THIS IS THE GALLERY OF
23	PEOPLE WHO ARE IN CIRM AT THE HARD WORKING INTERFACE
24	WITH SCIENCE AND ALL OUR ACTIVITIES.
25	IF WE GO TO THE NEXT SLIDE, YOU DID ASK US
	39
	J 7

1	TO PROVIDE YOU WITH A PRIORITY LIST FOR FUNDING. SO
2	THIS IS A STAFF SCIENTIFIC PRIORITY LIST. WE'VE
3	ACTUALLY WORKED PRETTY HARD ON THIS, AND WE WANT TO
4	GIVE YOU SOME INSIGHT INTO THE REASONS WHY WE
5	CREATED A LIST AS YOU REQUESTED OF US, WHY IT'S
6	CREATED IN THIS WAY.
7	AND SO I'M JUST GOING TO INTRODUCE SOME OF
8	THE BACKGROUND, AND THEN ASK DON ROBSON TO COME
9	FORWARD WITH THE FINANCIALS.
10	CHAIRMAN KLEIN: I THINK THAT WHAT WE
11	INTEND TO DO, DR. TROUNSON, I'D LIKE TO TALK WITH
12	JAMES HARRISON FOR A MOMENT, IS THAT IF WE COULD
13	HAVE THAT ITEM CLOSER IN TIME PROXIMITY TO THE
14	CONSIDERATION OF ITEM 16, 17, AND 18, THEN IT WILL
15	BE FRESH IN THE MINDS OF THE BOARD AS WE TRY AND GO
16	THROUGH THE FUNDING ITEMS. I THINK THAT WAS, FROM A
17	LEGAL PERSPECTIVE, AS WELL THE INTENT OF THE SOME
18	SEQUENCING THAT WE'VE WORKED OUT TO DEAL WITH
19	CONFLICTS ISSUES. IS THAT CORRECT, MR. HARRISON?
20	MR. HARRISON: THAT'S RIGHT.
21	CHAIRMAN KLEIN: IS THAT ACCEPTABLE, DR.
22	TROUNSON?
23	DR. TROUNSON: SURE. I THOUGHT THAT YOU
24	WOULD BE GOING ON TO THOSE ITEMS NEXT. SO SORRY.
25	CHAIRMAN KLEIN: RIGHT. WE HAVE SOME
	40

40

1	CONSENT ITEMS AND SOME OTHER THINGS TO COVER
2	QUICKLY, BUT THANK YOU VERY MUCH.
3	ALL RIGHT. SO
4	MS. KING: MR. CHAIRMAN, JUST FOR THE
5	RECORD, I WOULD LIKE TO INVITE OUR BOARD MEMBERS ON
6	THE PHONE TO STATE THEIR NAMES, PLEASE.
7	DR. FRIEDMAN: MICHAEL FRIEDMAN.
8	MR. SHESTACK: JON SHESTACK.
9	MS. KING: DR. PENHOET, I KNOW YOU'RE
10	THERE AS WELL, RIGHT?
11	SO FOR THE RECORD, MICHAEL FRIEDMAN, JON
12	SHESTACK, AND ED PENHOET HAVE JOINED THE MEETING,
13	AND WE DO HAVE A QUORUM.
14	CHAIRMAN KLEIN: FOR THE RECORD, WE JUST
15	HEARD FROM DR. PENHOET. WE KNOW HE'S THERE. HE MAY
16	BE ON MUTE FOR A MOMENT, BUT WE WILL RECONFIRM WITH
17	HIM THAT HE IS BACK. WE HAVE MORE THAN A QUORUM
18	WITHOUT DR. PENHOET BEING ON AT THIS MOMENT.
19	WITH THAT IN MIND, COULD WE GET A MOTION
20	ON CONSENT ITEMS UNLESS THERE IS A NEED FOR
21	DISCUSSION ON A CONSENT ITEM? AND MELISSA KING, OUR
22	EXECUTIVE DIRECTOR FOR THE BOARD, WOULD LIKE TO CALL
23	OUR ATTENTION TO THE FACT THAT THE MINUTES, ITEM NO.
24	4, IS NOT INCLUDED IN THE CONSENT ITEMS.
25	MS. KING: ITEM NO. 4 IS NOT INCLUDED.
	41

	DARRISTERS REPORTING SERVICE
1	ALL THREE OF THE OTHER ITEMS, 5, 6, AND 7 THAT
2	YOU'LL SEE ON THE CONSENT CALENDAR ARE INCLUDED.
3	AND SOMEONE COULD MAKE A MOTION TO APPROVE THE
4	ENTIRE CONSENT CALENDAR.
5	CHAIRMAN KLEIN: WITHOUT ITEM 4?
6	MS. KING: CORRECT.
7	DR. PULIAFITO: I'D LIKE TO MOVE THAT WE
8	ACCEPT THE ENTIRE CONSENT AGENDA EXCEPT FOR ITEM 4.
9	CHAIRMAN KLEIN: THANK YOU. IS THERE A
10	SECOND?
11	MR. SERRANO-SEWELL: SECOND.
12	CHAIRMAN KLEIN: THERE'S A MOTION AND A
13	SECOND. IS THERE DISCUSSION? SEEING NO DISCUSSION,
14	IS THERE PUBLIC DISCUSSION ON THE CONSENT CALENDAR?
15	SEEING NONE, VOICE VOTE WITH A ROLL CALL VOTE OF
16	THOSE THAT ARE ON THE PHONE. SO ALL IN FAVOR.
17	OPPOSED?
18	COULD WE THEN GO THROUGH ROLL CALL FOR
19	THOSE ON THE PHONE?
20	MS. KING: MICHAEL FRIEDMAN.
21	DR. FRIEDMAN: YES.
22	MS. KING: ED PENHOET.
23	DR. PENHOET: YES.
24	MS. KING: JON SHESTACK.
25	MR. SHESTACK: YES.
	42
	42

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	MS. KING: THANK YOU. MOTION CARRIES.
2	CHAIRMAN KLEIN: ALL RIGHT. THANK YOU.
3	AND WE'D LIKE TO AT THIS POINT MOVE ON TO ITEM NO.
4	10, AND I THINK WE'RE GOING TO JUST TAKE A
5	FIVE-MINUTE BREAK BEFORE WE GO THROUGH THIS ITEM.
6	(A RECESS WAS TAKEN.)
7	CHAIRMAN KLEIN: WE'RE GOING TO RECONVENE.
8	IF THE STAFF COULD RESCUE ANY OF THE MEMBERS WHO
9	MIGHT BE ACROSS THE HALL FOR A QUICK COFFEE. WE
10	NEED TO MOVE FORWARD. THANK YOU VERY MUCH. DR.
11	POMEROY DEMONSTRATED WE COULD GET COFFEE AND GET
12	BACK IN TIME.
13	DR. POMEROY: THANK YOU, BOB. I WANT FULL
14	CREDI T.
15	CHAIRMAN KLEIN: ALL RIGHT. RECONVENE THE
16	MEETING AND MOVE TO ITEM 10, THE BOND PRIVATE
17	PLACEMENT PROGRAM AND MORE MUSIC. SO THANK YOU,
18	JOAN, FOR MAKING THE SPECIAL EFFORT TODAY TO BE
19	HERE. WE GREATLY APPRECIATE THAT. WE KNOW HOW
20	CHALLENGING IT CAN BE AT TIMES.
21	I'D LIKE TO RECOGNIZE THAT ART TORRES IS
22	IN THE AUDIENCE. ART, YOU WANT TO RAISE YOUR HAND.
23	ONE OF THE TWO CANDIDATES FOR VICE CHAIR.
24	SO ON THE BOND PROGRAM, IN THE INTERIM
25	BETWEEN THE TWO MEETINGS, WE HAD A NUMBER OF

1	PRIORITIES TO DRIVE THROUGH. IN THE FIRST HIGHLIGHT
2	OF THAT PROCESS, I WILL TELL YOU THAT THE GOAL WAS
3	TO MAKE CERTAIN THAT NEW PRIVATE PLACEMENT BOND
4	PROCEEDS THAT WE OBTAINED WOULD NOT BE PULLED OFF TO
5	GO TO PAY DOWN THE \$250 MILLION PMI LOAN THAT WE
6	DREW DOWN LATE LAST SPRING. WE WANTED THE NEW FUNDS
7	WE RAISE TO GO TO NEW PROGRAM COMMITMENTS AND TO OUR
8	CASH FLOW FOR THIS PERIOD.
9	AFTER DISCUSSIONS WITH THE TREASURER'S
10	OFFICE, CONTROLLER'S OFFICE, THERE WAS A MEETING OF
11	THE POOLED MONEY INVESTMENT FUND BOARD. TED LOVE
12	AND MARCY FEIT, WHO ARE DESIGNEES THAT I HAVE MADE
13	TO THE STATE BOND CREDIT COMMITTEE, MORE
14	SPECIFICALLY THE CALIFORNIA STEM CELL RESEARCH AND
15	CURES BOND CREDIT COMMITTEE, WERE AT THE MEETING
16	THAT I ATTENDED WITH THE POOLED MONEY INVESTMENT
17	FUND BOARD WHERE THEY REACHED A DECISION THAT NONE
18	OF OUR 400 MILLION THAT WE WERE SEEKING IN THE NEXT
19	ITEM ON THE AGENDA, WHICH WAS TO CONVENE OUR BOND
20	CREDIT COMMITTEE, WOULD BE UTILIZED TO PAY BACK THE
21	250 MILLION. THE STATE WOULD TAKE THE \$250 MILLION
22	OBLIGATION AND FIT THAT INTO THEIR PUBLIC BOND SALE
23	PROGRAM SO THAT ALL OF OUR INDIVIDUAL EFFORTS TO
24	AUGMENT CASH FLOW FOR THE STATE WOULD GO INTO OUR
25	PROGRAMS. SO THAT'S OBVIOUSLY A MAJOR BENEFIT TO

1	US. IT TAKES THAT BURDEN TO PAY BACK THE 250
2	MILLION OUT OF OUR SPHERE OF RESPONSIBILITY.
3	SECONDLY, IT TURNS OUT THAT FROM LAST
4	SEPTEMBER AND OCTOBER, WHEN I BEGAN THE DISCUSSIONS
5	WITH THE TREASURER'S OFFICE ABOUT BOND CAPACITY AND
6	PRIVATE PLACEMENTS, AS THEY HAVE PROCEEDED ON THIS
7	CONCEPT, IT HAS GAINED THE POPULARITY, PARTICULARLY
8	A GREAT SPIKE IN POPULARITY AFTER OUR PUBLIC MEETING
9	IN JANUARY WHERE WE DISCUSSED THIS AT LENGTH.
10	AND SO AS THE CALIFORNIA STEM CELL
11	RESEARCH AND CURES BOND CREDIT COMMITTEE CONVENED,
12	WHICH IS COMPOSED OF A REPRESENTATIVE OF THE STATE
13	DIRECTOR OF FINANCE, THE CONTROLLER, AND THE STATE
14	TREASURER, WITH THE STATE TREASURER PERSONALLY BEING
15	THERE FOR THIS MEETING, TED AND MARCY AND I FOUND
16	THAT, WHILE WE HAVE OUR OWN BOND CREDIT COMMITTEE,
17	BECAUSE I WROTE THAT INTO THE INITIATIVE, THAT
18	IMMEDIATELY FOLLOWING OUR ITEM ON THE AGENDA, THEY
19	CONVENED THE BASIC BOND CREDIT COMMITTEE FOR THE
20	STATE, AND THERE WERE 13 OTHER BOND PRIVATE
21	PLACEMENTS FOLLOWING OUR MODEL.
22	IN FACT, ABOUT 25 PERCENT OF THOSE HAD
23	SPECIFICALLY, INSTEAD OF SPECIFYING TAX-EXEMPT BOND
24	PRIVATE PLACEMENT, HAD FOLLOWED OUR MODEL OF
25	SPECIFYING TAXABLE BOND PRIVATE PLACEMENT BECAUSE

1	THE TAXABLE BOND MARKET IS MORE THAN 20 TIMES LARGER
2	THAN THE TAX-EXEMPT MARKET. I'M UNDERESTIMATING
3	THAT LEVERAGE, JUST GIVING YOU AN ORDER OF MAGNITUDE
4	OF DIFFERENCE.
5	DR. POMEROY: CAN YOU REPEAT THAT
6	STATEMENT, THAT OTHERS ARE NOW GOING TAXABLE? IS
7	THAT WHAT YOU SAID?
8	CHAIRMAN KLEIN: ABOUT 25 PERCENT OF THE
9	OTHERS FOLLOWING THIS MODEL ARE NOW GOING TAXABLE.
10	NOW, WE HAVE, BESIDES THE VOLUME OF THE
11	MARKET COMPARISON, WE HAVE OTHER REASONS FOR HAVING
12	OURS BEING TAXABLE BECAUSE OUR LOAN PROGRAM IS A
13	PROGRAM THAT NEEDS TO BE FUNDED WITH TAXABLE BONDS.
14	WE HAVE A THREE-YEAR REPRICING DATE ON OUR NOTES, SO
15	THAT AFTER THREE YEARS, WE CAN LOOK AT THE
16	COMPOSITION OF THE FUNDING WE HAVE DONE, AND FOR
17	THOSE EXPENDITURES THAT WE'VE MADE WITH BOND
18	PROCEEDS THAT CAN BE TAX-EXEMPT, WE CAN SEGREGATE
19	THOSE OUT INTO A TAX-EXEMPT ISSUE.
20	SO OUR CURRENT FUNDING IN THE MARKETS IS
21	AN INTERIM FUNDING, AND WE WILL HAVE THE BENEFIT OF
22	LOOKING BACK TO SEE HOW MUCH WE CAN PULL OUT INTO
23	THE TAX-EXEMPT DEBT; BUT BY GOING TAXABLE WITH ALL
24	OF IT RIGHT NOW, IT SAVES US TIME, IT SAVES US
25	ISSUES THAT WE COULD BE CHALLENGED ON LEGALLY.

1	WE'RE TAKING THE MORE CONSERVATIVE APPROACH, AND WE
2	GET THE BENEFIT OF BEING IN A MARKET THAT'S VASTLY
3	LARGER THAN THE TAX-EXEMPT MARKET.
4	IN THE
5	MS. SAMUELSON: I JUST HAVE A QUESTION
6	ABOUT THAT. TO TRY TO UNDERSTAND IT, IS THAT
7	SOMETHING THAT WE HAVE CONTROL OVER? WHY WOULDN'T
8	THAT BE SOMETHING THAT IS SOME OTHER LEVEL OF
9	GOVERNMENT OR SOME OTHER PART OF GOVERNMENT?
10	CHAIRMAN KLEIN: SO WE UNIQUELY HAVE OUR
11	OWN BOND CREDIT COMMITTEE. BUT IN TERMS OF CONTROL,
12	IT HAS TO BE WORKED OUT WITH THE CONSTITUTIONAL
13	OFFICERS SO THAT WE GET ACCEPTANCE BOTH FROM THE
14	THREE CONSTITUTIONAL OFFICERS AS WELL AS OUR
15	REPRESENTATI VES.
16	MS. SAMUELSON: PURSUANT TO THE TERMS OF
17	THE INITIATIVE.
18	CHAIRMAN KLEIN: PURSUANT TO THE TERMS OF
19	THE INITIATIVE, THAT'S RIGHT. SO THERE'S
20	CONSTITUTIONAL LEADERSHIP PARTICIPATION IN THAT
21	DECISION, AND THE TREASURER'S LEADERSHIP IS VERY
22	IMPORTANT; BUT WE HAVE A BURDEN OF ADVOCACY TO MAKE
23	CERTAIN IN PRESENTING OUR CASE THAT IT IS VALIDLY
24	SUPPORTED BY DOCUMENTS AND FACTS AND WE PERSUADE THE
25	TREASURER, CONTROLLER, AND STATE DIRECTOR OF
	47

1	FI NANCE.
2	IT'S VERY IMPORTANT TO ALSO UNDERSTAND
3	THAT ONE OF THOSE TAXABLE ISSUES, IN FACT, THE
4	PRIVATE PLACEMENT ONE OF THE TAX-EXEMPT ISSUES OF
5	THE PRIVATE PLACEMENT WAS COMPLETED. IT'S THE BAY
6	AREA TOLL AUTHORITY COMPLETED ON 2/27/09 FOR 200
7	MILLION. THEY HAD A SIGNIFICANT ADVANTAGE IN
8	COMPLETING THIS QUICKLY IN THAT THEY USED THEIR OWN
9	CASH TO BUY THE BONDS, SO MADE IT A LITTLE LESS
10	DIFFICULT TO FIND A BUYER.
11	THE ALAMEDA COUNTY SUPERVISOR WHO CHAIRS
12	THE BRIDGE AUTHORITY, SCOTT HAGGERTY, I THINK, WAS
13	VERY IMPORTANT IN THAT TRANSACTION. AND IT DOES
14	HELP THEM IN TERMS OF STRUCTURING THEIR CASH FLOW.
15	IN WORKING WITH THE STATE TREASURER'S
16	OFFICE, WE HAVE WORKED OUT ALL BUT ONE FINAL TERM
17	NOW OF THE TERM SHEET, AND WE ARE IN THE PROCESS OF
18	WORKING WITH ENTITIES ON INITIAL INFORMATIONAL
19	PACKAGES TO PROCEED WITH THIS PRIVATE PLACEMENT
20	AGENDA.
21	AND I'D LIKE TO ASK TED OR MARCY IF THEY
22	HAVE ANY PARTICULAR COMMENTS THEY'D LIKE TO MAKE ON
23	THE MEETINGS. WE CERTAINLY HEARD FROM A NUMBER OF
24	AGENCIES AT THAT MEETING ABOUT THE SITUATION THAT
25	THEY WERE IN, THE CHALLENGES THEY WERE FACING IN

1	OBTAINING BOND FUNDS FOR CRITICAL PRIORITIES OF THE
2	STATE. IT'S IMPORTANT TO NOTE AND HIGHLIGHT IN ANY
3	DISCUSSION WE HAVE THAT BY GOING OUT OURSELVES AND
4	DOING PRIVATE PLACEMENTS, WE'RE NOT DISPLACING ANY
5	OF THOSE OTHER PRIORITIES OF THE STATE. WE'RE NOT
6	DISPLACING BOND NEEDS FOR THE SCHOOL SYSTEM. WE'RE
7	NOT DISPLACING BOND NEEDS FOR MENTAL HEALTH SYSTEM
8	OR HIGHWAY SYSTEMS. WE'RE RAISING FUNDS THAT
9	OTHERWISE WOULDN'T BE AVAILABLE TO THE STATE THROUGH
10	OUR PRIVATE PLACEMENTS.
11	SO IT IS, I THINK, INHERENTLY IMPORTANT
12	THAT WE ASSUME THE RESPONSIBILITY DURING THIS TIME
13	OF CHALLENGE FOR THE STATE THAT WE'RE BRINGING NEW
14	FUNDS INTO THE SYSTEM THAT ARE ADDRESSING OUR NEEDS
15	TO DRIVE FORWARD THERAPIES FOR PATIENTS WITHOUT
16	DETRACTING FROM ANY OF THE OTHER STATE OBJECTIVES.
17	IT'S ALSO VERY IMPORTANT TO NOTE THAT OUR
18	ECONOMIC STUDY SHOWS THAT FROM OUR MAJOR FACILITIES
19	PROGRAM ALONE, WE'LL PRODUCE BY 2010 \$100 MILLION IN
20	NEW TAX REVENUE FOR THE STATE BEFORE THE FIRST
21	PAYMENT IS MADE BY THE GENERAL FUND ON OUR BOND
22	DEBT, AND THAT PAYMENT IS APPROXIMATELY \$15 MILLION.
23	SO ON A CASH-FLOW BASIS, WE'VE ACTUALLY BEEN
24	BENEFITING THE STATE BECAUSE OF THE STRUCTURE WHERE
25	THE INTEREST ON OUR BOND IS CAPITALIZED THROUGH THE

1	END OF 2009.
2	THIS PRESENTS, HOPEFULLY, A CORRECT
3	PICTURE TO THE STATE, THAT WE TAKE OUR
4	RESPONSIBILITY VERY SERIOUSLY IN CONTRIBUTING TO THE
5	SOLUTION OF THE STATE'S PROBLEMS, NOT INCREASING THE
6	STATE'S PROBLEMS BECAUSE, IN FACT, ULTIMATELY IN THE
7	FINANCIAL HEALTH OF THE STATE LONG TERM, IT IS
8	CRITICAL THAT HEALTHCARE COSTS BE REDUCED WHILE
9	HEALTH OF PATIENTS IN CALIFORNIA BE ENHANCED, AND
10	HOPEFULLY INTERVENTIONIST THERAPIES THAT ARE
11	POTENTIAL THROUGH CELLULAR THERAPIES AND SMALL
12	MOLECULE THERAPIES DISCOVERED THROUGH EMBRYONIC OR
13	ADULT STEM CELL RESEARCH HAVE THE OPPORTUNITY TO
14	AVOID CHRONIC TREATMENT OVER DECADES FOR MANY
15	PATIENTS. THOSE CHRONIC TREATMENTS ARE A HUGE
16	PORTION OF THE STATE'S HEALTHCARE BURDEN.
17	TED OR MARCY, ANY COMMENTS ON THIS
18	PROCESS?
19	MS. FEIT: NO. JUST MY IMPRESSION THAT I
20	THINK ONE OF THE GROUPS THAT WAS THERE THAT DAY WERE
21	THE HOUSING, AND THEY WERE FEELING PRETTY DESPERATE
22	AROUND THEY HAVE PROJECTS UNDER WAY AND COULD NOT
23	SEE HOW THEY WERE GOING TO COMPLETE THEM, AND
24	COMMITMENTS HAVE BEEN MADE. JUST A DESPERATE TIME.
25	CHAIRMAN KLEIN: RIGHT. OKAY. TED, ANY
	50

COMMENT?
I WOULD ALSO LIKE TO THANK SHERRY LANSING,
WHO'S MADE ANOTHER SPECIAL EFFORT AND JUST ARRIVED.
BUT IN OUR PROCESS IN THE CASE STUDY ON
THE BOND ANTICIPATION NOTES, ONE OF THE ATTORNEYS
THAT WORKED ON THAT EFFORT, STEVE CHURCHWELL, CAME
AND MADE A PRESENTATION TO US. AND IT'S IMPORTANT
TO NOTE THAT IN EVERY ONE OF THE TRANSACTIONS IN THE
BOND ANTICIPATION NOTES, THERE WERE PROBABLY FIVE TO
SEVEN ATTORNEYS THAT ARE INVOLVED. SO WE HAVE HE
HAPPENED TO REPRESENT HIS CLIENT INDIVIDUALLY ALONG
WITH TWO OTHER ATTORNEYS FOR HIS CLIENT, AND THERE
WERE AT LEAST FOUR OTHER ATTORNEYS, INCLUDING THE
TREASURER'S ATTORNEY, OUR BOARD GENERAL COUNSEL, AND
TWO ATTORNEYS FROM THE STATE'S BOND COUNSEL'S FIRM,
ORRICK HERRINGTON, THAT WERE INVOLVED IN THAT
TRANSACTI ON.
SO I WANT TO GIVE THE BOARD ASSURANCES,
WHILE WE PROVIDED KIND OF ANECDOTAL INSIGHT INTO THE
COMPLEXITIES FACED BY A SPECIFIC ATTORNEY, THERE ARE
SEVEN FIVE TO SEVEN ATTORNEYS IN EVERY ONE OF
THOSE TRANSACTIONS TO MAKE SURE EVERY ASPECT LEGALLY
AND PROFESSIONALLY WAS COVERED. AND IN WHAT WE'RE
DOING NOW, WE'RE ALREADY UP TO SEVEN ATTORNEYS
LOOKING AT EVERY TRANSACTION BETWEEN THE DIFFERENT

1	AGENCIES OF THE STATE AND OUR COUNSEL AND TAX
2	COUNSEL IN ADDITION TO THE CLIENTS' COUNSELS, WHICH
3	SOMETIMES WILL BE TWO OR THREE IN NUMBER, NOT
4	SINGULAR. SO THE SCRUTINY IS MICROSCOPIC. AND I
5	WANT TO GIVE YOU ASSURANCES THAT IT'S THOUGHTFULLY
6	AND PROFESSIONALLY ACCOMPLISHED.
7	DR. PRICE: ALSO CONTRIBUTION TO ECONOMIC
8	STI MULUS.
9	CHAIRMAN KLEIN: CONTRIBUTION TO ECONOMIC
10	STI MULUS.
11	THE FEDERAL GOVERNMENT, I WOULD POINT OUT,
12	AS WELL HAS SOME INTERESTING NEW PROGRAMS THAT MIGHT
13	APPLY TO OUR PROGRAM, INCLUDING A POTENTIAL PROGRAM
14	FOR REIMBURSING 35 PERCENT OF TAXABLE BOND INTEREST
15	COST. THAT WILL IF THAT, IN FACT, DOES APPLY, IT
16	WILL INVOLVE A COUPLE MORE ATTORNEYS FROM THE
17	FEDERAL GOVERNMENT AND STATE GOVERNMENT. SO I WANT
18	TO INDICATE THAT, EVEN THOUGH I'M A MEMBER OF THE
19	CALIFORNIA BAR ASSOCIATION, I DO NOT PRACTICE LAW.
20	I HAVE NO INTEREST IN PROMOTING ANY FIRM. I HOLD NO
21	INTEREST IN ANY FIRM. IT'S MERELY AN ESSENTIAL PART
22	OF THE TRANSACTION.
23	SO THAT'S THE UPDATE ON THAT PRIVATE
24	PLACEMENT.
25	DR. PRIETO: QUESTION. IF WE HAVE SOME
	52
	5/

1	IDEA WHAT THE MARKET IS GOING TO BE OVER THIS NEXT
2	12 MONTHS FOR THIS TYPE OF BOND.
3	CHAIRMAN KLEIN: VERY SPECIALIZED. I
4	WOULD INDICATE THAT WE'RE LOOKING AT 400 TO 450
5	BASIS POINTS OR 4 TO 4.5 PERCENT OVER TREASURIES OF
6	LIKE MATURITY. SO WE'RE IN THE 5 TO 5.5 PERCENT
7	RANGE. AND ON A THREE-YEAR MATURITY FOR THE EIGHTH
8	LARGEST ECONOMY IN THE WORLD, THIS IS A VERY
9	REASONABLE INVESTMENT. IN ADDITION TO THE FACT THAT
10	MAJOR FOUNDATIONS WHO HAVE AN INTEREST IN MAKING A
11	PROGRAM INVESTMENT GET A BENEFIT FROM MAKING THE
12	PROGRAM INVESTMENT, IT'S A VERY REASONABLE,
13	COMPETITIVE RETURN.
14	AND WE SPEND A GREAT DEAL OF OUR TIME
15	GOING THROUGH THE FEDERAL AND STATE CONSTITUTIONS
16	AND THE PROTECTIONS AGAINST BANKRUPTCY AND CASH
17	FLOWS OF THE STATE AND THE HISTORY OF THE STATE'S
18	PAYMENTS. SO DESPITE THE VERY STRONG LEVELS OF
19	FINANCIAL RETURNS, IT IS AN IMPORTANT PROCESS.
20	I WOULD LIKE TO REMIND EVERYONE THAT UNDER
21	THE STATE CONSTITUTION, THE FIRST PRIORITY IS
22	EDUCATION, WHICH TAKES APPROXIMATELY 40 PERCENT OF
23	THE STATE'S REVENUE. DEBT SERVICE IS THE NEXT
24	PRIORITY. SO IF THE STATE CAN HANDLE 40 PERCENT OF
25	ITS REVENUE PROJECTIONS, IT CAN THEN MAKE THE NEXT
	F.0

1	TRANCHE, WHICH IS DEBT SERVICE PAYMENTS. OUR BOND
2	PLACEMENT PURCHASERS WILL BE IN A VERY STRONG
3	POSITION PURSUANT TO THE STATE CONSTITUTION, THE
4	STRUCTURE OF THE STATE'S CASH FLOWS.
5	ALL RIGHT. ANY PUBLIC COMMENT ON THAT
6	ITEM? JOHN SIMPSON.
7	DR. SIMPSON: JOHN SIMPSON FROM CONSUMER
8	WATCHDOG. OBVIOUSLY THIS DOES REQUIRE, AS YOU WERE
9	SUGGESTING, A LOT OF LAWYERS. AND OTHER THAN
10	PROVIDING ECONOMIC STIMULUS FOR LAWYERS, I WONDER DO
11	YOU HAVE AN ESTIMATE OF THE LEGAL FEES THAT ARE
12	GOING TO BE INVOLVED IN THE PRIVATE PLACEMENT?
13	AND SECOND QUESTION WOULD BE I'M ASSUMING
14	THAT THIS WOULD BE A HIGHER RATE OF INTEREST THAN IF
15	IT WERE NOT TAXABLE BONDS. SO DO YOU HAVE AN
16	ESTIMATE AS TO THE ADDITIONAL COSTS IN INTEREST AS
17	COMPARED TO WHAT IT MIGHT HAVE BEEN DOING THE OTHER
18	ROUTE, SO BOTH THE LEGAL FEES AND THE COSTS OF THE
19	DIFFERENCE IN INTEREST.
20	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
21	JEFF SHEEHY HAD ASKED A QUESTION ON COST IN A
22	BROADER PERSPECTIVE. AND SO FOR THE APRIL MEETING,
23	WE'RE GOING TO BRING BACK KIND OF A CONCEPTUAL
24	BUDGET FOR THE COST OF THE TRANSACTION AND PROBABLY
25	LOOK AT IT IN INCREMENTS, THE FIRST HUNDRED OR 200
	5.4

1	MILLION AND THEN THE NEXT 200 MILLION. WE'D LIKE TO
2	HAVE MORE INFORMATION AT THAT TIME.
3	THAT COST IS GOING TO BE VARIABLE BASED
4	UPON HOW MANY TRANSACTIONS WE HAVE TO GO THROUGH
5	THAT CAN'T CLOSE AS VERSUS THOSE THAT DO CLOSE.
6	IT'S HARD TO ESTIMATE. SO WE'RE GOING TO HAVE TO
7	GIVE RANGES ON THIS. BUT THIS IS AN UNPRECEDENTED
8	MARKET IN OUR LIFETIMES, AND IT IS A CHALLENGE TO
9	COME WITH THOSE NUMBERS, BUT WE'RE GOING TO DO OUR
10	BEST JOB IN BRINGING IT.
11	THE SECOND POINT IS THAT IT'S NOT
12	NECESSARILY A HIGHER RATE OF INTEREST. THE REASON
13	IS THAT IN A PUBLIC OFFERING, YOU'VE GOT TO REALLY
14	PRICE TO THE MARGINAL PURCHASER, THE LAST PURCHASERS
15	TO REALLY BE ABLE TO CLOSE THE TRANSACTION. SO THEY
16	DRIVE THE PRICING UNLESS YOU SIZE DOWN THE ISSUE.
17	IN THIS CASE, BECAUSE WE'RE ABLE TO DEAL WITH
18	INDIVIDUAL PRIVATE PLACEMENT TARGETS WHO HAVE, IN
19	MOST CASES, A SECOND IMPORTANT MOTIVATION, WHICH IS
20	PROGRAM INVESTMENT IN THE AREA THAT THEIR CHARTER
21	DECLARES IS THEIR CORE MISSION, WE MAY WELL HAVE
22	LESS THAN A MARKET RATE OF INTEREST.
23	WHAT'S IMPORTANT AS A BENCHMARK IS THAT
24	THE LEGISLATIVE ANALYST ORIGINALLY ESTIMATED OUR
25	AVERAGE COST FOR BONDS OVER THE PERIOD WOULD BE

1	ABOUT 5 PERCENT, AND WE'RE IN THAT RANGE. SO WE'RE
2	CONSISTENT WITH THAT RANGE DESPITE THE MOST
3	CHALLENGING FINANCIAL PERIOD THAT THIS STATE HAS
4	FACED IN THE LAST 80 YEARS.
5	I THINK IF THAT CONCLUDES THE PUBLIC
6	COMMENT, I'D LIKE TO MOVE TO THE NEXT ITEM, WHICH
7	MEANS WE WILL ADJOURN FOR AN EXECUTIVE SESSION. AND
8	THIS HOPEFULLY WILL BE IN THE RANGE OF 45 MINUTES,
9	BUT IT MAY GO LONGER BASED UPON THE WILL AND WISHES
10	OF THE BOARD. IF WE COULD ADJOURN. AND MELISSA
11	KING, WOULD YOU HAVE AN ANNOUNCEMENT BEFORE WE
12	ADJOURN?
13	MR. HARRISON: JUST TO BE CLEAR, CHAIR,
14	WE'RE ADJOURNING TO CLOSED SESSION PURSUANT TO
15	HEALTH AND SAFETY CODE SECTION 125290.30(D)(3)(D)
16	AND GOVERNMENT CODE SECTION 11126.
17	MS. KING: I JUST WANTED TO DO ONE MORE
18	CHECK FOR MEMBERS WHO ARE ON THE PHONE. I KNOW
19	THAT I BELIEVE THAT WE'VE HAD ONE MORE MEMBER
20	JOIN. I'D JUST LIKE TO ASK IF DR. LEVEY IS ON THE
21	LINE? OKAY. AND I'D ALSO LIKE TO ASK THE MEMBERS
22	WHO ARE ON THE PHONE AT THIS TIME TO HANG UP FROM
23	THE CONFERENCE LINE YOU'RE CURRENTLY DIALED INTO AND
24	DIAL INTO THE ONE THAT YOU HAVE FOR THE CLOSED
25	SESSION. THANK YOU.
	F./

1	(THE BOARD THEN ADJOURNED TO CLOSED
2	SESSION, NOT REPORTED NOR HEREIN TRANSCRIBED. THE
3	PROCEEDINGS THEN CONTINUED IN OPEN SESSION AS
4	FOLLOWS:)
5	CHAIRMAN KLEIN: ALL RIGHT. DO WE HAVE
6	ALL THE BOARD MEMBERS IN? AND DO WE HAVE THE
7	MEMBERS THAT ARE ON THE PHONE?
8	MS. KING: WORKING ON HAVING THEM ON THE
9	PHONE AS WE SPEAK.
10	CHAIRMAN KLEIN: ALL RIGHT. I'M GOING TO
11	WAIT A MINUTE UNTIL THE MEMBERS ARE ON THE PHONE. I
12	BELIEVE THAT
13	MS. KING: JUST A QUICK CHECK. IF YOU ARE
14	ON THE PHONE, COULD YOU PLEASE STATE YOUR NAME,
15	HOPEFULLY NOT ALL AT ONCE. ANYONE? LOOKS LIKE THEY
16	MAY NOT YET HAVE REJOINED US.
17	CHAIRMAN KLEIN: OR THEY'RE VERY QUIET.
18	(COMMENTS FROM THE TELEPHONE
19	OPERATOR.)
20	CHAIRMAN KLEIN: OPERATOR, THERE'S A THIRD
21	LINE AS WELL; IS THAT CORRECT?
22	THE OPERATOR: THERE'S A CONFERENCE LINE
23	AND THERE'S TWO CONNECTED LINES, AND THEN YOUR LINE.
24	MR. HARRISON: MR. CHAIRMAN, WE DO HAVE A
25	QUORUM IN THE ROOM.

1	CHAIRMAN KLEIN: I WANT THE BENEFIT OF ALL
2	THE MEMBERS, INCLUDING THOSE ON THE PHONE, TO BE
3	ABLE TO PARTICIPATE, BUT THANK YOU.
4	IF THE OPERATOR COULD BE ADVISED THAT THE
5	OPERATOR IS FEEDING BACK INTO THE SESSION.
6	THE OPERATOR: THAT'S SOMEONE FROM ONE OF
7	THE CONNECTED LINES TALKING. IT WASN'T MY VOICE.
8	CHAIRMAN KLEIN: IF THERE ARE STAFF ON THE
9	LINES WAITING FOR US TO COMMENCE OUR SESSION, PLEASE
10	ADVISE THEM WE'RE COMMENCING IMMEDIATELY. ARE ANY
11	BOARD MEMBERS ON THE CALL AT THIS TIME? LYNN, COULD
12	YOU ASSIST MELISSA AND COULD OTHER STAFF ASSIST
13	MELISSA IN CALLING THE BOARD MEMBERS TO INDICATE
14	THAT WE ARE COMMENCING IMMEDIATELY? THEIR LINES ARE
15	EVIDENTLY OPEN, BUT THEY'RE NOT YET ON THE LINE.
16	DR. LEVEY: I'M ON THE LINE NOW, BOB.
17	CHAIRMAN KLEIN: DR. LEVEY, THANK YOU. WE
18	JUST WANTED TO HEIGHTEN THE SUSPENSE FOR THE
19	AUDIENCE. THIS IS COMPLETELY ORCHESTRATED.
20	MS. LANSING: WE WANT FULL PARTICIPATION
21	OF EVERYBODY.
22	CHAIRMAN KLEIN: ALL RIGHT. ANY OTHER
23	BOARD MEMBERS HAVE JOINED?
24	DR. PENHOET: ED.
25	CHAIRMAN KLEIN: OKAY. AND DR. LEVEY.
	0
	50

1	AND DO WE HAVE ANOTHER MEMBER?
2	MS. KING: NOT AT THIS TIME.
3	CHAIRMAN KLEIN: SO I'M GOING TO PROCEED
4	AT THIS MOMENT. AND I'D LIKE TO SAY IN OPENING THE
5	DISCUSSION OF ITEM 12, CONSIDERATION OF AMENDMENTS
6	TO THE PROPOSITION 71 ICOC BYLAWS AND INTERNAL
7	GOVERNANCE POLICY REGARDING THE VICE CHAIRS, WE ARE
8	AN INSTITUTION THAT IS COMMITTED TO ADVANCING
9	THERAPIES FOR PATIENTS. THAT IS OUR MISSION. OUR
10	MISSION DOES NOT GIVE US A KNOWN PATH TO THERAPIES.
11	IT IS A MISSION THAT REQUIRES US TO BE OPEN,
12	CREATIVE, RESPONSIVE TO OPPORTUNITY. AND IN THAT
13	CONTEXT, TO BUILD OUR ORGANIZATION FOR OUR MISSION,
14	THIS IS A VERY IMPORTANT VOTE.
15	I WOULD LIKE TO TURN THIS OVER TO THE
16	CHAIR OF OUR GOVERNANCE COMMITTEE, SHERRY LANSING,
17	TO INTRODUCE THIS ITEM. AND LET IT BE KNOWN THIS
18	AGENCY IS OPEN TO GREAT OPPORTUNITY.
19	MS. LANSING: THANK YOU, BOB. I SO
20	APPRECIATE WHAT YOU'RE SAYING. AND WE ARE IN A
21	UNIQUE SITUATION. WE HAVE ALWAYS BEEN AN AGENCY
22	THAT SUPPORTS COLLABORATION. YOU'VE SEEN IT WITH
23	OUR SCIENTISTS, AND YOU'VE SEEN IT WITH THE WAY THAT
24	WE WORK WITH ALL OF THE OTHER GROUPS. WE ARE ALSO
25	IN A UNIQUE TIME WHEN OUR STATE IS FACING FINANCIAL

1	CHALLENGES.
2	WE HAVE ALSO PROMISED OUR CHAIRMAN
3	SUPPORT. IF YOU REMEMBER THE LAST TIME THAT WE MET,
4	WHEN BOB AGREED TO TAKE A REDUCED SALARY AND WORK 50
5	PERCENT OF THE TIME, WHICH WE KNEW WAS NOT IN HIS
6	NATURE, WE ALWAYS SAID THAT WE WOULD GIVE HIM
7	ADDITIONAL HELP. AND SO WE ARE PRESENTED WITH WHAT
8	I REFER TO AS A HIGH CLASS PROBLEM. WE HAVE TWO
9	EXTRAORDINARY CANDIDATES BEFORE US. AND I'M GOING
10	TO TALK JUST VERY BRIEFLY ABOUT EACH OF THEM IN
11	ALPHABETI CAL ORDER.
12	SO I WILL START WITH DUANE, AND I DON'T
13	WANT TO EMBARRASS YOU, DUANE, BUT WE KNOW OF DUANE'S
14	BACKGROUND, WE KNOW OF HIS WORK IN THE PRIVATE
15	INDUSTRY AND LIFE SCIENCES, IN BIOTECH, BUT MOST
16	IMPORTANT, WE KNOW OF THE EXTRAORDINARY DEDICATION
17	THAT HE HAS SHOWN TO THIS BOARD, HIS EXTRAORDINARY
18	LEADERSHIP, HIS HARD WORK, HIS COLLABORATIVE NATURE.
19	ALL OF US HAVE HAD THE PRIVILEGE OF WORKING WITH HIM
20	AND HAVE THOROUGHLY SEEN THE FRUITS OF YOUR
21	DEDICATION, OF YOUR INTELLIGENCE, AND OF YOUR
22	COMMI TMENT.
23	ART TORRES HAS BEEN A LIFELONG PUBLIC
24	SERVANT. HE'S BEEN COMMITTED TO EDUCATION, THE
25	ENVIRONMENT, HUMAN RIGHTS, AND MOST IMPORTANT TO US,

HEALTHCARE. HE'S A BIG SUPPORTER OF OUR
PROPOSITION. HE IS HIMSELF A COLON CANCER SURVIVOR,
AND HIS MOTHER IS A BREAST CANCER SURVIVOR.
HE HAS WORKED WITHIN THE STATE ASSEMBLY
AND AS A STATE SENATOR, ALWAYS CARING ABOUT PATIENT
RIGHTS. HE IS ALSO ONE OF THE MOST COLLABORATIVE
AND INTELLIGENT PEOPLE THAT I HAVE MET, AND IT HAS
BEEN A PLEASURE GETTING TO KNOW HIM.
SO HERE'S OUR HIGH CLASS PROBLEM. WE HAVE
TWO EXTRAORDINARY CANDIDATES, TWO CANDIDATES THAT
CAN HELP BOB AND THAT CAN HELP ALL OF US REACH OUR
COMMISSION. SO IT WAS THE UNANIMOUS CONSENT, THE
UNANIMOUS DECISION OF THE GOVERNANCE COMMITTEE TO
CREATE TWO CO-EQUAL VICE CHAIRS. TO RECOMMEND. IT
WAS THE RECOMMENDATION OF THE GOVERNANCE COMMITTEE
AND IT WAS A UNANIMOUS RECOMMENDATION BECAUSE WE
FEEL THAT THEY BOTH HAVE UNIQUE SKILLS, THAT THEY
BOTH HAVE BEEN OPERATING IN DIFFERENT AREAS, AND
THAT TOGETHER ONE PLUS ONE WON'T JUST EQUAL THREE,
IT WILL PROBABLY EQUAL FIVE, AS HAS BEEN SAID BY MY
PARTNER.
SO I WOULD LIKE TO TURN IT OVER TO JAMES
TO EXPLAIN HOW WE WOULD GO ABOUT DOING THIS, AND
THEN HAVE DISCUSSIONS FROM THE BOARD.
MR. HARRISON: THANK YOU, SHERRY. IN YOUR
61

1	BINDER YOU WILL FIND BEHIND TAB 12 PROPOSED
2	AMENDMENTS TO THE ICOC'S BYLAWS. LET ME FIRST SET
3	THE STAGE FOR THIS BECAUSE QUESTIONS HAVE BEEN
4	RAISED ABOUT THE AUTHORITY FOR ESTABLISHING A SECOND
5	CO-CHAIR POSITION.
6	AS ALL OF YOU KNOW, PROP 71 ESTABLISHES A
7	CHAIR AND A VICE CHAIR BY STATUTE. AND IT ALSO
8	SPECIFIES THE DUTIES OF THE CHAIR, AND STATES THAT
9	THE VICE CHAIR'S DUTY IS TO SUPPORT THE CHAIR IN
10	CARRYING OUT HIS DUTIES. OF COURSE, AS A PUBLIC
11	OFFICER, THE CHAIR ALSO HAS THE AUTHORITY TO
12	DELEGATE HIS DUTIES TO ANOTHER OFFICER OF THE
13	AGENCY.
14	IN ADDITION, PROPOSITION 71 SPECIFIES THAT
	THE BOARD HAS THE POWER TO TAKE ALL ACTS THAT ARE
15	THE DUARD HAS THE FOWER TO TAKE ALL ACTS THAT ARE
15 16	NECESSARY OR APPROPRIATE TO CIRM'S MISSION. IN
16	NECESSARY OR APPROPRIATE TO CIRM'S MISSION. IN
16 17	NECESSARY OR APPROPRIATE TO CIRM'S MISSION. IN LIGHT OF THE CHAIR'S AUTHORITY TO DELEGATE DUTIES
16 17 18	NECESSARY OR APPROPRIATE TO CIRM'S MISSION. IN LIGHT OF THE CHAIR'S AUTHORITY TO DELEGATE DUTIES AND THE BOARD'S AUTHORITY TO TAKE ALL ACTIONS
16 17 18 19	NECESSARY OR APPROPRIATE TO CIRM'S MISSION. IN LIGHT OF THE CHAIR'S AUTHORITY TO DELEGATE DUTIES AND THE BOARD'S AUTHORITY TO TAKE ALL ACTIONS NECESSARY OR APPROPRIATE TO CIRM'S MISSION, THE
16 17 18 19 20	NECESSARY OR APPROPRIATE TO CIRM'S MISSION. IN LIGHT OF THE CHAIR'S AUTHORITY TO DELEGATE DUTIES AND THE BOARD'S AUTHORITY TO TAKE ALL ACTIONS NECESSARY OR APPROPRIATE TO CIRM'S MISSION, THE BOARD HAS THE POWER TO AMEND THE BYLAWS TO CREATE A
16 17 18 19 20 21	NECESSARY OR APPROPRIATE TO CIRM'S MISSION. IN LIGHT OF THE CHAIR'S AUTHORITY TO DELEGATE DUTIES AND THE BOARD'S AUTHORITY TO TAKE ALL ACTIONS NECESSARY OR APPROPRIATE TO CIRM'S MISSION, THE BOARD HAS THE POWER TO AMEND THE BYLAWS TO CREATE A CO-VICE CHAIR POSITION IN ADDITION TO THE STATUTORY
16 17 18 19 20 21	NECESSARY OR APPROPRIATE TO CIRM'S MISSION. IN LIGHT OF THE CHAIR'S AUTHORITY TO DELEGATE DUTIES AND THE BOARD'S AUTHORITY TO TAKE ALL ACTIONS NECESSARY OR APPROPRIATE TO CIRM'S MISSION, THE BOARD HAS THE POWER TO AMEND THE BYLAWS TO CREATE A CO-VICE CHAIR POSITION IN ADDITION TO THE STATUTORY POSITION THAT ALREADY EXISTS.
16 17 18 19 20 21 22	NECESSARY OR APPROPRIATE TO CIRM'S MISSION. IN LIGHT OF THE CHAIR'S AUTHORITY TO DELEGATE DUTIES AND THE BOARD'S AUTHORITY TO TAKE ALL ACTIONS NECESSARY OR APPROPRIATE TO CIRM'S MISSION, THE BOARD HAS THE POWER TO AMEND THE BYLAWS TO CREATE A CO-VICE CHAIR POSITION IN ADDITION TO THE STATUTORY POSITION THAT ALREADY EXISTS. LET ME TAKE YOU THROUGH THE PROPOSED

1	ARTICLE 8, SECTION 1, THE BYLAWS DEFINE WHO THE
2	OFFICERS OF THE BOARD ARE. THEY ARE A CHAIR AND A
3	VICE CHAIR ELECTED PURSUANT TO PROPOSITION 71 UNDER
4	THE STATUTORY PROVISIONS. FOR SHORTHAND PURPOSES,
5	I'LL REFER TO THIS VICE CHAIR AS THE STATUTORY VICE
6	CHAI R.
7	WE WOULD ALSO AMEND THE BYLAWS TO ADD A
8	CO-VICE CHAIR POSITION ELECTED PURSUANT TO THE
9	BYLAWS. FOR SHORTHAND PURPOSES, WE'LL REFER TO THAT
10	POSITION AS THE BYLAWS VICE CHAIR.
11	IN SECTION 2 OF ARTICLE 8, WE ACCOMPLISH
12	THREE THINGS. ONE, WE PROVIDE THAT THE ICOC MAY
13	ELECT A BYLAWS VICE CHAIR FROM AMONG ALL THE MEMBERS
14	OF THE BOARD WITH THE EXCEPTION OF THE CHAIR AND THE
15	STATUTORY VICE CHAIR. TWO, WE SPECIFY THAT THE
16	TERMS THE TERM OF THE BYLAWS VICE CHAIR IS
17	COTERMINOUS WITH THAT INDIVIDUAL'S TERM AS A MEMBER
18	OF THE ICOC EXCEPT THAT IT WILL NOT EXCEED SIX YEARS
19	TO MAKE SURE THAT WE HAVE CONGRUENCE BETWEEN THE
20	TERMS OF THE CHAIR AND THE VICE CHAIRS. AND THIRD,
21	WHEN THE BYLAWS VICE CHAIR'S TERM EXPIRES, WE
22	PROVIDE THAT THE BOARD MAY ELECT A SUCCESSOR.
23	SECTION 3 OF ARTICLE 8 SPECIFIES THAT THE
24	BYLAWS VICE CHAIR WILL PERFORM DUTIES AS DELEGATED
25	BY THE CHAIR FROM AMONG THE CHAIR'S SPECIFIED DUTIES

1	UNDER PROP 71 AND SUCH OTHER DUTIES WHICH ARE NOT
2	ALREADY STATUTORILY ASSIGNED AS THE BOARD MAY
3	APPROVE.
4	FINALLY, SECTION 4 OF ARTICLE 8 MAKES
5	CLEAR THAT THE BYLAWS VICE CHAIR IS ENTITLED TO THE
6	SAME PER DIEM AS ALL OF THE MEMBERS OF THE BOARD AND
7	IS NOT ENTITLED TO A SALARY. THE STATUTORY VICE
8	CHAIR UNDER PROPOSITION 71 IS TREATED AS AN EMPLOYEE
9	FOR PURPOSES OF COMPENSATION.
10	FINALLY, ON PAGE 2 IN ARTICLE 4, SECTION
11	2, WE MADE CLEAR THAT TO THE EXTENT THAT THE BYLAWS
12	VICE CHAIR HAS THE AUTHORITY TO APPOINT AN
13	ALTERNATE, HE OR SHE MAY CONTINUE TO EXERCISE THAT
14	AUTHORITY, BUT CANNOT DELEGATE HIS OR HER DUTIES AS
15	VICE CHAIR TO AN ALTERNATE.
16	SO THROUGH THESE AMENDMENTS, THE BOARD
17	WOULD CREATE A CO-CHAIR POSITION IN THE BYLAWS IN
18	ADDITION TO THE CO-CHAIR IN ADDITION TO THE VICE
19	CHAIR THAT IS SPECIFIED IN PROP 71.
20	MS. LANSING: THANK YOU, JAMES. AND I'D
21	NOW LIKE TO ASK CLAIRE, MY CO-CHAIR OF GOVERNANCE,
22	FOR HER COMMENTS. CLAIRE.
23	DR. POMEROY: I JUST WANT TO THANK SHERRY
24	FOR HER LEADERSHIP ON THIS AND COMMENT ON THE FACT
25	THAT THE GOVERNANCE COMMITTEE REALLY DID UNANIMOUSLY

1	RECOMMEND THIS APPROACH. I THINK THAT THIS IS AN
2	OPPORTUNITY FOR US TO REALLY FOCUS ON THE MISSION,
3	AND IT'S AN OPPORTUNITY FOR US TO DEMONSTRATE OUR
4	CREATIVITY AND OUR COLLABORATIVE NATURE, AND IT'S AN
5	OPPORTUNITY FOR US TO GET TWO FABULOUS CO-VICE
6	CHAIRS. AND I'M VERY PLEASED WITH THE
7	RECOMMENDATION OF THE GOVERNANCE SUBCOMMITTEE.
8	THANK YOU.
9	MS. LANSING: I'D LIKE TO THANK CLAIRE FOR
10	HER LEADERSHIP AND ALL THE MEMBERS OF THE GOVERNANCE
11	COMMITTEE WHO WORKED LONG AND HARD ON THIS ISSUE.
12	AND, BOB, I'D LIKE TO TURN IT OVER TO YOU FOR
13	COMMENTS.
14	CHAIRMAN KLEIN: CERTAINLY. AS CHAIR OF
15	THIS BOARD AND AS A MEMBER OF THE GOVERNANCE
16	COMMITTEE, WHEN SHERRY AND CLAIRE BROUGHT THIS
17	SUGGESTION TO ME, I EMBRACED THIS IMMEDIATELY
18	BECAUSE I SAW THE FUNDAMENTAL STRENGTH THAT IT ADDED
19	TO THIS BOARD IN FACING A TIME OF HISTORICALLY
20	UNPRECEDENTED CHALLENGES AND OPPORTUNITIES. AND I'D
21	LIKE TO UNDERLINE OPPORTUNITIES.
22	WE HAVE AN OPPORTUNITY HERE, AGAIN
23	ADDRESSING THESE INDIVIDUALS ALPHABETICALLY IN
24	SEQUENCE, TO CAPTURE THE TREMENDOUS HISTORY WITH
25	THIS BOARD AND CONTRIBUTIONS THAT DUANE ROTH HAS

1	MADE AS CHAIRMAN OF THE LOAN TASK FORCE AND IN MANY
2	OTHER ROLES. HE HAS A HISTORY IN BIOTECH AS ONE OF
3	FOUR BIOTECH COMMERCIAL LIFE SCIENCE REPRESENTATIVES
4	ON THE BOARD. HE HAS A HISTORY IN BIOTECH OF
5	ADVANCING THROUGH THE FDA 20 DIFFERENT THERAPIES AND
6	PRODUCTS. THIS IS CRITICAL KNOWLEDGE TO US IN OUR
7	BOARD LEADERSHIP.
8	HE HAS INTIMATE KNOWLEDGE IN HIS ROLE WITH
9	SAN DIEGO CONNECT, A NONPROFIT ORGANIZATION, OF HOW
10	CRITICAL A TIME IT IS FOR BIOTECH TO SURVIVE THE
11	FINANCIAL CRISIS THAT THE STATE AND COUNTRY IS IN.
12	HE HAS AN INNOVATIVE HISTORY IN ADDRESSING AND
13	SOLVING THOSE PROBLEMS, WHICH IS VITAL BECAUSE
14	BIOTECH IS A VITAL PART OF OUR PARTNERSHIP IN
15	DELIVERING THERAPIES TO PATIENTS.
16	IT IS IMPORTANT TO ALSO NOTE THAT HE HAS
17	REACHED OUT IN HIS HISTORY TO HELP PATIENTS IN THE
18	AMERICAN HEART AND AMERICAN LUNG ORGANIZATIONS. SO
19	WE HAVE A TREMENDOUS CONTRIBUTION HERE HISTORICALLY
20	AND PROSPECTIVELY TO CAPTURE.
21	AND WE LOOK AT ART TORRES. IT'S ESSENTIAL
22	TO REALIZE THAT AS A PATIENT ADVOCATE, HE'S A COLON
23	CANCER SURVIVOR, BUT HE'S REACHED OUTSIDE BECAUSE HE
24	UNDERSTANDS OUR ROLE ON THIS BOARD IS TO SERVE NOT
25	JUST THE BACKGROUND OF OUR PARTICULAR FAMILY

1	SUFFERING OR CHRONIC DISEASE, BUT TO REALLY REACH
2	OUT TO THE ENTIRE COMMUNITY SUFFERING FROM CHRONIC
3	DISEASE AND INJURY. SO HE HAS A HISTORY OF BEING ON
4	AN AIDS FOUNDATION BOARD FOR MORE THAN A DECADE, A
5	HISTORY OF BEING ON AN ORGAN TRANSPLANT BOARD FOR A
6	DECADE. TREMENDOUS CONTRIBUTIONS BEFORE HE EVEN
7	KNEW THIS BOARD EXISTED.
8	HE HAS A HISTORY OF SERVING AS CHAIRMAN OF
9	THE ASSEMBLY HEALTH COMMITTEE WHERE HE LOOKED AT HOW
10	DO YOU ACCESS HOW DO YOU GET ACCESS TO PATIENTS
11	FOR NEW THERAPIES WHICH, IN FACT, IS ONE OF OUR BIG
12	CHALLENGES HERE. HE HAS THE TREMENDOUS KNOWLEDGE HE
13	GAINED AS CHAIRMAN OF THE SENATE INSURANCE
14	COMMITTEE, AS WELL AS WITH THE JOINT COMMITTEE ON
15	SCIENCE AND TECHNOLOGY. WE NEED TO UNDERSTAND HOW
16	INSURANCE IS GOING TO INTERFACE WITH GOVERNMENTAL
17	SUBSIDIES AND SUPPORT FOR THESE NEW THERAPIES TO
18	MEET OUR OBLIGATION FOR ACCESS AND AFFORDABILITY.
19	IF YOU LOOK AT THESE TWO INDIVIDUALS, THEY
20	BRING TREMENDOUS ASSETS TO THE LEADERSHIP TO HELP
21	BUILD OUR MISSION. OUR GOAL, OUR COMMITMENT IS TO
22	GET THERAPIES TO PATIENTS. THIS IS A WAY WE CAN GO
23	OUTSIDE THE BOX, CAPTURE A REMARKABLE OPPORTUNITY,
24	AND ADVANCE THE THERAPY DEVELOPMENT MISSION BRINGING
25	IT TO PATIENTS WHICH IS OUR OBLIGATION WHICH IS

1	OUR PRIVILEGE, AND WHICH IS OUR SOLEMN OATH.
2	SO WITH THAT, I WOULD LIKE TO SAY I THINK
3	THIS IS SOMETHING I HOPE WE CAN MOVE ON AND SUPPORT,
4	BUT THERE ARE OTHER MEMBERS WHO MAY WANT TO MAKE
5	INDIVIDUAL STATEMENTS BECAUSE EACH PERSON HAS
6	SERIOUSLY CONSIDERED THIS.
7	MR. SERRANO-SEWELL: AS TO THE MOTION
8	AHEAD OF US, WHICH IS FOR THE BYLAW AMENDMENTS, IF
9	YOU FEEL IT'S IN ORDER, I'D LIKE TO MAKE A MOTION TO
10	ADOPT.
11	MS. LANSING: SO I'D LIKE NOW TO ASK FOR A
12	MOTION TO ADOPT THE PROPOSED AMENDMENTS TO THE
13	BYLAWS TO CREATE A CO-VICE CHAIR POSITION. SO JUST
14	NOW I WANTED TO KNOW IF THERE ARE ANY COMMENTS BY
15	THE BOARD.
16	MR. SERRANO-SEWELL: FOR THE PURPOSES OF
17	ADOPTING THE BYLAWS WANTED TO MAKE THE MOTION.
18	CHAIRMAN KLEIN: SECOND.
19	MS. LANSING: SO NOW I WANT COMMENTS BY
20	THE BOARD.
21	DR. LEVEY: I THINK THAT THIS IS A
22	MAGNIFICENT DECISION. I WANT TO CONGRATULATE SHERRY
23	AND ALL THOSE ON THE GOVERNANCE COMMITTEE. THIS IS,
24	I THINK, A TERRIFIC STEP FORWARD. SO I CERTAINLY
25	WANT TO ADD MY STRONGEST SUPPORT. CLAIRE, ALSO YOU
	68

1	DID A MAGNIFICENT JOB.
2	DR. PENHOET: I TOO, AS THE OUTGOING VICE
3	CHAIR, I WANT TO ENTHUSIASTICALLY ENDORSE THE
4	SOLUTION OF FINDING THESE TWO INDIVIDUALS TO BE
5	CO-VICE CHAIR. I THINK THEY BOTH BRING STRONG
6	SKILLS TO THE POSITION, QUITE COMPLEMENTARY, BUT
7	VERY DIFFERENT SKILLS, BOTH OF WHICH ARE HIGHLY
8	NEEDED AT THIS PRESENT TIME. I HAVE MET WITH BOTH
9	OF THE INDIVIDUALS. THEY SOUGHT MY ADVICE AS THE
10	OUTGOING CHAIR ABOUT WHAT THE ROLE WOULD ENTAIL AND
11	HOW THEY MIGHT PROCEED IF THEY WERE ELECTED.
12	THEY' RE BOTH VERY THOUGHTFUL PEOPLE. THEY' RE BOTH
13	VERY EAGER TO SERVE IN THIS CAPACITY. AND I THINK
14	THAT, AS I SAID, THEY BRING DIFFERENT SKILLS.
15	AND I THINK, IN THE CASE, OF DUANE ROTH HE
16	ALSO WILL BRING A HIGH LEVEL PRESENCE OF CIRM TO
17	SOUTHERN CALIFORNIA, WHICH IS, I THINK, EXTREMELY
18	IMPORTANT GIVEN THE CONCENTRATION OF OUR ACTIVITIES
19	IN THE SOUTHERN PART OF THE STATE.
20	SO IT DOES HELP US BALANCE OUR
21	GEOGRAPHICAL REPRESENTATION THROUGHOUT THE STATE.
22	ON ALL THOSE GROUNDS, I'M VERY SUPPORTIVE OF THIS
23	SOLUTI ON.
24	MS. LANSING: THANK YOU, ED.
25	DR. LOVE: I WAS JUST GOING TO MAKE A

1	COUPLE OF COMMENTS, SHERRY. ONE, I WANTED TO JUST
2	SAY I THINK THAT WE SHOULD REALLY APPLAUD YOU AND
3	CLAIRE AND THE GOVERNANCE COMMITTEE. OFTENTIMES
4	ORGANIZATIONS BEHAVE IN A VERY BUREAUCRATIC WAY. I
5	THINK ONE OF THE KEY SUCCESS FEATURES THAT WE'VE
6	SEEN IN THIS ORGANIZATION IS THAT IT THINKS OUT OF
7	THE BOX AND REALLY DOES STEP BACK AND MAKE THE BEST
8	DECISION. WHILE THIS LOOKS LIKE AN EASY DECISION,
9	I'M SURE IT WASN'T EASY BECAUSE OF THE BUREAUCRATIC
10	NATURE.
11	I ALSO WANTED TO SAY THAT I, ALONG WITH
12	MANY OF US ON THIS BOARD, HAVE HAD THE CHANCE TO
13	WORK WITH DUANE, AND IT IS JUST A PLEASURE TO SEE
14	HIS CONTRIBUTIONS ACKNOWLEDGED AND US PUTTING YOU IN
15	A POSITION TO BRING GREATER REPRESENTATION TO
16	SOUTHERN CALIFORNIA, BUT ALSO BRING EVEN GREATER
17	CONTRIBUTIONS TO THIS BOARD, DUANE.
18	AND TO ART I JUST WANTED TO SAY THAT I'M
19	JUST SO PERSONALLY THRILLED THAT WE HAVE THE
20	OPPORTUNITY TO HAVE YOU JOIN US. I, LIKE MOST OF
21	THE BOARD MEMBERS, HAVE HAD SOME LIMITED
22	INTERACTIONS WITH YOU, SOME MORE, AND IT'S VERY
23	EXCITING TO SEE SOMEONE OF YOUR STATURE AND YOUR
24	HISTORY OF CONTRIBUTIONS TO THE STATE JOIN THE
25	BOARD.
	70

1	AND FINALLY, I DO WANT TO END BY SAYING
2	THAT I THINK THAT ED PENHOET HAS BEEN AN
3	EXTRAORDINARY VICE CHAIR. AND I THINK IT'S REALLY
4	IMPORTANT FOR US TO RECOGNIZE.
5	(APPLAUSE.)
6	MS. LANSING: ANY OTHER COMMENTS BY THE
7	BOARD? ANY
8	MS. GIBBONS: I AM SO EXCITED AT THIS
9	POSSIBILITY. AND AS EVERYONE ELSE HAS SAID, OUR
10	THANKS TO SHERRY AND CLAIRE IN THIS INCREDIBLE
11	POSSIBILITY BECAUSE TO HAVE EITHER DUANE ROTH OR ART
12	TORRES IS WILDLY EXCITING. THE POSSIBILITY TO HAVE
13	THEM BOTH IS SIMPLY IRRESISTIBLE.
14	MS. LANSING: AGAIN, I WANT TO EMPHASIZE
15	IT WAS THE WHOLE COMMITTEE THAT WORKED LONG AND
16	HARD. SO PLEASE THANK YOU TO EVERY SINGLE MEMBER OF
17	THE COMMITTEE.
18	CHAIRMAN KLEIN: SHERRY, I THINK IT WOULD
19	BE APPROPRIATE FOR US TO THANK THE GOVERNOR, THE
20	LIEUTENANT GOVERNOR, THE TREASURER, AND THE
21	CONTROLLER FOR GIVING US THIS TREMENDOUS OPPORTUNITY
22	TO BUILD ADDITIONAL STRENGTH FOR OUR BOARD.
23	MS. LANSING: THANK YOU. ANY OTHER
24	COMMENTS? MEMBERS OF THE PUBLIC? JOHN.
25	DR. SIMPSON: I WON'T BE JOINING YOU IN
	71

1	SINGING KUMBAYA. I THINK IT'S NOT THE WAY TO GO. I
2	HAVE THE HIGHEST REGARD FOR BOTH OF THESE GENTLEMEN
3	AND PARTICULARLY HIGH REGARD FOR THE OUTGOING VICE
4	CHAIRMAN. WHY DON'T YOU ALL NAME YOURSELVES VICE
5	CHAIRMAN AND HAVE 28 VICE CHAIRMEN AND GO FORWARD?
6	IF THREE IS GOOD, 28 IS BETTER.
7	BUT I DO HAVE A VERY SERIOUS QUESTION.
8	UNDER THE STATUTORY POSITION, THE VICE CHAIR IS
9	CONSIDERED AN EMPLOYEE AND IS HELD TO THE EMPLOYEE'S
10	CONFLICT OF INTEREST STANDARDS. I'M WONDERING
11	WHETHER THOSE ARE SOMEWHAT HIGHER STANDARDS. SO
12	UNDER THE BYLAWS WILL THE VICE CHAIRMAN ALSO BE
13	FOLLOWING THE EMPLOYEE'S CONFLICT OF INTEREST
14	STANDARDS EVEN THOUGH HE WOULD NOT BE DRAWING A
15	SALARY AND WOULD NOT BE AN EMPLOYEE? IT SEEMS TO ME
16	YOU WOULD HAVE TO HAVE, IF THEY'RE CO-EQUAL VICE
17	CHAIRMEN, THEY HAVE TO BOTH FOLLOW THE SAME CONFLICT
18	OF INTEREST STANDARDS.
19	CHAIRMAN KLEIN: THANK YOU, JOHN SIMPSON.
20	AND WE'VE THOUGHTFULLY LOOKED AT THIS. AND, JAMES,
21	CAN YOU, FOR THE PURPOSES OF THE PUBLIC, STATE THE
22	SPECIFIC STANDARD RELATED TO OWNERSHIP IN STEM CELL
23	COMPANIES THAT JOHN IS SPECIFICALLY ADDRESSING?
24	MR. HARRISON: YES. WHAT JOHN IS
25	REFERRING TO IS A PROVISION IN THE CIRM CONFLICT OF
	70
	70

1	INTEREST POLICY. AND I THINK IT'S IMPORTANT TO NOTE
2	AT THE OUTSET THAT THIS IS NOT A REQUIREMENT OF
3	STATE LAW. THIS IS A POLICY THAT THE BOARD ADOPTED
4	THAT GOES ABOVE AND BEYOND ANY OTHER STATE LAW
5	REQUIREMENT.
6	THE PROVISION SPECIFICALLY PROVIDES THAT
7	AN EMPLOYEE OF CIRM MAY NOT HOLD AN INVESTMENT IN A
8	COMPANY THAT DEVOTES 5 PERCENT OR MORE OF ITS
9	RESEARCH BUDGET TO STEM CELL RESEARCH.
10	CHAIRMAN KLEIN: AND MY UNDERSTANDING,
11	DUANE, IS YOU'RE AWARE OF THIS AND COMPLETELY AGREED
12	WITH CONFORMING TO THIS REQUIREMENT.
13	MR. ROTH: THAT'S CORRECT. I WENT THROUGH
14	THIS WITH JAMES AT THE VERY BEGINNING, AND I WILL
15	ABI DE.
16	MR. REED: ON MONDAY, LIKE BOB, I HAD THE
17	PRIVILEGE OF BEING INVITED TO BE IN THE ROOM WHEN
18	THE PRESIDENT SIGNED THAT MAGNIFICENT OVERTURNING OF
19	THE BUSH RESTRICTIONS. AND I HAVE TO SHARE WITH YOU
20	THAT ELECTRIC MOMENT WHEN THE PRESIDENT CAME IN AND
21	THEY SAID THE PRESIDENT OF THE UNITED STATES, AND
22	PEOPLE JUMPED UP. I'M SURE THERE WAS AIR BETWEEN
23	OUR FEET. WE WERE UNITED WITH THE JOY OF SEEING A
24	PRESIDENT FULLY COMMITTED AND ON OUR SIDE.
25	THE SITUATION WE FACE IN CALIFORNIA IS

1	VERY SIMILAR TO THE SITUATION FACED BACK THERE.
2	PEOPLE OF GOODWILL THAT AGREE WITH US ARE FACED WITH
3	TREMENDOUS FINANCIAL DIFFICULTIES, AND WE NEED
4	SOMEONE POLITICALLY ASTUTE TO GUIDE US THROUGH THOSE
5	TROUBLED WATERS. WE'VE HAD TO FACE BIG PROBLEMS IN
6	CALIFORNIA WITH LAWS WITH THE BEST INTENTIONS IN THE
7	WORLD WHICH COULD HAVE BEEN VERY DIFFICULT FOR US
8	HAD THEY BEEN ENACTED. THE IDEA OF HAVING ART
9	TORRES WITH US IS JUST TREMENDOUS.
10	BUT EVERY PATIENT ADVOCATE OWES A DEBT TO
11	DUANE ROTH. HE HAS ALWAYS BEEN TELLING US HOW TO
12	WORK WITH THE PRIVATE SECTOR, WHICH IS THE KEY ON
13	WHICH EVERYTHING WORKS. HE IS CLEAR, HE IS
14	COMPASSIONATE, HE IS CARING, HE IS UTTERLY
15	DEDICATED. HOW COULD WE POSSIBLY CHOOSE? THIS IS
16	THE ONLY ANSWER, AND I'M JUST DELIGHTED WITH IT.
17	THANK YOU VERY MUCH.
18	MS. LANSING: THANK YOU, DON.
19	CHAIRMAN KLEIN: SO I'D LIKE EVERYONE TO
20	UNDERSTAND THAT DON REED AND HIS SON, ROMAN REED,
21	WERE AT THIS CEREMONY. THEY HAVE A VERY SPECIFIC
22	AND SPECIAL CONNECTION TO THE ORIGINS OF EMBRYONIC
23	STEM CELL RESEARCH IN THE STATE BECAUSE DON FOUGHT
24	TO GET WHAT EVENTUALLY BECAME ABOUT \$3 MILLION OF
25	ASSISTANCE UNDER THE ROMAN REED ACT TO EMBRYONIC

	DANNISTERS REPORTING SERVICE
1	STEM CELL RESEARCH IN HANS KEIRSTEAD'S LAB AT UC
2	IRVINE THAT LED TO THE RESEARCH THAT IS NOW PART OF
3	THE ACUTE PARALYSIS HUMAN CLINICAL TRIAL WITH AN
4	EMBRYONIC STEM CELL THERAPY THAT GERON IS LEADING
5	AND HAS FDA APPROVAL FOR. SO WE MUST REMEMBER THE
6	HISTORY, AND CERTAINLY IT WAS AN ABSOLUTELY
7	PHENOMENALLY WELL EARNED HONOR FOR YOU TO HAVE ROMAN
8	THERE AS WELL. SO THANK YOU, DON.
9	MS. LANSING: SO I HAVE A MOTION ON THE
10	FLOOR. I'VE HEARD FROM MEMBERS OF THE PUBLIC. ALL
11	IN FAVOR? ANY OPPOSED?
12	CHAIRMAN KLEIN: THEN IF YOU WILL TAKE,
13	SHERRY, A TELEPHONIC ROLL CALL.
14	MS. LANSING: CAN I HAVE A TELEPHONIC ROLL
15	CALL?
16	MS. KING: MICHAEL FRIEDMAN. GERALD
17	LEVEY.
18	DR. LEVEY: YES.
19	MS. KING: ED PENHOET.
20	DR. PENHOET: YES.
21	MS. KING: JONATHAN SHESTACK.
22	MR. SHESTACK: YES.
23	MS. LANSING: MOTION CARRIES.
24	CHAIRMAN KLEIN: UNANIMOUSLY.
25	MS. LANSING: UNANIMOUSLY THE MOTION
	75
	75

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

CARRI ES. THANK YOU.
NOW, AS CHAIR OF THE GOVERNANCE
SUBCOMMITTEE, I HAVE THE GREAT HONOR OF MAKING A
MOTION IN ALPHABETICAL ORDER TO ELECT DUANE ROTH AS
BYLAWS VICE CHAIR AND TO ELECT ART TORRES AS
STATUTORY VICE CHAIR AT A SALARY OF 75,000 FOR
50-PERCENT TIME. IS THERE A SECOND?
MR. SERRANO-SEWELL: BEFORE WE PROCEED, I
HAD A POINT OF ORDER FOR SHERRY. THAT IS, FOR THIS
MOTION, BECAUSE I WANT TO MAKE SURE I UNDERSTAND IT,
I THINK I DO. I DON'T THINK DUANE IS PERMITTED TO
PARTICIPATE IN THIS VOTE; IS THAT RIGHT?
MS. LANSING: CORRECT.
MR. SERRANO-SEWELL: WHY IS THAT?
CHAIRMAN KLEIN: BECAUSE HE IS A CANDIDATE
FOR ONE OF THE POSITIONS, SO HE IS RECUSING HIMSELF
AS IS OUR STANDARD PRACTICE.
MR. SERRANO-SEWELL: UNDER THE MOTION IT'S
A YES FOR SENATOR TORRES FOR THE STATUTORY VICE
CHAIR AND A YES FOR DUANE ROTH AS THE BYLAWS VICE
CHAI R?
CHAIRMAN KLEIN: THAT'S A CORRECT
STATEMENT.
MR. SERRANO-SEWELL: OKAY.
CHAIRMAN KLEIN: AND THE SALARY APPLIES TO
76

1	THE STATUTORY VICE CHAIR FOR WHICH ART TORRES IS THE
2	NOMINEE BECAUSE THE INITIATIVE SPECIFIES THAT A
3	SALARY CAN ONLY BE WITH THE STATUTORY VICE CHAIR.
4	MR. SERRANO-SEWELL: I JUST WISH IN THE
5	SPIRIT OF UNITY THAT DUANE COULD PARTICIPATE IN THE
6	VOTE.
7	CHAIRMAN KLEIN: HE CAN'T, BUT WE'RE
8	ALWAYS CONSERVATIVE ON THESE ISSUES.
9	MS. LANSING: THANK YOU FOR THAT. DO I
10	HAVE A SECOND?
11	DR. PULI AFI TO: SECOND.
12	MS. LANSING: DO I HAVE ANY COMMENTS BY
13	MEMBERS OF THE BOARD?
14	DR. PRIETO: YES, JUST WITH REGARDS TO THE
15	SALARY. I UNDERSTAND THAT WE'VE BEEN CRITICIZED AND
16	ARE GOING TO BE CRITICIZED FOR OFFERING A SALARY,
17	BUT I BELIEVE VERY STRONGLY THAT EVERYBODY SHOULD BE
18	COMPENSATED APPROPRIATELY AND PAID FOR THE WORK
19	THEY'RE EXPECTED TO DO. AND IT'S A PRINCIPLE THAT
20	EXTENDS FAR BEYOND THIS BOARD AND THIS AGENCY. AND
21	I THINK IT'S INAPPROPRIATE AND WRONG TO DEMAND THAT
22	PEOPLE WORK FOR FREE. THERE'S A WORD FOR THAT.
23	I THINK IN THE CONTEXT OF THIS BOARD AND
24	THE STATE AGENCY, TO DEMAND SOMETHING LIKE THAT
25	EXCLUDES FROM PARTICIPATION ANYONE WHO ISN'T EITHER

1	PERSONALLY INDEPENDENTLY WEALTHY OR CAN DEPEND ON A
2	SUBSTANTIAL OUTSIDE INCOME. AND THAT'S A HUGE
3	PROPORTION OF THE POPULATION THAT DESERVES TO BE
4	REPRESENTED HERE AS EVERYWHERE ELSE.
5	GIVEN THE AMOUNT OF WORK THAT WE EXPECT
6	AND HAVE RECEIVED FROM OUR VICE CHAIR IN THE PAST,
7	I'M REALLY STRUCK BY HOW LOW THIS SALARY IS. I
8	WOULD HAVE PREFERRED IT BE HIGHER. I'M VERY HAPPY
9	THAT OUR CANDIDATES ARE WILLING TO WORK FOR THAT,
10	BUT I WOULD HAVE BEEN HAPPY TO PAY THEM MORE.
11	CHAIRMAN KLEIN: ON THAT ISSUE I'D LIKE TO
12	COMMENT THAT IN ORDER FOR HEALTHCARE COVERAGE IN THE
13	STATE OF CALIFORNIA, YOU HAVE TO HAVE AT LEAST A
14	HALF-TIME SALARY. SO IT'S IMPORTANT. WE HAVE
15	PATIENT ADVOCATES ON THIS BOARD THAT FIGHT EVERY DAY
16	AGAINST CHRONIC DISEASE, AND ART TORRES IS A COLON
17	CANCER SURVIVOR. HEALTHCARE IS ONE OF THE
18	FUNDAMENTAL RIGHTS WE'D LIKE TO HAVE FOR EVERY
19	CALIFORNIAN. AND IT IS CRITICAL FOR THIS AGENCY
20	DEDICATED TO THERAPIES FOR PATIENTS TO HONOR AND
21	MAKE SURE WE DELIVER THAT WHENEVER WE CAN.
22	DR. PRIETO: I'M HOPING OUR NEW PRESIDENT
23	FIXES THAT PROBLEM TOO.
24	MS. LANSING: ANY OTHER COMMENTS BY
25	MEMBERS OF THE BOARD?
	70

1	MR. SERRANO-SEWELL: WELL, I WANT TO START
2	OFF MAYBE EVERYONE HAS ALREADY SAID IT ABOUT
3	HAVING TWO HIGH CALIBER INDIVIDUALS. BUT I KNOW ONE
4	OF THESE HIGH CALIBER INDIVIDUALS PERSONALLY. ART
5	HAS BEEN A MENTOR OF MINE. HE'S ALMOST BEEN A
6	FATHER TO ME. OUR FAMILIES GO BACK FOR A VERY LONG
7	TIME, DECADES. AND MY PERSONAL EXPERIENCE HAS BEEN
8	SHAPED WALKING PRECINCTS FOR HIM AND MY OTHER MENTOR
9	RICHARD ALATORRE IN EAST LOS ANGELES THINKING
10	EVERYBODY DID THAT ON SUNDAYS. ONLY COME TO REALIZE
11	LATER THAT'S NOT WHAT EVERYBODY DOES ON A SUNDAY.
12	TO HAVE IT'S REAL, TO HAVE SOMEBODY OF
13	ART'S CALIBER JOIN THIS BOARD RESONATES, NOT JUST IN
14	OUR CIRCLES, BUT IN LOS ANGELES. PEOPLE KNOW ABOUT
15	THIS IN LOS ANGELES. THEY KNOW ABOUT IT IN THE
16	CENTRAL VALLEY BECAUSE FOR 30 PLUS YEARS ART TORRES
17	HAS TOUCHED PEOPLE'S LIVES. HE STARTED OFF WITH THE
18	UNITED FARM WORKERS AND WORKING SIDE BY SIDE WITH
19	CESAR CHAVEZ. HE THEN WENT ON TO SERVE IN THE STATE
20	LEGISLATURE. HIS ENTIRE LIFE HAS BEEN ABOUT PUBLIC
21	SERVICE. TO HAVE HIM COME BACK INTO THE PUBLIC
22	POLICY ARENA FOR US AND NOT SOME OTHER BOARD OR SOME
23	OTHER EFFORT SPEAKS, I THINK, TO THE GOOD WORK THAT
24	WE DO, BUT ALSO SPEAKS TO ART PERSONALLY, THAT HE IS
25	A REAL, REAL PERSON. AND I KNOW THAT THAT CAME

1	ACROSS I SUSPECT THAT CAME ACROSS WHEN ART MET
2	INDIVIDUALLY WITH PEOPLE AND THEY GOT TO UNDERSTAND
3	AND KNOW HIM A LITTLE BIT BETTER.
4	BUT I CAN THINK OF WHEN I WAS AT THE
5	DEMOCRATIC CONVENTION IN DENVER AND SENATOR TED
6	KENNEDY GAVE HIS SPEECH ON MONDAY NIGHT, WHICH WAS A
7	VERY MOVING AND TOUCHING SPEECH BECAUSE HE'S A
8	NATIONAL HERO, HE'S THE TREASURE FOR OUR COUNTRY,
9	THE INTRODUCTION VIDEO COULD HAVE SAID ANYTHING
10	ABOUT TED KENNEDY BECAUSE HE HAS SUCH AN IMPRESSIVE
11	RECORD. IT FOCUSED ON HIS WORK ON STEM CELL
12	RESEARCH BECAUSE THAT'S WHAT SENATOR KENNEDY WANTED.
13	HE WANTED A MENTION OF STEM CELL RESEARCH.
14	WE SAW THE FRUITION OF THAT ON MONDAY,
15	RIGHT? SO TO GET FOR ME IT MEANT A LOT WHEN I
16	HAD AN ENDORSEMENT LETTER FROM SENATOR KENNEDY
17	TALKING ABOUT ART TORRES. I DON'T KNOW SENATOR TED
18	KENNEDY, BUT I KNOW HE'S A VERY BUSY MAN, AND HE'S
19	AT A STAGE IN HIS LIFE WHERE HE DOESN'T NEED TO
20	WRITE LETTERS OR MAKE CALLS ANYMORE. BUT TO HAVE
21	HIM SAY THAT, AND I WON'T READ THE WHOLE LETTER, BUT
22	JUST A COUPLE SNIPPETS BECAUSE IT JUST IS VERY
23	TOUCHI NG.
24	"HIS RECORD OF PUBLIC SERVICE IS ONE THAT
25	ANY ELECTED OFFICIAL IN AMERICA WOULD BE PROUD OF."

1	I GUESS THAT INCLUDES BARACK OBAMA. "ART TORRES
2	ENTERED PUBLIC LIFE FOR THE RIGHT REASONS, TO
3	IMPROVE THE LIVES OF OUR CITIZENS, ESPECIALLY THOSE
4	WITHOUT A VOICE, AND TO SERVE HIS COUNTRY. HIS
5	YEARS OF ADVOCACY FOR MEDICAL RESEARCH AND BETTER
6	HEALTHCARE FOR CALIFORNIANS WILL BE A MAJOR ASSET TO
7	THIS COMMITTEE. A GREAT DEAL IS AT STAKE. AND I'M
8	CONFIDENT THAT ART TORRES WILL MAKE A DIFFERENCE FOR
9	OUR COUNTRY AS HE ALWAYS HAS."
10	MS. LANSING: VERY WELL SAID. AND AS I
11	SAID, THAT'S WHY WE'RE HERE BECAUSE WE FEEL VERY,
12	VERY BLESSED AND LUCKY TO HAVE ART AND DUANE AS OUR
13	REPRESENTATIVES AS VICE CHAIRS. OTHER COMMENTS FROM
14	THE BOARD?
15	DR. AZZIZ: I JUST WANT TO MAKE A COMMENT
16	MAINLY FOR THE MINUTES, BUT ALSO FOR OUR COLLEAGUES.
17	THIS IS A UNIQUE TIME FOR OUR BOARD. MOST OF US WHO
18	WORK ON BOARDS FOR PUBLIC BENEFIT FIND, IN FACT,
19	THAT WE CAN'T FIND LEADERSHIP INDIVIDUALS OR
20	INDIVIDUALS WILLING TO TAKE LEADERSHIP. AND THIS IS
21	A UNIQUE OPPORTUNITY. WE HAVE TWO GREAT CANDIDATES.
22	THEY BOTH BRING SKILLS THAT, IN FACT, ARE
23	COMPLEMENTARY, WHICH IS ABSOLUTELY DIFFERENT THAN
24	ANYTHING WE'VE SEEN. SO I DON'T THINK THAT WE WILL
25	BE IN THIS FORTUNATE POSITION FOR YEARS TO COME. SO

1	WE ARE BLESSED IN THAT REGARD, AND I THINK WE SHOULD
2	TAKE THAT OPPORTUNITY WHEN IT COMES.
3	MS. LANSING: AND THEY HAVE
4	ENTHUSIASTICALLY EMBRACED THIS PARTNERSHIP, WHICH
5	SHOWS THE CHARACTER, ONCE AGAIN, OF BOTH INDIVIDUALS
6	AND THE COLLABORATIVE NATURE OF BOTH INDIVIDUALS.
7	CAN I HAVE OTHER COMMENTS FROM THE BOARD?
8	MS. SAMUELSON: I THINK THE PHRASE I WOULD
9	USE FOR THIS IS CAUTIOUSLY OPTIMISTIC. AND I USE
10	THAT FOR THIS REASON. I HOPE VERY MUCH THAT IT WILL
11	SOLVE WHAT HAVE BEEN A COUPLE OF BIG OBSTACLES FOR
12	US. I'M NOT ON THIS BOARD TO SPEND TIME IN A LOT OF
13	PROCEDURES, AS CRITICAL AS THEY ARE. SO I'M NOT ON
14	THE GOVERNANCE COMMITTEE, FOR EXAMPLE. AND I'M
15	GRATEFUL THAT YOU'VE DONE THIS WORK BECAUSE WHEN I
16	WAKE UP IN THE MORNING, I'M JUST TRYING TO FIGURE
17	OUT HOW WE'RE GOING TO SHAPE THE POLICY.
18	AND OUR THE IMMENSE AMOUNT OF TIME
19	WE'VE HAD TO SPEND WITH THE LEGISLATURE HAS MADE IT
20	HARD FOR US TO FOCUS AS MUCH AS WE NEED TO ON THAT.
21	AND I HAVE FELT ALL ALONG THAT WE NEEDED MORE OF THE
22	BIOTECH COMMUNITY INVOLVED WITH US HELPING US INFORM
23	DECISIONS LIKE WHERE INTELLECTUAL PROPERTY AND THE
24	REGULATIONS FOR THAT BLEED OVER INTO THE ISSUE OF
25	GETTING A CURE SOONER RATHER THAN LATER, ETC. SO
	82

I'M VERY HOPEFUL THAT DUANE CAN BRING HIS EXPERTISE
TO MORE AND MORE OF THOSE DELIBERATIONS IN THIS
SPECIAL ROLE.
SO I'M EXCITED ABOUT BOTH OF THESE OPTIONS
FOR THAT REASON. BUT HOPING VERY MUCH THAT THEY
WILL PROVE TO SERVE US AS WE HOPE BECAUSE WE DON'T
HAVE ANY MORE TIME.
MS. LANSING: THANK YOU. ANY OTHER BOARD
COMMENT?
CHAIRMAN KLEIN: SO AS THE CHAIRMAN, I'D
LIKE TO SAY THAT I AM DEEPLY APPRECIATIVE TO ART
TORRES AND TO DUANE ROTH FOR AGREEING TO JOIN THE
LEADERSHIP TEAM IF THIS VOTE IS SUCCESSFUL.
REMARKABLE INDIVIDUALS WITH GREAT HISTORIES. I'VE
KNOWN DUANE'S DEDICATION FOR SOME TIME. I MET ART
FOR THE FIRST TIME NOT LONG AGO, NOW COUPLE OF
MONTHS AGO. AND I WAS IMMEDIATELY IMPRESSED WITH
HIS SINCERE, INTENSE COMMITMENT TO OUR MISSION. TO
HAVE THESE INDIVIDUALS OF SUCH GREAT TALENT AND
HISTORY JOIN THE LEADERSHIP TEAM IS OF IMMEASURABLE
IMPORTANCE, AND I STRONGLY BELIEVE OPTIMISTICALLY
THAT IT WILL HAVE A TREMENDOUSLY POSITIVE EFFECT ON
ADVANCING THERAPIES FOR PATIENTS, WHICH IS OUR
MI SSI ON.
MS. LANSING: THANK YOU. MAY I HAVE
83

1	COMMENTS FROM MEMBERS OF THE PUBLIC?
2	DR. SIMPSON: JOHN SIMPSON FROM CONSUMER
3	WATCHDOG. I WANT TO SPEAK TO THE SALARY ISSUE FOR
4	JUST A BRIEF SECOND, AND I MIGHT SURPRISE YOU. I
5	WANT TO UNDERSCORE WHAT DR. PRIETO SAID. AND I HAVE
6	BEEN CRITICAL OF SOME OF THE HIGH LEVEL SALARIES IN
7	THIS AGENCY AT THE VERY TOP LEVELS AND CONTINUE TO
8	BE SO. BUT I THINK THAT \$75,000 FOR THE STATUTORY
9	VICE CHAIR IS ENTIRELY APPROPRIATE AND, IN FACT, I
10	WOULD HAVE THOUGHT SOMETHING LIKE \$90,000 WOULD HAVE
11	BEEN FINE TOO, WHICH WOULD HAVE BEEN ABOUT HALF OF
12	WHAT THE LOWEST END OF THE RANGE WAS IN THE FORMER
13	SALARY SCHEDULE, WHICH IS WHAT WAS APPLIED TO THE
14	CHAIRMAN'S SALARY.
15	SO, YOU KNOW, I'M NOT GOING TO ADVOCATE
16	WASTING TAXPAYERS' MONEY, BUT I WOULD SUGGEST THAT
17	SOMEONE ON THE BOARD MIGHT WANT TO AMEND THE THING
18	THAT'S BEFORE YOU AND OFFER THE STATUTORY VICE
19	CHAIRMAN AN APPROPRIATE COMPENSATION OF \$90,000.
20	CHAIRMAN KLEIN: IT'S FIRST OF ALL,
21	BOTH OF THESE INDIVIDUALS BRING CONTRIBUTIONS WHERE
22	WE CERTAINLY IN A NORMAL ECONOMY, IN NORMAL
23	FINANCIAL POSITION SHOULD BE COMPENSATED AT A MUCH
24	HIGHER LEVEL. I WOULD HOPE THE STATE RETURNS TO A
25	POINT THAT WE CAN DO THAT BECAUSE WHERE WE CAN WITH

1	THE STATUTORY VICE CHAIR, IT IS INCREDIBLY VALUABLE
2	TO THE STATE OF CALIFORNIA AND TO PATIENTS TO HAVE
3	THIS SERVICE AND TO ALLOW THE PERSON TO CONTRIBUTE
4	AS MUCH OF THEIR TIME AS POSSIBLE. BUT WE HAVE AN
5	AGREEMENT WITH BOTH OF THE CANDIDATES. DUANE IS NOT
6	TAKING A SALARY, FOR WHICH WE'RE VERY APPRECIATIVE.
7	MR. SERRANO-SEWELL: WAIT. WAIT. THAT'S
8	NOT ENTIRELY TRUE. THE BYLAWS FAR BE IT FROM ME
9	TO DISAGREE AT THIS POINT, BUT THE BYLAWS VICE
10	CHAIR, AS I READ THEM, IS ENTITLED TO COMPENSATION
11	THAT IS COMMENSURATE WITH THAT OF AN ICOC MEMBER.
12	WHETHER YOU WANT TO PARCEL WITH THAT, IT'S A PER
13	DIEM, SO IT'S NOT THE FACT OF THE MATTER IS THE
14	BYLAWS VICE CHAIR RECEIVES MONEY.
15	CHAIRMAN KLEIN: I DON'T CONSIDER THE PER
16	DIEM THAT THIS BOARD GETS TO BE
17	MR. SERRANO-SEWELL: BUT TO SAY THAT THE
18	BYLAWS VICE CHAIR IS NOT AN ACCURATE STATEMENT.
19	CHAIRMAN KLEIN: I STAND CORRECTED.
20	MR. SERRANO-SEWELL: THANK YOU.
21	CHAIRMAN KLEIN: ART TORRES IN ACCEPTING
22	THE SALARY THAT HE'S GIVEN HAS BEEN EXTRAORDINARILY
23	GENEROUS BECAUSE OF HIS INTENSE COMMITMENT TO
24	PATIENTS AND TO OUR MISSION. SO WE HAVE CLOSURE ON
25	THAT ISSUE WITH THE CANDIDATES, AND I WOULD REQUEST

1	WE MOVE THE MOTION.
2	MS. LANSING: CAN I HAVE ALL IN FAVOR?
3	I'VE HAD A MOTION AND A SECOND. ALL IN FAVOR,
4	PLEASE. ANY OPPOSED? NOW I'LL HAVE A ROLL CALL
5	VOTE ON THE PHONE.
6	MS. KING: MICHAEL FRIEDMAN.
7	DR. FRIEDMAN: YES.
8	MS. KING: GERALD LEVEY.
9	DR. LEVEY: YES.
10	MS. KING: ED PENHOET.
11	DR. PENHOET: YES.
12	MS. KING: JON SHESTACK.
13	MR. SHESTACK: YES.
14	MS. LANSING: I AM DELIGHTED TO REPORT
15	THAT THE MOTION
16	MR. ROTH: I WANT THE RECORD TO SHOW I
17	ABSTAI NED.
18	MS. LANSING: I AM DELIGHTED TO SAY THAT
19	THE MOTION PASSES UNANIMOUSLY, AND I'D LIKE TO
20	CONGRATULATE OUR NEW VICE CHAIRS.
21	(APPLAUSE.)
22	CHAIRMAN KLEIN: I'D LIKE TO I'M GOING
23	TO HAVE A SHORT BREAK, BUT FIRST I'D LIKE TO GIVE
24	ART TORRES THE OPPORTUNITY TO INTRODUCE HIS FAMILY
25	AND GUESTS IN THE AUDIENCE, IF HE WOULD CHOOSE TO.

1	MR. TORRES: WELL, THANK YOU VERY MUCH.
2	AND AS I SAID TO DUANE LAST NIGHT, I REALLY
3	APPRECIATED HIS COLLABORATION IN TERMS OF MAKING
4	THIS WORK FOR ALL OF US. AND I REALLY APPRECIATE
5	THE CONSUMER WATCHDOG'S RECOMMENDED AMENDMENT TO THE
6	SALARY ISSUE.
7	BUT ALSO I WANT TO SAY THANK YOU TO SHERRY
8	AND TO CLAIRE WHO WORKED SO HARD IN THIS GOVERNANCE
9	COMMITTEE AND JEFF AS WELL AND ALL THE OTHER MEMBERS
10	OF THE GOVERNANCE COMMITTEE. I MORE THAN ANYONE
11	WILL RECOMMEND TO SECRETARY CLINTON TO SEND ALL OF
12	YOU TO THE MIDDLE EAST BECAUSE I THINK IF YOU CAN
13	SOLVE THIS PROBLEM, YOU CAN SOLVE THAT PROBLEM AS
14	WELL.
15	I'M VERY PROUD TO HAVE WITH ME TODAY THE
16	SENATE MAJORITY LEADER, MY FORMER CHIEF OF STAFF,
17	WHO I'M VERY PROUD OF, SENATOR DEAN FLOREZ FROM
18	FRESNO AND BAKERSFIELD.
19	(APPLAUSE.)
20	MR. TORRES: MY PARTNER GONZALO ESCODERO.
21	AND SOME OF YOU HAVE ALREADY SEEN HIS PLAY AT THE
22	BERKELEY REPERTORY THEATER, AND I SPOKE TO SHERRY
23	ABOUT THIS AS WELL, MY SON JOAQUIN TORRES.
24	(APPLAUSE.)
25	MR. TORRES: ONE THING I'VE LEARNED IS TO
	87
	87

ALWAYS FOLLOW THE THREE B'S, BE BRIEF, BE SEATED, BE
CAREFUL.
(APPLAUSE.)
CHAIRMAN KLEIN: WE ARE GOING TO TAKE A
SHORT BREAK SO WE CAN SWEAR IN ART TORRES, BUT I
WANTED TO KNOW, DUANE, IF YOU HAVE ANYONE YOU'D LIKE
TO INTRODUCE OR ANY COMMENTS YOU'D LIKE TO MAKE.
MR. ROTH: I HAVE NO ONE TO INTRODUCE, BUT
I'LL MAKE SOME COMMENTS.
DR. POMEROY: YOU HAVE ALL OF US.
MR. ROTH: FIRST OF ALL, I'M NOT
ACCUSTOMED TO HAVING MY LAST NAME BE ALPHABETICALLY
AHEAD OF ANYBODY ELSE'S. ALPHABETICAL ORDER I NEVER
PAY ATTENTION TO. AND TO SHERRY AND CLAIRE AND BOB
AND ALL THE PEOPLE THAT WORKED ON THIS AND YOUR NICE
COMMENTS, I KNOW ART APPRECIATES THEM VERY MUCH. SO
DO I. BUT I THINK BEHIND ALL THIS YOU CAME TO
REALIZE THAT IT'S GOING TO TAKE AT LEAST TWO PEOPLE
TO REPLACE ED PENHOET, SO THAT'S REALLY THE REASON
BEHIND ALL THIS.
AND THEN JUST FINALLY, TO ART, WHO I LOOK
FORWARD TO WORKING WITH, PLEASE DON'T TRY TO CONVERT
ME FROM MY POLITICAL AFFILIATION. I FEEL IN THE
ROOM TODAY LIKE I'M IN THE MINORITY, WHICH MY
BROTHER TED IS A PROMINENT DEMOCRAT FEELS THIS ALL
88

1	THE TIME IN SAN DIEGO. BUT I DO THINK HAVING BOTH
2	OF US ABLE TO WORK WITH THE LEGISLATORS AND
3	CERTAINLY WITH THE FOOD AND DRUG ADMINISTRATION AND
4	INDUSTRY PEOPLE. BOB MADE A COMMENT ABOUT THE
5	PRODUCTS I'VE WORKED WITH AND UNDERSTANDING THE FDA.
6	I JUST WANT TO CAUTION YOU. THAT'S A MOVING TARGET,
7	AND I DON'T THINK ANYBODY REALLY UNDERSTANDS THE
8	FDA.
9	THE MOST WE CAN DO THERE IS TO CONTINUE TO
10	MAKE SURE THE PATIENT VOICE IS HEARD, AND IT'S NOT
11	JUST BETWEEN THE COMPANY TRYING TO GET AN APPROVAL
12	AND A REGULATOR WHO'S TRYING NOT TO MAKE A MISTAKE.
13	I THINK WHAT'S MISSING IN THAT CONVERSATION THAT
14	TAKES PLACE AT THE FDA IS THE PATIENT. AND SO I
15	THINK WE NEED TO REINSERT THE PATIENT, MUCH LIKE
16	WHAT HAPPENED DURING THE HIV EPIDEMIC WHERE THEY DID
17	HAVE A VOICE AND THINGS DID HAPPEN VERY QUICKLY.
18	SO ONE OF MY OBJECTIVES AND GOALS WILL
19	CERTAINLY BE AROUND THAT.
20	MS. SAMUELSON: HERE. HERE.
21	(APPLAUSE.)
22	CHAIRMAN KLEIN: THANK YOU. THIS IS GOING
23	TO BE A VERY QUICK ADJOURNMENT. WE DO NEED TO SEAT
24	ART TORRES WITH THE BOARD. AND I NEED TO SWEAR ART
25	IN WITH JAMES HARRISON, SO GIVE US FIVE, SEVEN
	89

1	MINUTES, BUT LET'S WE'VE GOT VERY IMPORTANT
2	AGENDA ITEMS TO MOVE ON QUICKLY, AND WE NEED TO GET
3	THROUGH THIS AGENDA ITEM BEFORE LUNCH, SO THAT'S
4	YOUR INDUCEMENT.
5	(A RECESS WAS TAKEN.)
6	CHAIRMAN KLEIN: ALL RIGHT. WE'RE GOING
7	TO RECONVENE. WE'VE GOT SOME IMPORTANT ITEMS TO
8	COVER. IT'S REAL CRITICAL THAT WE MOVE FORWARD
9	EXPEDITIOUSLY. IF THE STAFF COULD NOTIFY DR.
10	TROUNSON THAT WE ARE THERE HE IS. I WAS LOOKING
11	FOR YOU IN THE BACK OF THE ROOM, DIDN'T LOOK AT THE
12	OBVIOUS. STAFF, PLEASE ASK THE BOARD MEMBERS TO
13	RETURN.
14	DR. TROUNSON: THANK YOU VERY MUCH, CHAIR.
15	CHAIRMAN KLEIN: WE'RE GOING TO WAIT JUST
16	A SECOND. WE'VE GOT A COUPLE OF OTHER MEMBERS. ALL
17	RIGHT. WE'RE GOING TO WAIT JUST A SECOND HERE.
18	WE'VE GOT A COUPLE OF OTHER MEMBERS. ALL RIGHT. SO
19	WE HAVE A COUPLE MORE MEMBERS, THREE OR FOUR,
20	MELISSA IS PULLING IN. WHAT YOU ARE ABOUT TO SAY,
21	DR. TROUNSON, IS VERY IMPORTANT. I WANT ALL THE
22	BOARD MEMBERS TO CAPTURE THIS.
23	HOW ARE WE DOING ONLINE? ONLINE CAN YOU
24	HEAR ME?
25	(ALL RESPOND YES.)
	90
	70

1	CHAIRMAN KLEIN: DR. LEVEY. DR. PENHOET,
2	I HEARD YOU. JON SHESTACK.
3	DR. FRIEDMAN: MIKE FRIEDMAN IS HERE.
4	CHAIRMAN KLEIN: SO THE ONLINE MEMBERS ARE
5	COMING BACK. MEMBERS ARE COMING BACK IN THE ROOM.
6	WE NEED SHERRY LANSING AND CLAIRE POMEROY.
7	WHILE THEY ARE COMING TO THE FRONT, I'D
8	LIKE TO COMMENT THAT NIH HAS RELEASED THEIR FORMAL
9	ANNOUNCEMENT OF THE RECOVERY AND REINVESTMENT ACT
10	FUNDING OPPORTUNITIES, INCLUDING THEIR APPLICATIONS,
11	I THINK, AS OF THE LAST COUPLE OF DAYS. THIS
12	PARTICULAR ANNOUNCEMENT ADDRESSES A BILLION
13	AVAILABLE FOR EXTRAMURAL CORE FACILITIES AND OTHER
14	CONSTRUCTION, RENOVATION, OR REPAIR AWARDS. ART,
15	I'M SURE THAT YOU'RE GOING TO IMMEDIATELY BE HELPING
16	ME FIGURE OUT WHERE THE HALF BILLION WAS THAT WE GOT
17	INTO THAT FOR EXTRAMURAL FACILITIES AND EQUIPMENT.
18	MAY WELL BE IN EQUIPMENT CATEGORY. THE NATIONAL
19	SCIENCE FOUNDATION HAS NOT COME OUT WITH THEIR
20	ANNOUNCEMENT ABOUT THE 400 MILLION THAT'S THERE FOR
21	RENOVATIONS AND EQUIPMENT.
22	WE'D LIKE TO OBVIOUSLY TRACK THAT VERY
23	QUICKLY. IT'S IMPORTANT TO NOTE THAT WHILE THE ACT
24	ITSELF AND THE NATIONAL SCIENCE FOUNDATION DOESN'T
25	HIGHLIGHT THAT BIOMEDICAL RESEARCH FACILITIES WAS
	01

1	ONE OF THE CORE OBJECTIVES OF THE STIMULUS BILL AS
2	TO THAT SECTION, THAT THE COMMITTEE REPORTS ON THE
3	HOUSE SIDE SPECIFICALLY TALKED ABOUT BIOMEDICAL
4	RESEARCH BEING UNDERFUNDED, AND THAT THESE FUNDS
5	BEING INTENDED TO BENEFIT BIOMEDICAL RESEARCH
6	FACILITIES, RENOVATIONS, AND EQUIPMENT. SO WE'RE
7	GOING TO BE TRACKING THAT AND FORWARDING ANYTHING
8	THAT SEEMS LIKE AN EXCEPTION TO THE INTENT OF
9	CONGRESS TO THE PUBLIC AND THE MEMBERS OF THE BOARD.
10	WITH THAT, WE HAVE TWO MEMBERS, INCLUDING
11	OUR FINANCE CHAIR, WHICH WOULD BE IMPORTANT TO
12	DI SCOVER.
13	MS. KING: HE JUST NEEDED A BRIEF BREAK
14	AND WILL RETURN IN A COUPLE OF MINUTES.
15	CHAIRMAN KLEIN: SO I BRIEFED HIM ON
16	HERE HE IS. THANK YOU, MICHAEL.
17	DR. TROUNSON: THANK YOU VERY MUCH, CHAIR.
18	AT THE LAST BOARD MEETING, THE BOARD ASKED US TO
19	PREPARE A FUNDING PRIORITIES LIST FROM OUR POINT OF
20	VIEW THE PRIORITIES THAT WE WOULD RECOMMEND TO YOU.
21	AND WE SHOULD SAY THAT IF THERE IS NO CONTRIBUTIONS,
22	WE WOULD HAVE TO CEASE FUNDING AROUND SEPTEMBER THIS
23	YEAR. SO IT'S PREDICATED ON AN ASSUMPTION, WHICH I
24	THINK IS A REALISTIC AND GETTABLE ASSUMPTION, THAT
25	THERE WOULD BE WE WOULD BE ABLE TO RAISE THROUGH

1	THE PRIVATE PROGRAM AROUND \$200 MILLION, 100 MILLION
2	BY AROUND JULY THIS YEAR AND ANOTHER 100 MILLION
3	EARLY NEXT YEAR. SO OTHERWISE PRIORITIES ARE
4	MEANI NGLESS.
5	SO THAT'S A BACKGROUND ASSUMPTION. I'M
6	GOING TO GET JOHN ROBSON TO SORT OF COME BACK AT THE
7	END OF MY COMMENTS AND GIVE YOU THE DETAILS
8	UNDERPINNING THE RECOMMENDATIONS THAT WE'RE GOING TO
9	MAKE TO YOU. SO YOU SEE THIS LIST IS A LITTLE
10	DIFFERENT TO WHAT WOULD HAVE BEEN THE WHOLE PROGRAM
11	LIST BASICALLY BECAUSE WE'RE SAYING WE REALLY CAN'T
12	DO ALL OF EVERYTHING IF IT'S ONLY 200 MILLION THAT
13	WE'RE ABLE TO RAISE IN THIS TIMEFRAME. WE'RE ABLE
14	TO RAISE MORE THAN THAT, OF COURSE, YOU CAN DO MORE.
15	AND SO THE TRANSLATION, FOR EXAMPLE, AND
16	THE BASIC BIOLOGY AND DISEASE TEAMS HAVE BEEN SPLIT
17	SO THAT OUR RECOMMENDATION IS TO DO SOME, BUT NOT
18	ALL OF WHAT YOU AGREED TO IN THE CONCEPT APPROVAL.
19	SO UNDERPINNING THAT, AND THE FIRST SEVEN ARE REALLY
20	THE ONES THAT WE WILL FOCUS ON, THEN I WANT TO JUST
21	GIVE YOU SOME BACKGROUND AS TO WHY WE'RE MAKING
22	THESE RECOMMENDATIONS.
23	SO THE NEXT SLIDE. HERE IS THE PIPELINE,
24	AND YOU CAN SEE IN THE GREEN, THE GREEN AREAS, IT'S
25	REALLY THE BASIC RESEARCH, THE LAYING OF THE

1	FOUNDATION, IF YOU LIKE. WE'VE ACTUALLY PUT A LOT
2	OF MONEY INTO THE SEED GRANTS, COMPREHENSIVE
3	PROJECTS, THE NEW FACULTY AWARDS I AND II WAS VERY
4	LARGE, AND I THINK IT'S GOING TO BE VERY EFFECTIVE,
5	NEW CELL LINES, TO SOME EXTENT THE TOOLS AND
6	TECHNOLOGY BECAUSE THEY ARE BASIC IN MANY RESPECTS,
7	THE TRAINING GRANTS, OF COURSE, THEY HAVE A STRONG
8	ACCENT FOR THE BASIC RESEARCH, AND THE BIOLOGY OF
9	STEM CELLS, WHICH IS A PROGRAM THAT WE HAVE UP IN
10	ONE OF THE PROGRAMS THAT WE HAVE IN FRONT OF US, ALL
11	FOCUSED ON THE BASIC END.
12	AND IT'S VERY IMPORTANT THAT WE DO THIS
13	BASIC RESEARCH BECAUSE I THINK, AS I DEMONSTRATED
14	EARLIER, THE OBSERVATIONS AND THE DISCOVERIES COMING
15	OUT OF THE BASIC RESEARCH ACTUALLY UNDERPIN HOW YOU
16	GO FORWARD AND HOW YOU DESIGN CLINICAL TRIALS. AND
17	WITHOUT THAT, YOU CAN BE IN SOME RESPECT GUESSING
18	THAT A TREATMENT MIGHT BE EFFECTIVE RATHER THAN
19	REALLY HAVING SOUND KNOWLEDGE. AND, OF COURSE, IT'S
20	CHANGING MANY ASPECTS OF THE WAY WE LOOK AT THINGS
21	ALL THE TIME. AND THE NEW DISCOVERIES IN THE BASIC
22	AREA ARE PROFOUND AND EXTREMELY IMPORTANT.
23	BUT IN THE BLUE AREA IS THE TRANSLATIONAL
24	AREA, AND WE STRONGLY, AS STAFF, BELIEVE THAT WE'VE
25	GOT TO ENTER TRANSLATION. AND WE'VE GOT TO START

1	THIS PIPELINE FLOWING TOWARDS THE CLINIC. WE
2	BELIEVE THERE ARE VERY STRONG APPLICATIONS IN THAT
3	AREA, AND THEY DESERVE TO BE SUPPORTED, AT LEAST
4	SOME OF THOSE, IN THE TOP CATEGORY.
5	WE ALSO BELIEVE THAT IT IS TIME FOR THE
6	DISEASE TEAM PROGRAM. WE BELIEVE THAT WITHIN A FEW
7	WEEKS WE WILL HAVE A LARGE CADRE OF TOP QUALITY
8	PROPOSALS WHICH WILL BE CHALLENGING. AND, OF
9	COURSE, THE APPLICANTS BELIEVE THAT THEY'RE GOING TO
10	MAKE AN IND, AN APPLICATION FOR CLINICAL TRIAL,
11	WITHIN FOUR YEARS. I HAVE ABSOLUTELY NO DOUBT THERE
12	WILL BE A LARGE NUMBER OF THEM THAT COULD DO THAT.
13	ABSOLUTELY WE'LL BE ABLE TO DO THAT. I DON'T THINK
14	WE SHOULD SHIRK FROM GOING FORWARD AT THIS POINT IN
15	TIME BECAUSE I THINK IT'S THE PEOPLE OUT THERE, THE
16	PATIENTS THAT ARE SAYING, WELL, ISN'T IT TIME THAT
17	WE HAD SOME OF THIS WORK IN CLINICAL TRIAL. AND LET
18	ME TRY AND FILL THAT IN A LITTLE BIT FOR YOU.
19	SO WHAT IS GOING TO THE CLINIC AT THE
20	PRESENT TIME? WHAT ARE THE THINGS THAT ARE ACTUALLY
21	GOING THERE? WELL, GERON'S HUMAN EMBRYONIC STEM
22	CELL-DERIVED OLIGODENDROCYTE TRANSPLANT WORK IS
23	GOING TO THE CLINIC. THEY HAVE THEIR PERMISSION FOR
24	THEIR TRIAL, AND THEY'LL BE UNDER WAY VERY QUICKLY.
25	THE MESENCHYMAL STEM CELLS, THE BONE MARROW-TYPE

1	STEM CELLS, ARE IN CLINICAL TRIAL NOW FOR IMMUNE
2	SUPPRESSION, HEART MUSCLE REPAIR, BONE AND CARTILAGE
3	REPAIR, AND PULMONARY FIBROSIS, THESE STUDIES ARE
4	ONGOING AT THE MOMENT. THEY'RE PHASE I, II, AND III
5	STUDIES THAT ARE UNDER WAY. SO WE'RE IN THE CLINIC
6	IN STEM CELLS. AND IT'S INTERESTING AND I THINK IN
7	SOME RESPECTS PUZZLING, BUT ALSO INVIGORATING THAT
8	WE'RE GETTING VERY POSITIVE RESPONSES IN SOME OF
9	THESE TRI ALS.
10	SO THE PUZZLING PART IS THAT SOMETIMES WE
11	DON'T KNOW WHY WE'RE GETTING THAT. SO AS A
12	SCIENTIST, THERE'S ALWAYS A LITTLE CONCERN BECAUSE
13	IF YOU DON'T KNOW WHY HOW YOU'RE GETTING THE
14	EFFECT, THEN YOU CAN'T ALWAYS PREDICT WHAT MIGHT BE
15	AN ADVERSE REACTION. AND WE WANT TO ABSOLUTELY
16	MINIMIZE THAT.
17	THE NEURAL STEM CELLS FOR LYSOSOMAL
18	STORAGE DISEASE, THE WORK PARTICULARLY FROM STEM
19	CELLS, INC. UNDER WAY AND REINVIGORATED BY A SECOND
20	IND TO GET THAT WORK GOING AGAIN. THERE ARE SIX
21	PATIENTS WHO HAVE BEEN TREATED FOR THIS. IT'S UNDER
22	WAY. IT'S IN THE CLINIC.
23	THE SMALL MOLECULES FOR A WIDE RANGE OF
24	TISSUE REGENERATIVE INDICATIONS BASED ON STEM CELL
25	ASSAYS. CATRIONA JAMIESON IS ONE THAT WE'VE HEARD A

1	LOT ABOUT, BUT THERE ARE MANY MORE THAT ARE REALLY
2	COMING UP, AND THEY'RE ON THEIR WAY, AND THEIR IND'S
3	ARE BEING APPLIED FOR RIGHT NOW. SO WE'LL SEE A
4	CADRE OF THESE. I HAVE ABSOLUTELY NO DOUBT. I'VE
5	BEEN IN THE LABORATORIES OF CALIFORNIA RESEARCHERS,
6	AND I KNOW THEY'RE GOING FOR THESE IND'S NOW.
7	AND CANCER PARTICULARLY IS A GREAT TARGET
8	FOR SOME OF THOSE SMALL MOLECULES AND PARTICULAR
9	ANTIBODIES. THIS IS OUR BUSINESS, CANCER STEM CELLS
10	ARE OUT BUSINESS. HEMATOPOETIC STEM CELL EXPANSION,
11	THEY'VE GOT MOLECULES FOR THAT NOW. THIS IS A BIG
12	CHANGE THAT WAS NEVER ABLE TO EXPAND THOSE CELLS AND
13	FOR MOBILIZATION OF ADULT STEM CELLS. SO WE'RE IN.
14	THE GAME IS ON. WE NEED TO BECOME NOW PART OF IT,
15	IN MY VIEW.
16	SO IF YOU LOOK AT THIS, YOU CAN DERIVE
17	MANY DIFFERENT TYPES OF TISSUES, FOR EXAMPLE, FROM
18	PLURIPOTENTIAL STEM CELLS. IN THE CASE OF EMBRYONIC
19	STEM CELLS, YOU CAN GROW BLOOD AND BONE AND
20	CARTILAGE, AND MAKE NEURONS, A VARIETY OF NEURONS.
21	PIGMENTED RETINAL EPITHELIUM IS RELATIVELY EASILY
22	GROWN. YOU CAN GET SOME OF THE PRODUCTS THAT WILL
23	REPAIR LUNG TISSUE, AND NOW THERE'S MORE AND MORE
24	STUDIES SHOWING THAT YOU CAN GET BETA ISLET-TYPE
25	CELLS. SO THE CELL THERAPIES ARE MOVING. THEY'RE

1	MOVING UP THERE. AND THE TRANSLATION IS THE PLACE
2	WHERE WE NEED TO CHECK ON THE EFFICACY AND THE
3	RISKS, AND WE NEED TO PUT A BIT OF PRESSURE IN THERE
4	TO GET THAT DONE BECAUSE WE DON'T WANT UNDERDONE
5	STUDIES GOING TO THE CLINIC.
6	THE STEM CELL MOBILIZATION WORK, I THINK,
7	IS INCREDIBLY EXCITING. AND IN MANY RESPECTS IT MAY
8	NOT BE THE PANACEA FOR REGENERATING TISSUES, ALL
9	TISSUES, BUT CLEARLY IT WILL BE FOR SOME. THERE ARE
10	STEM CELLS IN MOST ADULT TISSUES. AND IF YOU CAN
11	GET THEM MOBILIZED, THEY WILL REPAIR FUNCTION, BUT
12	NOT MAYBE REALLY ADVANCED CASES. BUT EARLY STAGE
13	MOBILIZATION IN EARLY STAGE DISEASES IS A VERY GOOD
14	STRATEGY.
15	AND THE SMALL MOLECULES HAVE THE NEXT
	ONE MELLOCA VOLLOAN OO TO THESE LABORATORIES IN
16	ONE, MELISSA YOU CAN GO TO THESE LABORATORIES IN
16 17	CALIFORNIA. THEY'RE FANTASTIC. I WENT TO ONE WHERE
17	CALIFORNIA. THEY'RE FANTASTIC. I WENT TO ONE WHERE
17 18	CALIFORNIA. THEY'RE FANTASTIC. I WENT TO ONE WHERE THERE ARE 600 STAFF WORKING ON MACHINES THAT ARE
17 18 19	CALIFORNIA. THEY'RE FANTASTIC. I WENT TO ONE WHERE THERE ARE 600 STAFF WORKING ON MACHINES THAT ARE ASTONISHING, AND THEY'RE GROWING TISSUES FROM STEM
17 18 19 20	CALIFORNIA. THEY'RE FANTASTIC. I WENT TO ONE WHERE THERE ARE 600 STAFF WORKING ON MACHINES THAT ARE ASTONISHING, AND THEY'RE GROWING TISSUES FROM STEM CELLS SO THAT NOW THE PEOPLE THAT WE'VE BEEN
17 18 19 20 21	CALIFORNIA. THEY'RE FANTASTIC. I WENT TO ONE WHERE THERE ARE 600 STAFF WORKING ON MACHINES THAT ARE ASTONISHING, AND THEY'RE GROWING TISSUES FROM STEM CELLS SO THAT NOW THE PEOPLE THAT WE'VE BEEN SUPPORTING AND MOVING IN WITH THEIR ASSAYS INTO
17 18 19 20 21	CALIFORNIA. THEY'RE FANTASTIC. I WENT TO ONE WHERE THERE ARE 600 STAFF WORKING ON MACHINES THAT ARE ASTONISHING, AND THEY'RE GROWING TISSUES FROM STEM CELLS SO THAT NOW THE PEOPLE THAT WE'VE BEEN SUPPORTING AND MOVING IN WITH THEIR ASSAYS INTO THESE LABORATORIES, AND THEY'RE PUTTING THEM THROUGH
17 18 19 20 21 22	CALIFORNIA. THEY'RE FANTASTIC. I WENT TO ONE WHERE THERE ARE 600 STAFF WORKING ON MACHINES THAT ARE ASTONISHING, AND THEY'RE GROWING TISSUES FROM STEM CELLS SO THAT NOW THE PEOPLE THAT WE'VE BEEN SUPPORTING AND MOVING IN WITH THEIR ASSAYS INTO THESE LABORATORIES, AND THEY'RE PUTTING THEM THROUGH THE HIGH THROUGHPUT SCREENING SYSTEMS. THERE'S SOME

1	CLUSTERS, I'LL JUST SHOW YOU, BOUND WITH DNA.
2	THERE'S SOME ASTONISHING NEW TECHNOLOGY THAT IS
3	THERE, AND IT'S IN THAT TRANSLATIONAL AREA. SO WE
4	NEED, I THINK, VERY MUCH NEED TO BE PART OF THAT.
5	SO WHEN YOU COME TO TRAINING, THERE'S
6	YOU CAN DEBATE THIS, OF COURSE, WHETHER IT'S GOOD OR
7	NOT. BUT I AND THE STAFF BELIEVE IT'S VERY
8	IMPORTANT THAT WE CONTINUE TO SUPPORT THE TRAINING.
9	THERE'S A CRITICAL MASS WHICH WE'VE NOW GOT
10	CO-LOCATED AND RESOURCED. WE'RE DOING THAT. THE
11	INSTITUTIONS ARE IN THE PROCESS OF BUILDING GREAT
12	NEW FACILITIES, BUT THEY'RE CO-LOCATING THEIR
13	SCIENTISTS. AND EVERY PLACE I GO I SEE THESE PEOPLE
14	MOVING TOGETHER. IT'S BECOMING A COMPETITIVE AND
15	VERY SUPPORTIVE ENVIRONMENT. IT'S JUST THE PLACE
16	WHERE YOU NEED TO GO AS A YOUNG SCIENTIST. PEOPLE
17	WITH AMBITION, WITH DRIVE, THEY'RE THERE. BUT WHAT
18	THEY'RE SHORT OF IS VERY CLEAR. THEY DON'T HAVE
19	ENOUGH TECHNICAL SUPPORT PEOPLE FOR THE REALLY SMART
20	ASSAYS AND INSTRUMENTATION AND TECHNOLOGIES. AND
21	THAT'S A RAPID GROWTH; AND IF WE ARE GOING TO EXPECT
22	PEOPLE TO DO THE TRAINING ON-SITE, WE'VE GOT TO HELP
23	THEM DO THAT.
24	SO I THINK, FOR EXAMPLE, THE BRIDGES
25	PROGRAM, TO ME, SEEMS SO LOGICAL, SO SOCIALLY

1	CORRECT. AND I TELL YOU I JUST KNOW THAT THESE ARE
2	THE SORT OF PLACES THAT I AND OTHER PEOPLE CAME
3	FROM. FROM THESE SITUATIONS IN THESE PLACES, THESE
4	PEOPLE, IF GIVEN A CHANCE, WITH HIGH AMBITION,
5	THEY' RE VERY SMART, THEY' RE VERY DEDICATED, THEY' LL
6	DO SUPREMELY WELL. THEY WILL BE THE POSSIBLE NOBEL
7	PRIZE PEOPLE OF THE FUTURE. THEY COME WITH SUCH
8	DEDICATION, THAT THEY'RE UNSTOPPABLE. AND WHAT WE
9	NEED TO DO IS PROVIDE THEM A PIPELINE TO GET THERE.
10	AND IF YOU PUT THEM IN CONJUNCTION WITH
11	THE SMART SCIENTISTS, THE REALLY CUTTING-EDGE
12	SCIENTISTS THAT WE'VE GOT IN CALIFORNIA NOW, IT WILL
13	BE A HUGE DIFFERENCE. YOU WILL GROW SOMETHING
14	REALLY MAGNIFICENT. AND I BELIEVE THOSE YOUNG
15	PEOPLE WILL GO BACK TO THEIR COMMUNITIES AND SAY
16	AND SPREAD THE WORD, WOW. YOU KNOW, IT'S SCIENCE
17	FOR ALL OF US. IT'S NOT JUST SCIENCE FOR THE
18	WELL-TO-DO PEOPLE AND IT SHOULDN'T BE. IT SHOULD BE
19	FOR ALL OF US, AND WE SHOULD BE REACHING BACK AND
20	REACHING FORWARD.
21	SO WE WOULD LIKE TO STRONGLY, STRONGLY
22	BACK THE BRIDGES PROGRAM, AND WE WANT TO BACK THE
23	TRAINING PROGRAM, ALTHOUGH I THINK WE'RE GOING TO
24	HAVE TO PUT IT BACK A YEAR, AND THAT'S ONE OF THE
25	RECOMMENDATIONS WE'LL MAKE TO YOU.

1	SO I'M GOING TO NOW HAND OVER TO JOHN.
2	SINCE I HAD THE EASY PART, HE'S NOW GOING TO TELL
3	YOU REALLY WHAT IT IS ABOUT THE ASSUMPTIONS AND THE
4	ARGUMENTS ABOUT THE BUDGET FOR WHICH WE'RE MAKING
5	RECOMMENDATIONS.
6	CHAIRMAN KLEIN: WHAT I'D LIKE TO SAY, TO
7	GIVE EVERYONE A FRAMEWORK, A LEGAL FRAMEWORK FOR THE
8	DISCUSSION AND THE SEQUENCE OF DISCUSSION, IS THAT
9	WHEN WE FINISH WITH JOHN ROBSON'S REPORT, IN ORDER
10	TO ALLOW A FULL RANGE OF DEBATE AMONG ALL THE
11	MEMBERS OF THE BOARD, GIVEN THAT THERE ARE BOARD
12	MEMBERS WITH ITEMS AT ISSUE UNDER BRIDGES AND
13	TRAINING II AND THE EARLY TRANSLATION, WE NEED TO,
14	AND I'M GOING TO HAVE JAMES AFTER JOHN ROBSON'S, DR.
15	ROBSON'S PRESENTATION, EXPLAIN THE LEGAL BASIS FOR
16	THIS, MOVE THROUGH THREE VERY NARROW SPECIFIC
17	DISCUSSIONS ON FUNDING THOSE ITEMS. THEN WE'RE
18	GOING TO COME BACK TO THE OVERALL POLICY. THOSE
19	THREE ITEMS REPRESENT UNDER THE RECOMMENDATIONS A
20	VERY SMALL DOLLAR AMOUNT. BECAUSE OF THESE
21	CONFLICTS, WE CAN'T HAVE A DISCUSSION OF ALL THE
22	BOARD MEMBERS ON THE OVERALL RECOMMENDATIONS UNTIL
23	WE'VE DISPENSED WITH THOSE THREE ITEMS.
24	BUT BY DELIVERING THIS INFORMATION AT THIS
25	TIME, WHEN WE ARE VOTING ON THOSE THREE ITEMS, YOU
	101

1	CAN TAKE IT INTO CONSIDERATION TO THE EXTENT YOU'RE
2	VOTING AND YOU DO NOT HAVE A CONFLICT. SO THERE
3	WILL BE A VERY ROBUST DISCUSSION OF THE ENTIRE
4	STRATEGY THAT FOLLOWS AFTER THOSE THREE ITEMS.
5	DR. ROBSON: OKAY. SO I'M GOING TO REPORT
6	ON SOME OF THE FINANCIAL IMPLICATIONS OF THIS
7	PRIORITIZATION EXERCISE THAT WE WENT THROUGH SINCE
8	THE LAST BOARD MEETING. BEFORE I DO THAT, THERE'S
9	THREE ASSUMPTIONS I WANT YOU TO UNDERSTAND THAT WE
10	TOOK INTO THIS EXERCISE. THE FIRST IS THAT WE
11	SHOULDN'T MAKE ANY CUTS TO ONGOING PROGRAMS. THE
12	ONES THAT HAVE CURRENTLY BEEN FUNDED WILL CONTINUE
13	AT THE SAME LEVELS OF FUNDING THAT THEY WERE
14	AWARDED. SO NO IMPACT THERE SO FAR.
15	OTHER ASSUMPTION IS THAT WE REALLY WERE
16	COMMITTED THAT WE HAVE TO KEEP MOVING FORWARD.
17	WE HAVE TO KEEP FUNDING NEW PROGRAMS. IF WE STOP AT
18	THIS POINT AND THEN FUNDS THEN COME AGAIN IN TWO
19	YEARS WHEN WE THINK THAT THIS FINANCIAL CRISIS OR WE
20	CERTAINLY HOPE WILL GET BACK TO A MORE NORMALIZED
21	STATE, THAT WE DON'T WANT TO BE IN A POSITION OF
22	HAVING TO RETOOL AT THAT POINT.
23	CHAIRMAN KLEIN: DR. ROBSON, THE
24	PARENTHETICAL THUS FAR, I'D LIKE TO POINT OUT, WE
25	HAVE CONTRACTS ON EXISTING PROGRAMS. WE'RE NOT IN A

1	POSITION TO ADJUST THOSE. WE HAVE NO INTENTION OF
2	ADJUSTING THOSE.
3	DR. ROBSON: MY POINT IS WE HAVEN'T
4	MODELED THAT.
5	AND FINALLY, WE'VE ASSUMED THAT WE WILL,
6	AS ALAN SAID, GET A COUPLE OF INFLUXES OF MONEY,
7	ABOUT \$100 MILLION SOMETIME IN THE THIRD QUARTER OF
8	THIS YEAR BETWEEN JULY 1ST AND THE END OF SEPTEMBER,
9	AND THEN ANOTHER HUNDRED MILLION SOMETIME EARLY NEXT
10	YEAR.
11	BEFORE I SHOW YOU THE IMPLICATIONS FOR OUR
12	PRIORITIES, LET'S JUST TAKE A QUICK LOOK AT WHAT
13	WOULD HAPPEN IF WE FUNDED THE PROGRAMS THAT YOU HAVE
14	ALREADY CONCEPT APPROVED. THEY'VE BEEN THROUGH
15	CONCEPT APPROVAL, AT THE FULL LEVEL THAT YOU EITHER
16	RECOMMENDED OR IN THE CASE OF TRAINING AND BRIDGES,
17	WHAT YOU'VE APPROVED SO FAR.
18	JUST ON THE LEFT LISTS THE PROGRAMS THAT
19	I'M GOING TO TALK ABOUT: TRAINING II, BRIDGES,
20	EARLY TRANSLATION, BASIC BIOLOGY, AND DISEASE TEAMS,
21	AND BASIC BIOLOGY II. THE CENTER COLUMN SHOWS THE
22	BUDGETS THAT YOU APPROVED, AND THE RIGHT COLUMN
23	SHOWS WHAT WOULD BE THE EXPENDITURES WE WOULD HAVE
24	TO MAKE BASED ON THOSE BUDGETARY AMOUNTS BETWEEN NOW
25	AND THE END OF DECEMBER 2010. AND THAT'S BASED ON
	103

1	QUARTERLY PAYMENTS. WE HAD A DISCUSSION ABOUT THAT
2	LAST TIME. I CAN TELL YOU WE'VE ALREADY MOVED TO
3	MAKING QUARTERLY PAYMENTS. WE'VE STARTED THAT.
4	SO LET'S LOOK AT THE IMPLICATIONS OF THAT.
5	I'M SHOWING YOU THIS IN GRAPHIC FORM. THIS IS WHAT
6	THEY CALL A DASHBOARD. DAN DORNBUSH, A COLLEAGUE OF
7	MICHAEL GOLDBERG'S, HELPED US GET THIS SET UP. AND
8	I THINK IT'S QUITE HELPFUL. IT'S NOT AS COMPLICATED
9	AS IT LOOKS, SO LET ME WALK YOU THROUGH IT.
10	SO THE BARS THAT ARE SHOWN ALONG THE X
11	AXIS THERE INDICATE THE PAYMENTS THAT WE WOULD MAKE
12	DURING EACH QUARTER. JANUARY TO MARCH 2009 IS THE
13	BAR ON THE LEFT, OCTOBER TO DECEMBER 2010 IS THE BAR
14	ON THE RIGHT. THE LIGHTER COLOR AT THE BOTTOM
15	INDICATES THE COST WE WOULD HAVE FOR ADMINISTRATION
16	AT CIRM, AND THE BLUE BAR IS THE AMOUNT THAT WE
17	EXPEND ON GRANT FUNDS, RESEARCH FUNDS, DURING THAT
18	PERI OD.
19	THE NUMBERS ON THE LEFT REFER TO THOSE OUT
20	PAYMENTS, TO THE BARS THAT I JUST DESCRIBED. FOR
21	EXAMPLE, IN JANUARY MARCH, THE BAR ON THE LEFT,
22	WE'RE PROJECTING WE'RE GOING TO PUT OUT ABOUT \$30
23	MILLION. WITH ME SO FAR? THE NUMBERS ON THE RIGHT,
24	NOW, THEY REFER TO THE AMOUNT OF MONEY THAT WE HAVE
25	IN THE BANK. THIS IS WHAT'S IN THE BOND FUND. SO

1	THOSE NUMBERS ON THE RIGHT, AND YOU CAN SEE ZERO
2	SORT OF ABOUT A THIRD OF THE WAY UP GOES UP TO ABOUT
3	200 MILLION. THE RED LINE MARKS THE ZERO POINT. SO
4	ANY AMOUNT ABOVE THAT IS A POSITIVE BALANCE WITHIN
5	THE BOND FUND. THAT'S A GOOD THING. ANY NUMBER
6	THAT'S BELOW THAT IS A NEGATIVE BALANCE IN THE BOND
7	FUND. THAT'S A BAD THING.
8	SO WE'RE TALKING ABOUT THESE NUMBERS HERE,
9	THAT RED LINE RIGHT THERE. SO HOW MUCH MONEY WE
10	HAVE IN THE BANK IS INDICATED BY THE GREEN LINE.
11	YOU CAN SEE HERE. SO THAT'S THOSE INDIVIDUAL POINTS
12	CALCULATED FOR EACH QUARTER, AND THEN THE LINE IS
13	JUST CONNECTED. AND YOU WILL SEE THERE ARE TWO
14	PLACES WHERE THE LINE GOES UP. IT GOES UP IN THE
15	THIRD QUARTER HERE, AND THAT'S BASED ON OUR
16	EXPECTATION OF AN INFUSION OF \$100 MILLION AT THAT
17	POINT, AND IT GOES UP AGAIN HERE IN JANUARY TO MARCH
18	QUARTER OF NEXT YEAR, AGAIN, BASED ON THE
19	EXPECTATION OF ANOTHER \$100 MILLION COMING UP.
20	EVEN IN THIS SCENARIO, WITH THE \$200
21	MILLION IN ADDITION, YOU WILL SEE THAT WE GO BROKE
22	ABOUT THE END OF SEPTEMBER IN 2010. WE WOULD FALL
23	BELOW ZERO AT THAT POINT. WHEN WE DID OUR MODELING,
24	WE HAD THIS INFORMATION IN MIND, AND WE SAID IT
25	WOULD BE INAPPROPRIATE FOR US. WE HAVE TO DEAL WITH
	105

1	THIS ISSUE. OUR GOAL AND ALL OF OUR GOAL HAS TO BE
2	TO KEEP OUR PROGRAMS MOVING FORWARD, BUT WE'VE GOT
3	TO KEEP THAT RED LINE ABOVE THE GREEN LINE THE
4	OTHER WAY AROUND. WE HAVE TO KEEP THE GREEN LINE
5	ABOVE THE RED LINE.
6	CHAIRMAN KLEIN: TO GIVE BENCHMARKS TO THE
7	BOARD, WE HAVE APPROVAL FOR 400 MILLION. SO WHAT
8	WE'RE SHOWING YOU IS A CONSERVATIVE CASE WITH 200
9	MILLION. IN ADDITION, WHEN IT SAYS ALL CONCEPT
10	PROGRAMS, THAT'S AT THEIR FULL APPROVED LEVELS. SO
11	IF WE DO LESS THAN THEIR APPROVED LEVELS, BECAUSE WE
12	GET DOWN TO SEPTEMBER AND WE FIND WE DON'T HAVE THE
13	FULL HUNDRED MILLION IN, LET'S SAY WE HAVE 75
14	MILLION IN, WE CAN ADJUST THAT FUNDING LEVEL. SO WE
15	HAVE ONGOING DECISION POINTS THAT WE CAN ADJUST, BUT
16	OUR INTENT IS ACTUALLY, I HOPE, TO DO BETTER THAN
17	THIS WITH REACHING MORE TOWARDS AN OPTIMIZED PROGRAM
18	AND REACHING TOWARDS 400 MILLION, BUT THIS IS THE
19	CONSERVATI VE CASE.
20	MS. SAMUELSON: QUESTION. IS THERE A
21	TIMEFRAME FOR WHEN WE RUN OUT OF ALL OF OUR MONEY TO
22	THE EXTENT WE CAN PREDICT THAT?
23	CHAIRMAN KLEIN: YOU MEAN THE 3 BILLION?
24	MS. SAMUELSON: I KNOW WE'VE GOT VARIOUS
25	SOURCES OTHER THAN THE 3 BILLION, BUT THE 3 BILLION
	10/

	BARRISTERS REPORTING SERVICE
1	PLUS, IF YOU WILL.
2	CHAIRMAN KLEIN: WELL, APPROXIMATELY NINE
3	YEARS OUT, WITHOUT ANY LOAN MONEY RECYCLING, WE
4	WOULD RUN OUT. SO IF WE HAVE LOAN MONEY RECYCLING,
5	THERE'S A SEPARATE ANALYSIS THAT WE HAVE TO GO
6	THROUGH AT A LATER DATE.
7	MS. SAMUELSON: CAN YOU GIVE ME YOUR BEST
8	ESTI MATE?
9	CHAIRMAN KLEIN: I'D LIKE TO SEE AN
10	ABILITY WITH LOAN MONEY RECYCLING AS A BEST CASE
11	RUNNING OUT LIKE 13 YEARS OUT, BUT AS A CONSERVATIVE
12	CASE, MARSHALING OUR FUNDS AND USING THEM WITH GREAT
13	ACUITY ABOUT NINE YEARS OUT. IF WE ARE, IN FACT,
14	WIDELY SUCCESSFUL AND RESEARCH IS GOING FASTER, THE
15	OPPORTUNITIES ARE GREATER, IT COULD BE EIGHT YEARS
16	OUT, BUT SOMEWHERE IN THAT RANGE.
17	DR. ROBSON: CAN WE
18	MS. SAMUELSON: NINE YEARS WITHOUT THE
19	LOAN RECYCLING AND 13 YEARS WITH.
20	CHAIRMAN KLEIN: YES.
21	MS. SAMUELSON: AND THAT'S FROM NOW OR
22	FROM DAY ONE?
23	CHAIRMAN KLEIN: FROM THE BEGINNING OF
24	2009.
25	DR. ROBSON: WHY DON'T YOU LET ME FINISH,
	107
	107

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	AND THEN YOUR BOARD CAN HAVE A
2	DR. LOVE: JUST ONE CLARIFICATION.
3	CHAIRMAN KLEIN: JOAN SAMUELSON DOESN'T
4	HAVE ANY CONFLICTS AND TED DOESN'T HAVE ANY
5	CONFLI CTS.
6	MS. SAMUELSON: THESE ARE VERY GENERIC
7	POLICY QUESTIONS.
8	CHAIRMAN KLEIN: WE'VE LOOKED AT THIS VERY
9	CAREFULLY WITH TWO DIFFERENT ATTORNEYS, SO WE'RE
10	TRYING TO BE CAREFUL.
11	DR. LOVE: BOB, YOU THREW OUT THE 400, 200
12	DELTA. COULD YOU EXPLAIN THAT A LITTLE BIT BETTER?
13	CHAIRMAN KLEIN: WE HAVE AN AUTHORIZATION
14	FROM THE CALIFORNIA STEM CELL RESEARCH AND CURES
15	BOND COMMITTEE FOR 400 MILLION. BUT IN THIS
16	FINANCIAL ENVIRONMENT, WE HAVE TO BE CONSERVATIVE
17	ABOUT HOW MUCH WE CAN PLACE. SO THIS IS ASSUMING
18	THAT WE'RE ABLE TO PLACE 200 OF THE 400 MILLION. AS
19	I'LL DISCUSS LATER, UNDER OPTIMIZED CASES, YOU, FOR
20	EXAMPLE, DON'T SEE A CATEGORY HERE FOR CLINICAL
21	TRIALS. THAT COULD BE A VERY, VERY CRITICAL
22	CATEGORY FOR OUR ROLE COMPLEMENTING THE NIH, WHICH
23	WITH 400 MILLION WE CAN DO, WITH 200 MILLION WE
24	CAN'T REACH.
25	DR. ROBSON: SO NOW THIS IS THE LIST THAT
	100

108

1	ALAN DISCUSSED WITH YOU BEFORE SHOWING OUR
2	PRIORITIES. AND AS HE WENT THROUGH, IT'S REALLY
3	SORT OF A TWO-PRONGED APPROACH. FIRST, THERE WAS
4	THE PROGRAMMATIC APPROACH, WHICH ARE THE PROGRAMS
5	THAT WE THINK ARE THE MOST IMPORTANT FOR US TO START
6	EMPHASIZING? AND HE DESCRIBED THE FACT THAT WE FEEL
7	THAT NEED TO START SHIFTING OUR EMPHASIS FROM A
8	BASIC SCIENCE VIEW TO ADD MORE OF A CLINICAL
9	APPROACH TO IT. SO THAT'S REFLECTED IN THIS LIST.
10	IN ADDITION, WE HAVE THE FINANCIAL
11	RESPONSIBILITY OF KEEPING THE INSTITUTION SOLVENT.
12	SO WE HAD TO ADJUST SOME OF THE AMOUNTS THAT WE
13	WOULD RECOMMEND THAT YOU CONSIDER FUNDING AT THIS
14	POINT. SO WE'RE REALLY GOING TO TALK ABOUT THOSE
15	ITEMS THAT ARE ABOVE THE BLUE LINE THERE. THERE'S
16	ONE THERE THAT'S NOT BEEN CONCEPT APPROVED. THAT'S
17	IMMUNOLOGY. WE'VE PUT THAT IN THERE BECAUSE WE
18	THINK IT'S CRUCIAL. WE HAVE TO KEEP THAT IN MIND,
19	THAT WE HAVE TO HAVE FUNDS AVAILABLE TO FUND THAT
20	SORT OF RESEARCH AS PART TO ACHIEVE OUR OVERALL
21	MI SSI ON.
22	NOW, OF COURSE, IF THE FINANCIAL SITUATION
23	CHANGES, WE CAN ALWAYS MOVE THAT BLUE DOWN AND
24	INCORPORATE SOME OF THE BALANCE OF THOSE VARIOUS
25	PROGRAMS, THE BALANCE OF FUNDS THAT'S LISTED BELOW.

1	SO THE BUDGETS SHOWN THERE ARE THE BUDGETS
2	THAT WE ARE RECOMMENDING FOR YOU AT THIS PARTICULAR
3	POINT, AND THIS IS WHAT WE'VE MODELED OUR
4	PROJECTIONS ON. AND, AGAIN, THE EXPENDITURES SHOW
5	THE IMPLICATIONS FOR THOSE DIFFERENT BUDGETS BETWEEN
6	NOW AND THE END OF 2010, HOW MUCH WOULD WE HAVE TO
7	SPEND, AGAIN, BASED ON QUARTERLY PAYMENTS.
8	SO LET'S LOOK AT THAT GRAPH. AND YOU WILL
9	SEE THAT'S MADE A DIFFERENCE NOW. ACTUALLY IT'S THE
10	SAME MODEL YOU SAW BEFORE, BUT NOW IF WE FOLLOW THAT
11	PRIORITY LIST, AT THE END OF 2010, WE'LL STILL BE IN
12	THE BLACK. WE'LL HAVE ON OUR CALCULATIONS HERE
13	ABOUT A MILLION AND A HALF DOLLARS LEFT IN THE BOND
14	FUND. THIS, AGAIN, BASED ON \$200 MILLION IN FLUX
15	NOW. IF WE GET MORE, WE DO BETTER. IF WE GET LESS,
16	WE'LL HAVE TO MAKE ADJUSTMENTS TO OUR PRIORITIES AS
17	WE GO FORWARD.
18	SO FOR TODAY THAT'S OUR OVERALL
19	PROJECTION, BUT FOR TODAY I'D LIKE TO EMPHASIZE OUR
20	RECOMMENDATIONS FOR THREE PROGRAMS, WHICH ARE UNDER
21	CONSIDERATION. AND THAT'S THE THREE THAT ALAN
22	MENTIONED TO YOU. THE BRIDGES PROGRAM, I WON'T
23	SPEAK AS PASSIONATELY AS HE DID ABOUT IT, BUT IT'S
24	SOMETHING THAT'S IMPORTANT. IT'S IN THE STRATEGIC
25	PLAN. IT MEETS A WELL-KNOWN NEED THAT WE HEAR OVER
	110

1	AND OVER. IT'S A RELATIVELY SMALL AMOUNT OF MONEY,
2	AND THIS IS A TARGET GROUP THAT DOESN'T HAVE ACCESS
3	TO ANY OTHER SORT OF FUNDING THROUGH CIRM. THIS IS
4	THE ONE SHOT FOR THAT TARGET POPULATION.
5	TRAINING II, WE THINK THAT IT'S IMPORTANT
6	TO KEEP THOSE PROGRAMS GOING. BUT GIVEN THE
7	CONSTRAINTS, WE THINK WE'RE RECOMMENDING THAT YOU
8	DELAY FUNDING ON THAT FOR 12 MONTHS. THE REASONS
9	FOR THAT ARE, ONE IS WE SAY THE UNIVERSITIES COULD
10	CHOOSE TO PARTIALLY FUND THESE, CARRY THE
11	ADMINISTRATIVE COSTS, SOME OF THE COURSES, PERHAPS,
12	AND THEN REPAY THEMSELVES IN A YEAR WHEN THE FUNDS
13	ARE RELEASED. AND SECONDLY, THE GROUP THAT'S
14	TARGETED HERE, THESE ARE GRADUATE STUDENTS, POST
15	DOCS, CLINICAL FELLOWS, THERE'S GOING TO BE A LOT OF
16	MONEY AVAILABLE TO THEM THROUGH OUR GRANTING
17	PROGRAMS.
18	YOU LOOK AT THE EARLY TRANSLATION AND
19	DISEASE TEAMS, BASIC BIOLOGY, A HIGH PERCENTAGE OF
20	THOSE BUDGETS WILL BE FOR SALARIES FOR GRADUATE
21	STUDENTS, POST DOCS, AND CLINICAL FELLOWS. SO THAT
22	TARGET GROUP IS STILL GOING TO RECEIVE A LOT OF
23	SUPPORT FROM CIRM EVEN IF WE WERE TO DELAY THIS.
24	NOT SAYING THIS IS A PAINLESS CHOICE. I'M JUST
25	SAYING THESE ARE THE CHOICES WE WERE TRYING TO MAKE.

1	AND FINALLY, EARLY TRANSLATION, WE THINK
2	THAT THAT IS AN IMPORTANT PROGRAM TO GET GOING.
3	HOWEVER, WE THINK YOU SHOULD WE'RE RECOMMENDING
4	THAT YOU FUND ONLY THE BEST OF THE BEST, ONLY THE
5	TOP OF THE TOP ONES AS REVIEWED BY THE GRANT WORKING
6	GROUP. BASED ON WHAT WE'VE SEEN SO FAR FROM
7	PRELIMINARY REPORTS FROM THAT REVIEW, WE THINK
8	SOMETHING IN THE NEIGHBORHOOD OF \$36.5 MILLION WILL
9	COVER THE HIGHEST QUALITY PROPOSALS.
10	SO THOSE ARE OUR RECOMMENDATIONS FOR YOU
11	FOR CONSIDERATION TODAY.
12	CHAIRMAN KLEIN: ALL RIGHT. AT THIS
13	MOMENT WE'RE GOING TO DEFER THE BULK OF THESE
14	QUESTIONS TO THE TIME AFTER WE'VE ADDRESSED THESE
15	THREE INDIVIDUAL APPLICATIONS. I WOULD SAY THAT ON
16	TRAINING II, THE GRANTEE INSTITUTION, AGAIN,
17	COULD THERE'S TWO POINTS. ONE IS SOME OF THE
18	GRANTEE INSTITUTIONS HAVE 2008 CARRYOVER FUNDING
19	THAT THEY CAN USE AND CONTINUE TO USE UNDER PRIOR
20	COMMITMENTS. SECONDLY, THE GRANTEE INSTITUTIONS CAN
21	FUND THIS THEMSELVES. THEY COULD ALSO GO TO A
22	FOUNDATION, GET AN ADVANCE FROM A FOUNDATION, AND
23	THEN WE WOULD PAY BACK THAT FOUNDATION PAY BACK
24	THE GRANTEE, THEY COULD PAY BACK THE FOUNDATION AT
25	THE TIME THAT THE SCHEDULED ADVANCE OF THOSE FUNDS

1	DID OCCUR.
2	SO THERE'S SOME CREATIVE OPTIONS HERE TO
3	MAKE SURE THAT THE GRANTEE INSTITUTIONS HAVE ALL THE
4	POSSIBILITIES TO CONTINUE TO MOVE THE TRAINING II
5	FORWARD EVEN THOUGH WE'RE GOING TO DEFER, AS
6	RECOMMENDED, IF YOU APPROVE THAT DEFERRAL, THE
7	FUNDING OF TRAINING II FOR 12 MONTHS UNDER THIS
8	SCENARI O.
9	NOW, I'D LIKE TO HAVE JAMES HARRISON
10	EXPLAIN THE CONFLICTS ISSUES AND HOW WE'RE
11	ADDRESSING THOSE SO THAT WE CAN ADDRESS THREE ITEMS
12	AND THEN RETURN TO THE ROBUST DISCUSSION OF THIS
13	OVERALL STRATEGY RECOMMENDATION.
14	MS. SAMUELSON: DOES THAT MEAN ON THOSE
15	THREE ITEMS, ANYONE WITH ANY CONFLICT ON ANY GRANT
16	CAN'T SPEAK TO THE LARGER ISSUE BECAUSE THERE'S A
17	HUGE ISSUE HERE UNDER EARLY TRANSLATION, HUGE. AND
18	I'M HOPING THAT WE CAN HAVE ROBUST PARTICIPATION BY
19	THE PATIENT ADVOCATES, AND SOME OF THEM HAVE LOTS OF
20	
	THOSE CONFLICTS.
21	THOSE CONFLICTS. CHAIRMAN KLEIN: I'D LIKE JAMES HARRISON
21 22	
	CHAIRMAN KLEIN: I'D LIKE JAMES HARRISON
22	CHAIRMAN KLEIN: I'D LIKE JAMES HARRISON TO PRESENT THE LEGAL CONSTRAINTS, AND CERTAINLY OPEN
22 23	CHAIRMAN KLEIN: I'D LIKE JAMES HARRISON TO PRESENT THE LEGAL CONSTRAINTS, AND CERTAINLY OPEN TO ANY SUGGESTIONS. MR. HARRISON.

1	BUT WE ARE IN A SOMEWHAT UNIQUE SITUATION IN THAT WE
2	HAVE THE BOARD HAS APPROVED FUNDING FOR BRIDGES
3	PROGRAM AND THE TRAINING GRANT II PROGRAM CONTINGENT
4	UPON THE BOARD'S LATER DETERMINATION THAT SUFFICIENT
5	FUNDS ARE AVAILABLE AND THAT THESE PROGRAMS REMAIN
6	PRIORITIES OF THE AGENCY.
7	IN ADDITION, APPLICATIONS HAVE BEEN
8	SUBMITTED FOR THE EARLY TRANSLATION PROGRAM.
9	THEY'VE BEEN REVIEWED BY THE GRANTS WORKING GROUP
10	AND WILL COME BACK IN THE FORM OF RECOMMENDATIONS TO
11	THIS BOARD IN APRIL. AS A RESULT OF THE PENDENCY OF
12	THOSE THREE PROGRAMS, WE HAVE A CHALLENGE WITH
13	RESPECT TO MANAGING OUR CONFLICTS OF INTEREST AND
14	ALSO TRYING TO PROMOTE AS MUCH DISCUSSION AS WE CAN
15	CONSISTENT WITH THE LAW.
16	THE CHALLENGE IS THAT IF WE'RE TALKING
17	ABOUT THE RELATIVE PRIORITY OF GRANT PROGRAMS, IT'S
18	POSSIBLE, FOR EXAMPLE, THAT IF THE BOARD WERE TO
19	DECIDE THAT EARLY TRANSLATION IS THE AGENCY'S
20	HIGHEST PRIORITY, THAT IT'S, THEREFORE, LESS LIKELY
21	THAT THERE WILL BE FUNDS AVAILABLE FOR TRAINING
22	GRANT II. WHAT THAT MEANS UNFORTUNATELY IS THAT
23	MEMBERS WHO HAVE AN INTEREST IN AN APPLICATION FOR
24	BRIDGES, TRAINING GRANT II, OR EARLY TRANSLATION
25	CANNOT PARTICIPATE IN THAT DISCUSSION.

1	TO TRY TO ADDRESS THIS ISSUE, AS THE CHAIR
2	SUGGESTED, WHAT WE HAVE RECOMMENDED IS THAT WE
3	ATTEMPT TO SEGMENT THE DISCUSSION. SO THAT FIRST WE
4	WOULD BEGIN WITH A BRIDGES PROGRAM. AGAIN, ONLY
5	THOSE MEMBERS WHO DO NOT HAVE AN INTEREST IN EITHER
6	BRIDGES, TRAINING GRANT II, OR EARLY TRANSLATION CAN
7	PARTICIPATE IN THAT DISCUSSION. NEXT WE WOULD GO TO
8	TRAINING II. AGAIN, ONLY THOSE MEMBERS WHO DON'T
9	HAVE ANY OTHER INTEREST COULD PARTICIPATE IN THAT
10	DISCUSSION. AND FINALLY, THE BOARD COULD DISCUSS
11	EARLY TRANSLATION. AGAIN, ONLY THOSE MEMBERS WHO
12	DON'T HAVE AN INTEREST IN ONE OF THE THREE PROGRAMS.
13	WHEN THAT DISCUSSION HAS COME TO AN END,
14	WE CAN THEN HAVE A MORE WIDERANGING DISCUSSION ABOUT
15	THE OTHER FUTURE PROGRAMS BECAUSE WE DON'T YET HAVE
16	ANY CONFLICTS OF INTEREST RELATED TO THOSE PROGRAMS.
17	I UNDERSTAND THAT THIS IS AWKWARD, BUT UNDER THE
18	CIRCUMSTANCES WE BELIEVE IT'S THE BEST APPROACH
19	CONSISTENT WITH OUR NEEDS TO ADHERE TO THE CONFLICT
20	OF INTEREST RULES.
21	CHAIRMAN KLEIN: AND THIS, IAN, MY
22	UNDERSTANDING IS YOU CONCUR WITH THIS APPROACH?
23	MR. SWEEDLER: YES.
24	CHAIRMAN KLEIN: SO WE HAVE TRIED TO TAKE
25	THE VIEWS OF BOTH COUNSEL AND WORK WITH ALL THE

1	OPPORTUNI TI ES.
2	DR. LEVIN: I HAVE A QUESTION. I'M NOT
3	SURE IF IT'S FOR JAMES OR FOR BOB HERE. YOU
4	HAVEN'T I'M, FIRST OF ALL, CONFLICTED ON ALL THE
5	CATEGORIES. SO FIRST OF ALL, DOES NOT THAT MEAN I
6	CAN' T SPEAK?
7	CHAIRMAN KLEIN: IT MEANS THAT YOU CANNOT
8	SPEAK UNTIL WE GET TO THE OVERALL STRATEGY, WHICH
9	WILL FOLLOW THESE THREE ITEMS.
10	DR. LEVIN: I WOULD LIKE, IF THERE'S A
11	SPACE FOR IT, TO MAKE A COMMENT JUST ABOUT THE
12	RANKINGS OF THE CATEGORIES WITH RESPECT TO EACH
13	OTHER, NOT ANY PARTICULAR CATEGORY.
14	CHAIRMAN KLEIN: WHICH YOU'RE GOING TO BE
15	ABLE TO DO WHEN WE GET TO THE OVERALL, BUT YOU CAN'T
16	DO IT AT THIS POINT UNLESS IT'S BELOW. WELL, THE
17	PROBLEM IS THAT THESE PRIORITIES ARE BOTH ABOVE THE
18	LINE AND BELOW THE LINE. SO FOR YOU TO TALK ABOUT
19	ONE OF THESE THREE ITEMS PROBABLY CREATES A REAL
20	PROBLEM AT THIS POINT.
21	TED AND THEN DR. HAWGOOD.
22	DR. LOVE: I DON'T THINK I HAVE ANY
23	CONFLICTS, SO I THINK I CAN ASK A QUESTION. I THINK
24	IT WOULD BE NICE TO HEAR A GOOD ELABORATION OF WHY
25	THE PRIORITIES ARE RANKED THIS WAY. AND LET ME JUST

1	ASK WITH A CONTEXT. SOME OF YOUR POINTS, ALAN, AT
2	THE BEGINNING TALKED ABOUT WE'RE READY TO START
3	MOVING TO THE CLINIC, REALLY START READY TO START
4	ADVANCING THERAPIES. AND IF I LOOK AT THAT JUST
5	KIND OF AT A HIGH LEVEL, I WOULD SAY, BOY,
6	TRANSLATION RESEARCH IS THE MOST PROXIMATE STEP TO
7	GETTING WHERE YOU DESCRIBED IN THE BEGINNING.
8	SO IT WOULD MAKE ME WONDER, WELL, IS THAT
9	THE RIGHT ORDER, OR IS IT ALMOST A FLIP OF THE ORDER
10	THAT'S UP THERE? I KNOW YOU'VE GOT A GOOD ANSWER,
11	AND I WANT TO ASK IT WITH THAT CONTEXT.
12	DR. TROUNSON: TED, SOME OF THESE PROGRAMS
13	LIKE TRANSLATION AND DISEASE TEAMS HAVE A REALLY BIG
14	IMPACT BECAUSE THEY'RE BIG PROGRAMS. AND
15	TRANSLATION HAS A REALLY BIG IMPACT BECAUSE IT'S UP
16	CLOSER TO US. IT'S UP FRONT, IF YOU LIKE. SO IT'S
17	NOT REALLY A GOOD IDEA TO TALK ABOUT THE PROJECTS
18	THEMSELVES EXCEPT TO SAY THAT THE GRANTS WORKING
19	GROUP HAD THEM EVEN IN THE TOP CATEGORY IN TWO
20	SECTIONS. AND SO THAT'S THE REASON WHY WE'VE
21	SUGGESTED, WELL, IN THIS BUDGET SITUATION, IT'S
22	BETTER TO PICK UP REALLY THE TOP LINE IN THAT
23	PARTICULAR PROGRAM AND NOT TO DO THE BOTTOM LINE,
24	BUT TO PUT IT WAY DOWN THERE OR WAY DOWN THE LIST AT
25	THE SECOND PART OF IT IN ORDER TO ACCOMMODATE THE

1	FINANCIAL MODELING INASMUCH AS ANYTHING ELSE.
2	WE TRIED TO KEEP THE DISEASE TEAMS UP
3	BECAUSE THEY'RE GOING TO HAVE A MUCH MORE THEY'RE
4	GOING TO HAVE A MUCH MORE IMPORTANT EFFECT STRAIGHT
5	AWAY BECAUSE THEY'RE REALLY FURTHER DOWNSTREAM. AND
6	WE UNDERSTAND THAT THERE'S A LARGE NUMBER OF THEM.
7	WE HAVEN'T SEEN THEM AS YET. YOU ASKED US TO TRY
8	AND SORT OF LOOK INTO THE CRYSTAL BALL, SO WE'VE
9	DONE THAT, AND THAT'S THE WAY WE FEEL IS PROBABLY
10	THE BEST WAY TO GET THE BUDGET TO STAY IN THE BLACK.
11	AND TO ALSO GIVE US THE HARD RUN AND THE PROGRAMS TO
12	THE END OF THE 2010.
13	OF COURSE, IF THERE'S MORE MONEY, AS BOB
14	SAYS, WE'LL BE ABLE TO MAKE ADJUSTMENTS. BUT HERE
15	YOU WILL SEE IN APRIL THAT THERE'S, WHEN YOU COME TO
16	REVIEW TRANSLATION, IT DOES BREAK INTO TWO, AND IT
17	IS A POSSIBLE POINT. THAT'S ALL WE'RE SAYING. FROM
18	OUR CRYSTAL BALL, IT WOULD BE ONE THAT WE'D ASK YOU
19	TO THINK ABOUT. YOU CAN'T DECIDE NOW, BUT TO THINK
20	ABOUT.
21	CHAIRMAN KLEIN: TED, IN RESPONSE TO YOUR
22	QUESTION AS WELL, IF YOU WILL NOTICE, THE BALANCE OF
23	DISEASE TEAMS IS RIGHT BELOW THE LINE. SO I
24	ACTUALLY BELIEVE, CONSISTENT WITH YOUR APPROACH AND
25	THIS BOARD'S DISCUSSION AND OUR ROLE, WHICH WE NEED

1	TO EMPHASIZE AS COMPLEMENTARY TO NIH AND FOLLOWING
2	DOWNSTREAM RESEARCH OPPORTUNITIES, I THINK WE SHOULD
3	MODIFY OUR GOAL OF RAISING A HUNDRED MILLION IN THE
4	SEPTEMBER QUARTER TO RAISING 130 BECAUSE IF WE
5	RAISED 130, THEN THE 26 MILLION THAT'S BELOW THE
6	LINE IN DISEASE TEAMS CAN MOVE UP, AND WE CAN FUND
7	THE WHOLE DISEASE TEAMS IF THE SCIENTIFIC QUALITY
8	AND THE OPPORTUNITY JUSTIFIES IT.
9	DR. ROBSON: JUST TO AVOID ANY
10	MISUNDERSTANDING, THIS IS NOT THE PRIORITY LIST.
11	THE PRIORITY LIST WAS ON THE PREVIOUS SLIDE. IF
12	MELISSA WOULD SHOW IT, YOU WILL SEE THAT EARLY
13	TRANSLATION IS AT THE TOP. IF WE GO BACK TO THIS
14	SLIDE, THIS SLIDE JUST DEALS WITH PROGRAMS THAT ARE
15	COMING BEFORE YOU EITHER THIS MEETING OR THE NEXT
16	MEETI NG.
17	THE REASON I PUT BRIDGES AND TRAINING II
18	AT THE TOP IS BECAUSE YOU HAVE A DECISION TO MAKE
19	ABOUT THEM TODAY. EARLY TRANSLATION DOESN'T COME TO
20	YOU UNTIL APRIL. WE'RE JUST KIND OF GIVING YOU A
21	WARNING AS TO WHAT WE THINK THAT YOU SHOULD BE
22	CONSIDERING FOR THAT. THAT'S THE REASON THEY'RE
23	ORDERED THAT WAY HERE.
24	CHAIRMAN KLEIN: DR. HAWGOOD HAS A POINT
25	HE'D LIKE TO MAKE. THIS IS DR. HAWGOOD, THOUGH,

1	YOU HAVE CONFLICTS DEALING WITH THESE.
2	DR. HAWGOOD: I AM CONFLICTED. I'M ASKING
3	JUST FOR CLARIFICATION. IF THE BRIDGES AND TRAINING
4	GRANT DECISIONS ARE MADE TODAY, THAT LOCKS IN A
5	CERTAIN COMPONENT OF THE PRIORITIZATION.
6	CHAIRMAN KLEIN: THAT DOES LOCK IN THE
7	IF TRAINING GRANTS IS DEFERRED, THAT IS NOT LOCKING
8	SOMETHING IN BECAUSE IT'S DEFERRED, SO THAT ORDER,
9	IN FACT, COULD LATER BE ADJUSTED. AND UNDER BRIDGES
10	IT'S 8.8 MILLION OF THE TOTAL THAT OCCURS DURING
11	THAT TIME PERIOD ON A CASH-FLOW BASIS, SO IT'S A
12	VERY SMALL INCREMENT OF THE TOTAL. BECAUSE
13	TRANSLATION IS COMING BEFORE US IN APRIL, WHATEVER
14	DECISION WE MAKE TODAY, BASED UPON OUR LOOKING AT
15	THE FACTS, WE COULD IN APRIL ADJUST THAT FIGURE. SO
16	WE'RE NOW MAKING A FINAL DECISION ON TRANSLATION
17	BECAUSE OUR FINAL DECISION ON TRANSLATION WON'T BE
18	DONE UNTIL APRIL, AND WE WILL INCREMENTALLY,
19	HOPEFULLY, HAVE INFORMATION AS WE GO FORWARD.
20	MR. SHEEHY: THIS IS PROBABLY THE LAST
21	TIME I THINK I'LL BE ABLE TO TALK, AND I'LL TRY TO
22	AVOID GETTING IN ANY TROUBLE. NO. 1, COULD WE GET
23	THOSE SLIDES? I FIND IT VERY DIFFICULT TO FOLLOW
24	YOUR FLIPPING BACK AND FORTH, AND THESE REALLY
25	SHOULD HAVE BEEN IN OUR PACKET, I THINK. BECAUSE
	120
24	YOUR FLIPPING BACK AND FORTH, AND THESE REALLY SHOULD HAVE BEEN IN OUR PACKET, I THINK. BECAUSE
	120

1	MR. SHESTACK: CAN WE GET THEM ON E-MAIL?
2	MR. SHEEHY: BECAUSE THEY'RE VERY HELPFUL.
3	THEY' RE BEAUTIFUL SLIDES.
4	CHAIRMAN KLEIN: ARE WE ON THE INTERNET
5	HERE? HOW ABOUT TAKING THEM DOWN AND E-MAILING
6	THEM? OR CAN ONE OF THE STAFF E-MAIL THEM?
7	DR. TROUNSON: I CAN ASK PAT BECKER TO DO
8	THAT, BOB. SORRY. WE WERE STILL TRYING TO MANEUVER
9	SOME OF THOSE GRAPHICS YESTERDAY.
10	MR. SHEEHY: MY OTHER TWO POINTS, HAVING
11	JUST SAT IN GOVERNANCE AND SEEING A WHOLE LIST OF
12	CONTRACTS, SOME OF WHICH WERE NOT MISSION CRITICAL,
13	WE HAVEN'T DONE ANY EXAMINATION OF ADMINISTRATIVE
14	COST, AND I THINK THAT THAT COMPONENT I CERTAINLY
15	WOULD NOT WANT TO IMPACT ANYONE'S EMPLOYMENT, THEIR
16	SALARY, BUT I THINK THAT WE HAVE A LOT OF OUTSIDE
17	CONTRACTS. WE NEED OUR LAWYERS TOO, SO I'M GOING TO
18	MAKE THAT PITCH RIGHT NOW BECAUSE TO DO THESE, I AM
19	AWARE THAT THE LEGAL SUPPORT THAT WE'RE GOING TO
20	NEED TO DO THE PRIVATE PLACEMENT IS MISSION
21	CRITICAL. BUT THERE'S OTHER THINGS THAT I THINK WE
22	SHOULD REALLY TAKE A HARD LOOK AT AND SAY DO WE NEED
23	TO GIVE ISSCR \$100,000, THAT'S A YEAR OF A GRANT, TO
24	HAVE A CONFERENCE. I'M NOT SO SURE.
25	SO I'D REALLY LIKE TO LOOK AT THAT. AND
	404

1	THE OTHER QUESTION, AND THIS MAY BE BORDERLINE SO
2	CHAIRMAN KLEIN: LET'S NOT GET BORDERLINE.
3	MR. SHEEHY: MY ONLY POINT IS THAT MY
4	UNDERSTANDING IS THAT THIS GLOBAL DISCUSSION ON
5	PRIORITIES, I THINK YOU'RE TRYING TO MAKE IT
6	POSSIBLE FOR ME TO TAKE PART IN THAT BY HAVING THIS
7	EARLIER DISCUSSION. I WOULD BE COMFORTABLE LETTING
8	THOSE THAT ARE UNCONFLICTED LOOK AT THE WHOLE
9	PACKAGE RATHER THAN I DON'T KNOW HOW YOU CAN
10	REALLY TAKE IT APART. NOW, AM I CROSSING THE LINE
11	BY JUST SAYING THAT BECAUSE I'M JUST GIVING OUT
12	MY I'M HAPPY NOT, BUT YOU'RE ASKING TO MAKE
13	CHOICES ON THREE GRANT ROUNDS WHEN REALLY THE
14	CHOICES COVER A WHOLE RANGE OF GRANT ROUNDS, AND I
15	CAN SIT QUIETLY AND LISTEN AND BE COMFORTABLE WITH
16	THAT. I DON'T WANT
17	CHAIRMAN KLEIN: LET ME TRY AND ADDRESS
18	THAT AND NARROW IT DOWN, DRILL DOWN HERE.
19	TRANSLATION COMES BEFORE US IN APRIL. SO WHATEVER
20	DECISION WE MAKE TODAY, WE CAN READJUST THAT
21	DECISION IN APRIL BASED UPON WE CAN READJUST THE
22	ALLOCATION IN APRIL. WE COULD ADVANCE MORE MONEY TO
23	IT WITHOUT ADJUSTING THE MONEY IN ANY OTHER
24	CATEGORY.
25	MS. SAMUELSON: BUT WE'RE BEING ASKED TO
	122
	122

8	MS. LANSING: THIS IS A QUESTION I CAN ASK
9	FROM OUR SECTION.
10	CHAIRMAN KLEIN: YOU'RE ASKING THIS
11	I NDI VI DUALLY.
12	MS. LANSING: I'M ASKING THIS
13	INDIVIDUALLY. HOW MUCH MONEY DO WE HAVE LEFT?
14	CHAIRMAN KLEIN: WE HAVE AS OF JANUARY,
15	WE HAD 160 MILLION.
16	DR. ROBSON: WE'RE AT ABOUT 130 NOW.
17	CHAIRMAN KLEIN: 128 MILLION, I BELIEVE.
18	DR. LOVE: SO WITH NOTHING IN THE DOOR,
19	WHEN DO WE RUN OUT OF MONEY WITH THE CURRENT
20	EXPENDITURE WITHOUT ANY ADJUSTMENT?
21	DR. TROUNSON: TED, WE HAD THIS DISCUSSION
22	LAST TIME. TO KEEP THE AGENCY ACTUALLY GOING, WE
23	WOULD ACTUALLY HAVE TO CEASE IN ALL ONGOING PAYMENTS
24	AFTER THE END OF SEPTEMBER THIS YEAR.
25	CHAIRMAN KLEIN: NOW, LET'S REFINE THAT.
	123

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	THAT'S IF WE MADE ALLOCATIONS IN SEPTEMBER. IF WE
2	DIDN'T MAKE THE ALLOCATIONS IN SEPTEMBER, DR.
3	ROBSON, I THINK WE WOULD BE ABLE TO GET THROUGH THE
4	END OF THE YEAR. IS THAT A CORRECT STATEMENT?
5	DR. TROUNSON: SO THE ONLY DIFFERENCE IS
6	THAT IF WE DON'T KEEP ANY MONEY ASIDE FOR
7	MAINTAINING THE AGENCY, THE AGENCY WILL NOT HAVE ANY
8	MONEY TO MAINTAIN ITSELF.
9	CHAIRMAN KLEIN: I UNDERSTAND THAT. THE
10	CASH FLOWS, I THINK, ARE VERY CLEAR, THAT IF WE
11	DIDN'T MAKE ALLOCATIONS IF WE WENT WITH THIS
12	MODIFIED LIST, INCLUDING EXISTING COMMITMENTS, AND
13	WE DID NOT MAKE AN ALLOCATION TO DISEASE TEAMS IN
14	SEPTEMBER.
15	DR. TROUNSON: IF NO FURTHER ALLOCATIONS
16	AT ALL, BOB, THAT'S NO FURTHER ALLOCATIONS.
17	CHAIRMAN KLEIN: WHERE WOULD WE BE?
18	DR. TROUNSON: SEPTEMBER, END OF SEPTEMBER
19	WITH NO FURTHER ALLOCATION WHATSOEVER.
20	DR. ROBSON: IT MIGHT BE A LITTLE LATER
21	THAN THAT.
22	CHAIRMAN KLEIN: IT'S DECEMBER, I THINK.
23	DR. TROUNSON: YOU CAN ARGUE WHICH WAY,
24	BUT WE WERE TALKING ABOUT KEEPING, SAY, 20 MILLION
25	ASIDE FOR THE ORGANIZATION.
	124

1	DR. LOVE: WHAT IS OUR MONTHLY BURN JUST
2	TO RUN THE ORGANIZATION?
3	DR. TROUNSON: SHOWN ON THOSE GRAPHS, TED,
4	3.7 MILLION.
5	DR. LOVE: MONTHLY?
6	DR. ROBSON: NO. NO. ADMINISTRATION, IS
7	THAT WHAT YOU ARE ASKING? ABOUT 3.7 MILLION
8	QUARTERLY OR 3.5.
9	CHAIRMAN KLEIN: QUARTERLY.
10	DR. POMEROY: I HAVE A GENERIC QUESTION
11	WHICH I'M PRETTY CONFIDENT I'M ALLOWED TO ASK. HAVE
12	YOU MODELED WHAT WE CAN DO IF WE GET ZERO, WHAT WE
13	CAN DO IF WE GET A HUNDRED MILLION? DO YOU HAVE
14	THOSE MODELS, AND CAN WE GET COPIES OF THOSE?
15	BASICALLY WHAT YOU'VE JUST ASKED IS WHAT HAPPENS IF
16	WE GET ZERO, WHAT HAPPENS, SO I'D LIKE TO KNOW IF WE
17	GET ZERO, WHAT HAPPENS IF WE GET A HUNDRED MILLION,
18	WHAT HAPPENS IF WE GET 200, 300, AND 400.
19	DR. TROUNSON: SO IF WE HAD ZERO, THIS WAS
20	DEALT WITH LAST TIME. IN MY VIEW, WE'D RUN OUT AT
21	THE END OF SEPTEMBER. WE RUN OUT OF ALL CASH AT THE
22	END OF DECEMBER IF WE KEEP THE CONTRACTS GOING. BUT
23	WE RUN OUT WITHOUT ANY MORE INFUSION AT THE END OF
24	SEPTEMBER IF WE WISH TO KEEP THE AGENCY ACTUALLY
25	STILL RUNNING.
	105

1	DR. POMEROY: I DO UNDERSTAND THAT. MY
2	QUESTION IS DO YOU HAVE THAT MODELED, AND CAN WE GET
3	IT IN WRITING?
4	DR. TROUNSON: IT WAS PROVIDED TO YOU LAST
5	TIME.
6	CHAIRMAN KLEIN: WE'LL PROVIDE IT AGAIN.
7	DR. POMEROY: NO. YOU PROVIDED WHEN WE
8	WOULD RUN OUT IF WE GOT ZERO. MY QUESTION WAS HAVE
9	YOU MODELED IT FOR ZERO, 100, 200, 300, AND 400, AND
10	CAN WE GET THOSE MODELS?
11	CHAIRMAN KLEIN: YES. THE ANSWER IS YES.
12	LET ME RELATE TO WHAT DR. TROUNSON IS SAYING. LAST
13	TIME I STATED THAT WE WOULD RUN OUT WITH ZERO IN
14	SEPTEMBER. IT'S ACTUALLY CLOSER TO THE END OF
15	DECEMBER.
16	NO. 2 IS THE MODEL, THERE IS A MODEL AT
17	400 MILLION, WHICH WE CAN PROVIDE. THE INTENT OF
18	STAFF WAS TO COME WITH A MORE CONSERVATIVE MODEL TO
19	THIS MEETING, BUT THAT CAN CERTAINLY BE PROVIDED.
20	WHAT IS BEING ADDRESSED HERE IN TERMS OF
21	CASH FLOW AND IMPACT ON OUR CASH IS ACTUALLY AN
22	EXPENDITURE OF 8.8 MILLION. LET ME EXPLAIN WHY.
23	THEY'RE SUGGESTING TO DEFER TRAINING II,
24	SO THAT'S NO CASH DISTRIBUTION AT THIS TIME. THEY
25	ARE SUGGESTING AN AMOUNT FOR EARLY TRANSLATION, BUT
	126

1	THE REAL DECISION ON EARLY TRANSLATION WILL BE MADE
2	IN APRIL. AND WE'RE GOING TO CONTINUE TO GO BACK
3	THROUGH PROCESS. THEY CAN BRING BACK ALL THOSE
4	MODELS IN APRIL, SO THIS IS A PRELIMINARY ALLOCATION
5	ON EARLY TRANSLATION AT THIS TIME. THERE IS NO
6	EXPENDITURE. YOU HAVEN'T EVEN APPROVED ANY GRANTS
7	FOR EARLY TRANSLATION.
8	SO THE IMPACT HERE THAT IS RECOMMENDED IS
9	A DECISION REALLY EFFECTIVELY ON BRIDGES FOR 8.8
10	MILLION BECAUSE IT IS TIME CRITICAL TO WHEN THESE
11	INSTITUTIONS CAN IMPLEMENT THEIR PROGRAMS, TELL
12	STUDENTS THAT THEY CAN ENROLL IN THESE PROGRAMS, AND
13	INITIATE A PROGRAM THAT THEY FELT WAS IMPORTANT TO
14	OUR MISSION TO PROVIDE THE EXPERTISE TO MOVE THESE
15	PROGRAMS FORWARD.
16	DR. LOVE: BUT TOTALLY I WANT TO MAKE
17	SURE I UNDERSTAND. TO BE TOTALLY TRANSPARENT, IF WE
18	MAKE A COMMITMENT OF \$8 MILLION TO BRIDGES, AND
19	THINGS DON'T GO WELL IN THE FUTURE
20	CHAIRMAN KLEIN: LET ME MAKE A SPECIFIC
21	INDICATION. WE'D BE MAKING A COMMITMENT OF 17.5
22	MILLION. EIGHT MILLION LIES WITHIN THE NEXT 24
23	MONTHS OR 19 MONTHS.
24	DR. TROUNSON: SO, TED, IT'S PREDICATED
25	ON YOU CAN PREDICATE IT ON WHATEVER NUMBERS. YOU

1	COULD HAVE CHOSEN ANY NUMBERS. WE DECIDED THAT
2	OPTIMISTICALLY THAT 200 MILLION OVER THIS TIMEFRAME,
3	WHICH IS HALF OF WHAT BOB WAS PROPOSING, WAS A
4	CONSERVATIVE, BUT DOABLE THING. I HAVE GREAT
5	CONFIDENCE THAT WE'LL BE ABLE TO DO THAT.
6	THE PROPORTIONAL CONFIDENCE GETTING TO THE
7	400 MILLION MUST BE REDUCED. SO THE SENSE OF IT IS
8	WE CAN ALTER IN REAL-TIME, BUT WE WERE ASKED TO GIVE
9	A SET OF PRIORITIES. THE ONLY WAY YOU CAN GIVE A
10	SET OF PRIORITIES IS TO MATCH IT WITH WHAT YOU MIGHT
11	EXPECT TO COME. SO UNDER THE CIRCUMSTANCE THAT YOU
12	GOT 200, WHICH WAS A CONSERVATIVE, BUT OPTIMISTIC
13	OPTION, YOU COULD THEN FRAME A SET OF PRIORITIES
14	THAT HAD SOME MEANING FOR THE BOARD. OTHERWISE IF
15	WE'RE ONLY GOING TO TALK ABOUT GETTING 10 MILLION OR
16	12 MILLION, IT'S REALLY GOING TO BE EXTREMELY MINOR.
17	PRESUMABLY WELL, TO INTERROGATE THE
18	VIEW WHETHER 200 MILLION IS GETTABLE OR OPTIMISTIC,
19	I THINK OTHER PEOPLE SHOULD CHIME IN AND SORT OF
20	DISCUSS THAT, BUT WE FELT THAT WAS A DOABLE THING
21	GIVEN THE CIRCUMSTANCES AND THE BUDGET CHANGE AND
22	THE PRESIDENTIAL OBAMA A WHOLE LOT OF THINGS HAVE
23	CHANGED SINCE THE LAST BOARD MEETING. I WOULD FEEL
24	ON BEHALF OF STAFF OPTIMISTIC THAT'S THAT DOABLE. I
25	DON'T KNOW WHETHER THE 400 IS DOABLE, BUT TO CARRY

1	THE WHOLE PROGRAM FORWARD, I THINK, BOB, IT WAS 370
2	MILLION, SOMETHING LIKE THAT, BUT WE
3	CHAIRMAN KLEIN: THAT'S CORRECT.
4	DR. TROUNSON: THAT WAS NOT SORT OF
5	PUTTING ANYTHING INTO A CLINICAL PROGRAM SHOULD IT
6	TURN UP THAT IF WE FELT THAT THAT WAS A GOOD OPTION
7	TO BE INVOLVED. WE HADN'T COUNTED THAT IN, FOR
8	EXAMPLE.
9	CHAIRMAN KLEIN: OKAY. SO, SHERRY, COULD
10	I SEE IF DR. ROBSON HAS SOME ADDITIONAL INFORMATION
11	THEN CALL ON YOU?
12	DR. ROBSON: ONE COMMENT ABOUT BRIDGES.
13	THERE IS A TIMING ISSUE HERE. THERE IS SOME URGENCY
14	IF YOU WANT TO APPROVE THAT BECAUSE THIS IS A
15	PROGRAM THAT WOULD START WOULD RUN ACCORDING TO
16	THE ACADEMIC YEAR, AND THEY NEED SOME ADVANCE TIME
17	TO PLAN IT TO GET IT SET UP. SO THAT'S ONE REASON
18	WE THINK THERE'S SOME URGENCY TO MOVE THAT FORWARD
19	NOW.
20	MS. LANSING: I THINK I'M ALLOWED TO ASK
21	THIS. JUST SO I GET THIS IN MY HEAD, IN FULL
22	TRANSPARENCY, THE DIFFICULT THING IS THAT WE'RE
23	BEING ASKED TO APPROVE SOMETHING, AND GOD KNOWS WE
24	WANT YOU TO BE SUCCESSFUL, BUT IF IT WASN'T, WE
25	COULD FIND OURSELVES NOT HAVING ENOUGH MONEY IN FULL
	120

1	TRANSPARENCY TO FUND SOME OTHER PROGRAMS; IS THAT
2	CORRECT?
3	CHAIRMAN KLEIN: IT IS A CORRECT
4	STATEMENT. BUT REMEMBER IN THE TWO-YEAR PERIOD,
5	BRIDGES, WHICH IS THE ONLY ONE DECISION THAT WOULD
6	BE MADE TODAY THAT WOULD ACTUALLY COMMIT MONEY IN
7	THIS PERIOD, IS 8.8 MILLION. AS A PART OF THE TOTAL
8	PROGRAM, IT'S A VERY SMALL CASH FLOW.
9	MS. LANSING: I'M NOT QUESTIONING THAT.
10	CHAIRMAN KLEIN: THAT'S ABSOLUTELY
11	CORRECT. ABSOLUTELY CORRECT. OKAY.
12	SO WHAT I'D LIKE TO DO HERE IS ON ITEM 16,
13	TO GIVE US A FRAMEWORK FOR THIS BRIDGES PROGRAM,
14	WHICH WE PREVIOUSLY DISCUSSED, IS I'D LIKE TO GIVE
15	THE PUBLIC, BECAUSE THERE ARE A NUMBER OF PUBLIC
16	REPRESENTATIVES FROM THE STATE COLLEGE SYSTEM AND
17	POTENTIALLY COMMUNITY COLLEGE SYSTEM, A CHANCE TO
18	COMMENT SO THAT WE HAVE THEIR INFORMATION IN THIS
19	MAKING DECISION.
20	WHO WOULD LIKE TO COMMENT? IF YOU'D
21	PLEASE APPROACH THE PODIUM.
22	MR. RICHMOND: THANK YOU VERY MUCH,
23	CHAIRMAN KLEIN, MEMBERS OF THE BOARD. MY NAME IS
24	ROLAND RICHMOND. I HAVE THE PLEASURE AND HONOR OF
25	BEING THE PRESIDENT OF HUMBOLDT STATE UNIVERSITY,
	130
	130

1	WHICH IS A PART OF THE CALIFORNIA STATE UNIVERSITY
2	SYSTEM, BUT I'M HERE TODAY REPRESENTING THE
3	CALIFORNIA STATE UNIVERSITY AND THE CALIFORNIA
4	COMMUNITY COLLEGE SYSTEM WHO HAVE PUT FORWARD THIS
5	PROPOSAL TO YOU.
6	AS A REMINDER, WE CAME BEFORE YOU IN
7	AUGUST OF 2006 WITH A PROPOSAL TO CREATE SOMETHING
8	LIKE THE BRIDGES PROGRAM. AND WHEN YOU ISSUED AN
9	RFA IN 2008, THE CALIFORNIA STATE UNIVERSITY AND THE
10	CALIFORNIA COMMUNITY COLLEGE SYSTEM, WITH THE HELP
11	OF YOUR STAFF, ORGANIZED WORKSHOPS TO EDUCATE OUR
12	FACULTY ABOUT HOW TO PROCEED WITH APPLYING FOR THESE
13	GRANTS. MY INSTITUTION, FOR EXAMPLE, HAS INVESTED
14	MORE THAN \$100,000 IN PREPARATION. WE WERE
15	ENTHUSIASTIC ABOUT THIS PROPOSAL. WE'VE INVESTED
16	MONEY TO UPGRADE OUR EQUIPMENT TO MAKE SURE THAT WE
17	HAVE FACILITIES READY TO SERVE THE BRIDGES PROGRAM.
18	OTHER CAMPUSES WITHIN THE CALIFORNIA STATE
19	UNIVERSITY SYSTEM AND THE COMMUNITY COLLEGE SYSTEM
20	HAVE MADE SIMILAR INVESTMENTS READY TO GO ON THIS.
21	THE POINT THAT WAS MADE EARLIER BY A STAFF MEMBER,
22	THAT WE NEED TO MOVE FORWARD NOW SO THAT WE CAN GET
23	STUDENTS ENROLLED AS SOON AS POSSIBLE IS AN
24	EXCELLENT POINT.
25	I ALSO WOULD POINT OUT THAT MANY OF OUR
	131
	IJI

1	FACULTY HAVE INVESTED CONSIDERABLE TIME IN PREPARING
2	THESE PROPOSALS, NOT TO MENTION THE COSTS INVOLVED
3	IN IT. TO BACK AWAY FROM THAT NOW, I THINK, WOULD
4	PLACE CIRM AND THIS WHOLE PROCESS IN SOME QUESTION.
5	I ALSO WOULD POINT OUT, AS DR. TROUNSON
6	HAS DONE, THAT IT IS TIME TO RECOGNIZE THAT, AND
7	YOU'VE GOTTEN A LOT OF VERY INTERESTING DATA THIS
8	MORNING WHICH SHOW THAT WE ARE MOVING VERY QUICKLY,
9	THAT INDUSTRY IS MOVING VERY QUICKLY TOWARDS
10	TRANSLATING SOME OF THE BASIC RESEARCH RESULTS INTO
11	IDEAS THAT CAN BE USED TO TREAT PATIENTS. WE NEED
12	TO MOVE FORWARD ON THAT.
13	SO I URGE YOU THAT THIS IS A REAL
14	OPPORTUNITY. THE CSU AND THE CALIFORNIA COMMUNITY
15	COLLEGE SYSTEM WILL BRING A RANGE OF STUDENTS, A
16	DIVERSITY OF STUDENTS INTO THE STEM CELL PROGRAMS,
17	INTO THIS INDUSTRY. IT'S VERY IMPORTANT THAT WE
18	MOVE FORWARD ON THIS FUNDING. AS SEVERAL OF YOU
19	HAVE POINTED OUT, WE'RE NOT ASKING FOR VERY MUCH
20	MONEY IN COMPARISON TO THE OVERALL EXPENDITURES THAT
21	YOU MAKE. THANK YOU FOR YOUR CONVERSATIONS AND
22	THANK YOU FOR YOUR ATTENTION TO THIS PROGRAM.
23	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
24	MS. AMBOSE: MY NAME IS ELIZABETH AMBOSE,
25	AND I'M ASSISTANT VICE CHANCELLOR FOR RESEARCH
	120

1	INITIATIVES AND PARTNERSHIPS AT THE CALIFORNIA STATE
2	UNI VERSI TY SYSTEM.
3	IN ADDITION TO PRESIDENT RICHMOND, I'D
4	LIKE TO OFFER TESTIMONY THAT RELATES TO THE TIMING
5	OF THE AWARDS OF BRIDGES WITH RELATION TO THE
6	FEDERAL STIMULUS DOLLARS. I THINK WE ARE ALL AWARE,
7	AS HAS BEEN MENTIONED EARLIER, THAT PRESIDENT
8	OBAMA'S LIFTING OF THE FEDERAL STEM CELL RESEARCH
9	BAN, COUPLED WITH A NEW ADMINISTRATION STIMULUS
10	MONIES AND THEIR PROJECTIONS FOR FY 10 OFFER US AN
11	UNPRECEDENTED OPPORTUNITY TO CREATE SYNERGIES AND
12	LEVERAGING WITH CIRM-FUNDED PROGRAMS.
13	BOTH THE NIH AND NSF ARE NOW AUGMENTING
14	THEIR BUDGETS, PARTICULARLY AS SUPPLEMENTS TO
15	EXISTING GRANTS, FUNDING OF GRANTS CURRENTLY UNDER
16	CONSIDERATION, AND SPECIAL FUNDS SET ASIDES THAT
17	HAVE ALREADY BEEN ALLUDED TO FOR FACILITIES AND
18	EQUIPMENT. IN THE CSU AND CCC, AS IS TRUE FOR THE
19	PUBLIC AND PRIVATE RESEARCH UNIVERSITIES, WE ARE NOW
20	CONSIDERING SUPPLEMENTAL REQUESTS. THE FACT THAT WE
21	HAVE OPPORTUNITIES AFFORDED TO US AS HISPANIC
22	SERVING INSTITUTIONS, WHICH IS A NUMBER OF OUR
23	INSTITUTIONS IN BOTH SYSTEMS, AS WELL AS MINORITY
24	SERVING SHOULD NOT GO UNREGARDED.
25	WE HAVE A TIME WINDOW IN THE NEXT THREE TO
	122

1	FOUR MONTHS IN WHICH WE WILL ALL BE PREPARING FOR
2	THESE STIMULUS MONIES. DUE TO THE GREAT INTEREST
3	AND COMMITMENT ALREADY EXPRESSED BY PRESIDENT
4	RICHMOND IN THE CSU AND CCC LIFE SCIENCES RANKS, WE
5	BELIEVE THAT THIS IS TIME AND MOMENTUM AND CAPACITY
6	FOR US TO EXPRESS TO THE FEDERAL GOVERNMENT OUR
7	PRIORITIES FOR EQUIPMENT AND INFRASTRUCTURE, AND
8	THAT THESE WILL BE ALIGNED WITH THE BROADER ASPECTS
9	OF THE STEM CELL RESEARCH AND WORKFORCE TRAINING.
10	SO AGAINST THIS BACKDROP, AGAIN, WE ASK
11	FOR YOUR CONSIDERATION IN SUPPORT FOR RAPID FUNDING
12	AND, AGAIN, TO REITERATE THE FACT THAT THE FUNDS
13	THAT WE ARE COMMITTING TO REFLECT ABOUT A HALF OF A
14	PERCENT OF THE TOTAL BOND FUNDING PERHAPS PUTS IN
15	PERSPECTIVE THE TREMENDOUS LEVERAGING OPPORTUNITIES
16	AFFORDED TO US.
17	AGAIN, WE WANT TO THANK YOU VERY MUCH FOR
18	YOUR CONSIDERATION.
19	CHAIRMAN KLEIN: THANK YOU VERY MUCH,
20	ELIZABETH. AND THANK YOU FOR YOUR REFERENCE TO THE
21	LEVERAGE OPPORTUNITIES FOR THE STIMULUS BILL BECAUSE
22	HAVING A PROGRAM APPROVED AND FUNDED BY THE STATE
23	WOULD OBVIOUSLY HELP PUT YOU IN A GOOD POSITION FOR
24	POTENTIAL STIMULUS LEVERAGE.
25	MS. BAXTER: I'M SUSAN BAXTER. I'M THE
	134
	101

1	EXECUTIVE DIRECTOR OF THE CALIFORNIA STATE
2	UNIVERSITY PROGRAMS IN BIOTECHNOLOGY. AND I ALSO
3	WANTED TO TALK ABOUT THE APPLICATION OF THE BRIDGES
4	PROGRAM OR THE RELATIVE IMPORTANCE OF IT TO ACTUALLY
5	TRANSLATIONAL RESEARCH. AS WE'VE SAID DURING
6	CONVERSATIONS HERE AT THE ICOC AS EARLY AS AUGUST
7	2007, THE CSU REGARDS STEM CELL TRAINING AT ALL
8	LEVELS VITAL TO THE SUCCESS OF CIRM'S GOAL IN
9	TRANSLATING RESEARCH DISCOVERIES INTO CURES.
10	WE SIMPLY CANNOT SEPARATE THE GOALS OF
11	BUILDING A STEM CELL COMMUNITY AND DEVELOPING STEM
12	CELL-BASED PRODUCTS FROM THE NEED FOR PROFESSIONALS
13	TO CARRY OUT, NOT ONLY DISCOVERY RESEARCH, BUT TO
14	FINANCE AND BUILD THAT INDUSTRY TO DRIVE THE
15	REGULATORY APPROVAL AND THE PRODUCTION OF PRODUCTS
16	THAT WILL BE SAFE AND EFFECTIVE IN THE MARKETPLACE.
17	THE COMPLEX GROUPS OF PROFESSIONALS THAT
18	ARE THE ONES WHO DO THIS COME AT ALL LEVELS OF
19	TRAINING, AND PARTICULARLY AT THE MASTER'S DEGREE OR
20	LOWER. WE KNOW THAT THE EMPLOYEES IN THE INDUSTRY
21	ARE TYPICALLY MASTER'S DEGREE OR LOWER, ABOUT 80
22	PERCENT OF THE EMPLOYEES.
23	AS YOU KNOW AND RECOGNIZE, WE STAND READY
24	TO CARRY OUT THIS MISSION, AND WE FEEL THAT WE CAN
25	SIGNIFICANTLY BUILD THE CAPACITY, BUT ALSO TO THE

1	ACCELERATION OF STEM CELL TECHNOLOGIES AND PRODUCT
2	DEVELOPMENT THAT WE ALL WANT SO BADLY. OVER THE
3	PAST FEW YEARS WE'VE REPRESENTED BOTH THE CCC AND
4	CSU, THAT WE DO EDUCATE THE MAJORITY OF THE STATE'S
5	BACHELOR'S AND MASTER'S EDUCATED STUDENTS AND
6	PROFESSIONALS. MOST OF THESE WORKERS ARE BORN AND
7	RAISED IN CALIFORNIA AND REPRESENT THE FULL
8	DIVERSITY OF CALIFORNIA'S CITIZENRY. WITHOUT
9	FUNDING OF THE BRIDGES PROGRAM, THE IMPACT ON THAT
10	FUTURE WORKFORCE IS OBVIOUS AND IMMEDIATE.
11	JILL TRAYNOR, THE DEAN OF THE COLLEGE OF
12	NATURAL SCIENCES AND MATHEMATICS AT CAL STATE IN
13	SACRAMENTO HERE TOLD US A COMPELLING STORY THAT
14	DEMONSTRATES THE POTENTIAL BENEFITS OF THE BRIDGES
15	PROGRAM FOR STEM CELL RESEARCH THAT SHE HAS AND THE
16	STORY'S HEROINE HAVE ALLOWED ME TO SHARE WITH YOU
17	TODAY.
18	JAN NOLTA IS THE DIRECTOR OF THE UC DAVIS
19	STEM CELL PROGRAM, AND SHE'S AN ALUMNA OF SACRAMENTO
20	STATE. LIKE MANY SAC STATE STUDENTS, SHE GREW UP IN
21	AN ECONOMICALLY DISADVANTAGED FAMILY AND COULD NOT
22	HAVE GONE TO COLLEGE WITHOUT GRANTS AND
23	SCHOLARSHIPS. AS AN UNDERGRADUATE SHE INTENDED TO
24	BECOME A PHYSICIAN, BUT EXPRESSED SECOND THOUGHTS TO
25	HER BIOLOGY PROFESSORS. RECOGNIZING HER TALENT, HER
	407

1	PROFESSOR SUGGESTED SHE CONSIDER A CAREER IN
2	LABORATORY RESEARCH, SOMETHING JAN DIDN'T EVEN KNOW
3	WAS POSSIBLE. JAN'S PROFESSOR HELPED HER FIND AN
4	INTERNSHIP DURING WHICH SHE FIRST BECAME INTERESTED
5	IN STEM CELL RESEARCH.
6	SO JAN NOLTA, WHO'S HERE TODAY, IS LIVING
7	PROOF OF THE POWER OF THE CSU TO STEER FUTURE
8	SCIENTISTS TOWARDS CAREERS IN STEM CELL RESEARCH AND
9	PRODUCT DEVELOPMENT.
10	IF THE BRIDGES PROGRAM ULTIMATELY PRODUCES
11	A FEW MORE LIKE JAN NOLTA, IT WILL BE A HOME RUN FOR
12	CI RM.
13	IN CLOSING, THANK YOU FOR LISTENING TO US
14	AND CONSIDERING THIS PROGRAM.
15	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
16	MR. O'NEAL: JEFFREY O'NEAL. I'M THE
17	STATE DIRECTOR FOR BIOTECHNOLOGY FOR THE CALIFORNIA
18	COMMUNITY COLLEGES AND WORKFORCE DEVELOPMENT. AND
19	WE HAVE PARTNERSHIPS THROUGH THE BRIDGES GRANTS WITH
20	CSU'S. AND THE COMMENT I WANTED TO MAKE IS THAT,
21	YOU KNOW, WE DO A LOT OF TECHNICIAN TRAINING AND
22	ENTRY LEVEL TRAINING, A LOT OF HANDS-ON TRAINING
23	THROUGHOUT THE STATE OF CALIFORNIA. AND WHAT WE DO
24	ALSO, WE TARGET UNDERSERVED POPULATIONS. WE SUPPORT
25	A LOT OF HIGH SCHOOL PROGRAMS, HIGH SCHOOL PROGRAMS

WITH BIOTECH, AND WE ALSO DO TEACHER TRAINING.
WHAT WE'RE TRYING TO DO IS ATTRACT A
DIVERSE POPULATION INTO SCIENCE. BECAUSE YOU WALK
INTO A SCIENCE LAB AND I WAS AT A BIOTECH COMPANY
FOR ABOUT 12 OR 13 YEARS IN DAVIS AND WOUND UP BEING
DISPLACED BECAUSE OF DOWNSIZING, WENT TO THE LABS AT
UC DAVIS FOR A NUMBER OF YEARS. I WAS KIND OF AWED
BY THE FACT THAT THE VAST MAJORITY OF GRADUATE
STUDENTS THERE WERE NOT NATIVE BORN AMERICANS. THEY
WERE FOREIGN BORN STUDENTS.
SO WHAT WE'RE TRYING TO DO IS BRING THE
POPULATION OF CALIFORNIA INTO SCIENCE. LET THEM
KNOW THEY CAN DO THIS. IT'S AVAILABLE TO THEM. SO
THE BRIDGES GRANT HELPS US IMMENSELY WITH THAT.
THANK YOU.
CHAIRMAN KLEIN: THANK YOU VERY MUCH. SO
I'D LIKE TO KNOW IF THERE IS A MOTION AT THIS TIME
FOR FUNDING THE BRIDGES GRANTS AS PROPOSED, AND THEN
WE'RE GOING TO HAVE ADDITIONAL DISCUSSION.
DR. PULIAFITO: MR. CHAIRMAN, I'D LIKE TO
MAKE THAT MOTION IF I CAN.
CHAIRMAN KLEIN: YOU CAN'T MAKE THAT
MOTION. LET'S GO THROUGH WHO HAS CONFLICTS AND WHO
DOESN'T AND WHO CAN MAKE A MOTION.
MR. HARRISON: LET ME POINT OUT THAT THIS
138

138

1	IS A SOMEWHAT UNUSUAL SITUATION BECAUSE MOST OF THE
2	APPLICANT INSTITUTIONS OBVIOUSLY ARE NOT
3	INSTITUTIONS FROM WHICH MEMBERS OF THIS BOARD ARE
4	APPOINTED. HOWEVER, THERE IS POTENTIAL RELATIONSHIP
5	BETWEEN SOME OF THE APPLICANT INSTITUTIONS AND HOST
6	INSTITUTIONS, WHICH WOULD HOST THE INTERNS THROUGH
7	THIS PROGRAM. AS A RESULT, THERE ARE CONFLICTS THAT
8	WE HAVE TO DEAL WITH ALTHOUGH SOMEWHAT ATTENUATED.
9	LET ME JUST READ A LIST, IF I COULD, MR.
10	CHAIR, OF THOSE MEMBERS WHO CAN PARTICIPATE IN THIS
11	DISCUSSION, AND THIS LIST WILL HOLD TRUE FOR
12	TRAINING AND EARLY TRANSLATION AS WELL.
13	THE MEMBERS THAT CAN PARTICIPATE ARE
14	KLEIN, GIBBONS, LOVE, QUINT, ROTH, SAMUELSON,
15	SERRANO-SEWELL, SHESTACK, AND TORRES.
16	CHAIRMAN KLEIN: IS THERE A MOTION
17	WE'RE GOING TO DEAL WITH THE DISCUSSION, BUT IS
18	THERE A MOTION FROM THOSE WHO ARE NOT CONFLICTED?
19	MR. SERRANO-SEWELL: SO MOVED.
20	CHAIRMAN KLEIN: SO MOVED BY DAVID
21	SERRANO-SEWELL. IS THERE A SECOND?
22	MR. SHESTACK: I SECOND.
23	CHAIRMAN KLEIN: OKAY. THANK YOU.
24	DR. PRIETO: CAN I ASK A PROCEDURAL
25	QUESTION? ARE WE GOING TO HAVE AN OPPORTUNITY TO
	139

1	HAVE THE GENERAL DISCUSSION BEFORE VOTES ARE TAKEN
2	ON THE INDIVIDUAL PROGRAMS?
3	CHAIRMAN KLEIN: THE
4	DR. PRIETO: THAT SORT OF DEFEATS THE
5	PURPOSE OF EVEN HAVING THE GENERAL DISCUSSION, I
6	THI NK.
7	CHAIRMAN KLEIN: LET ME GO THROUGH THIS
8	VERY QUICKLY. SO OUT OF 328 MILLION THAT'S
9	ESSENTIALLY IN THIS CASH FLOW, 128 MILLION IN CASH
10	AND 200 MILLION PROPOSED ADDITIONAL FUNDS, THE TOTAL
11	EXPENDITURE UNDER THIS ITEM, AND, IN FACT, SINCE
12	THERE'S A DEFERRAL ON TRAINING II, THERE IS NO CASH
13	EXPENDITURE IMMEDIATELY, BUT THE TOTAL EXPENDITURE
14	UNDER THIS ITEM IS 8.8 MILLION.
15	SO THE WAY THIS IS STRUCTURED IS THAT WE
16	HAVE ABOUT A LITTLE LESS THAN 3 PERCENT OF THE TOTAL
17	EXPENDITURE WE CAN'T REALLY HAVE THIS OVERALL
18	DISCUSSION ON. AS TO TRANSLATIONAL, WHATEVER IS
19	DECIDED IS GOING TO BE SUPERSEDED BY WHAT'S DECIDED
20	IN APRIL. SO THERE IS A VERY NARROW RESTRICTED
21	POINT HERE WHERE WE HAVEN'T BEEN ABLE WITH THE
22	BENEFIT OF COUNSEL TO FIGURE OUT HOW TO HAVE THE
23	GENERAL DISCUSSION OF ALL THE MEMBERS BEFORE WE VOTE
24	ON THIS ONE ITEM THAT'S A CASH-FLOW COMMITMENT.
25	MR. HARRISON: COULD I JUST ADD ONE THING,
	140

1	THAT THE MEMBERS WHOSE NAMES I JUST READ, OF COURSE,
2	CAN HAVE A DISCUSSION ABOUT THE RELATIVE PRIORITY OF
3	THE BRIDGES PROGRAM AS IT RELATES TO THE OTHER
4	PROGRAM. IT'S JUST THAT DISCUSSION CANNOT INVOLVE
5	THE OTHER MEMBERS OF THE BOARD. IN OTHER WORDS,
6	WHAT WE'RE TRYING TO DO IS TO SEGMENT THESE
7	DECISIONS AND TAKE THEM FIRST SO THAT AS TO THE
8	REMAINING PROGRAMS ALL OF THE BOARD CAN THEN
9	PARTI CI PATE.
10	MR. SHEEHY: CAN I ASK JAMES A QUICK
11	QUESTION? WHY WASN'T IT AGENDAD THAT WAY? YOU SET
12	THIS UP SO THERE'S NO REAL DECISION MAKING FOR
13	ALMOST ANY MEMBER OF THE BOARD. YOU HAVE AGENDAD
14	THE BRIDGES, AGENDAD THE TRAINING, AGENDAD THE EARLY
15	TRANSLATION. I REMEMBER AT THE LAST MEETING I WAS
16	HOPING, EVEN IF IT'S ONLY FIVE OR SIX OF US, THAT
17	SOME MEMBERS OF THIS BOARD ACTUALLY GET TO SET THE
18	PRIORITIES. WE'RE NOT MONKEYS HERE. I'M NOT A
19	MONKEY.
20	CHAIRMAN KLEIN: JEFF, I THINK THAT'S
21	INAPPROPRIATE AND DOESN'T TAKE INTO ACCOUNT THE
22	TREMENDOUS EFFORT THAT COUNSEL PUTS INTO THIS. BUT
23	PRIOR TO THE COMMENT THAT MR. HARRISON JUST MADE,
24	COMMENT WAS MADE EARLIER IN THE DISCUSSION THAT THE
25	MEMBERS WHO WERE NOT CONFLICTED COULD HAVE A GENERAL

1	DISCUSSION ON THIS IN TERMS OF THE OVERALL
2	SCIENTIFIC RECOMMENDATIONS. SO PLEASE REALIZE THAT
3	A LOT OF EFFORT HAS GONE INTO THIS BY COUNSEL.
4	MR. ROTH: I'M GOING TO SUPPORT THAT WE
5	MOVE FORWARD WITH THIS MOTION AND APPROVE IT. AND
6	JUST TO POINT OUT THAT WE'VE HAD THIS DISCUSSION
7	WITH THESE PEOPLE FOREVER AND EVER, AND WE'VE
8	POSTPONED AND POSTPONED. AND I THINK NOW IS THE
9	TIME TO GO AHEAD AND GET THEM THEIR FUNDS.
10	THIS MORNING I OVERHEARD A CONVERSATION AT
11	BREAKFAST ABOUT THE PROBLEM OF FINDING TECHNICIANS
12	TO RUN EQUIPMENT, TO DO THE KINDS OF THING IN OTHER
13	PARTS OF THESE RESEARCH FACILITIES. AND THAT'S WHAT
14	EXACTLY WE WOULD BE DOING. WE'RE TRAINING PEOPLE
15	THAT TAKE THE POSITIONS WE NEED TO SUPPORT THE
16	SCIENTISTS THAT ARE DRIVING THIS. SO I THINK WE
17	SHOULD MOVE FORWARD AND VOTE.
18	CHAIRMAN KLEIN: OKAY.
19	DR. LOVE: I'M GOING TO AGREE WITH DUANE
20	IN THAT I THINK ULTIMATELY I'VE COME OUT THAT WE
21	NEED TO GO FORWARD WITH THIS. BUT I DO WANT TO
22	ARTICULATE THAT I THINK ONE OF THE ISSUES GOING ON
23	HERE IS THAT THERE DOES APPEAR TO BE A BIT OF A
24	DISCONNECT BETWEEN THE PRIORITY AND PUTTING THIS
25	MONEY OUT THE DOOR WHEN THERE'S A POTENTIAL THAT
	142

1	OTHER MONEY ON A PRIORITY COULD NOT BE THERE.
2	CHAIRMAN KLEIN: IF SOMEONE WHO IS
3	TRAVELING, IF THEY COULD PUT THEIR PHONE ON MUTE,
4	PLEASE. I GUESS THERE ARE PAPERS THAT ARE
5	SHUFFLI NG.
6	DR. LOVE: I THINK I UNDERSTAND THE
7	RATIONALE FOR THAT BASICALLY IS THAT WHILE THERE IS
8	A PRIORITY LIST THAT ONE COULD COME UP WITH, IN
9	FACT, THE DEMAND FOR MONEY FROM US IS NOT LINEAR
10	WITH THAT LIST. SO TO SOME EXTENT WHAT WE'RE TRYING
11	TO DO HERE IS TAKE SOME HEDGING, IF YOU WILL, AROUND
12	THE POSSIBILITY OF RAISING MORE MONEY IN THE FUTURE,
13	AND THE FACT THAT WE HAVE SOME CONFIDENCE THAT WE
14	CAN RAISE MORE MONEY IN THE FUTURE ALLOWS US TO DO
15	SOMETHING WHICH MAY NOT BE AT THE TOP OF THE
16	PRIORITY LIST, BUT IT DOES REPRESENT AN OVERALL
17	STRATEGY FOR BALANCE AND MULTIPLE COMPETING ISSUES.
18	CHAIRMAN KLEIN: I THINK THAT'S VERY
19	ACCURATE. WHAT THE SCIENTIFIC STAFF HAS ATTEMPTED
20	TO DO IS A RISK BALANCE SET OF PRIORITIES ON A
21	CONSERVATIVE BASIS ASSUMING THAT WE COULD AT LEAST
22	RAISE A CERTAIN AMOUNT OF MONEY EVEN IN
23	EXTRAORDINARILY DIFFICULT COMPLEX TIMES, THAT WITHIN
24	THIS BALANCE STRATEGY, THIS WOULD HAVE AN
25	APPROPRIATE PLACE PARTICULARLY, AS DUANE SAID,
	140

1	BECAUSE THEY'VE INVESTED A HUGE AMOUNT OF EFFORT IN
2	BRINGING THIS TOGETHER. THESE INSTITUTIONS HAVE PUT
3	MONEY OUT THE DOOR. SOME OF THEM HAVE ALREADY BEEN
4	PUTTING FACULTY AND/OR STUDENTS THROUGH A PROCESS OF
5	BRINGING THEM UP TO A LEVEL, TAKING PREREQUISITE
6	COURSES SO THEY COULD QUALIFY. SO WE HAVE AN
7	INVESTED PARTNER IN THIS PROCESS THAT WE'RE TRYING
8	TO HONOR A RELATIONSHIP WITH.
9	I'D LIKE TO CALL THE QUESTION IF I COULD.
10	MS. SAMUELSON: AND I WANT TO I THINK
11	WE SHOULD FUND THE BRIDGES PROGRAM IN FULL. AT THE
12	SAME TIME, I'M RELATIVELY UNCONCERNED ABOUT MORE
13	MONEY FOR THE TRAINING PROGRAM. I THINK WE GAVE IT
14	A GOOD SHOT AT THE BEGINNING. WE CAN DO A LOT OF
15	TRAINING THROUGH THE SUBSTANTIVE SCIENTIFIC PROGRAMS
16	OF THE OTHER CATEGORIES. WE CAN CONTINUE TO TRAIN
17	PEOPLE, SO WE DON'T NEED JUST TRAINING PER SE AT
18	THIS POINT AS MUCH AS I THINK WE DO NEED, FOR
19	EXAMPLE, A ROBUST EARLY TRANSLATION PROGRAM. IT'S
20	TIME FOR THAT. THOSE ARE DIFFICULT PROGRAMS TO
21	FUND. THEY'RE HARDER TO GET HIGH SCORES.
22	SO IF OUR DESCRIPTION OF WHAT WE WANT TO
23	FUND IS THE BEST OF THE BEST, THAT MEANS THERE ARE A
24	LOT THAT WE ARE REGARDING AS THE BEST WHICH ARE NOT
25	GOING TO BE FUNDED. AND I WATCH THE TRANSLATIONAL
	144

1	PROGRAMS HAVE A DIFFICULT TIME GETTING EQUALLY HIGH
2	SCORES IN THE WORKING GROUP BECAUSE THEY'RE RISKY,
3	BECAUSE THERE ISN'T AS MUCH DATA, BECAUSE THE
4	OUTCOME IS UNKNOWN, AND THAT'S IN THE NATURE OF
5	TRANSLATIONAL WORK. I WATCH PARKINSON'S RESEARCH
6	HIT THE WALL DAY IN AND DAY OUT, IMPORTANT,
7	WELL-THOUGHT OUT IDEAS THAT ARE SIMPLY HYPOTHETICAL
8	AT THIS POINT BY DEFINITION. THAT IS THE NATURE OF
9	THAT WORK.
10	WE HAVE GOT TO START FUNDING IT. WE'RE A
11	THIRD OF THE WAY THROUGH OUR LIFE, AS I'M
12	UNDERSTANDING THE LONGER TERM THAT WE WILL BE IN
13	EXISTENCE FUNDING ANYTHING. AND WE'RE NOT IN THE
14	CLINIC, AND PERHAPS IT'S TOO SOON TO BE. BUT BEFORE
15	WE'RE GOING TO ACTUALLY GET INTO THE CLINIC, WE'VE
16	GOT TO DO THAT HYPOTHETICAL WORK.
17	SO FOR ALL THOSE REASONS, THAT AMOUNT OF
18	MONEY IS JUST TINY, AND WE CAN'T BE RESTRICTING
19	OURSELVES. AND I ALSO WANT TO SAY I HOPE WE CAN GO
20	BACK TO THE DRAWING BOARDS ON THE APPLICATION OF
21	CONFLICT OF INTEREST LAW. AS A LAWYER, MY
22	UNDERSTANDING IS THAT YOU SOLVE A LOT PROBLEMS OF
23	POTENTIAL CONFLICT OF INTEREST WITH FULL DISCLOSURE
24	SO THAT WE CAN HEAR THE WISDOM OF OUR COLLEAGUES AND
25	THEN MAKE OUR OWN JUDGMENTS ABOUT WHETHER THEIR

1	PROFESSIONAL CONNECTIONS BEAR ON WHAT WE'VE JUST
2	HEARD, NOT TO MUTE THEM. I WANT TO HEAR FROM MY
3	COLLEAGUES, SO I WOULD THINK MAYBE WE COULD CRAFT
4	OUR CONFLICT OF INTEREST RULES TO ALLOW MORE OF
5	THAT.
6	CHAIRMAN KLEIN: JOAN, I COMPLETELY
7	SUPPORT THAT. I TELL YOU WE HAD ACTUALLY ABOUT
8	SEVEN LAWYERS WHEN I WAS WRITING THIS INITIATIVE
9	DEBATE INTENSELY HOW WE COULD DEAL WITH CONFLICTS OF
10	INTEREST AND BE TRUE TO THE INTENT AND TRANSPARENCY.
11	WE BROKE NEW GROUND IN MAKING IT CLEAR IN THE
12	INITIATIVE THAT PATIENT ADVOCATES WERE NOT IN
13	CONFLICT BECAUSE OF DEBATING THEIR OWN DISEASE AREA.
14	AND OBVIOUSLY WE GOT SUED ON THAT AND
15	CONSTITUTIONALLY THEN HAD TO DEFEND IT.
16	MS. SAMUELSON: BUT THEN THE GREAT IRONY
17	FOR ME IS I GET TO HEAR VERY LITTLE OF THE EXPERTISE
18	OF MY COLLEAGUE JEFF. AND SO THIS IS OPERATING ON
19	THE ASSUMPTION THAT HE'S GOING TO BE SWAYED IN FAVOR
20	OF, LET'S SAY, A MEDIOCRE GRANT AT HIS OWN
21	INSTITUTION WHERE HE'S EMPLOYED AGAINST THE INTEREST
22	OF A WONDERFUL HIV GRANT AT ANOTHER CAMPUS IN A
23	COMPLETELY UNRELATED SCHOOL OR LAB.
24	CHAIRMAN KLEIN: I COMPLETELY
25	MS. SAMUELSON: IT MAKES NO SENSE TO ME.
	146

	2.1.1.1.2.2.1.2.3.1.4.0.2.1.4.1.0.2.1.4.1.0.2.1.4.1.0.2.1.4.1.0.2.1.4.1.0.2.1.4.1.0.2.1.4.1.0.2.1.4.1.0.2.1.4.1.0.2.1.4.1.0.2.1.4.1.4.1.0.2.1.4.1.4.1.2.1.4.1.4.1.4.1.2.1.4.1.4.1
1	CHAIRMAN KLEIN: I AGREE. WE'RE TRYING TO
2	DO THE BEST WE CAN WITH THE STATUTES WE HAVE TO DEAL
3	WITH. CRITICAL TIMEFRAME HERE. I'D LIKE TO CALL
4	THE QUESTION ON THIS ITEM.
5	MS. GIBBONS: COULD YOU PLEASE RESTATE THE
6	MOTION, BOB?
7	CHAIRMAN KLEIN: YES. I'M GOING TO HAVE
8	MR. HARRISON RESTATE THE MOTION.
9	MR. HARRISON: THIS RELATES TO ITEM NO.
10	16, AND THE MOTION IS TO APPROVE THE FUNDING OF THE
11	BRIDGES APPLICATIONS THAT YOU APPROVED AT THE LAST
12	MEETI NG.
13	CHAIRMAN KLEIN: OKAY.
14	MS. KING: LEEZA GIBBONS.
15	MS. GIBBONS: YES.
16	MS. KING: BOB KLEIN.
17	CHAIRMAN KLEIN: YES.
18	MS. KING: TED LOVE.
19	DR. LOVE: YES.
20	MS. KING: ROBERT QUINT.
21	DR. QUINT: YES.
22	MS. KING: DUANE ROTH.
23	MR. ROTH: YES.
24	MS. KING: JOAN SAMUELSON.
25	MS. SAMUELSON: YES.
	147
	1 17

	DAMMISTERS REPORTING SERVICE
1	MS. KING: DAVID SERRANO-SEWELL.
2	MR. SERRANO-SEWELL: YES.
3	MS. KING: JON SHESTACK.
4	MR. SHESTACK: YES.
5	MS. KING: AND ART TORRES.
6	MR. TORRES: AYE.
7	MS. KING: THAT MOTION CARRIES FOR THE
8	RECORD.
9	CHAIRMAN KLEIN: THANK YOU.
10	(APPLAUSE.)
11	CHAIRMAN KLEIN: I'D LIKE TO THANK THE
12	CALIFORNIA STATE UNIVERSITY SYSTEM AND THE COMMUNITY
13	COLLEGE SYSTEM FOR THEIR COMMITMENT TO THIS PROGRAM,
14	THEIR DEDICATION TO THE DEVELOPMENT OF CURRICULUM AT
15	EACH OF THESE CAMPUSES, AND THE EXTRAORDINARY
16	MATCHING FUNDS THAT THEY LED WITH IN GOOD FAITH THAT
17	ARE GOING TO CONTRIBUTE TO IN MANY CASES PRODUCING
18	MORE STUDENTS THAN WE'RE SUPPORTING. THANK YOU.
19	GO TO ITEM 17, TRAINING II.
20	DR. POMEROY: CAN I ASK WHEN WE'RE GOING
21	TO LUNCH?
22	CHAIRMAN KLEIN: SHORTLY. BEFORE I HAVE A
23	REVOLT HERE, ON TRAINING II IS THERE A MOTION TO
24	DEFER FOR 12 MONTHS THE FUNDING OF TRAINING II?
25	MS. GIBBONS: I SO MOVE.
	148

CHAIRMAN KLEIN: MOVED BY LEEZA GIBBONS.
IS THERE A SECOND?
MR. SERRANO-SEWELL: SECOND.
CHAIRMAN KLEIN: THE MANNER IN WHICH THE
SCIENTIFIC STAFF HAS RECOMMENDED THIS IS THAT WE
WILL FUND IT, BUT WITH A DEFERRAL OF 12 MONTHS. AND
TO BE CLEAR, MR. HARRISON, MY UNDERSTANDING, AND
PLEASE CORRECT ME, LEEZA, IS THAT YOU'VE
INCORPORATED THE SCIENTIFIC STAFF'S RECOMMENDATION
HERE, THAT IF A GRANTEE INSTITUTION WANTS TO FUND IT
AND GET REIMBURSED LATER, THEY COULD DO THAT; IS
THAT CORRECT?
MS. GIBBONS: RIGHT.
MR. HARRISON: JUST TO BE CLEAR, CHAIR,
WHAT THAT MEANS IS THAT THE AGENCY WOULD BE
AUTHORIZED TO ISSUE THE NGA WITH PAYMENT BEING
DEFERRED FOR A PERIOD OF 12 MONTHS.
CHAIRMAN KLEIN: THAT'S RIGHT. AND THAT
THEY WE CAN GET REIMBURSEMENT IF THEY SO ELECT TO.
MS. LANSING: ASSUMING WE HAVE THE MONEY.
CHAIRMAN KLEIN: NO. THE VOTE HERE, WHICH
WOULD COVER \$6.8 MILLION DURING OUR PERIOD THAT
WE'RE LOOKING AT, WOULD BE COMMITTING US TO 6.8
MILLION IF YOU ELECTED TO VOTE FOR IT.
DR. TROUNSON: SORRY, CHAIR. ALL OF THE
149

1	PROPOSALS GOING OUT WILL INCLUDE SUBJECT TO FUNDS
2	AVAILABLE OR FOR THE TIME BEING. SO THAT WOULD
3	STILL BE POSSIBLE. WE AGREED TO THAT LAST TIME.
4	MS. GIBBONS: SUBJECT TO FUNDS AVAILABLE.
5	CHAIRMAN KLEIN: UNDER THE TRAINING II
6	PROGRAM.
7	DR. TROUNSON: YES. I THINK WE HAVE TO DO
8	THAT FOR ALL OF THEM GOING FORWARD AT THE MOMENT
9	SINCE THERE'S NO
10	CHAIRMAN KLEIN: OKAY. THAT DID NOT COVER
11	THE BRIDGES PROGRAM. THAT WAS NOT PART OF THE
12	MOTION.
13	MR. SWEEDLER: ALL NOTICES OF GRANT AWARD,
14	STARTING WITH TOOLS AND TECHNOLOGY, HAVE INCLUDED
15	LANGUAGE THAT SAYS THE AWARDS ARE MADE SUBJECT TO
16	AVAILABLE FUNDS FUNDS BEING AVAILABLE. LET ME
17	CLARI FY.
18	THE TIMING IS SUBJECT TO SUFFICIENT FUNDS
19	BEING AVAILABLE IN THE STEM CELL FUND.
20	CHAIRMAN KLEIN: NOT THE OBLIGATION TO
21	PAY.
22	MR. SWEEDLER: SO IT'S TIMING, AND THEN
23	THAT'S WITHIN THE AGENCY'S DISCRETION WHAT
24	CONSTITUTES SUFFICIENT AVAILABILITY, SO IT'S ABOUT
25	THE TIMING.
	450

150

1	CHAIRMAN KLEIN: WITH COMMUNITY COLLEGES
2	AND THE STATE UNIVERSITY SYSTEM, THEY'RE UNDER A
3	GREAT DEAL OF STRESS AT THIS POINT. WE PASSED A
4	MOTION WITHOUT THAT STATEMENT. AND I DON'T THINK WE
5	CAN GO BACK AND NOW ADD THAT STATEMENT. IT'S A
6	SMALL AMOUNT OF FUNDS.
7	DR. TROUNSON: CHAIR, IT'S IN ALL THE
8	NGA'S NOW.
9	MS. LANSING: IT'S OUR POLICY.
10	MR. SERRANO-SEWELL: THE COMMISSION HAS
11	ARTICULATED VERY CLEARLY A POLICY STATEMENT, AND
12	THAT POLICY STATEMENT IS THAT FOR THE BRIDGES THEY
13	ARE TO BE FUNDED, PERIOD.
14	CHAIRMAN KLEIN: HOLD ON. WE HAVEN'T
15	GIVEN THEM THE NGA. WE HAVE NOT GIVEN THEM THE NGA
16	AT THIS POINT. IS THAT A CORRECT STATEMENT?
17	DR. TROUNSON: YEAH.
18	CHAIRMAN KLEIN: SO WE PASSED A MOTION.
19	I'M HAPPY THERE IS SINCE THIS VOTE HAS ALREADY
20	TAKEN PLACE, WE KNOW THERE IS \$8.8 MILLION. THE
21	FUNDS ARE AVAILABLE.
22	DR. HAWGOOD: FUNDS ARE AVAILABLE THROUGH
23	DECEMBER '10, THEN WE'RE MAKING A LARGE NUMBER OF
24	CHAIRMAN KLEIN: BUT IT'S IMPORTANT TO
25	MAKE THE STATEMENT THAT YOU JUST MADE, IAN, AND WE
	151

1	APPRECIATE THAT ON A GOING-FORWARD BASIS, THE POLICY
2	THAT YOU ARE STATING, AND I WANT THE BOARD TO BE
3	AWARE OF THAT POLICY, IS I WASN'T AWARE WHEN IT WAS
4	GOING TO START, THAT POLICY YOU'RE SUGGESTING WILL
5	INCLUDE THIS MOTION SPECIFICALLY, WHICH IS TRAINING
6	II; IS THAT CORRECT?
7	DR. ROBSON: JUST TO CLARIFY, WE DON'T
8	NECESSARILY HAVE 8.8 MILLION RIGHT NOW. WHAT WE
9	HAVE IS ENOUGH MONEY FOR TWO QUARTERLY PAYMENTS.
10	THAT MUCH WE CAN GUARANTEE.
11	CHAIRMAN KLEIN: WELL, I DON'T UNDERSTAND
12	THAT STATEMENT. WE'LL FOLLOW THAT. I WANT TO
13	TALK I WANT TO GET SHERRY LANSING'S STATEMENT.
14	MS. LANSING: THIS IS VERY CONFUSING TO
15	ME. THIS IS VERY CONFUSING TO ME. A BOARD HAS
16	FIDUCIARY RESPONSIBILITIES. A BOARD ALSO HAS
17	LIABILITY. I WANT TO UNDERSTAND HOW MUCH MONEY WE
18	HAVE, AND I WANT TO MAKE CLEAR BOB, I HAVE THE
19	GREATEST FAITH IN YOU, SO THIS IS NOT IN ANY I
20	SPEAK FOR ALL OF US IN SAYING THAT. BUT WE CAN ONLY
21	FUND WHAT WE HAVE MONEY FOR. AND SO YOU ARE SAYING
22	NO?
23	I'M GOING TO GIVE YOU A DIRE CASE. WHAT
24	HAPPENS IF YOU RUN OUT OF I CAN'T VOTE ON THIS
25	ANYWAY. BUT WHAT HAPPENS IF YOU RUN OUT OF MONEY?
	150

R
E
Έ
E
0
2

1	HAS ANY EXPOSURE.
2	MS. LANSING: THAT'S ALL I WANTED.
3	CHAIRMAN KLEIN: WE'RE IN A POSITION IN
4	THE STATE WHERE THE ENTIRE STATE HAS TO OPERATE ON
5	THE BASIS THAT THERE ARE FUNDS. THE STATE CAN ONLY
6	MAKE GOOD FAITH COMMITMENTS, AND WE'RE TRYING TO
7	MAKE CONSERVATIVE COMMITMENTS.
8	MS. LANSING: I'M ON YOUR WE'RE ON THE
9	SAME SIDE. WHAT I'M REALLY TRYING TO UNDERSTAND,
10	AND I CAN'T VOTE OR DO ANYTHING, BUT I REALLY WANT
11	TO UNDERSTAND THAT WE'RE COMMITTING, WE PUT THAT IN
12	ALL OF OUR RFA'S. I'M NOT AGAINST BRIDGES, I'M NOT
13	ALLOWED EVEN TO SAY THAT, BUT AT ANY RATE, I JUST
14	WANT TO BE SURE THAT WE'RE COMMITTING SHOULD FUNDS
15	BE AVAILABLE, WHICH WE ALL BELIEVE WILL BE.
16	CHAIRMAN KLEIN: SO DR. AZZIZ.
17	DR. AZZIZ: AGAIN, I'M NOT VOTING. I
18	PRESUME I CAN COMMENT.
19	CHAIRMAN KLEIN: YOU CAN'T COMMENT ON
20	TRAINING II'S.
21	DR. AZZIZ: NO, I'M NOT COMMENTING ABOUT
22	TRAINING II. I'M TALKING ABOUT IN GENERAL TO FOLLOW
23	UP ON SHERRY'S COMMENT.
24	CHAIRMAN KLEIN: IT'S VERY IMPORTANT HERE
25	THAT YOU NOT BE COMMENTING ON THE PLAN ITSELF.

154

1	DR. AZZIZ: NO. NO. NO. I JUST WANT TO
2	MAKE SURE, BECAUSE THERE'S A LOT OF CONFUSION.
3	ANYTHING WE ARE NOW ISSUING, WHETHER IT'S BRIDGE
4	GRANTS THAT SEEM TO BE TALKED ABOUT OR TRAINING OR
5	WHATEVER, GOES WITH THIS STATEMENT, THAT IT IS GIVEN
6	PENDING FUNDS, RIGHT. THIS APPLIES TO EVERYTHING WE
7	DO NOW MOVING FORWARD. AM I CORRECT?
8	DR. TROUNSON: WELL, YOU KNOW, FROM MY
9	POINT OF VIEW, YOU ARE CORRECT, THAT WE WILL HAVE
10	LANGUAGE IN THE CONTRACTS THAT GO OUT THAT IT IS
11	THAT THESE PAYMENTS ARE GOING TO BE SUBJECT TO FUNDS
12	AVAILABLE. THAT'S WHAT'S REQUIRED OF ALL STATE
13	AGENCIES. AND WE'VE BEEN AN EXCEPTION IN A WAY, SO
14	THAT LANGUAGE NEEDS TO BE THERE BECAUSE I CAN'T
15	WRITE A CHECK. THE CHECK HAS TO BE WRITTEN BY THE
16	STATE.
17	DR. AZZIZ: I UNDERSTAND THAT. NOTHING OF
18	WHAT WE'VE SPOKEN ABOUT TODAY IS MEANT TO BE
19	CONSTRUED DIFFERENTLY THAN THAT. AM I CORRECT?
20	DR. TROUNSON: NO. THAT'S MY
21	UNDERSTANDING, NOT AT ALL.
22	DR. AZZIZ: THANK YOU VERY MUCH.
23	CHAIRMAN KLEIN: ALL RIGHT. THIS IS
24	HELPFUL. SO LET ME FOCUS US HERE BEFORE WE GO ANY
25	FURTHER ON WHAT WE HAVE BEFORE US. TRAINING II IS

1	SUBJECT TO FUNDS AVAILABLE.
2	MS. SAMUELSON: I HAVE A QUESTION ABOUT
3	THAT. I THINK IT'S A QUESTION FOR JAMES. I WOULD
4	LIKE TO MY VOTE TO MEAN THAT THIS, BECAUSE WE'RE
5	PRIORITIZING HERE, THE TRAINING II IS A LOWER
6	PRIORITY THAN ANY OF THESE OTHER PRIORITIES, AND SO
7	WE WILL NOT FUND IT UNTIL WE'VE MET WHATEVER OTHER
8	MORE HIGHER PRIORITY OBLIGATIONS HAVE BEEN FUNDED.
9	CHAIRMAN KLEIN: IT'S BEING DEFERRED BY 12
10	MONTHS UNDER THIS MOTION, WHICH MEANS IT WILL COME
11	IN TIME SEQUENCE AFTER THESE OTHER ITEMS HAVE BEEN
12	FUNDED.
13	MS. SAMUELSON: BUT I DON'T KNOW
14	FINANCIALLY WHAT THE IMPACT OF THAT IS ON A CEILING
15	FOR EARLY TRANSLATION, FOR EXAMPLE. IF IT HAS ANY
16	IMPACT ON IT, I WANT THAT TO DELAY FUNDING, I MEAN
17	INDEFINITELY UNTIL THE FINANCIAL CRISIS IS DONE, OR
18	I DON'T KNOW WHAT. THAT MAY NOT DO IT IS WHAT I'M
19	SAYI NG.
20	DR. TROUNSON: JOAN, IT HAS A MINIMAL
21	IMPACT. THAT'S THE REASON WHY WE'RE PUSHING IT
22	BACK. IT HAS A MINIMAL IMPACT ON THE CASH FLOW. SO
23	WE'RE TRYING TO MINIMIZE IT, BUT STILL BE
24	RESPONSIBLE ENOUGH TO BE ABLE TO GET IT TO GO. IT
25	IS ABOUT MINIMAL AS WE COULD. TROUBLE IS IF WE PUT
	154

1	IT BACK TWO YEARS, THEN WE'D HAVE TO GO FOR ANOTHER
2	RFA, IN OUR VIEW, BECAUSE IT WOULD BE OUT OF DATE.
3	SO CURRENTLY THERE WOULD BE, IN OUR VIEW,
4	IN DATE IF WE DO IT WITH A 12-MONTH DELAY. AND, OF
5	COURSE, IF THE INSTITUTIONS ARE PREPARED TO PREFUND
6	IT THEMSELVES, WELL, IN DUE COURSE THEY'LL BE
7	RECEIVING THE FUNDS.
8	MS. SAMUELSON: I GUESS IN THIS FISCAL
9	ENVIRONMENT, I DON'T WANT TO VOTE FOR REIMBURSEMENT
10	OBLI GATI ON.
11	CHAIRMAN KLEIN: IT'S SUBJECT TO AVAILABLE
12	FUNDS.
13	DR. LOVE: DOES THIS MOTION MEAN THAT WE
14	COULDN'T FURTHER DELAY AT SOME POINT IN THE FUTURE?
15	LET'S SAY THAT WE GO FORWARD, AND 12 MONTHS HENCE
16	WHEN WE SHOULD START
17	CHAIRMAN KLEIN: IF WE HAVE TOLD THEM IT'S
18	12 MONTHS, WHAT I UNDERSTAND IS IT'S GOING TO HAVE A
19	PROVISION IN THERE THAT SAYS IF THERE ARE NOT
20	AVAILABLE FUNDS, THEY'RE NOT TO GET FUNDED AT THAT
21	POINT EVEN THOUGH WE ONLY VOTED FOR A 12-MONTH
22	DELAY.
23	DR. LOVE: SO WE COULD FURTHER DELAY IF WE
24	NEEDED TO?
25	CHAIRMAN KLEIN: THAT'S RIGHT.
	157

1	DR. TROUNSON: JOAN, THE CEILING INCLUDES
2	MORE THINGS THAN THAT, BUT YOU WILL HAVE TO WAIT
3	TILL APRIL. BUT, AGAIN, YOUR DECISION TO ADJUST
4	THAT WILL COME IN APRIL. WE'RE JUST GIVING YOU A
5	RECOMMENDATION. IT'S UP TO THE BOARD CLEARLY TO
6	MAKE THE DECISION.
7	MS. SAMUELSON: THIS PERTAINS, RIGHT. I'M
8	WONDERING IF WE MIGHT NOT REVISE THE TRAINING II
9	LANGUAGE TO SAY DELAY FUNDING FOR AT LEAST 12
10	MONTHS, AND THEN WE WOULD NOT THERE WOULDN'T
11	IT WOULD MAKE IT CLEAR WE DON'T INTEND TO HAVE A
12	REIMBURSEMENT OBLIGATION KICK IN IN ANY FISCAL
13	SCENARIO. WE COULD GO BACK AND DELAY IT FURTHER.
14	CHAIRMAN KLEIN: IF
15	MS. SAMUELSON: BECAUSE THAT MIGHT NOT BE
16	CLEAR.
17	CHAIRMAN KLEIN: THE BOARD COULD DO THAT
18	IF THE BOARD WISHED TO DO THAT. OKAY.
19	MS. SAMUELSON: I'M NOT SURE.
20	CHAIRMAN KLEIN: DR. HAWGOOD, YOU ARE
21	DISCUSSING JUST THE CONCEPT.
22	DR. HAWGOOD: I'M DISCUSSING JUST THE
23	CONCEPT, BUT MY REQUEST IS THAT WHATEVER THE MOTION
24	IS, THAT THERE'S REAL CLARITY TO THE GRANTEE
25	ORGANIZATIONS BECAUSE YOU LAUNCH INTO SELF-FUNDING,
	159

1	AND THEN THERE'S A DECISION TO FURTHER POSTPONE,
2	FURTHER POSTPONE.
3	CHAIRMAN KLEIN: I THINK IT'S IMPORTANT.
4	DR. HAWGOOD: BIG PROBLEM THERE.
5	CHAIRMAN KLEIN: SO TO MAKE IT CLEAR HERE,
6	IF WE DO VOTE ON THIS, AND THESE ENTITIES ARE GOING
7	TO NEED A DEFINITIVE TARGET, THAT TARGET IS
8	CONDITIONED UPON I MEAN IF THERE'S AN EARTHQUAKE
9	IN THE STATE, THERE'S EMERGENCIES AS WELL THAT CAN
10	AFFECT IT, BUT WE HAVE A FINANCIAL CRISIS, WE
11	BELIEVE THAT THIS IS A REASONABLE AMOUNT EVEN IN
12	THIS FINANCIAL CRISIS TO RAISE SO THAT WE CAN FUND
13	THIS PROGRAM WITH A 12-MONTH DELAY. IT MEANS \$6.8
14	MILLION DURING THIS TIME PERIOD. BUT IF WE WERE
15	GOING TO VOTE FOR THIS MOTION, WE NEED TO ACCEPT THE
16	FACT THAT SUBJECT TO DELAYS IF WE DON'T IF WE'RE
17	NOT SUCCESSFUL IN RAISING MONEY AT THIS CONSERVATIVE
18	LEVEL, THAT IT WILL BE DELAYED FURTHER. ALL RIGHT.
19	BUT IF WE ARE SUCCESSFUL IN RAISING MONEY, THEY WILL
20	GET FUNDED UNDER THIS PROGRAM STARTING 12 MONTHS
21	OUT.
22	DR. POMEROY: BOB, I CAN'T VOTE ON IT, SO
23	I'M NOT GOING TO EXPRESS AN OPINION, BUT IT'S STILL
24	NOT CLEAR TO ME WHAT YOU'RE VOTING ON. ARE YOU
25	VOTING THAT IF IT HAPPENS IN 12 MONTHS, THERE CAN BE
	160

1	RETROACTIVE REIMBURSEMENT OR NOT BECAUSE THAT'S BEEN
2	SAID AND THEN NOT SAID. WHAT IS THE MOTION?
3	CHAIRMAN KLEIN: MY UNDERSTANDING OF THE
4	MOTION IS THAT INSTITUTIONS THAT FUND CAN GET
5	RETROACTIVE REIMBURSEMENT UNDER THIS MOTION AS
6	PROPOSED BY THE SCIENTIFIC STAFF AND INCLUDED IN THE
7	MOTION. IS THAT CORRECT, MR. HARRISON?
8	MR. HARRISON: AS I UNDERSTAND IT, BUT
9	THAT WOULD COME WITH THE STANDARD CAVEAT, THAT THE
10	TIMING OF THAT REIMBURSEMENT WOULD BE CONTINGENT
11	UPON THE AVAILABILITY OF FUNDS.
12	DR. POMEROY: LET ME JUST GIVE YOU A VERY
13	SPECIFIC QUESTION THAT I THINK WILL CLARIFY THIS.
14	ONE INSTITUTION CHOOSES TO SELF-FUND, AND 12 MONTHS
15	FROM NOW THEY GET FOUR YEARS OF FUNDING. THAT
16	REALLY MEANS THEY HAVE ONE IN REIMBURSEMENT AND
17	THREE YEARS GOING FORWARD.
18	ANOTHER INSTITUTION DECIDES NOT TO
19	SELF-FUND. DO THEY THEN HAVE THREE YEARS OR FOUR
20	YEARS, SO YOU'LL HAVE DIFFERENT END DATES
21	CHAIRMAN KLEIN: THAT'S RIGHT.
22	DR. POMEROY: FOR THE TRAINING PROGRAM.
23	THAT'S CORRECT?
24	CHAIRMAN KLEIN: THAT'S CORRECT.
25	DR. POMEROY: OKAY.
	161

1	CHAIRMAN KLEIN: WE ALSO HAVE DIFFERENT
2	ENDING DATES BECAUSE SOME INSTITUTIONS HAVE
3	CARRY-OVER FUNDS FROM 2008 SO THAT OUR ENDING DATES
4	ARE STAGGERED ALREADY.
5	MS. GIBBONS: IF THE GRANTEES IF WE
6	PASS THIS, EVEN IF WE SAY WE CAN DELAY IT FURTHER,
7	THE GRANTEES THAT DO CHOOSE TO SELF-FUND, HOWEVER,
8	THERE'S STILL OUR OBLIGATION FOR REIMBURSEMENT,
9	WHICH IS WHAT JOAN WAS GETTING AT, RIGHT, SO, IN
10	ESSENCE, WE'RE REALLY NOT SAYING WE CAN CHOOSE TO DO
11	THIS ONLY BASED ON AVAILABLE FUNDS BECAUSE WE WILL
12	ALREADY BE COMMITTING FUNDS TO THOSE GRANTEES WHO
13	SELF-FUND.
14	CHAIRMAN KLEIN: WE'RE ONLY AGREEING TO
15	REIMBURSE THEM SUBJECT TO AVAILABLE FUNDS. WE ARE
16	COMMITTING TO REIMBURSE THEM, WE WILL REIMBURSE
17	THEM, THE STATE OF CALIFORNIA THIS IS A CONTRACT.
18	THE QUESTION IS TIMING. THE QUESTION IS TIMING.
19	THEY KNOW THAT THEY WILL GET REIMBURSED. THE ENTIRE
20	STATE OF CALIFORNIA IS BETTING ON THE FACT THAT AS
21	THE EIGHTH LARGEST ECONOMY OF THE WORLD, WE CAN PULL
22	OUR ACT TOGETHER AS A STATE AND GET OUR ECONOMICS
23	BACK IN PLACE AND START OPERATING BY STANDARD
24	PROCEDURE.
25	WE HAVE A HEDGE PROGRAM WHICH IS WE'RE
	162
	1117

1	GOING TO GO OUT AND PRIVATELY PLACE BONDS TO MAKE
2	SURE THAT WE CAN PROVIDE MORE TIME CERTAINTY TO WHEN
3	THAT'S GOING TO HAPPEN FOR US. I'D LIKE TO
4	DR. OLSON: MAY WE JUST MAKE ONE COMMENT
5	TO MAKE SURE THAT, USING CLAIRE'S EXAMPLE, FIRST,
6	LET US REMIND YOU THAT THE TRAINING II IS A
7	THREE-YEAR AWARD. THE MAXIMUM WE CAN DO.
8	CHAIRMAN KLEIN: THANK YOU, DR. OLSON.
9	I'D LIKE TO CALL THE QUESTION ON THIS, AND WOULD YOU
10	REPEAT THE MOTION, MR. HARRISON? WE WILL HAVE
11	PUBLIC COMMENT BEFORE THE VOTE.
12	MR. HARRISON: SO THE MOTION, AS I
13	UNDERSTAND IT, IS TO DEFER FUNDING OF THE TRAINING
14	GRANT II PROGRAM FOR 12 MONTHS PROVIDED THAT THE
15	BOARD CAN REVISIT THAT ISSUE. A SECOND PART OF THE
16	MOTION IS THAT IF INSTITUTIONS
17	CHAIRMAN KLEIN: EXCUSE ME. WHAT WAS
18	THAT, PROVIDED WE'RE NOT HAVING THE BOARD REVISIT
19	THE ISSUE UNDER THE MOTION.
20	MR. HARRISON: LET ME READ THAT AGAIN
21	THEN. THE MOTION IS TO DEFER FUNDING OF THE
22	TRAINING GRANT II PROGRAM FOR 12 MONTHS. IF
23	INSTITUTIONS ELECT, INSTITUTIONS THAT HAVE APPROVED
24	APPLICATIONS ELECT TO SELF-FUND AND ENTER AN NGA
25	WITH CIRM, THEN CIRM WILL REIMBURSE SUBJECT TO THE

1	STANDARD PROVISION IN OUR CONTRACTS THAT THE TIMING
2	OF THE FUNDING, OR IN THIS CASE THE REIMBURSEMENT,
3	IS CONTINGENT UPON THE AVAILABILITY OF FUNDS.
4	CHAIRMAN KLEIN: ALL RIGHT. PUBLIC
5	COMMENT. SEEING NO PUBLIC COMMENT, CALL FOR THE
6	QUESTI ON.
7	MS. SAMUELSON: BEFORE WE CALL FOR THE
8	VOTE, TAKE THE VOTE, I WOULD I HAVE A QUESTION
9	FOR COUNSEL. HOW DO I VOTE IF I WANT TO VOTE
10	AGAINST ANY CONTRACTUAL OBLIGATION BY CIRM OF
11	FUNDING TO THE TRAINING II PROGRAM AT THIS TIME.
12	MR. HARRISON: YOU WOULD VOTE NO.
13	MR. SHESTACK: COULD JOAN RESTATE THE
14	QUESTI ON?
15	CHAIRMAN KLEIN: JOAN'S QUESTION WAS HOW
16	DOES SHE VOTE IF SHE'S AGAINST ANY FUNDING FOR
17	TRAINING II AT THIS TIME, AND THE ANSWER WAS YOU
18	VOTE NO. OKAY. IT'S ANY COMMITMENT BECAUSE UNDER
19	THE MOTION THERE IS NO FUNDING FOR 12 MONTHS, AND
20	THEN IT'S SUBJECT TO AVAILABLE FUNDS.
21	MS. SAMUELSON: THERE IS A CONTRACTUAL IF
22	THEY SELF-FUND.
23	CHAIRMAN KLEIN: SUBJECT TO AVAILABLE
24	FUNDS.
25	MS. SAMUELSON: RIGHT. BUT THAT'S CASH
	164
	IO+

	DARRISTERS REPORTING SERVICE
1	FLOW AS OPPOSED TO
2	CHAIRMAN KLEIN: EXACTLY. ALL RIGHT.
3	ALL RIGHT. CALL THE QUESTION, PLEASE.
4	MS. KING: LEEZA GIBBONS.
5	MS. GIBBONS: YES.
6	MS. KING: BOB KLEIN.
7	CHAIRMAN KLEIN: YES.
8	MS. KING: TED LOVE.
9	DR. LOVE: YES.
10	MS. KING: ROBERT QUINT.
11	DR. QUINT: YES.
12	MS. KING: DUANE ROTH.
13	MR. ROTH: YES.
14	MS. KING: JOAN SAMUELSON.
15	MS. SAMUELSON: NO.
16	MS. KING: DAVID SERRANO-SEWELL.
17	MR. SERRANO-SEWELL: NO.
18	MS. KING: JON SHESTACK.
19	MR. SHESTACK: YES.
20	MS. KING: AND ART TORRES.
21	MR. TORRES: AYE.
22	MS. KING: THAT MOTION CARRIES.
23	CHAIRMAN KLEIN: ALL RIGHT. WE'RE GOING
24	TO AT THIS POINT ADJOURN TO LUNCH WHERE?
25	MS. KING: ACROSS THE HALL IN ROOM 301.
	165
	100

1	(A RECESS WAS TAKEN.)
2	CHAIRMAN KLEIN: ALL RIGHT. WE'VE GOT THE
3	INDIVIDUALS BACK ON THE PHONE. THE BOARD MEETING IS
4	BACK IN SESSION. WE CAN PROCEED, PLEASE. SHERRY
5	LANSING IS IN THE HALL. DAVID SERRANO-SEWELL IS
6	GETTING SUSTENANCE, AND WE ARE PROCEEDING.
7	SO THE ITEM BEFORE US I WOULD LIKE TO
8	LEAVE FOR A MOMENT AND ADDRESS TWO OTHER ITEMS VERY
9	QUICKLY. CONSIDERATION OF NEW SCIENTIFIC MEMBERS
10	FOR THE GRANT WORKING GROUP.
11	MS. KING: DON'T NEED TO DO THAT ITEM.
12	CHAIRMAN KLEIN: AND BECAUSE WE HAVE BOND
13	PROPOSALS, WE'RE USING A LOT OF REMCHO'S TIME, I'D
14	LIKE TO TRY AND ADDRESS THAT ITEM. AND DO WE HAVE
15	MATERIALS ON THAT ITEM?
16	MS. KING: WE DO AND THEY ARE BEHIND TAB
17	20 IN YOUR BINDERS. AND JUST ON A RELATED MATTER, I
18	WANT TO LET THE BOARD MEMBERS KNOW THAT EARLIER
19	TODAY YOU HAD HANDED TO YOU A ONE-PAGE DOCUMENT THAT
20	IS NOT WITH REGARD TO THE REMCHO FIRM, BUT WITH
21	REGARD TO ANOTHER LEGAL CONTRACT WITH NANCY KOCH
22	THAT THE GOVERNANCE SUBCOMMITTEE REQUESTED
23	BACKGROUND INFORMATION. DIRECTING YOUR ATTENTION TO
24	THAT.
25	CHAIRMAN KLEIN: AT THIS POINT WE'RE ON
	144
	166

1	ITEM 20. CAN SHERRY LANSING, BECAUSE THIS IS AN
2	ITEM THAT WENT THROUGH GOVERNANCE. AND CLAIRE IS
3	HERE. CLAIRE, YOU WANT TO DO IT WITH SHERRY OR
4	WI THOUT HER?
5	DR. POMEROY: I THINK WITH.
6	CHAIRMAN KLEIN: ALL RIGHT. SHERRY, WE'RE
7	MOMENTARILY GOING TO SKIP AN ITEM BECAUSE WE WANT TO
8	MAKE SURE ON OUR CRITICAL PATH THAT WE HAVE LAWYERS
9	WORKING ON THE PRIVATE PLACEMENT MEMO, SO THE REMCHO
10	CONTRACT IS THE DISCUSSION. THE BACKGROUND
11	INFORMATION IS BEFORE US AS ITEM 20. IT INCLUDES
12	INFORMATION THAT THE GOVERNANCE COMMITTEE ASKED FOR
13	IN MOVING THIS RECOMMENDATION HERE. AND WOULD YOU
14	LIKE TO COMMENT ON THE SUPPLEMENT OF 180,000 TO THE
15	REMCHO CONTRACT AS PRESENTED TO THE GOVERNANCE
16	COMMITTEE.
17	MS. LANSING: WELL, THE GOVERNANCE
18	COMMITTEE LOOKED OVER THIS, FELT THAT IT WAS
19	COMPLETELY JUSTIFIED, THAT REMCHO THE GOVERNANCE
20	COMMITTEE LOOKED OVER THIS VERY CAREFULLY AND FELT
21	THAT THIS WAS COMPLETELY JUSTIFIED. THERE WAS
22	BACKUP DOCUMENTATION FOR IT, THAT THE SERVICES THEY
23	WERE PROVIDING WERE EXCELLENT AND NEEDED. AND SO IT
24	WAS, I THINK, A UNANIMOUS RECOMMENDATION THAT THIS
25	COME BEFORE THE FULL BOARD.
	167

1	CHAIRMAN KLEIN: AND I BELIEVE THAT IT'S
2	IMPORTANT TO NOTE THAT SINCE THE CONTRACT WAS
3	PREVIOUSLY APPROVED, THERE'S A NUMBER OF ITEMS THAT
4	HAVE BEEN BULLET POINTED IN YOUR DOCUMENTATION THAT
5	EXPLAIN SUPPLEMENTAL TASKS. AMONG THOSE
6	SUPPLEMENTAL TASKS IS WORK ON THE PRIVATE PLACEMENT
7	OF THE BONDS, AS WELL AS JAMES HARRISON WORKED WITH
8	ME ON THE POOLED MONEY INVESTMENT CONTRACT WHERE WE
9	WERE ABLE TO I HAD ANTICIPATED, IN FACT, THAT THE
10	POOLED MONEY TERMS MIGHT CHANGE, AND WE WERE ABLE TO
11	ACCELERATE DOCUMENTATION AND PROPER PAYMENTS, SO WE
12	HAD ANOTHER 55 OR 60 MILLION THAT WE ACTUALLY GOT
13	OUT BEFORE THE TERMS WERE CHANGED. SO JAMES HAS
14	WORKED ALONG WITH IAN ON A NUMBER OF CRITICAL TASKS
15	FOR US IN MOVING THIS AGENCY FORWARD. BUT WE'RE
16	GOING TO HAVE A TREMENDOUS AMOUNT OF WORK ON THE
17	PRIVATE PLACEMENT OF THESE BONDS, AND THIS 180,000,
18	I BELIEVE, IS IMPORTANT.
19	IS THERE ANY OTHER BOARD DISCUSSION ON
20	THIS ITEM?
21	DR. POMEROY: I'D JUST LIKE TO MAKE A
22	COMMENT. THE REASON THAT YOU HAVE THIS SUPPLEMENTAL
23	INFORMATION IN FRONT OF YOU WAS BECAUSE WE FELT THAT
24	IT WAS VERY IMPORTANT AND PART OF OUR DUE DILIGENCE
25	WHEN WE WERE EXPENDING MONEY FOR CONTRACTS OF THIS
	1/0

SIZE, BECAUSE THIS IS GOING TO BE A TOTAL OF
630,000, THAT WE HAVE INFORMATION IN WRITING WHICH
THE BOARD COULD REVIEW AND UNDERSTAND ABOUT THE
JUSTIFICATION FOR THIS KIND OF EXPENSE.
AND THIS COMES WITHIN THE CONTEXT OF, I
THINK, A VERY HEIGHTENED AWARENESS OF THE IMPORTANCE
OF TRYING TO MINIMIZE OUR ADMINISTRATIVE COSTS AT
THIS TIME SO THAT THE GOVERNANCE COMMITTEE FELT
STRONGLY, I THINK, THAT IT WOULD BE FAIR TO SAY,
THAT WE SHOULD LOOK CAREFULLY AT EACH OF THESE, AND
THAT THE BOARD DESERVED TO HAVE WRITTEN INFORMATION
ABOUT THIS SIZE CONTRACT.
CHAIRMAN KLEIN: RIGHT. AND WE HAD SOME
WRITTEN INFORMATION THAT I WENT OVER THAT THE
ACCOUNTING STAFF HAD SUPPLIED TO ME AND THE REMCHO
FIRM HAD, BUT IT'S IMPORTANT FOR ALL THE BOARD
MEMBERS TO HAVE IT, INCLUDING THE HISTORY OF THE
CONTRACT AND THE COMPARABLES TO OTHER STATE RATES
FOR ATTORNEYS THAT THE REMCHO FIRM REPRESENTS.
SO THAT INFORMATION HAS BEEN SUPPLEMENTED,
AND I THINK THE ACCOUNTING STAFF NOW UNDERSTANDS
THAT THIS IS THE STANDARD WE WANT TO FOLLOW.
MR. ROTH: I'M GOING TO MAKE A MOTION TO
APPROVE, BUT I ALSO WANT TO MAKE A COMMENT AND
RECOMMENDATION, THAT IN THE FUTURE WITH THESE TYPES
169

1	OF CONTRACTS, THAT WE PROSPECTIVELY LAY OUT THE
2	SCOPE OF WORK AND WHAT WE ANTICIPATE AND EVEN
3	SUGGEST YOU PUT A LITTLE UNANTICIPATED WORK BECAUSE
4	THIS IS GOING TO HAPPEN OVER AND OVER AGAIN. AND
5	IT'S VERY HARD TO MEASURE THE TOTAL SCOPE THAT YOU
6	DIDN'T ANTICIPATE WHEN I DON'T KNOW FOR SURE.
7	MS. LANSING: I ACTUALLY THINK THAT'S A
8	VERY GOOD POINT, THAT WE PUT MAYBE SOME CONTINGENCY
9	IN FOR CONTRACTS LIKE THIS. BUT, AGAIN, WE DIDN'T;
10	AND BECAUSE OF THAT, AS CLAIRE SAID, WE REALLY
11	OUTLINE IN FULL THE INFORMATION THAT WE HAD.
12	MR. ROTH: SO THAT'S THE MOTION.
13	DR. LOVE: SECOND.
14	CHAIRMAN KLEIN: OKAY.
15	MS. LANSING: DO I NEED A ROLL CALL OR
16	JUST ALL IN FAVOR? PUBLIC COMMENT. I'M SORRY. I
17	APOLOGI ZE.
18	DR. SIMPSON: JOHN SIMPSON, CONSUMER
19	WATCHDOG. I JUST REALLY WANT TO THANK THE
20	GOVERNANCE COMMITTEE FOR INSISTING THAT THIS BE
21	PREPARED IN WRITING. IT SHOULD, IN FACT, HAVE BEEN
22	PRESENTED AT THE COMMITTEE IN WRITING. AND IT WAS
23	VERY GOOD TO SEE THE GOVERNANCE COMMITTEE EXERCISING
24	DUE DILIGENCE.
25	THEY ALSO REQUESTED A WRITTEN EXPLANATION
	170
	170

1	OF A CONTRACT THAT DOES NOT NEED TO BEFORE THE FULL
2	BOARD. THAT'S ALSO BEEN MADE AVAILABLE TO ME AND I
3	THANK YOU FOR THAT, AND THAT'S THE WAY THINGS SHOULD
4	WORK. THANK YOU.
5	MS. LANSING: THANK YOU, JOHN. ANY OTHER
6	PUBLIC? ANY OTHER BOARD, JUST TO BE SURE I DIDN'T
7	CUT ANYONE OFF? SO
8	CHAIRMAN KLEIN: CALL FOR THE QUESTION.
9	MS. LANSING: ALL IN FAVOR. ANY OPPOSED?
10	CHAIRMAN KLEIN: AND THE TELEPHONIC.
11	MS. KING: I DON'T KNOW EXACTLY WHO HAS
12	REJOINED, SO I WILL JUST CALL EVERYBODY.
13	DR. FRIEDMAN: DR. FRIEDMAN ANSWERS YES.
14	MS. KING: GERALD LEVEY. ED PENHOET.
15	DR. PENHOET: YES.
16	MS. KING: AND JON SHESTACK.
17	OKAY. THAT MOTION CARRIES.
18	MS. SAMUELSON: MR. CHAIRMAN, I WOULD JUST
19	LIKE TO ADD FOR THE RECORD A BIG THANK YOU TO JAMES
20	HARRISON AND HIS FIRM.
21	(APPLAUSE.)
22	MS. SAMUELSON: AND THIS ISN'T JUST A NICE
23	GUY AWARD, FOR THE RECORD. HE'S SHOWN IMMENSE
24	WISDOM AND 20-20 VISION IN A VERY COMPLICATED LEGAL
25	ENVI RONMENT.
	171

1	MR. HARRISON: THANK YOU VERY MUCH.
2	CHAIRMAN KLEIN: AND THE OTHER ITEM THAT
3	CAME BEFORE US, I BELIEVE, VERY QUICKLY BEFORE WE GO
4	BACK TO THE MAIN ITEM IS THE TRAVEL POLICY, IF WE
5	COULD ADDRESS NO. 18.
6	MS. LANSING: JAMES, I'D LIKE TO ASK YOU
7	TO EXPLAIN THE AMENDMENT TO THE TRAVEL POLICY, WHICH
8	HAS BEEN VIEWED BY GOVERNANCE AND IS ALSO
9	RECOMMENDED.
10	CHAIRMAN KLEIN: I THINK IAN IS GOING TO.
11	MR. SWEEDLER: THIS JUST CORRECTS AN
12	INCONSISTENCY THAT RECENTLY CAME TO LIGHT IN OUR
13	TRAVEL POLICY AND CURRENTLY HOLDING UP SOME EXPENSE
14	REI MBURSEMENTS.
15	OUR TRAVEL POLICY ALLOWS FOR REIMBURSEMENT
16	OF REASONABLE MEAL EXPENSES WHILE TRAVELING ON CIRM
17	BUSINESS, INCLUDING FOR TRIPS THAT LAST LESS THAN 24
18	HOURS. IT ALSO SAYS THAT CIRM DOES NOT REIMBURSE
19	TRAVEL EXPENSES THAT WOULD BE CONSIDERED BY THE IRS
20	AS TAXABLE INCOME. AND THEREIN IS THE CONFLICT
21	BECAUSE THERE ARE SOME TYPES OF MEAL REIMBURSEMENTS
22	FOR TRIPS LESS THAN 24 HOURS THAT THE IRS CONSIDERS
23	TO BE TAXABLE INCOME.
24	MOST STATE AGENCIES DEAL WITH THAT BY
25	ALLOWING THE REIMBURSEMENTS AND ACCOUNTING FOR IT AS

1	TAXABLE INCOME, AND THAT IS WHAT THIS CHANGE WOULD
2	DO. SO IT JUST SIMPLY RESOLVES THAT CONFLICT SO
3	THAT THEY CAN RESUME PROCESSING OF TRAVEL CLAIMS.
4	MS. LANSING: THANK YOU SO MUCH. DO I
5	HAVE ANY COMMENTS FROM THE BOARD?
6	DR. LOVE: MOVE APPROVAL.
7	DR. POMEROY: SECOND.
8	MS. LANSING: ANY OTHER COMMENTS FROM THE
9	BOARD?
10	MS. SAMUELSON: ONE QUICK QUESTION, I
11	THINK. THERE ARE SOME INSTANCES IN WHICH THE
12	DISABLING NATURE OF PARKINSON'S CAUSES ME TO NEED TO
13	EAT A MEAL IN THE ROOM AND THAT SORT OF THING, AND
14	THAT IS NOT NORMALLY COMPENSABLE. SO I GUESS I'M
15	ASKING SOME ATTENTION TO THAT.
16	MR. SWEEDLER: WHAT I WOULD SUGGEST IS IT
17	WOULD BE MARGARET FERGUSON IN THE FIRST INSTANCE WHO
18	WOULD BE ACCOUNTING FOR A PARTICULAR REIMBURSEMENT
19	AS TAXABLE OR NONTAXABLE. SO IF THERE'S AN
20	INDIVIDUAL SITUATION WHERE THE USUAL IRS
21	REIMBURSEMENT RULES DON'T APPLY, JUST LET HER KNOW
22	SO THAT SHE CAN ACCOUNT FOR IT PROPERLY.
23	CHAIRMAN KLEIN: THANK YOU. SHERRY.
24	MS. LANSING: YES. I HAD A SECOND. I
25	HAVEN'T GONE TO THE PUBLIC YET. I WAS JUST ASKING
	173
	I / J

1	THE BOARD. ANYTHING ELSE? JOAN, THANKS FOR
2	BRINGING THAT UP. WE WERE ACTUALLY TRYING TO
3	ADDRESS IT AS BEST WE COULD.
4	ANY COMMENTS FROM THE PUBLIC? THAT BEING
5	SAID, ALL IN FAVOR. ANY OPPOSED? MOTION CARRIES.
6	MS. KING: THIS IS FOR AGENDA ITEM NO. 18,
7	AND I WILL CALL MICHAEL FRIEDMAN.
8	DR. FRIEDMAN: YES.
9	MS. KING: DR. PENHOET.
10	DR. PENHOET: YES.
11	MS. KING: I DON'T BELIEVE DR. LEVEY IS ON
12	THE LINE. DR. LEVEY. AND JON SHESTACK, JUST
13	CHECKING. OKAY. THANK YOU. MOTION DOES CARRY.
14	MS. LANSING: THANK YOU AGAIN.
15	CHAIRMAN KLEIN: THANK YOU, SHERRY.
16	SO LIKE TO RETURN TO THE CONSIDERATION OF
17	THE ITEMS BEFORE US. MR. HARRISON, COULD YOU ORIENT
18	US AS TO THE TRANSLATIONAL INITIAL ALLOCATION AND
19	EXPLAIN THE CONFLICTS ISSUES? AND ALSO I'VE HAD A
20	CONVERSATION WITH YOU IN THE INTERIM WITH AN IDEA
21	ABOUT HOW, AS LONG AS THE INITIAL ALLOCATION IS A
22	FLOOR ALLOCATION, HOW WE COULD HAVE A LATER INCREASE
23	OF THAT ALLOCATION AS LONG AS IT DIDN'T TAKE ANY
24	FUNDS AWAY FROM ANY OTHER PROGRAM. IF YOU COULD
25	RELATE THAT, PLEASE.
	17/

1	MR. HARRISON: SURE. SO WE HAVE NOW
2	DISCUSSED THE BRIDGES PROGRAM, TRAINING GRANTS II.
3	THE LAST PROGRAM IN WHICH MEMBERS HAVE AN INTEREST
4	IS THE EARLY TRANSLATIONAL PROGRAM. SO
5	UNFORTUNATELY FOR THIS CONVERSATION THE SAME RULE
6	PERTAINS. ONLY THOSE MEMBERS WHO I IDENTIFIED
7	EARLIER CAN PARTICIPATE IN THIS DISCUSSION. AND THE
8	PURPOSE OF THIS DISCUSSION, AT THE BOARD'S DESIRE,
9	IS TO IDENTIFY THE RELATIVE PRIORITY OF THE EARLY
10	TRANSLATIONAL PROGRAM WITH RESPECT TO THE OTHER
11	GRANT PROGRAMS AND, AS BOB SUGGESTED, CONSIDER THE
12	STAFF'S RECOMMENDATION WITH THE UNDERSTANDING THAT
13	THE BOARD COULD SUBSEQUENTLY DECIDE TO ADD TO THAT
14	AMOUNT WHEN IT ACTUALLY CONSIDERS THE APPLICATIONS
15	THAT COME BEFORE THE BOARD IN APRIL WITHOUT TAKING
16	MONEY FROM OTHER PROGRAMS.
17	ONCE THE BOARD HAS COMPLETED THIS
18	DISCUSSION, WE WILL HAVE DEALT WITH ALL OUR CONFLICT
19	OF INTEREST ISSUES, AND THAT WOULD PERMIT THE FULL
20	BOARD TO THEN ENGAGE IN THE DISCUSSION ABOUT THE
21	PRIORITY OF THE REMAINING PROGRAMS AND WHERE THEY
22	FIT IN TERMS OF THE AGENCY'S STRATEGY GOING FORWARD.
23	CHAIRMAN KLEIN: THANK YOU, MR. HARRISON.
24	SO ON THE TRANSLATIONAL PROGRAM, WE'VE HEARD THE
25	STAFF PRESENTATION TO DATE, BUT I'M OPENING THIS TO
	475

1	BOARD DISCUSSION. MR. HARRISON, COULD YOU CITE THE
2	MEMBERS WHO DO NOT HAVE A CONFLICT?
3	MR. HARRISON: YES. MEMBERS KLEIN,
4	GIBBONS, LOVE, QUINT, ROTH, SAMUELSON,
5	SERRANO-SEWELL, SHESTACK, AND TORRES.
6	CHAIRMAN KLEIN: THANK YOU. JOAN.
7	MS. SAMUELSON: I'D LIKE TO OPEN THE
8	DISCUSSION WITH A DIFFERENT AMENDMENT, WHICH WOULD
9	BE THAT WE ESTABLISH A FLOOR OR CEILING, BUT THAT IT
10	BE THE SUM TOTAL OF, I GUESS IT'S, PROGRAM ITEMS NO.
11	1 AND NO. 12 SO THAT WE GO INTO THE NEXT MEETING
12	WHERE WE'LL BE CONSIDERING INDIVIDUAL GRANTS WITHOUT
13	ANY RESTRICTION ON THE ABILITY TO FUND EVERY ONE OF
14	THEM SHOULD WE DECIDE THEY'RE ALL COMPELLING ENOUGH.
15	I THINK THAT'S THE ORDER IN WHICH THAT SHOULD HAPPEN
16	GIVEN THE EXTREME IMPORTANCE OF THIS AREA TO JUMP
17	START DEVELOPMENT OF THERAPIES.
18	CHAIRMAN KLEIN: OTHER BOARD POINTS AND
19	DISCUSSION? OKAY. I'D LIKE TO SUGGEST THAT WE SEE
20	IF THERE IS A MOTION IF THERE'S A SECOND TO THIS
21	MOTION OR WHETHER OR NOT THE DESIRE OF THE BOARD IS
22	TO CONSIDER THIS AT THE TIME THEY LOOK AT THE GRANTS
23	IN APRIL. AND I'D LIKE SOME COMMENT FROM THE BOARD
24	ABOUT THE ISSUE OF TRANSLATIONAL IMPORTANCE IN OUR
25	GENERAL PROGRAM FOR THIS YEAR.
	176

1	MR. ROTH: I'LL MAKE A COMMENT. I THINK
2	IN LIGHT OF ALL THE DISCUSSION TODAY, AND EVEN
3	ALAN'S PRESENTATION EARLIER ABOUT THE EARLY CLINICAL
4	TRIALS THAT ARE TAKING PLACE AROUND THE COUNTRY AND
5	AROUND THE WORLD, THAT THIS HAS TO HAVE A VERY HIGH
6	PRIORITY RIGHT NOW. IN TERMS OF THE FEDERAL
7	FUNDING, HOPEFULLY THERE WILL BE MORE FEDERAL
8	FUNDING FOR THE BASIC RESEARCH PROGRAMS. THAT WILL
9	TAKE SOME TIME, BUT THE TRANSLATIONAL PIECE IS, I
10	THINK, THE MOST CRITICAL. AND, THEREFORE, I WOULD
11	AGREE THAT WE SHOULD PROBABLY HOLD OFF AND HAVE THIS
12	DISCUSSION IN APRIL WHEN WE SEE THE GRANTS AND THE
13	SCORING ON THEM TO SET THE FUNDING.
14	CHAIRMAN KLEIN: IF WE SET AN INITIAL
15	FLOOR HERE, THEN IT ALLOWS US MORE FLEXIBILITY IN
16	THE NEXT MEETING IN APRIL WITH THE INTENT WITH YOUR
17	EMPHASIS ON TRANSLATION, I CERTAINLY HAVE AN
18	EMPHASIS ON TRANSLATION, THAT WE CAN INCREASE IT AS
19	LONG AS IN APRIL WE DO NOT TAKE MONEY AWAY FROM ANY
20	OTHER PROGRAM. SO EFFECTIVELY, INSTEAD OF HAVING A
21	\$200 MILLION GOAL HERE FOR OUR CONSERVATIVE CASE TO
22	RAISE MONEY, THE EFFECT OF WHAT JOAN WOULD BE
23	SUGGESTING IS THAT IF WE FOUND THE QUALITY WAS THERE
24	IN APRIL, WE WOULD RAISE OUR FLOOR TO 211.7 MILLION.
25	SO WE CAN'T BE IN A POSITION ONCE WE SET
	177

1	THE FLOOR OF LOWERING THE FLOOR, BUT WE DON'T HAVE
2	TO EVEN IF WE HAVE A FLOOR, IF THERE'S ONLY \$9
3	MILLION OF EARLY TRANSLATION THAT WOULD BE HIGH
4	QUALITY, WHICH I DON'T REALLY THINK IS REAL, BUT
5	WE'RE NOT CONSTRAINED BECAUSE WE HAVE AN ALLOCATION
6	FLOOR OF ACTUALLY APPROVING THAT. IT'S ALWAYS GOING
7	TO BE BASED ON ONLY FUNDING THE BEST SCIENCE.
8	DR. POMEROY: I CAN'T COMMENT ON THE
9	MERITS OF THE RECOMMENDATION, BUT CAN I ASK FOR A
10	CLARIFICATION? SO I'M TRYING TO UNDERSTAND. WHAT I
11	HEARD JOAN SAY AND WHAT I HEARD YOU SAY WERE TWO
12	VERY DIFFERENT THINGS. I THOUGHT I HEARD JOAN SAY
13	THAT NO. 12 SHOULD BE MOVED UP ABOVE THE BASIC
14	BIOLOGY. AND I HEARD YOU SAY IT STAYS AS WE COULD
15	ADD IF IT DIDN'T IMPACT BASIC BIOLOGY.
16	CHAIRMAN KLEIN: SO NO. I AM SAYING
17	DR. POMEROY: WHAT ARE YOU GUYS DEBATING
18	SINCE I'M NOT ALLOWED TO?
19	CHAIRMAN KLEIN: I WAS NOT MAKING A
20	COMMENT ON WHETHER OR NOT WE MOVE IT ABOVE BASIC
21	BIOLOGY. WHAT I WAS MAKING A COMMENT TO THE EXTENT
22	WAS THAT IF WE WANT TO INCREASE THIS CATEGORY, AND I
23	THANK YOU, CLAIRE, FOR POINTING OUT, WANT TO MAKE IT
24	CLEAR THAT IF YOU WANT TO INCREASE THIS CATEGORY
25	WITHOUT DECREASING SOMETHING ELSE IN THIS LIST AT

1	THIS POINT, YOUR OPTION IN APRIL WOULD BE TO
2	INCREASE THE TOTAL CONSERVATIVE CASE FUNDING FROM
3	200 TO 211.7 MILLION.
4	YOU DO HAVE THE OPTION IN A MOTION NOW TO
5	ADDRESS BASIC BIOLOGY IF YOU WANTED TO REDUCE THAT
6	AS AN OFFSET AND INCREASE THAT TOTAL NOW. I WOULD
7	SAY THAT WHEN WE GET TO PASS THIS ITEM, ALL THE
8	BOARD MEMBERS WOULD HAVE AN OPTION TO MAKE ANOTHER
9	MOTION, WHICH WOULD BE TO RESTORE BASIC BIOLOGY AND
10	REDUCE SOME OTHER CATEGORY THAT'S NOT IN THE FIRST
11	THREE, IS NOT IN EARLY TRANSLATION, BRIDGES, OR
12	TRAINING II.
13	I'M SORRY THIS IS SUCH A COMPLEX SUBJECT.
14	DR. POMEROY: WE'RE IN TROUBLE. JAMES IS
15	LOOKING CONFUSED.
16	CHAIRMAN KLEIN: I THINK JAMES FOLLOWED
17	THAT.
18	DR. HAWGOOD: I WILL ADMIT TO BE CONFUSED.
19	YOU'RE SAYING WE BASICALLY JUST INCREASE THE TARGET
20	THAT WE NEED TO RAISE IN THE BOND OFFERING.
21	CHAIRMAN KLEIN: TWO THINGS. ONE IS WE
22	COULD TODAY INCREASE THE TARGET. WE COULD INCREASE
23	THE TARGET IN APRIL AFTER WE SEE THOSE GRANTS AND
24	UNDERSTAND THE QUALITY OF THE GRANTS. BUT WHAT I'M
25	ALSO STATING IS THAT IF WE SET A TARGET TODAY THAT
	170

1	IS 36.5 MILLION UNDER THE RECOMMENDATION, WE COULD
2	ALSO FUND LESS THAN THAT BASED ON QUALITY IF THAT'S
3	APPROPRIATE IN APRIL.
4	SO THIS IS AN INITIAL OR PRELIMINARY
5	PLANNING TARGET.
6	MR. SHEEHY: I'M JUST I GUESS WE
7	ALREADY HAVE AN APPROVED NUMBER THAT IS, WHAT, 60
8	MILLION, RIGHT. SO IF WE DO NOTHING, THAT STAYS THE
9	WAY IT IS. AND AM I CORRECT, I'M JUST ASKING A
10	CLARIFICATION QUESTION, THIS WOULD BE THE ONLY ONE
11	OF THE THREE ITEMS WE'VE LOOKED AT WHERE WE ACTUALLY
12	HAVEN'T SEEN THE GRANT REVIEWS
13	CHAIRMAN KLEIN: THAT'S CORRECT.
14	MR. SHEEHY: AND THE GRANT
15	APPLICATIONS? I CAN'T OFFER AN OPINION ABOUT THAT,
16	RIGHT, OR WHETHER I THINK IT'S APPROPRIATE?
17	CHAIRMAN KLEIN: YOU'RE JUST MAKING A
18	FACTUAL OBSERVATION.
19	MR. SHEEHY: JUST A FACTUAL OBSERVATION.
20	MR. HARRISON: JEFF IS CORRECT, THAT IF
21	THE BOARD TOOK NO ACTION AT THIS POINT, THE \$60
22	MILLION BUDGET THAT THE BOARD APPROVED IN THE
23	CONCEPT PROPOSAL FOR EARLY TRANSLATION WOULD REMAIN.
24	THE POINT OF DETERMINING, IF THE BOARD SO
25	DESIRES, A PARTICULAR PRIORITY FOR THIS PROGRAM IS
	180

1	REALLY TO CREATE THE POSSIBILITY FOR THE BOARD THEN
2	TO HAVE A DISCUSSION ABOUT THE REMAINING PROGRAMS
3	AND THEIR RELATIVE PRIORITY.
4	CHAIRMAN KLEIN: I WANT TO MAKE IT CLEAR
5	WHAT JAMES JUST SAID. IF WE SET A PRELIMINARY
6	NUMBER HERE, THEN THE CONFLICTS ARE ELIMINATED FOR
7	DISCUSSION OF THE OVERALL PLAN FOR THE BOARD RELATED
8	TO ALL THE OTHER ITEMS.
9	MR. ROTH: OR IF WE DO NOTHING, WE COULD
10	THEN HAVE THAT CONVERSATION.
11	MR. HARRISON: RIGHT. IF YOU DID NOTHING,
12	EFFECTIVELY WHAT YOU'D BE SAYING IS THAT 60 MILLION
13	REMAINS.
14	MR. ROTH: I WOULD PERSONALLY JUST LIKE TO
15	WAIT TILL APRIL.
16	MS. GIBBONS: I WOULD LIKE TO WAIT TILL
17	APRI L.
18	DR. PRIETO: DO WE NEED TO SPECIFICALLY
19	AGENDIZE THAT DISCUSSION FOR APRIL?
20	MR. HARRISON: WHAT WILL BE ON THE AGENDA
21	IN APRIL IS THE CONSIDERATION OF THE ACTUAL
22	APPLICATIONS. YOU WILL BE DEALING WITH A BUDGET OF
23	\$60 MILLION, AND YOU CAN CONSIDER THE APPLICATIONS
24	AND MAKE DECISIONS ON THEM BASED ON YOUR FEELING OF
25	THE RELATIVE MERIT OF THEM.

1	
1	DR. PRIETO: WITHOUT EXCLUSIONS BASED ON
2	CONFLI CTS?
3	MR. HARRISON: WITH EXCLUSIONS BY
4	APPLICATION AS WE DO NORMALLY.
5	DR. PRIETO: WELL, THEN I WOULD LIKE TO
6	REQUEST THAT WE AGENDIZE A GENERAL DISCUSSION OF THE
7	PRIORITIES BEFORE WE ADDRESS INDIVIDUAL.
8	MR. HARRISON: WE COULD DO THAT, AND THE
9	NINE MEMBERS WHO DO NOT HAVE ANY INTEREST COULD
10	PARTICIPATE IN THAT DISCUSSION.
11	DR. PRIETO: IF WE'RE NOT DISCUSSING
12	INDIVIDUAL APPLICATIONS, WHY COULDN'T OTHER MEMBERS
13	DI SCUSS THAT?
14	MR. SHEEHY: CAN I OFFER A SUGGESTION,
15	FRANCISCO? MAYBE THE BETTER WAY TO GO, IF THOSE WHO
16	ARE NOT CONFLICTED CHOOSE TO DO SO, WOULD BE I DO
17	THINK WE NEED TO HAVE AN AGENDIZED DISCUSSION ABOUT
18	PRIORITIES, BUT WE COULD, WITH THAT IN MIND, GO
19	AHEAD AND LOOK PRIOR TO THAT AT THE EARLY
20	TRANSLATION ROUND AND LOOK AT APPLICATION BY
21	APPLICATION WITH THE KNOWLEDGE IN OUR MINDS THAT,
22	NO. 1, WE CAN'T VOTE ON THE ONES WE'RE CONFLICTED ON
23	AND WE CAN'T MAKE ANY OPINIONS ABOUT THAT; TWO, THAT
24	THAT'S GOING TO COME OUT OF SOMEWHERE ELSE.
25	WE'VE BEEN PRESENTED WITH THE INFORMATION
	192

1	THAT WE'VE BEEN PRESENTED WITH THE PRIORITY LIST,
2	WITH THE FUNDING SCHEDULE, AND SO WE WOULD KNOW THAT
3	IF WE EXCEEDED 36.5 MILLION, THEN WE'RE GOING TO
4	HAVE TO FIND THAT SOMEWHERE ELSE. WHERE WE FOUND
5	IT, IF WE DECIDED TO EXCEED THAT, WOULD BE A CHOICE
6	THAT WE CAN MAKE IN A DISCUSSION FOLLOWING THAT.
7	CHAIRMAN KLEIN: I THINK THAT YEAH.
8	ALL RIGHT. FINE.
9	MR. HARRISON: MR. CHAIR, EXCUSE ME FOR
10	JUST ONE MOMENT. THE OTHER CHALLENGE THAT WE WILL
11	CONFRONT IN APRIL IS THAT WE WILL HAVE YET ANOTHER
12	PROGRAM, BASIC BIOLOGY, WHERE AN INVITATION TO
13	SUBMIT APPLICATIONS WILL HAVE GONE OUT. IN OTHER
14	WORDS, WE'LL HAVE ANOTHER PROGRAM IN WHICH MEMBERS
15	HAVE A POTENTIAL INTEREST THAT COULD BE AFFECTED BY
16	THE DETERMINATION OF THE FUNDING LEVEL FOR EARLY
17	TRANSLATI ON.
18	CHAIRMAN KLEIN: SO JUST LET ME MAKE A
19	STATEMENT AGAIN. THERE'S TIMEFRAMES AND OVERLAPPING
20	CRITICAL PATHS, AND THEN YOU TRY AND WORK THE LEGAL
21	STRUCTURE TO CONSIDER ALL THESE INTERRELATED ITEMS.
22	I DO THINK THAT EITHER WE EFFECTIVELY AMEND OUR
23	FUNDING TO HAVE OUR FLOOR TO HAVE OUR FUNDING
24	CONSERVATIVE CASE BE 211.7 MILLION, WHICH MEANS THAT
25	EFFECTIVELY WE HAVEN'T AFFECTED ANY OF THE OTHER

1	PROGRAMS. WE WOULD DO THAT IF WE LEAVE THE FIGURE
2	CURRENTLY AT 60 MILLION. WE ARE NOT OBLIGATED TO
3	APPROVE THAT MANY, BUT THAT WOULD THEN REMOVE OUR
4	CONFLICTS; IS THAT CORRECT, MR. HARRISON?
5	MR. HARRISON: THAT'S RIGHT.
6	CHAIRMAN KLEIN: IT'S A CONJUNCTIVE ISSUE
7	HERE. YOU SOLVE YOUR CONFLICTS IF YOU EFFECTIVELY
8	ADJUST YOUR MINIMUM BUDGET TO AVOID A TRADE-OFF IF
9	WE WERE TO ELECT TO MAXIMALLY APPROVE OUR CATEGORY.
10	DR. GILL: CAN I ASK A QUESTION OF
11	CLARI FI CATI ON.
12	CHAIRMAN KLEIN: YES. DR. GILL.
13	DR. GILL: WHY WITH THESE ARE WE
14	CONSIDERING FUNDING BEFORE WE SEE THE GRANTS RATHER
15	THAN ANY OTHER CATEGORY?
16	CHAIRMAN KLEIN: BECAUSE OF THE
17	INTRICACIES OF THE POLITICAL REFORM ACT IN
18	CALIFORNIA. AND IN WRITING THE INITIATIVE, TRIED TO
19	BE ACUTELY FOCUSED IN ONLY CHANGING THOSE ESSENTIAL
20	AREAS OF THE POLITICAL REFORM ACT THAT WE HAD TO
21	CHANGE AND NOT UNDERSTANDING COMPLETELY THE DYNAMICS
22	OF HOW THESE DISCUSSIONS WOULD WORK WHEN YOU HAD
23	MULTIPLE PROGRAMS AT ONE TIME TO BE CONSIDERED. I
24	DIDN'T WRITE AN EXCLUSION FOR THIS SITUATION, AND I
25	HAD A VERY INTELLIGENT SET OF FIVE COUNSEL, SOME OF
	19/

1	WHOM ARE PRESENT, AND THEY DIDN'T THINK OF IT
2	EITHER. SO WE JUST DIDN'T UNDERSTAND THAT WE NEEDED
3	ADDITIONAL CHANGES TO THE POLITICAL REFORM ACT OTHER
4	THAN WE KNEW THAT THERE'S A GREAT DEAL OF RESPECT
5	FOR THE POLITICAL REFORM ACT, SO WE NEEDED TO
6	MINIMALLY AFFECT THAT ACT IF WE'RE GOING TO GET
7	PASSAGE OF THE WHOLE PROPOSITION.
8	MR. SWEEDLER: MAYBE I COULD GIVE IT A
9	STAB BECAUSE I THINK I SEE WHERE SOME OF THE
10	CONFUSION IS. IF YOU DO AN OVERALL PRIORITIES
11	DISCUSSION WITH EARLY TRANSLATIONAL STILL ON THE
12	TABLE, THEN THAT DISCUSSION WILL AFFECT EARLY
13	TRANSLATIONAL, WHICH MEANS ANYONE WITH A CONFLICT
14	FOR THAT ROUND HAS A CONFLICT WITH THE WHOLE
15	DI SCUSSI ON.
16	IF THE DECISION ABOUT EARLY TRANSLATIONAL
17	OVERALL FUNDING LEVEL IS MADE, IT'S OFF THE TABLE
18	AND IT'S NO LONGER PART OF THAT GENERAL DISCUSSION.
19	SO PEOPLE WITH AN INTEREST IN EARLY TRANSLATIONAL
20	ARE FREE TO PARTICIPATE. BUT POSTPONING IT DOESN'T
21	RESOLVE THE CONFLICT BECAUSE THEN YOU'RE STILL LEFT
22	KNOWING THAT OVERALL FUNDING DISCUSSIONS CONFLICT
23	AFFECT IT.
24	CHAIRMAN KLEIN: SO LET ME MAKE A
25	SUGGESTION THAT HOPEFULLY WILL HELP ADDRESS SOME OF

1	THESE ISSUES. WE UNDERSTAND THE NEED FOR
2	DISCIPLINE, BUT IT'S ALSO CRITICAL IN ACTUALLY
3	SELLING THESE BONDS THAT WE HAVE A STRONG MESSAGE.
4	AND THAT STRONG MESSAGE IS THAT WE HAVE A VERY
5	SPECIFIC ROLE THAT IS STRONGLY WEIGHTED TOWARDS
6	TRANSLATIONAL MEDICINE. THAT INCLUDES DISEASE
7	TEAMS. RIGHT NOW THERE'S 26 MILLION IN DISEASE
8	TEAMS BELOW THE LINE. IF, IN FACT, WE ARE GOING TO
9	SAY, LOOK, OUR MINIMUM CASE IS, INSTEAD OF RAISING
10	200 MILLION, WE HAVE TO RAISE 240 MILLION, THEN WE
11	WOULD HAVE THE ABILITY TO FUND BASED ON THE QUALITY
12	OF THE SCIENCE AND THE IMPORTANCE OF THE THERAPY UP
13	TO THE AMOUNTS WE PREVIOUSLY SET FOR THESE PROGRAMS.
14	BUT IT MEANS THAT EFFECTIVELY WE HAVE
15	ASSUMED SLIGHTLY MORE RISK, IN FACT, 20 PERCENT MORE
16	RISK, BECAUSE 20 PERCENT MORE RISK BECAUSE WE'VE
17	INCREASED OUR CONSERVATIVE CASE FROM 200 MILLION TO
18	240 MILLION.
19	SO I WOULD ALSO SAY, THOUGH, AGAIN, WHEN
20	WE GO TO INDIVIDUAL ORGANIZATIONS TO SELL THESE
21	BONDS, IF WE HAVE \$210 MILLION DISEASE TEAM
22	PROPOSAL, PROGRAM, IT'S GOING TO BE EXTREMELY CLEAR
23	THAT WE'RE TRYING TO DEVELOP A STRONG ROLE FOR US,
24	FOR OURSELVES, BETWEEN DISCOVERY AND PHASE II
25	CLINICAL TRIALS, WHICH WE'VE DISCUSSED BEFORE IN

1	THIS BOARD MANY TIMES. AND SO IT MAY BE
2	COUNTERINTUITIVE, BUT IN PARTICULAR DISEASE TEAMS IS
3	A UNIQUE PROGRAM OF GREAT MERIT, RECOGNIZED
4	THROUGHOUT THIS COUNTRY AT THIS POINT, AND I WOULD
5	SUGGEST THAT WE RAISE THAT ABOVE THE LINE AND ADJUST
6	OUR CONSERVATIVE CASE.
7	IF WE DID THE SAME THING WITH TRANSLATION,
8	WE WOULD HAVE A 200 IT'S ACTUALLY \$238 MILLION
9	CONSERVATIVE CASE BECAUSE THERE'S 11.7 MILLION BELOW
10	THE LINE FOR TRANSLATION, THERE'S 26.3 MILLION BELOW
11	THE LINE FOR DISEASE TEAMS.
12	IN THIS PERIOD WHERE THE QUESTION IS HOW'S
13	OUR ROLE RELATED TO ALL THE MONEY GOING THROUGH NIH,
14	THEY HAVE 8 BILLION OF 18-MONTH TO 24-MONTH MONEY
15	EXCEPT FOR THE PORTION THAT'S USED AS A SUPPLEMENT
16	ON EXISTING LONG-TERM GRANTS. BUT FUNDAMENTALLY A
17	LOT OF THAT MONEY IS GOING TO HAVE TO BE LOGICALLY,
18	THERE MAY BE SOME EXCEPTIONS, FOCUSED ON BASIC AND
19	APPLIED RESEARCH. SO TO THE EXTENT THAT WE HAVE
20	HEAVY FOCUS ON DISEASE TEAMS AND TRANSLATION WITH
21	LONGER TERMS WITH A GOAL OF GETTING TO A PHASE I
22	HUMAN TRIAL, WE HAVE SHOWN OURSELVES TO BE A
23	COMPLEMENTARY PARTNER TO THE NIH, AND WE'VE
24	TELESCOPED DOWNSTREAM THAT WHEN ALL OF THIS BASIC
25	AND APPLIED RESEARCH ROLLS OUT TWO YEARS FROM NOW

1	FROM NIH, WE'RE GOING BE ONE OF THOSE PLAYERS THAT'S
2	GOING TO PICK UP THE BEST RESEARCH AND CARRY IT
3	DOWNSTREAM IN TRANSLATIONAL WORK.
4	SO MY SUGGESTION, AND I WAS TRYING TO WAIT
5	FOR THE SUGGESTION TO GET TO WHERE WE GOT PAST
6	TRANSLATION SO WE COULD HAVE EVERYBODY ELSE VOTE ON
7	THIS, AND WE CAN DO THIS IN TWO PARTS, IS TO AMEND
8	THE FIGURE SO THAT OUR CONSERVATIVE CASE HAS AT THIS
9	POINT, SUBJECT TO THE QUALITY OF THE SCIENCE, IS
10	SLI GHTLY HI GHER.
11	MR. SHEEHY: COULD I JUST ASK A POINT OF
12	ORDER? I DON'T SEE ANY ITEM ON PRIORITIES AGENDIZED
13	FOR THIS MEETING. SO REALLY YOU WOULD HAVE TO DO IT
14	WITHIN THE CONTEXT OF EARLY TRANSLATION ANYWAY.
15	CHAIRMAN KLEIN: IT'S ITEM 15, JEFF. IT'S
16	CONSIDERATION OF STAFF RECOMMENDATION ON RESEARCH
17	FUNDING PRIORITIES.
18	MR. SHEEHY: SORRY.
19	MR. ROTH: IF I UNDERSTAND WHAT WAS JUST
20	SAID, WE COULD, IN ORDER TO HAVE A DISCUSSION, LET'S
21	INCREASE THE CAP THAT WE'VE PUT UP TO 238 OR 240
22	MILLION, HAVE THE DISCUSSION IN APRIL; IS THAT
23	CORRECT?
24	CHAIRMAN KLEIN: WELL, WE COULD HAVE A
25	VOTE TODAY.
	188

MR. ROTH: HAVE A VOTE TODAY ON THE 238.
CHAIRMAN KLEIN: AND THEN IN APRIL WE'LL
JUST GO THROUGH THE TRANSLATION AND LOOK AT ON THE
MERITS AND FUND WHAT SHOULD BE FUNDED.
MR. ROTH: WHEN CAN WE HAVE THE DISCUSSION
ABOUT THE REST OF THE PRIORITIES?
CHAIRMAN KLEIN: WE CAN HAVE A DISCUSSION
IMMEDIATELY TODAY IF WE PASS THIS.
MS. SAMUELSON: WE'VE PUT NO CAP. THERE'S
A PROPOSED STAFF RECOMMENDATION BEFORE US, RIGHT?
CHAIRMAN KLEIN: THE QUESTION IS ARE IN
ORDER TO HAVE THE GENERAL DISCUSSION, WE WOULD ONLY
NEED TO INCREASE THE CAP BY 11.7 MILLION. SO IF
THERE'S A MOTION TO SAY TO MOVE THE CAP FROM 200 TO
211.7, THEN WE COULD HAVE A GENERAL DISCUSSION.
MR. ROTH: I WILL MAKE THAT MOTION SO THAT
WE CAN HAVE THE GENERAL DISCUSSION. I QUESTION
WHETHER WE CAN CONCLUDE IT TODAY BEFORE EVERYBODY
HAS TO LEAVE.
CHAIRMAN KLEIN: I WOULD SECOND THE
MOTION. IS THERE A DISCUSSION? IS THERE PUBLIC
DISCUSSION ON THAT MOTION? CALL THE QUESTION. ALL
IN FAVOR. EXCUSE ME. WE HAVE TO DO A ROLL CALL
BECAUSE OF MAKE SURE THAT THE ONLY PEOPLE THAT
SAID AYE ARE THE PEOPLE WHO DO NOT HAVE A CONFLICT.
189

	2.11.11.0.12.10.11.1.1.0.22.1.1.1.0.2
1	MS. KING: LEEZA GIBBONS.
2	MS. GIBBONS: YES.
3	MS. KING: BOB KLEIN.
4	CHAIRMAN KLEIN: YES.
5	MS. KING: TED LOVE.
6	DR. LOVE: YES.
7	MS. KING: ROBERT QUINT.
8	DE. QUINT: YES.
9	MS. KING: DUANE ROTH.
10	MR. ROTH: YES.
11	MS. KING: JOAN SAMUELSON.
12	MS. SAMUELSON: AYE.
13	MS. KING: DAVID SERRANO-SEWELL.
14	MR. SERRANO-SEWELL: YES.
15	MS. KING: I DON'T BELIEVE JON SHESTACK IS
16	ON THE LINE. ART TORRES.
17	MR. TORRES: AYE.
18	MS. KINGS: LOOKS LIKE THAT MOTION CARRIES
19	FOR THE RECORD.
20	CHAIRMAN KLEIN: ALL RIGHT. SO AT THIS
21	POINT MY UNDERSTANDING, MR. HARRISON, IS THAT THE
22	ENTIRE BOARD CAN DISCUSS ALL THE REMAINING
23	PRI ORI TI ES.
24	MR. HARRISON: THAT'S RIGHT. THE ENTIRE
25	BOARD IS NOW FREE TO DISCUSS ALL THE REMAINING GRANT
	190
	170

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	PROGRAMS AND THEIR RELATIVE PRIORITY.
2	DR. LEVIN: I WANT TO CLARIFY WHAT JUST
3	GOT APPROVED. ARE YOU IMPLICITLY APPROVING THE
4	STAFF FUNDING PRIORITIES BY THAT?
5	CHAIRMAN KLEIN: NO, WE DID NOT. WHAT WE
6	DID IS WE APPROVED WE HAVE TO DATE APPROVED
7	BRIDGES, WE HAVE APPROVED THE DEFERRAL OF TRAINING
8	TO 12 MONTHS, AND IN THE LAST VOTE WHAT WE DID IS WE
9	TOOK EARLY TRANSLATION AND RESTORED THE BUDGET TO 60
10	MILLION WITH AN 11.7 MILLION MORE DOLLARS THAT WOULD
11	BE INCURRED IN THE NEXT BEFORE THE END OF 2010
12	SUBJECT TO AVAILABLE FUNDING IF WE APPROVE GRANTS
13	FOR EARLY TRANSLATION UP TO THAT FIGURE IN APRIL.
14	DR. LEVIN: HOW IS THAT DIFFERENT FROM
15	BEFORE THE VOTE WHEN THERE WAS \$60 MILLION ALREADY
16	ALLOCATED?
17	CHAIRMAN KLEIN: UNDER THE POLITICAL
18	REFORM ACT, WE ARE NOW FREE TO DISCUSS ALL THE REST
19	OF THE PRIORITIES. THIS ACTION HAD TO BE TAKEN TO
20	TAKE A POSITION TODAY TO SET THE ALLOCATIONS.
21	BEFORE THE 60 MILLION WAS NOT PART OF ANY ALLOCATION
22	SYSTEM. IT WAS AN INDEPENDENTLY ARRIVED DECISION.
23	IT'S NOT BEEN INCORPORATED INTO OUR DECISIONS TO
24	DATE FOR OUR ALLOCATIONS.
25	DR. LEVIN: I THOUGHT THAT'S WHAT WE HAD
	191

1	DONE WITH CONCEPT APPROVAL.
2	CHAIRMAN KLEIN: THAT WAS NOT AT THIS
3	POINT WE'RE DOING RELATIVE PRIORITIES AND
4	CHANGING WE HAD TO CONSIDER THE POTENTIAL CHANGE
5	IN ALLOCATIONS.
6	ALL RIGHT. WE'RE OPEN. JEFF, DO YOU HAVE
7	A COMMENT?
8	MR. SHEEHY: I DON'T KNOW IF YOU WANT TO
9	START WORKING ON THE PRIORITIES, OR IF YOU WANT TO
10	PUNT THEM BECAUSE WE COULD HAVE, LIKE, A TELEPHONIC
11	MEETING AND PEOPLE COULD THINK ABOUT IT, BUT I
12	PERSONALLY, IF I WERE GOING TO DO IT, I WOULD GO
13	I'D MOVE DISEASE TEAM UP FROM NO. 8 TO 4, AND I'D
14	MOVE IMMUNOLOGY UP TO 5, AND THEN DO THE BASIC
15	BI OLOGI ES.
16	CHAIRMAN KLEIN: OKAY.
17	MR. SHEEHY: THAT WOULD BE MY DRUTHERS.
18	GET THE CLINICAL OUT AND IMMUNOLOGY IS A VERY HIGHLY
19	TARGETED OBSTACLE TO BEING IN THE CLINIC. I GUESS
20	THAT'S MY ADVOCATE KIND OF ROLE. I THINK WE OUGHT
21	TO BE IN THE CLINIC, AND THAT WOULD BE MY PRIORITY.
22	CHAIRMAN KLEIN: SO IF, FOR PURPOSES OF
23	DISCUSSION, IF YOU WANT TO MAKE THAT A MOTION.
24	MR. SHEEHY: I WILL MAKE THAT NOTION.
25	CHAIRMAN KLEIN: I'LL SECOND THE MOTION TO
	192
	1 / L

1	HAVE A DISCUSSION. AND I WOULD POINT OUT THAT SINCE
2	THERE ARE APPLICATIONS SHORTLY DUE FOR DISEASE
3	TEAMS, IT WOULD BE IMPORTANT TO GET A MESSAGE OUT
4	THERE BEFORE OUR NEXT MEETING AS TO WHAT POTENTIAL
5	PRIORITY THEY WILL HAVE. ARE WE WILLING TO FUND TO
6	A HIGHER LEVEL OF 210 MILLION AND NOT A 105 MILLION
7	IF THE QUALITY IS THERE BECAUSE WE COULD HURT OUR
8	CYCLE UNDER THE RFA IF WE DON'T, IN FACT,
9	COMMUNICATE HOW IMPORTANT THIS IS.
10	MR. SHEEHY: CAN I MAKE A POINT ABOUT
11	DISEASE TEAMS BECAUSE THAT'S SUPPOSED TO BE A
12	RECYCLABLE GRANT. SO THOSE HAVE VERY FIRMLY
13	ENFORCED MILESTONES. WHILE WE'RE TALKING ABOUT A
14	ROUND 210 MILLION, IT IS HIGHLY LIKELY THAT WE WILL
15	NOT SPEND ALL OF THAT EVEN IF WE DO FUND TO THAT
16	LIMIT BECAUSE A PERCENTAGE OF THOSE WILL NOT HIT
17	THEIR MILESTONES, WE'LL STOP THE PROJECTS, AND THE
18	MONEY WILL COME BACK TO BE RECYCLED, WHICH IS ONE OF
19	THE REASONS WHY I THINK PERSONALLY IT'S SO IMPORTANT
20	TO GET THIS CYCLE STARTED BECAUSE THIS IS SUPPOSED
21	TO BE A CONTINUAL CHURN. AMBITIOUS PROJECTS, SOME
22	SUCCEED, SOME FAIL. THE ONES THAT FAIL ARE CUT OFF
23	AND THAT MONEY COMES BACK TO BE USED AGAIN.
24	DR. CSETE: THIS IS A VERY GOOD
25	DISCUSSION, AND I REALLY APPRECIATE YOU HAVING IT.

1	YOU MIGHT IMAGINE THAT THERE WAS A LOT OF DISCUSSION
2	THAT WENT INTO THIS LIST IN THE OFFICE. I WANT TO
3	JUST REMIND PEOPLE THAT, FIRST OF ALL, THE BASIC
4	BIOLOGY FUNDING UP THERE IS VERY SMALL. AND AT BOTH
5	PUBLIC MEETINGS IN NORTHERN CALIFORNIA AND IN
6	SOUTHERN CALIFORNIA, THE ONE CLEAR MESSAGE THAT CAME
7	THROUGH FROM OUR SCIENTISTS IN THE AUDIENCE WAS THAT
8	WE NOT ABANDON BASIC BIOLOGY. SO I THINK THAT GIVEN
9	ITS RELATIVE IMPACT PER DOLLAR, WE SHOULD BE VERY
10	CAREFUL ABOUT PRESERVING IT, AND IT'S ALREADY BEEN
11	CUT. THOSE NUMBERS ARE A MUCH LOWER AMOUNT THAN THE
12	ORIGINAL PROPOSAL THAT WE HAD PUT BEFORE YOU.
13	CHAIRMAN KLEIN: I THINK THAT'S AN
14	IMPORTANT FRAMEWORK. TALKING ABOUT 5 MILLION BEFORE
15	DECEMBER 2010, AND REALIZE IT'S 5 MILLION OUT OF 360
16	MILLION WE'RE TALKING ABOUT SPENDING. SO WE'RE
17	TALKING ABOUT KEEPING THAT PROGRAM GOING, BUT IT'S
18	BEEN WEIGHTED IN DOLLAR AMOUNTS SO THAT CLEARLY
19	THERE'S STILL THE EMPHASIS ON DISEASE TEAMS AND
20	OTHER TRANSLATION.
21	DR. HAWGOOD: I WOULD MAKE TWO COMMENTS.
22	ONE, I WOULD AGREE VERY MUCH WITH WHAT MARIE JUST
23	SAID. I THINK WHILE EVERYONE HAS TREMENDOUS
24	ENTHUSIASM TO MOVE TO THE CLINIC AS RAPIDLY AS
25	POSSIBLE, I THINK THE REALITY CHECK IS THAT WE NEED

1	TO LEARN A LOT MORE ABOUT THE BASIC BIOLOGY BEFORE
2	WE'RE GOING TO HAVE REAL SUCCESS. SO I THINK IT
3	WOULD BE A MISTAKE AND SEND A WRONG SIGNAL DESPITE
4	WHAT'S HAPPENING AT THE NIH TO GET OUT OF BASIC
5	BI OLOGY ALTOGETHER.
6	SECOND COMMENT IS THAT I'M A LITTLE
7	CONFUSED ABOUT WHAT WE'RE DOING HERE, TO BE HONEST.
8	I AM VERY SYMPATHETIC WITH WHAT JEFF SAID; BUT IF WE
9	MOVE WE JUST MOVED 23 MILLION OF EARLY
10	TRANSLATION ABOVE THE LINE. IF WE NOW MOVE 105 OF
11	DISEASE TEAM ABOVE THE LINE, WE'RE JUST EXTENDING
12	THE
13	CHAIRMAN KLEIN: WHAT YOU NEED TO LOOK AT
14	IS NOT THE 105 THAT'S OUR LONG-TERM COMMITMENT.
15	IT'S THE 26.3 THAT'S DURING OUR CRITICAL PLANNING
16	PERI OD.
17	DR. HAWGOOD: SURE. I UNDERSTAND. IN
18	ESSENCE, WE'RE JUST INCREASING WE'RE NOT EXERTING
19	A LOT OF DISCIPLINE. WE'RE JUST ADDING THINGS TO
20	WHAT WE NEED TO FIND FUNDING FOR.
21	CHAIRMAN KLEIN: OUR OPTIMIZED SCHEDULE
22	WAS ALMOST 400 MILLION. SO IF WE'RE AT 210 MILLION,
23	INCLUDING MOVING DISEASE TEAMS ABOVE THE LINE, WE
24	WOULD HAVE REDUCED OUR OPTIMIZED SCHEDULE BY 40
25	PERCENT. SO THAT'S A SIGNIFICANT DISCIPLINE.

1	SO WHAT WE'RE LOOKING AT HERE IS OUR
2	NUMBERS ALMOST EFFECTIVELY CUT OUR OPTIMIZED PROGRAM
3	IN HALF, AND SO THE VARIATIONS THAT ARE BEING
4	SUGGESTED WOULD BRING IT TO 60 PERCENT OF OUR
5	OPTIMIZED PROGRAM.
6	DR. HAWGOOD: TO ME I THINK THE DISCUSSION
7	WE SHOULD BE HAVING IS WHAT IS OUR BUDGET THAT WE'RE
8	TRYING TO PRIORITIZE TO, AND NOT ADJUST OUR EVERY
9	TIME WE CHANGE THE PRIORITY, WHAT WE'RE SIMPLY DOING
10	IS CHANGING THE BUDGET. I'M JUST CONFUSED AS TO
11	WHAT WE'RE DOING. IF WE HAVE A SET BUDGET OF 200
12	MILLION, THEN WE CAN PRIORITIZE. IF THE BUDGET IS
13	FLEXIBLE, THAT'S ANOTHER QUESTION.
14	CHAIRMAN KLEIN: WELL, PART OF THIS
15	PROCESS IS EFFECTIVELY WE'RE IN A PROCESS OF
16	TENTATIVELY, SUBJECT TO INFORMATION, ADOPTING A
17	WORKING BUDGET. SO THAT IS WHAT WE'RE DOING IN THIS
18	PROCESS. NOT A BUDGET WE CAN'T CHANGE. AND DR.
19	GILL. EXCUSE ME. ART TORRES, YOU HAD A COMMENT,
20	AND THEN I'M GOING TO GO TO DR. GILL.
21	MR. TORRES: TRUST THAT I WILL LEARN ALL
22	OF YOUR NAMES SHORTLY, BUT, DOCTOR, I JUST WANTED TO
23	ASK YOU A QUESTION. THE MOTION THAT JEFF PROPOSES
24	IS TO CHANGE THE PRIORITY OF THE NUMBERS THAT ARE ON
25	THE CHART. YOU OBVIOUSLY TOOK A LOT OF TIME AND
	106

1	PUBLIC COMMENT TO COME UP WITH THIS LIST. WHAT
2	WOULD YOU ARGUE AGAINST THE MOTION?
3	CHAIRMAN KLEIN: SO THAT EVERYBODY
4	DR. CSETE: SO I THINK THAT I'M GOING TO
5	ANSWER THIS IN A DIFFERENT WAY THAN YOU EXPECT.
6	CHAIRMAN KLEIN: DR. CSETE, COULD WE JUST
7	RESTATE THE MOTION SO EVERYONE'S GOT IT IN MIND?
8	MR. HARRISON: I BELIEVE THE MOTION MADE
9	BY MEMBER SHEEHY AND SECONDED BY CHAIRMAN KLEIN IS
10	TO MOVE THE BALANCE OF THE DISEASE TEAM PROGRAM,
11	WHICH IS CURRENTLY IDENTIFIED IN LINE 8, TO LINE 4
12	AND TO MOVE THE IMMUNOLOGY PROGRAM, WHICH IS
13	CURRENTLY AT LINE 6, TO LINE 5, AND THEREBY MOVE THE
14	BASIC BIOLOGY PROGRAM DOWN.
15	CHAIRMAN KLEIN: A CONCURRENTLY, THOUGH,
16	INCREASING THE TOTAL GOAL TO 240 MILLION SO THAT THE
17	OTHER ITEMS THROUGH SEVEN WOULD REMAIN ABOVE THE
18	LI NE.
19	DR. CSETE: I THINK JOHN ROBSON WAS ABOUT
20	TO ANSWER, AND WE CAN DO THIS TOGETHER, BUT WE WERE
21	TASKED AT THE LAST BOARD MEETING WITH COMING UP WITH
22	A BUDGET THAT WAS SCIENTIFICALLY OPTIMAL GIVEN THE
23	CASH-FLOW CONSTRAINTS OF ABOUT \$200 MILLION IN
24	BONDS. SO I THINK WHAT MR. KLEIN IS ASKING US TO DO
25	IS TO CONSIDER A LARGER OVERALL BOND AVAILABILITY SO
	197

1	THAT WE WOULD NOT BE DITCHING SOMETHING IF WE MOVED
2	THESE UP ABOVE THE LINE. SO I THINK THAT'S WHAT'S
3	HAPPENING HERE, IF I UNDERSTAND IT CORRECTLY.
4	MR. TORRES: THANK YOU.
5	MS. SAMUELSON: BUT THAT'S NOT TAKING INTO
6	CONSIDERATION THE EVENT OF THIS WEEK BECAUSE THE NIH
7	FUNDS THAT WORK. THEY REALLY DON'T FUND NEARLY AS
8	SIGNIFICANTLY TRANSLATIONAL WORK. AND THAT IS OUR
9	MI SSI ON.
10	DR. CSETE: AS I ANSWERED OUR SCIENTISTS
11	WHO AND THIS CAME UP IN THE PUBLIC SESSIONS VERY
12	MUCH. RIGHT NOW NIH DOES NOT HAVE PROGRAMS TO
13	CAPTURE THEY DON'T HAVE RFA'S OUT TO CAPTURE THE
14	KIND OF WORK THAT WE'RE FUNDING IN BASIC HUMAN
15	EMBRYONIC STEM CELLS
16	MS. SAMUELSON: WE JUST GOT AN EXECUTIVE
17	ORDER COUPLE DAYS AGO.
18	DR. CSETE: YOU HAVE TO HAVE PROGRAMS. IT
19	IS GOING DID TO TIME. THIS IS NOT AN INSTANTANEOUS
20	SWITCH. ONE OF THE REASONS THAT I FEEL IT'S
21	CRITICALLY IMPORTANT FOR US TO INVEST IN BASIC
22	BIOLOGY IN A TIMELY WAY IS THAT WE GOT THOSE RFA'S
23	OUT WITH CONSIDERABLE EFFORT ON THE PART OF STAFF TO
24	CAPTURE THE INITIAL SEED GRANTS AS THEY WERE
25	FINISHING UP TO REALLY TAKE THE BEST OF THE SCIENCE
	198

1	THAT WE'VE SEEDED AND MOVE IT FORWARD. AND REALLY,
2	FOR RIGHT NOW, THE BEST OF OUR SEED WORK DOES NOT
3	HAVE A HOME AT THE NIH.
4	CHAIRMAN KLEIN: AND I WOULD REMIND
5	EVERYONE THAT CATRIONA JAMIESON, WHO IS IN OUR FIRST
6	HUMAN TRIAL, CAME OUT OF A SEED MONEY GRANT. SO IN
7	TERMS OF THE RELATIVE RATIO OF TOTAL DOLLARS UP
8	THERE, IN OUR TIMEFRAME THERE'S ONLY 5 MILLION,
9	AGAIN, THAT'S IN THE TIMEFRAME WE'RE DEALING WITH.
10	SO WE'RE PROVIDING CONTINUITY TO THE BASIC BIOLOGY,
11	AND WE'RE NOT EFFECTIVELY DISPLACING ANY MAJOR
12	PROGRAM.
13	MS. SAMUELSON: OUR BUDGET IS HARDLY
14	ABANDONING BASIC BIOLOGY. IT'S A ROBUST PROGRAM,
15	AND THE EARLY TRANSLATION DOESN'T EXIST YET A THIRD
16	OF THE WAY INTO OUR ENTIRE LIFE.
17	MR. SHEEHY: MAKE THE POINT, I AGREE WITH
18	JOAN. WE'RE NOT ABANDONING BASIC BIOLOGY. WE'RE
19	JUST SAYING THAT WITH THE LIMITED AMOUNT OF MONEY,
20	THE FIRST THING WE'RE GOING TO FUND, WE CAN STILL DO
21	GRANT REVIEW AND APPROVE GRANTS PENDING MONEY BEING
22	AVAILABLE LIKE WE DID WITH TRAINING II. BUT I DON'T
23	WANT TO HAMSTRING THE DISEASE TEAMS, WHICH HAS BEEN
24	REALLY THE BIG INNOVATION OF OUR STRATEGIC PLAN THAT
25	WE'VE BEEN WORKING ON FOR ALMOST TWO YEARS NOW

1	THAT'S ALREADY ALMOST A YEAR BEHIND SCHEDULE. I'M
2	NOT CONVINCED THAT WE'RE GOING TO HAVE NECESSARILY
3	10 APPLICATIONS OR 15 APPLICATIONS THAT MAY BE
4	MERITORIOUS. BUT I WANT TO START OFF SAYING THAT
5	THE MOST IMPORTANT PLACE TO BE IS HEADED TOWARDS THE
6	CLINIC. I'M AWARE THAT THERE'S SOME, DR. HAWGOOD,
7	THAT SOME STUFF IS NOT GOING TO BE READY. THEY'RE
8	NOT GOING TO GET GOOD SCORES. I DON'T THINK WE HAVE
9	A RECKLESS REVIEW GROUP. AND IF THE PROJECTS AREN'T
10	READY TO GO TO THAT PHASE, WE WON'T APPROVE THEM.
11	BUT I THINK IF WE DON'T SIGNAL THAT WE'RE
12	REALLY SERIOUS ABOUT DOING THIS, THEN I THINK WE
13	LOSE SOME OF THE MOMENTUM WE CREATED AS AN AGENCY
14	BECAUSE IF YOU LOOK, A LOT OF WORK THAT WE'RE DOING
15	IS FAIRLY NIH-LIKE. THIS WAS THE REAL THING THAT WE
16	CAME TO THAT WAS REALLY INNOVATIVE AS A FUNDING
17	MECHANISM. AND I JUST WOULD HATE TO SEE US PULLING
18	BACK ON THAT. AND IT'S NOT LIKE WE'RE NOT GOING TO
19	FUND BASIC BIOLOGY. WE WILL.
20	CHAIRMAN KLEIN: YOU'VE GOT ABOVE THE LINE
21	THE BASIC BIOLOGY THEY RECOMMENDED BEING ABOVE THE
22	LINE. LET ME ASK, BASIC BIOLOGY I, WHEN DOES IT GO
23	TO THE BOARD? IN AUGUST? IS THAT CORRECT, AUGUST?
24	DR. CSETE: NO. WE'VE RECEIVED THE
25	PREAPPLICATIONS. IT WILL BE JUNE IT WILL BE A
	200

1	JUNE REVIEW MEETING, SO WHATEVER FOLLOWS, AUGUST.
2	CHAIRMAN KLEIN: SO DISEASE TEAMS ARE
3	AUGUST. WELL, I'M NOT SURE THEY'RE OCTOBER.
4	DR. CSETE: THE REVIEW IS IN SEPTEMBER.
5	CHAIRMAN KLEIN: I UNDERSTAND. WE HAVE
6	DISCUSSED POTENTIALLY TAKING THE TOP LEVEL DISEASE
7	TEAMS, IF THERE'S FUNDING AVAILABLE, AND HAVING A
8	MEETING AT A SPECIAL MEETING AT THE END OF
9	SEPTEMBER. SO I'M NOT SURE THAT IT'S OCTOBER. BUT
10	WITH THAT CAVEAT, WE SHOULD HAVE A FAIRLY GOOD READ
11	BY AUGUST OF WHERE WE ARE ON OUR ABILITY TO RAISE
12	FUNDS. SO WE'LL BE ABLE TO MAKE SOME DECISIONS.
13	BUT WHAT WE'VE DONE IS KEPT THESE ALL ABOVE THE
14	LINE, INCLUDING WHAT THEY RECOMMENDED FOR BIOLOGY.
15	AND I WOULD REMIND EVERYONE UNTIL THE DICKEY WICKER
16	AMENDMENT IS PASSED, THE FEDERAL GOVERNMENT CANNOT
17	CREATE NEW CELL LINES, INCLUDING DISEASE-SPECIFIC
18	LINES THAT MAY BE IMPORTANT THAT MIGHT BE FUNDED BY
19	BASIC BIOLOGY.
20	SO THERE ARE A NUMBER OF CONSIDERATIONS,
21	BUT THE LEVEL OF CONTINUITY THAT'S ABOVE THE LINE IN
22	BASIC BIOLOGY IS NOT PROVIDING ANY SIGNIFICANT
23	OFFSET TO THE OTHER PROGRAMS THAT ARE IN THE
24	PRIORITIES THAT JEFF RECOMMENDED. AND THEY'RE ALL
25	ABOVE THE LINE.
	201

1	MS. SAMUELSON: ALL OF THAT IS GOING TO
2	COME UP AT THE SAME TIME. IF WE'RE REVIEWING THE
3	BASIC BIOLOGY GRANTS IN AUGUST, THAT'S THE SAME TIME
4	THAT APPROPRIATIONS IS BEFORE THE CONGRESS. AND
5	DICKEY WICKER WILL BE CAST AS AN AMENDMENT ON AN
6	APPROPRIATIONS BILL. THAT'S HOW THAT STUFF ALWAYS
7	GETS RESOLVED, AND THAT'S THE SAME TIMEFRAME. SO
8	THE BOTTOM LINE IS THAT THERE ARE GOING TO BE
9	OTHER ANOTHER BIG POOL OF MONEY FOR THE SAME
10	WORK, NOT THAT WE DON'T DO IT. OF COURSE, WE DO.
11	WE DON'T HAVE TO FUND HUNDRED CENTS ON THE DOLLAR TO
12	GET THAT ENTIRE PORTFOLIO FUNDED; WHEREAS, WITH
13	EARLY TRANSLATION, WE DON'T HAVE THAT BACKUP.
14	CHAIRMAN KLEIN: WE'RE GOING TO NEED TO
15	MOVE TO A VOTE BECAUSE WE'RE GOING TO LOSE OUR
16	QUORUM HERE. AND WHAT I'D LIKE TO DO IS DR. GILL
17	HAD A POINT AND, MARCY, DID YOU HAVE A POINT? DID
18	YOU WANT TO COMMENT?
19	MS. FEIT: NO.
20	CHAIRMAN KLEIN: SO DR. GILL AND DR.
21	PRICE. THEN MAYBE WE CAN HAVE PUBLIC COMMENT, AND
22	THEN WE CAN HAVE A VOTE.
23	DR. GILL: I'LL TRY AND KEEP IT BRIEF.
24	USED TO BE DEAN OF TRANSLATIONAL RESEARCH, SO I AM
25	STRONGLY AN ADVOCATE OF THIS. HOWEVER, I'VE ALSO
	202

1	SAT ON A NUMBER OF PANELS, INCLUDING THE ARMY BREAST
2	CANCER REVIEW PANEL. AND THE PEOPLE WHO ARE NOT
3	ACTUALLY DOING THE WORK ALWAYS EXPECT THAT THEY'RE
4	FURTHER ALONG THAN THEY ARE WHEN IT COMES TO REALLY
5	APPLYING THE BASIC BIOLOGY. THEY DON'T HAVE AS MUCH
6	BASIC BIOLOGY AS THEY THINK THEY DO, AND SO MANY
7	THINGS FAIL.
8	SO I THINK THAT THE PUBLIC COMMENT THAT
9	YOU GOT REFLECTED THAT. AND I WOULD BE VERY
10	CAUTIOUS OF DOWNGRADING BASIC BIOLOGY BECAUSE I CAN
11	ASSURE YOU IN A NEW FIELD LIKE THIS, WE DON'T HAVE
12	IT YET. WE JUST GOT INDUCED PLURIPOTENT CELLS. I
13	MEAN WHAT AN AMAZING BREAKTHROUGH, BUT TWO YEARS AGO
14	WE DID NOT HAVE THAT. SO I WOULD BE VERY CAUTIOUS
15	ABOUT DOWNGRADING BASIC BIOLOGY. WE ARE NOT THERE
16	YET, AND TO THINK SOMEONE ELSE WILL DO IT FOR US,
17	I'D BE CAUTIOUS ABOUT THAT.
18	CHAIRMAN KLEIN: IN KEEPING IT ABOVE THE
19	LINE FOR FUNDING, I COMPLETELY AGREE WITH YOUR
20	COMMENT. DR. PRICE.
21	DR. PRICE: I WAS GOING TO SAY ESSENTIALLY
22	THE SAME THING, BUT IN MUCH MORE LAY TERMS. THERE'S
23	A SIMPLE LOGIC HERE, I THINK, WHICH IS THAT
24	ULTIMATELY AT THE END OF THE DAY, THE SUCCESS AND
25	THE POWER OF CURES AND THERAPIES ARE CLOSELY RELATED
	203

1	TO THE ROBUSTNESS OF OUR UNDERSTANDING OF THE
2	SCIENCE OF STEM CELLS, THE BASIC SCIENCE OF STEM
3	CELLS, BASIC BIOLOGY OF STEM CELLS. SO TO ARGUE
4	THAT SOMEHOW YOU PUT THE TRANSLATIONAL AND THE
5	DISEASE AHEAD OF THE UNDERSTANDING OF WHAT'S GOING
6	ON THAT YOU'RE TRYING TO USE JUST DEFIES LOGIC, I
7	THINK. AND SO TRANSLATION AND THE DISEASE CURES
8	ARE THE BASIC BIOLOGY IS THE PLATFORM FROM WHICH
9	THOSE THINGS ARE BUILT.
10	CHAIRMAN KLEIN: DR. LOVE HAD A POINT AND
11	THEN SHERRY LANSING.
12	DR. LOVE: WELL, I THINK MY POINT WAS A
13	SIMILAR ONE TO THE POINTS THAT HAVE BEEN MADE. THAT
14	IS, THAT I THINK IT IS IMPORTANT THAT WE CONTINUE TO
15	SUPPORT BASIC BIOLOGY BECAUSE, IN FACT, WHAT I THINK
16	MARIE SAID IS THAT THEY WERE ASKED TO BASICALLY COME
17	UP WITH A PORTFOLIO STRATEGY OF HOW YOU'D ALLOCATE
18	RESOURCES IN A CONSTRAINED ENVIRONMENT. AND THIS IS
19	THE PORTFOLIO THEY CAME UP WITH.
20	WHAT WE'VE BEEN TALKING ABOUT IS A VERY
21	SIMILAR A VERY DIFFERENT ISSUE, AND THAT IS KIND
22	OF A NUMERICAL ORDER. AT THE END OF THE DAY, IT
23	SEEMS LIKE THE RATIONAL APPROACH HERE IS THE
24	PORTFOLIO APPROACH. SO REALLY THE DISCUSSION, AT
25	LEAST TO ME, THAT MAKES THE MOST SENSE IS WHAT'S

1	ABOVE AND WHAT'S BELOW THE LINE, NOT THE RANK ORDER.
2	CHAIRMAN KLEIN: AS THE MAKER OF THE
3	SECOND, I TOTALLY AGREE WITH THAT. AND I WOULD
4	INDICATE THAT IT'S HARD FOR ME TO ANTICIPATE, SINCE
5	THIS IS A \$5 MILLION EXPENDITURE OVER TWO YEARS,
6	THAT WE WOULD CUT THIS OUT OF FUNDING. WE'RE EITHER
7	GOING TO HAVE SOME MORE MAJOR MOMENTUM HERE OR WE'RE
8	NOT. FIVE MILLION IS NOT GOING TO MAKE THE
9	DIFFERENCE. SO IF IT'S ABOVE THE LINE, I'M COUNTING
10	ON MAKING SURE THAT IT'S FUNDED.
11	MS. LANSING: I THINK WHAT YOU'RE HEARING
12	FROM A GREAT MANY OF US IS OUR DESIRE TO MAKE SURE
13	THAT IF THERE ARE VALID DISEASE TEAMS, SINCE THAT
14	WILL HELP US SO MUCH IN MOVING TO CLINICAL TRIALS IF
15	THERE ARE VALID ONES, THAT WE HAVE THE MONEY. SO
16	I'M A LITTLE CONFUSED AS TO HOW I GUESS, I'M SO
17	RESPECTFUL OF WHAT JEFF AND JOAN AND OTHERS ARE
18	SAYING, BUT THE QUESTION IS WE CAN'T ALL PARTICIPATE
19	IN THE DISCUSSION UNLESS WE MOVE FOR A BIGGER BUDGET
20	TODAY. WE ALREADY DID THAT.
21	CHAIRMAN KLEIN: WE DON'T HAVE TO FURTHER
22	INCREASE THE BUDGET IF YOU DON'T WANT TO. BUT IF
23	YOU WANT TO MOVE DISEASE TEAMS ABOVE THE LINE,
24	THERE'S 26 MILLION THAT YOU'D HAVE TO INCREASE
25	THE
	205

1	MS. LANSING: I UNDERSTAND THAT. SO WHAT
2	I'M REALLY TRYING TO GET TO IS IF YOU GET THE I'M
3	TURNING TO YOU. IF YOU GET THE SENSE THAT WE DON'T
4	WANT TO HAVE A DISEASE TEAM AND NOT FUND IT, I GUESS
5	WHAT I WOULD SAY IS IF YOU COULD COME BACK TO US
6	WITH WHAT NUMBER WE WOULD NEED WHEN WE EVALUATE
7	THOSE GRANTS, WHICH IS 200.
8	CHAIRMAN KLEIN: WHAT I WOULD LIKE TO SAY
9	AS WELL IS THAT IF WE RESTORE DISEASE TEAMS TO THE
10	\$210 MILLION BUDGET, IT'S ACTUALLY, I THINK, GOING
11	TO HELP US SELL THESE BONDS.
12	MS. LANSING: THAT'S VERY IMPORTANT.
13	CHAIRMAN KLEIN: BECAUSE THIS IS A GOAL
14	THAT'S A UNIQUE CONTRIBUTION. WE'RE IN A
15	TRANSLATIONAL SPACE. IT'S CLEARLY COMPLEMENTARY TO
16	THE NIH. I THINK IT WILL BENEFIT US SUBSTANTIALLY.
17	MS. LANSING: SO I WOULD LIKE TO MAKE A
18	FRIENDLY AMENDMENT. CAN WE JUST DEAL WITH DISEASE
19	TEAMS AND NOT DEAL WITH
20	MR. SHEEHY: THAT'S A GOOD IDEA.
21	CHAIRMAN KLEIN: SO WE'RE TALKING ABOUT
22	MOVING DISEASE TEAMS ABOVE THE LINE AND RESTORING IT
23	TO ITS FULL
24	MS. LANSING: IT'S ALREADY ABOVE THE LINE.
25	WE'RE TALKING ABOUT ADDING.
	201

206

1	CHAIRMAN KLEIN: WE'RE RESTORING IT TO
2	FULL AMOUNT, SO WE'RE INCREASING THE BUDGET BY 26.2.
3	WE'RE INCREASING THE TOTAL FUNDING FLOOR FROM 211.7
4	MILLION TO 238 MILLION, AND WE'RE JUST RESTORING
5	DISEASE TEAMS TO THE FULL BUDGET.
6	MS. LANSING: SHOULD THERE BE SUFFICIENT
7	SCIENTIFIC MERIT. WE'RE NOT GOING TO SPEND IT
8	CHAIRMAN KLEIN: WE'RE NOT GOING TO SPEND
9	IT UNLESS WE'VE GOT THE MERIT.
10	DR. LOVE: ARE WE JUST MOVING 8 BEFORE THE
11	LINE?
12	CHAIRMAN KLEIN: BUT WE HAVE TO INCREASE
13	THE TOTAL BUDGET TO 200
14	DR. HAWGOOD: AT THIS POINT ALL WE'VE DONE
15	IS LEFT 10 MILLION BELOW THE LINE.
16	MS. LANSING: SO THAT'S MY FRIENDLY
17	AMENDMENT.
18	CHAIRMAN KLEIN: I WOULD REMIND US THAT IN
19	THE LAST SESSION WE WERE AT, AGAIN, IT WAS \$376
20	MILLION, WHICH WAS ACTUALLY THE AMOUNT CONSIDERED
21	FOR THE BUDGET, AND WE ARE NOW LOOKING AT A
22	CONSERVATIVE CASE, IF WE PASS THIS AMENDMENT, OF 238
23	MILLION INSTEAD 376 MILLION, SO THERE'S BEEN A
24	SUBSTANTI AL REDUCTI ON.
25	DR. ROBSON: IF I COULD JUST KIND OF
	207

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	REMIND YOU OF THE EXERCISE WE DID. WE WENT ALL
2	OF THESE THINGS ARE IF WE HAVE THE MONEY, WE WOULD
3	LIKE TO FUND EVERYTHING ON THAT LIST. YOU'VE
4	ALREADY APPROVED THAT. WE SUPPORT THAT.
5	THE LINE WAS REALLY A LINE DRAWN BASED ON
6	OUR EXPECTATION THAT WE COULD RAISE \$200 MILLION.
7	IT WASN'T REALLY TO SET PRIORITIES. IT WAS BASED
8	ON THE LINE FLOATS. SO TO SAY SOMETHING IS ABOVE
9	THE LINE OR BELOW THE LINE IS NOT A VALUE JUDGMENT.
10	IT'S A JUDGMENT BASED ON HOW CONFIDENT YOU ARE IN
11	HOW MUCH MONEY YOU CAN RAISE. THAT'S, I THINK, THE
12	WAY YOU SHOULD BE LOOKING AT THIS.
13	CHAIRMAN KLEIN: WE'RE EFFECTIVELY SAYING
14	THAT OUR GOAL
15	DR. ROBSON: SO BY THE CHANGES YOU'VE
16	MADE, YOU'RE GOING FROM WE'RE CONFIDENT WE CAN RAISE
17	200 MILLION TO WE'RE CONFIDENT WE CAN RAISE 240.
18	CHAIRMAN KLEIN: IT'S AN ARTIFICIAL
19	NUMBER. 200 DIDN'T HAVE A BASIS. 240 IS CLOSE
20	ENOUGH TO 200, THAT IF WE CAN I'M NOT ABOUT TO
21	DIFFERENTIATE ON THAT BASIS. I THINK WE HAVE
22	PROGRAM PRIORITIES, WHICH, IN FACT, THIS REFLECTS,
23	AND IT PROVIDES A MESSAGE THAT WE ARE PROVIDING A
24	SPECIFIC EMPHASIS AND CONTRIBUTION WITH
25	TRANSLATIONAL MEDICINE AND A UNIQUE DISEASE TEAM
	208

1	PROGRAM.
2	SO WE HAVE PUBLIC COMMENT, PLEASE.
3	MS. ROBERSON: I'M JUDY ROBERSON. MY
4	FAMILY HAS BEEN AFFECTED BY HUNTINGTON'S DISEASE.
5	I'M THE PRESIDENT OF THE NORTHERN CALIFORNIA CHAPTER
6	OF HDSA. AND I WANTED TO MAKE A COMMENT. I TOTALLY
7	AGREE WITH JOAN.
8	FOR US, FOR PATIENTS, 15,000 PEOPLE IN
9	CALIFORNIA AFFECTED WITH HUNTINGTON'S, WE'RE WAITING
10	FOR SOMETHING TO HAPPEN IN THE CLINICS. SO WE CAN
11	ACTUALLY BELIEVE WHAT WE'VE BEEN READING ABOUT STEM
12	CELLS IS ACTUALLY GOING TO WORK.
13	I KNOW A MULTIMILLIONAIRE WHO'S WAITING.
14	HE HAS TWO CHILDREN WITH HUNTINGTON'S DISEASE, BUT
15	HE'S WAITING TO POUR HIS MONEY INTO SOMETHING THAT'S
16	ACTUALLY GOING TO HELP. SO I THINK THERE'S I
17	THINK WHEN THINGS START HAPPENING IN THE CLINICS,
18	PEOPLE WILL START WRITING CHECKS.
19	SO, AGAIN, I AGREE WITH JOAN. THANK YOU
20	SO MUCH.
21	CHAIRMAN KLEIN: JOHN SIMPSON.
22	MS. SAMUELSON: THANK YOU.
23	MR. SIMPSON: JOHN SIMPSON, CONSUMER
24	WATCHDOG. IN A LARGE SENSE I THINK THIS IS AN
25	ACADEMIC DISCUSSION TODAY. YOU NEED TO BE HAVING
	200
	209

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	IT, BUT WHAT YOU ESSENTIALLY, I UNDERSTAND THIS IS
2	DOING, IS COMMITTING TO RAISING \$240 MILLION. AND
3	THAT IS A TREMENDOUSLY DIFFICULT AND COMMENDABLE
4	GOAL, BUT IT'S GOING TO BE AWHILE BEFORE WE KNOW
5	WHETHER THAT'S DOABLE. SOME OF THIS WITH THE 200,
6	240, I THINK THE MOST IMPORTANT THING IS TO GET OUT
7	THERE AND GET A SENSE OF WHETHER THESE THINGS CAN BE
8	PLACED. I FOR ONE THINK THE ECONOMY IS GOING TO GET
9	WORSE BEFORE IT GETS BETTER, AND I GENERALLY LIKE TO
10	THINK OF MYSELF AS AN OPTIMIST. AND THAT'S MY
11	OPTIMISTIC LOOK RIGHT NOW.
12	THE ONLY OTHER THING I WOULD ADD TO THE
13	BOND RAISING QUESTION, ONE OF THE THINGS THAT MADE
14	THE FIRST OFFERING SO SUCCESSFUL WAS THE ABILITY TO
15	OFFER IT TO AVERAGE PEOPLE. I THINK YOU PLACED A
16	HUNDRED MILLION OR SO BONDS THAT PEOPLE JUST BOUGHT
17	THEMSELVES. IS THERE ANY WAY TO TAP INTO THAT
18	POPULAR BOND PLACEMENT SUPPORT?
19	CHAIRMAN KLEIN: JOHN, WE CAN REACH OUT IN
20	A PUBLIC OFFERING, BUT NOT AT THIS TIME BECAUSE WHAT
21	WE'RE REALLY DOING IS BRINGING A NEW GROUP OF
22	PURCHASERS IN TO BENEFIT THE STATE. THERE ARE A
23	GREAT NUMBER OF DEMANDS ON WHAT CAN BE RAISED IN
24	PUBLIC OFFERINGS, WHICH IS VERY LIMITED. AND
25	THERE'S SOME PRIORITY REQUIREMENTS THAT COMMITMENTS
	010

1	HAVE BEEN MADE BY THE STATE THAT ARE ALREADY OUT
2	THERE.
3	WE WILL HAVE REAL-TIME INFORMATION BY THE
4	TIME WE GET TO AUGUST AND SEPTEMBER TO REEVALUATE
5	WHAT WE CAN APPROVE, SO WE CAN READJUST THESE
6	FIGURES. IT IS A TOUGH GOAL. IT IS GOING TO GET
7	TOUGHER. AND WE'RE JUST MAKING A COMMITMENT TO GO
8	AFTER THAT GOAL AND TRY AND DELIVER.
9	WITH THAT, I'D LIKE TO CALL THE QUESTION.
10	AND MY UNDERSTANDING, MR. HARRISON, IS THAT EVERYONE
11	CAN VOTE. SO OF THOSE PRESENT, ALL IN FAVOR.
12	OPPOSED?
13	DR. GILL: OPPOSED.
14	CHAIRMAN KLEIN: GORDON GILL IS OPPOSED.
15	IS THERE ANYONE ELSE OPPOSED? AND TELEPHONICALLY?
16	MS. KING: MICHAEL FRIEDMAN.
17	DR. FRIEDMAN: YES.
18	MS. KING: ED PENHOET.
19	DR. PENHOET: YES.
20	MS. KING: JUST CHECKING, GERALD LEVEY OR
21	JON SHESTACK.
22	CHAIRMAN KLEIN: OKAY. THANK YOU. THE
23	MOTION PASSES.
24	CAN I ASK STAFF HAVE WE COVERED EVERYTHING
25	WE NEED TO COVER TODAY? THANK YOU. THANK ALL THE
	044

211

1	BOARD MEMBERS AND THANK THE PUBLIC FOR BEING HERE.
2	I WOULD LIKE TO END THIS BY HAVING A ROUND OF
3	APPLAUSE FOR THE TWO HIGHLY TALENTED, WONDERFUL,
4	DEDICATED VICE CHAIRS.
5	(APPLAUSE.)
6	MR. TORRES: I FORGOT TO ANNOUNCE THAT I'M
7	WORKING PRO BONO UNTIL MAY 1ST.
8	(THE MEETING WAS THEN ADJOURNED AT
9	03: 42 P. M.)
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
	212
	L

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

SACRAMENTO CONVENTION CENTER
3D FLOOR
SACRAMENTO, CALIFORNIA
ON
MARCH 12, 2009

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152

BARRI STER' S REPORTING SERVICE

Th C. Draw

1072 BRI STOL STREET

SUITE 100

COSTA MESA, CALIFORNIA

(714) 444-4100